Skip to Late-Breaking Abstracts »
All accepted abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC).
Abstract Titles
Poster Presentation Dates
All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.
Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.
| # | Type | Title | Authors | Category | Keywords |
|---|---|---|---|---|---|
| 1 | Poster Presentation | Tumour associated macrophages in HPV-related carcinoma with adenoid cystic like features of the sinonasal tract; a review of three cases | Kasimu U. Adoke, MBBS, FMCPath; Jonathan Madukwe; Faruk Mohammed, Msc; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Monocyte/Macrophage; Tumor microenvironment; Tumor stroma |
| 2 | Poster Presentation | The Multi-physics Automated Reconfigurable Separation (MARS®) System Provides High Purity, High Recovery and High Throughput Enrichment of Immune Cells for Immunotherapy | Liping Yu, MD Ph.D.; Gregory Schneider, Ph.D.; Alice Wang, Ph.D.; | Biomarkers, Immune Monitoring and Novel Technologies | CAR T cells; Immune monitoring; Inflammation; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 3 | Poster Presentation | Butyrophilin-3A is Expressed in Multiple Solid Tumors: Translational Research Supporting the EVICTION Study with ICT01, an Anti-BTN3A mAb activating Vg9Vd2 T-Cells | Clement Ghigo; Aude de Gassard; Patrick Brune; Caroline Imbert; Clemence Demerle; Marie-Sarah Rouviere; René Hoet; Daniel Olive; Emmanuel Valentin, PhD; Emmanuel Valentin, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; Biomarkers; Immune monitoring; T cell; Targeted therapy |
| 4 | Poster Presentation | Molecularly guided multiplexed digital spatial analysis reveals differential gene expression profiles in the WNT-β-catenin pathway between melanoma and prostate tumors | Anushka Dikshit, PhD; Dan Zollinger; Karen Nguyen; Jill McKay-Fleisch; Kit Fuhrman, MS PhD; Xiao-jun Ma, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; RNA; Solid tumors; Tumor microenvironment |
| 5 | Poster Presentation | Multiple Myeloma Flow Cytometry Panel Validated for Clinical Monitoring of Patients | Bevan Gang, PhD; Vicky Sgouroudis, PhD; Virginia Litwin; Anita Boyapati; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; B cell; Biomarkers; Immune monitoring; Tumor antigens |
| 6 | Poster Presentation | Pre-clinical pharmacodynamic biomarker assays of immune modulation can translate to inform exploratory endpoints of target engagement in first-in-human clinical trial stages of drug discovery | Russell J. Garland, PhD; Christopher Kirkham, PhD; Michelle Yap, PhD; Louise S. Brackenbury, PhD; Tommaso Iannitti, PhD; Robert Nunan; S R. Jenkinson; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Immune monitoring; Inflammation; T cell; T cell lineages |
| 7 | Poster Presentation | Prognostic Factors for Overall Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Therapy – The MELimmune Score | Soraia Lobo-Martins, MD; Diogo Martins-Branco; Patrícia Miguel Semedo; Cecília Melo Alvim; Ana Maria Monteiro; Inês Vendrell; Emanuel Gouveia; Maria José Passos; Luís Costa; André Mansinho; Rita Teixeira de Sousa; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Inflammation; Solid tumors |
| 8 | Poster Presentation | Immune correlates associated with clinical outcomes in patients with advanced malignancies treated with avelumab and OX40 agonist | Aung Naing, MD, FACP; Daniel D. Karp, MD; Sarina A. Piha-Paul, MD; Cara Haymaker, PhD; Edwin R. Parra, MD, PhD; Fei Yang, MD, Ph.D.; Shubham Pant, MD; David S. Hong, MD; Siqing Fu, MD, PhD; Timothy A. Yap, MD, PhD; Bettzy Stephen, MBBS; Yali Yang, PhD; Heather Lin, MS, PhD; Cheuk Hong Leung, MS; Naval Daver, MD; Yeonjoo Choi, MD; Joud Hajjar, MD; Ignacio Wistuba, MD; Patrick M. Hwu, MD; Funda Meric-Bernstam, MD; Jordi Rodon; | Biomarkers, Immune Monitoring and Novel Technologies | Antigen presenting cells; Biomarkers; Checkpoint blockade; Immune monitoring; Solid tumors |
| 9 | Poster Presentation | Mesenchymal Features of a Novel 27-Gene Algorithm Associate with Canonical Tumor Promoting Signaling Pathways which may Identify Therapeutic Options for Immunotherapy Resistant Patients | Tyler J. Nielsen, MS; Rob S. Seitz; Douglas T. Ross, MD, PhD; David R. Hout, PhD; Brock L. Schweitzer, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Angiogenesis; Biomarkers; Checkpoint blockade; Immune contexture; Immune monitoring; Solid tumors; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 10 | Poster Presentation | A multiparameter flow cytometry assay to monitor natural killer cell proliferation and activation in immuno-oncology clinical trials | Jennifer Tsau, PhD; Brittney Atzmiller; David Quinn, PhD; Tanya Mulvey; Sema Kurtulus, PhD; Jennifer Mataraza, PhD; Shabnam Tangri, PhD; Naveen Dakappagari, PhD; Ghanashyam Sarikonda, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Clinical trial; Monocyte/Macrophage; NK/NK T cell; T cell |
| 11 | Poster Presentation | A Multi-physics Approach Enabling Rare Cell Isolation with High Recovery and High Purity | Liping Yu; Silin Sa, PhD; Alice Wang, Ph.D.; | Biomarkers, Immune Monitoring and Novel Technologies | B cell; Biomarkers; Gene expression; NK/NK T cell; Proteomics; Solid tumors; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 12 | Poster Presentation | Development of an in vitro assay to assess bispecific T cell engager using T cells from CD3e humanized mice | Jun Zhou; Shuang Zhu; Hongjuan Zhang, PhD; Lei Zheng; Mingfa Zang; Annie Xiaoyu An; Shuzong Wang; Davy Xuesong Ouyang; Henry Q. Li; Yujun Huang; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; Bispecifics; T cell |
| 13 | Poster Presentation | Use of anti-viral T cells to model HLA-restricted anti-tumor cytotoxic lymphocyte responses | Michael Overstreet, PhD; Vanessa M. Muniz-Medina; Ruoyan Chen; James Kurasawa; Stacy R. Kentner; Deepali Malhotra, PhD; Jane Osbourn; Jill Walker; Gordon Moody; Michael Overstreet, PhD; Michael Overstreet, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Adoptive immunotherapy; Checkpoint blockade; Solid tumors; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs) |
| 14 | Poster Presentation | Novel CD3 epsilon humanized N-terminal epitope model for assessment of efficacy of T-cell engagers | Gaëlle Martin; Fabiane Sonego; Audrey Beringer; Chloé Beuraud; Yacine Cherifi; Alexandre Fraichard; Patricia Isnard-Petit; Kader Thiam, PhD; Fabiane Sônego, PhD, MS; | Biomarkers, Immune Monitoring and Novel Technologies | Bispecifics; Inflammation; T cell; Targeted therapy |
| 15 | Poster Presentation | A novel CD28 humanized mouse model for efficacy assessment of CD28-targeting therapies | Fabiane Sônego, PhD, MS; Gaelle Martin, PhD; Chloé Beuraud; Audrey Beringer; Yacine Cherifi; Alexandre Fraichard; Patricia Isnard-Petit; Kader Thiam; | Biomarkers, Immune Monitoring and Novel Technologies | Costimulation; Inflammation; T cell; Targeted therapy |
| 16 | Poster Presentation | Antibody profiling of prostate cancer patients reveals differences in antibody signatures among disease stages and following treatment | Hemanth K. Potluri, BA; Hemanth K. Potluri, BA; Tun Lee Ng; Michael A. Newton, PhD; Jin Zhang, PhD; Christopher A. Maher, PhD; Peter S. Nelson, MD; Douglas G. McNeel, MD, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; Autoimmunity; Bioinformatics; Biomarkers; Vaccine |
| 17 | Poster Presentation | Activity sensors for noninvasive monitoring of immune response and tumor resistance during immune checkpoint blockade therapy | Quoc Mac, BS; James Bowen; Hathaichanok Phuengkham; Anirudh Sivakumar; Congmin Xu; Fang-Yi Su; Samuel Z. Stentz; Hyoung Sim; Adrian Harris; Tonia Li; Peng Qiu; Gabriel Kwong; Quoc Mac, BS; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immune monitoring; T cell; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 18 | Poster Presentation | New method of assessing tumor heterogeneity utilizing both circulating tumor DNA and tissue DNA to predict the response to immunotherapy | Jaeyoun Choi, M.D.; Myungwoo Nam, MD; Stanislav Fridland; Jinyoung Hwang; Chan Mi Jung; Christmann Low; Young Kwang Chae, MD, MPH, MBA; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade |
| 19 | Poster Presentation | Whole-exome sequencing based immunogenomic profiling with potential clinical applicability in circulating cell-free DNA and tissue from advanced stage colorectal cancer patients | Zheng Feng; Juergen Scheuenpflug, PhD; Mengyao Tan; Danyi Wang; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Gene expression; Immune monitoring; Neoantigens; Regulatory T cell (Treg cell); RNA; Solid tumors; T cell; Tumor microenvironment |
| 20 | Poster Presentation | Quantification of sBCMA in Human Plasma using a High-Throughput Mass Spectrometry Workflow for Exploratory, CAP/CLIA or Regulated Studies | Luca Genovesi, PhD; Michael Schirm; Gwenaël Pottiez; Rudolf Guilbaud; Lorella Di Donato; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Clinical trial; Leukemia/Lymphoma; Proteomics |
| 21 | Oral Presentation | Plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients | Michal Harel, PhD; Coren Lahav, MSc; Eyal Jacob, PhD; Eran Issler, MSc; Haim Bar, PhD; Adam P. Dicker, MD, PhD; Ofer Sharon, MD; Antonietta Bacchiocchi, MSc; Ruth Halaban, PhD; Mario Sznol, MD; Yuval Shaked, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Checkpoint blockade; Clinical trial; Immune suppression; Proteomics; Solid tumors; Systems biology |
| 23 | Poster Presentation | Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA4 rescue in patients with mismatch repair deficient metastatic colorectal cancer | Pashtoon M. Kasi, MD, MS; Carlos HF. Chan, MD, PhD; Pashtoon M. Kasi, MD, MS; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical study; Immune tolerance; Neoantigens; Solid tumors; Tumor antigens; Tumor evasion |
| 24 | Poster Presentation | Utility of tumor-informed molecular residual disease assays in patients with complete response to immune checkpoint blockade | Pashtoon M. Kasi, MD, MS; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical study; Neoantigens; Solid tumors |
| 25 | Poster Presentation | Line of therapy adjustment in a patient with advanced triple-negative breast cancer (TNBC) by using personalized ctDNA test for treatment response monitoring | Georges Azzi, MD; Shifra Krinshpun, MS, LCGC; Antony Tin, PhD; Allyson K. Malashevich, PhD; Meenakshi Malhotra; Paul Billings, MD, PhD; Angel Rodriguez, MD; Alexey Aleshin, MD, MBA; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Chemotherapy; Immune adjuvant |
| 26 | Poster Presentation | ctDNA clearance and radiographic resolution of lymph node metastasis in a patient with metastatic microsatellite stable colorectal cancer on immunotherapy | Charles J. Schneider, MD, FACP; Michael Krainock, MD; Meenakshi Malhotra; Paul Billings, MD, PhD; Alexey Aleshin, MD, MBA; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Chemotherapy; Immune adjuvant; Solid tumors |
| 27 | Poster Presentation | The role of ligands of activatory receptor NKG2D in the immune-dependent pathogenesis and evolution of inflammatory bowel disease (IBD) | Heba Sidahmed; Shilpa Ravindran, MSc; Harshitha S. Manjunath; William Mifsud; Adrian Charles; Adham A. Ammar; Muhammad U. Khan; Saad Al-Kaabi; Anthony Akobeng; Muneera J. Al-Mohannadi; Mamoun Elawad; Sara Tomei, PhD; Cristina Maccalli, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Autoimmunity; Biomarkers; Gene expression; Genetic polymorphism; Inflammation |
| 28 | Poster Presentation | Retrospective pooled analysis of epacadostat clinical studies identifies doses required for maximal pharmacodynamic effect in anti-PD-1 combination studies | Michael Smith, PhD; Robert C. Newton; Sherry Owens; Xiaohua Gong, PhD; Chuan Tian, PhD; Janet Maleski, RN, BSN; Lance Leopold, MD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Coinhibition; Inflammation; Tumor microenvironment |
| 29 | Poster Presentation | Profiling Tumor Circulating Cell-Free DNA with an Enhanced Whole-Exome to Enable Sensitive Assessment of Somatic Mutations | Simo V. Zhang, PhD; Mengyao Tan; Fabio C. P. Navarro; Josette M. Northcott; Shuyuan Ma; Christopher S. Nelson; Devayani P. Bhave, PhD; L. Gordon Bentley; Manju Chinnappa; Dan Norton; Gabor Bartha, PhD; Jason Harris; John Lyle, PhD; Sean M. Boyle, PhD, MS; John S. West, MBA; Richard Chen, MD, MS; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Genetic polymorphism; Immune monitoring |
| 30 | Poster Presentation | NLR (Neutrophil Lymphocyte Ratio) and PLR (Platelet Lymphocyte Ratio) Changes as a Predictor of Eventual Treatment Failure and Death on Nivolumab Therapy in Renal Cell Carcinoma | Arnab Basu, MD, MPh, FACP; yash Suri; Lakshminarayan Nandagopal; Mollie R. Deshazo, MD; Lyse A. Norian, PhD; Eddy Yang; | Biomarkers, Immune Monitoring, and Novel Technologies | Checkpoint blockade; Immune monitoring |
| 31 | Oral Presentation | Dynamic change of PD-L1 expression on extracellular vesicles predicts response to immune-checkpoint inhibitors in non-small cell lung cancer patients. | Diego de Miguel Perez, PhD, MSc; Alessandro Russo, MD, PhD; Muthukumar Gunasekaran, PhD; Andrés F. Cardona, MD, PhD; Rena Lapidus, PhD; Brandon Cooper, MSc; Sunjay Kaushal; Christine B. Peterson, PhD; Rivka Colen, MD; Aung Naing, MD, FACP; Vincenzo Adamo, MD, PhD; Christian Rolfo, M.D, PhD, MBA; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Solid tumors; Extracellular vesicles/exosomes |
| 32 | Poster Presentation | C-reactive protein (CRP) as a prognostic biomarker in advanced non-small cell lung cancer treated with Immune Checkpoint Inhibitors. Results from a multi-center international observational study | Abdul Rafeh Naqash, MD; Alessio Cortellini, MD; Emma Mi; Sanna M. Livanainen; Daria Gramenitskaya; James Clark; Kevin O'Brien; Jussi P. Koivunen; Shravanti Macherla; Sweta Jonnalagadda; Shanker R. Polsani; Rahim A. Jiwani, MD; Nitika Sharma, MD; Chipman RG. Stroud; Mahvish Muzaffar, MD; Paul R. Walker, MD; David J. Pinato, MD, MRes, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Checkpoint blockade; Immune suppression; Inflammation; T cell |
| 33 | Poster Presentation | Dynamic monitoring of response to immune checkpoint blockade through deep-learning empowered ultra-sensitive liquid biopsy in melanoma | Adam J. Widman, MD; Cole Khamnei; Jake Bass; Will Liao, PhD; Minita Shah; Nicolas Robine, PhD; Jedd D. Wolchok, MD, PhD; Margaret K. Callahan, MD, PhD; Dan A. Landau, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Checkpoint blockade; Immune monitoring |
| 34 | Poster Presentation | Multi-step antibody validation for the GeoMx® Digital Spatial Profiler | Alyssa Rosenbloom; Jenny Cronin; Shilah A. Bonnett, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; Biomarkers; Immune monitoring; Proteomics |
| 35 | Poster Presentation | Targeted non-viral integration of large cargo in primary human T cells by CRISPR/Cas9 guided homology mediated end joining | Beau R. Webber, PhD; Matthew J. Johnson, PhD; Nicholas J. Slipek; Walker S. Lahr; Xiaohong Qiu; Blaine Rathmann; Miechaleen D. Diers; Bryce Wick; R. Scott McIvor, PhD; Branden S. Moriarity, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; CAR T cells; T cell |
| 36 | Oral Presentation | Molecular events regulating solid tumor cell responses to natural killer cells | Michal Sheffer, PhD; Constantine S. Mitsiades; Michal Sheffer, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Immune suppression; NK/NKT cell; Solid tumors; Systems biology; Tumor evasion |
| 37 | Poster Presentation | Monitoring the evolution of inflammatory bowel disease (IBD) in pediatric and adult cohorts of patients to identify biomarkers to predict cancer risk | Shilpa Ravindran, MSc; Heba Sidahmed; Harshitha S. Manjunath; Rebecca A. Mathew, MSc; Tanwir Habib; William Mifsud; Adrian Charles; Adham A. Ammar; Muhammad U. Khan; Saad Al-Kaabi; Anthony Akobeng; Muneera J. Al-Mohannadi; Mamoun Elawad; Sara Tomei, PhD; Cristina Maccalli, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Autoimmunity; Biomarkers; Epigenetics; Gene expression; Inflammation; RNA; Stem cell/cancer-initiating cell |
| 38 | Poster Presentation | Clinical validation of an image analysis assay for determining programmed death-ligand 1 (22C3) in non-small cell lung cancer | Roberto Gianani, MD, FCAP; Will Paces, MEng; Elliott Ergon, BS; Kristin Shotts, PhD; Vitria Adisetiyo, PhD; Vitria Adisetiyo, PhD; Charles Caldwell, Jr., PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; Biomarkers; Clinical study; Solid tumors |
| 39 | Poster Presentation | Spatial single-cell quantitative analyses of human head and neck squamous cell carcinomas | Katie E. Blise, BA; Shamilene Sivagnanam, MS; Lisa M. Coussens, PhD; Jeremy Goecks, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Immune contexture; Solid tumors; Systems biology; Tumor microenvironment |
| 40 | Poster Presentation | The Orion™ platform from RareCyte® enables same-day 21-plex fluorescence tissue analysis | Daniel Campton; Jeremy Cooper; Steven Reese; Kyla Teplitz; Jeffrey Werbin; Joshua Nordberg; Eric P. Kaldjian, MD; Tad George, PhD | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 41 | Poster Presentation | Optimization of an ultrasensitive, quantitative immunoassay for detection of CD20 in Non-Hodgkin's Lymphoma (NHL) FFPE samples | Apollina Goel, PhD; Michael Ross; Jeanette Rheinhardt; Peter Duval; Michael Maker; Hiroyuki Yokota; Kenneth Bloom; George Abe; Ann Ranger; Joseph S. Krueger, BS PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; B cell; Biomarkers; Bispecifics; Leukemia/Lymphoma; Tumor antigens |
| 42 | Poster Presentation | Intravital multiphoton microscopy of infiltrating T cell and tumor cell metabolism in a murine melanoma model | Alexa R. Heaton, PhD; Tiffany M. Heaster, PhD; Anna Hoefges, MS; Alexander L. Rakhmilevich, MD, PhD; Amy K. Erbe, PhD; Paul M. Sondel, MD, PhD; Melissa C. Skala, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Adoptive immunotherapy; Checkpoint blockade; Cytokine; Metabolism; Radiotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 43 | Poster Presentation | Highly multiplexed digital spatial profiling of the tumor microenvironment of non-small-cell lung cancer (NSCLC) | Arutha J. Kulasinghe, PhD; Connor O'Leary; Rahul Ladwa; Majid Warkiani, PhD; Kenneth J. O'byrne, MD; Arutha J. Kulasinghe, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Proteomics; Solid tumors; T cell; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 44 | Poster Presentation | Body composition may be prognostic and predictive of clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI) | Dylan J. Martini, BA; Dylan J. Martini, BA; T. Anders Olsen, BA; Subir Goyal, Ph.D; Yuan Liu, Ph.D; Sean T. Evans, BS; Benjamin L. Magod, BS; Jacqueline T. Brown, MD; Lauren Yantorni, NP; Greta A. Russler, MSN, FNP-BC; Sarah Caulfield, PharmD, BCOP; Jamie M. Goldman, MD; Bassel Nazha, MD; Wayne B. Harris, MD; Omer Kucuk, MD; Bradley C. Carthon, MD Ph.D; Viraj A. Master, MD Ph.D; Mehmet A. Bilen, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Checkpoint blockade; Clinical study; Metabolism; Solid tumors |
| 45 | Poster Presentation | Body composition as a predictive and prognostic biomarker in advanced urothelial carcinoma (UC) patients treated with immune checkpoint inhibitors (ICI) | Dylan J. Martini, BA; Julie M. Shabto, BA; Subir Goyal, Ph.D; Yuan Liu, Ph.D; T. Anders Olsen, BA; Sean T. Evans, BS; Benjamin L. Magod, BS; Deepak Ravindranathan, MD, MS; Jacqueline T. Brown, MD; Lauren Yantorni, NP; Greta A. Russler, MSN, FNP-BC; Sarah Caulfield, PharmD, BCOP; Jamie M. Goldman, MD; Bassel Nazha, MD; Shreyas S. Joshi, MD, MPH; Haydn T. Kissick, Ph.D; Kenneth Ogan, MD; Wayne B. Harris, MD; Omer Kucuk, MD; Bradley C. Carthon, MD Ph.D; Viraj A. Master, MD Ph.D; Mehmet A. Bilen, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical study; Metabolism; Solid tumors |
| 46 | Poster Presentation | A novel H&E-like staining method compatible with multiplexed IF on the same tissue section for integrated translational workflows | Michael J. McLane, II; Glenn Milton; Linying Liu; Rachel Schaefer; Yi Zheng; Carla Coltharp, PhD; Peter Miller, MS; Clifford C. Hoyt, MS; Michael J. McLane, II, BS; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Immune contexture; Tumor microenvironment; Tumor stroma |
| 47 | Poster Presentation | Pathologists enhance interpretation of automated multiplex immunohistochemistry assays in cancer immunotherapy trials | Emmanuel Pacia; Ju Young Kim, PhD; Evelyn Diaz; Beiru Chen, MD; Nathan Roscoe; Jason Hughes; Thai Tran, PhD; Jennifer M. Bordeaux, PhD; Bashar Dabbas, MD; Shabnam Tangri, PhD; Margaret McLaughlin, MD; Alexander Savchenko, MD, PhD; Naveen Dakappagari, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Clinical study |
| 48 | Poster Presentation | Advances in Multiplexed Ion Beam Imaging (MIBI) for immune profiling of the tumor microenvironment | Jason Ptacek, PhD; Felipe C. Geyer, MD; Andre Mignault; James Deeds; Jimmy Giedt, Ph.D.; Jane Gu; Margaret McLaughlin, MD; Yari Sigal, Ph.D.; Jay G. Tarolli, Ph.D.; Murat Aksoy, Ph.D.; Yi Zhang; Monirath Hav, MD; Rachel Finck; Jessica Finn, MD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Dendritic cell; Immune contexture; Immune monitoring; Immune suppression; Solid tumors; Systems biology; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 49 | Poster Presentation | In situ phenotypic analysis of T cells in the tumor microenvironment of a pre-clinical model of non-small cell lung cancer (NSCLC) by tissue sectioning and whole-mount immunofluorescence imaging | Elen Torres, PhD; Stefani Spranger, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 50 | Poster Presentation | Spatially Resolved Molecular Investigation of Triple Negative Breast Cancer and Its Immune Microenvironment | Stephen R. Williams, PhD; Cedric R. Uytingco, PhD; Neil Weisenfeld, PhD; Nigel Delaney, PhD; Solongo Ziraldo, PhD; Yifeng Yin, PhD; Jennifer Chew, BS; Sharmila Chatterjee; Daniel P. Riordan, PhD; Zachary W. Bent, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | B cell; Bioinformatics; Biomarkers; Gene expression; Genetic polymorphism; RNA; Stem cell/cancer-initiating cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 51 | Poster Presentation | Small cell/lymphohistiocytic morphology is associated with CD8 positivity, retained T cell markers, a trend of decreased PD-L1 expression, but not outcome in adults with ALK+ ALCL | Mahsa Khanlari; Shaoying Li, MD; Roberto N. Miranda, MD; Swaminathan Iyer, MD; Cameron Yin, MD, PhD; Pei Lin, MD; Guilin Tang, MD, PhD; Sergej N. Konoplev, MD, PhD; L. Jeffrey Medeiros, MD; Jie Xu, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Epidemiology; Leukemia/Lymphoma; Targeted therapy |
| 52 | Poster Presentation | Advanced T Lymphocyte Analysis System (ATLAS) for In-depth Immunological Interrogation in Real-World Conditions, a Methodological Strategy | Stephanie Berg, DO; Stephanie Berg, DO; Cara Joyce, PhD; Michael Delos Reyes; Brianna Burke; Lourdes Plaza-Rojas, PhD; Kushal Prajapati; Cynthia Perez; Courtney Wagner, MD; Elizabeth Elliott, DO; Blaine Knox, MD; Daniel Linden, DO; Joseph I. Clark, MD; Jose Guevara, MD PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Immune monitoring; T cell |
| 53 | Poster Presentation | Predictors of response to Immune checkpoint inhibitor therapy in metastatic solid tumors: Real world evidence | Aasems Jacob, MD; Jianrong Wu, PhD; Jill Kolesar, PharmD; Eric Durbin, MS, DrPH; Aju Mathew, MD, MPH; Susanne M. Arnold, MD; Aman Chauhan, MD; Aasems Jacob, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring; Immune tolerance; Immune toxicity; Solid tumors |
| 54 | Poster Presentation | Patient Stratification using Clinical Proteomics – Validated multiplexed MRM assays to quantify HER2 and other biomarkers in clinical FFPE tissues | Maxim Isabelle, PhD; Maxim Isabelle, PhD; Maxim Isabelle, PhD; Michael Schirm; Gwenaël Pottiez; Rudolf Guilbaud; Lorella Di Donato; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Clinical study; Proteomics |
| 55 | Poster Presentation | Thousands of antigens are recognized in mice via endogenous antibodies after being cured of a B78 melanoma via immunotherapy | Anna Hoefges, MS; Amy K. Erbe, PhD; Sean J. Mcilwain, PhD; Trang Q. Le; Angie Xu; Nicholas Mathers; Eric Zhang; Andrew S. Melby; Claire Baniel; Alexander L. Rakhmilevich, MD, PhD; Jacquelyn A. Hank, PhD; Richard Pinapati, PhD; Brad Garcia, PhD; Jigar Patel, PhD; Zachary S. Morris, MD, PhD; Irene M. Ong, PhD; Paul M. Sondel, MD, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; Antigen presenting cells; B cell; Bioinformatics; Biomarkers; Neoantigens; Proteomics; Radiotherapy; Solid tumors; Tumor antigens |
| 56 | Poster Presentation | Improved next generation sequencing based Class I HLA typing through exome enhancement | Lee D. McDaniel, Jr., MD, MSE; Rachel M. Pyke, PhD; Charles Abbott, PhD; Gabor Bartha, PhD; John S. West, MBA; Richard Chen, MD, MS; Sean M. Boyle, PhD, MS; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Neoantigens |
| 57 | Poster Presentation | Precision neoantigen discovery using novel algorithms and expanded HLA-ligandome datasets | Dattatreya M. Mellacheruvu, PhD; Rachel M. Pyke, PhD; Charles Abbott, PhD; Nick Phillips, MS; Sejal Desai, PhD; Rena McClory, PhD; John S. West, MBA; Richard Chen, MD, MS; Sean M. Boyle, PhD, MS; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Neoantigens; Proteomics; Tumor antigens; Vaccine |
| 58 | Poster Presentation | Excluding Treg epitopes and integrating CD8 and CD4 effector neoepitope content improves prognostic biomarker tool in bladder cancer | Guilhem Richard, PhD; Gary D. Steinberg; Tzintzuni Garcia; Matthew Ardito, BA; William Martin, BA MD; Gad Berdugo, MBA, MSc.; Michael F. Princiotta, PhD; Arjun V. Balar, MD; Anne S. de Groot, MD; Randy F. Sweis, MD; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Neoantigens; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor antigens; Vaccine |
| 59 | Poster Presentation | Integrating deep proteomics profiling with survival analysis to identify novel biomarkers of response to PD-1 blockade in NSCLC patients | Kamil Sklodowski, PhD; Vito Dozio, PhD; Silvia Lopez-Lastra, PhD; Andrés Lanzós, PhD; Kristina Beeler, Dr.; Emanuela Romano, MD, PhD; Kamil Sklodowski, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Proteomics; Solid tumors; Targeted therapy |
| 60 | Poster Presentation | Development and validation of blood tumor mutational burden reference standards | Eun-Ang Rabier-Moreau, PhD; Guillem Portella, PhD; Matthew Butler, PhD; Yves Konigshofer, PhD; James Hadfield, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers |
| 61 | Poster Presentation | Tumor mutational burden assessments by two commercial targeted sequencing assays | Ruchi Chaudhary; Gitanjali Vaidya; Meeta Sunil; Sakthivel Murugan S.M; Ramprasad VL; Ravi Gupta; Eric Stawiski; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade |
| 62 | Oral Presentation | Identify immune cell types and biomarkers associated with immune-related adverse events using single cell RNA sequencing | Jiamin Chen, PhD; Lance Pflieger, PhD; Sue M. Grimes, MSc; Tyler Baker, PhD; Michael Brems; Gail Fulde; Shawnee Snow; Parker Howe; Anuja Sathe, PhD; Bryce Christensen; Hanlee P. Ji, MD; Terence Rhodes, MD, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Gene expression; Immune toxicity; Inflammation; T cell |
| 63 | Poster Presentation | Microsatellite instability/mismatch repair biomarker testing disparities in patients with advanced colorectal cancer: Implications for immune checkpoint inhibitors | Bryan Iorgulescu, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade |
| 64 | Poster Presentation | Cancer testis antigen co-expression landscape in solid tumors | R.J. J. Seager, Jr., Ph.D.; Erik Van Roey; Shuang Gao; Jonathan Andreas, MS; Vincent Giamo, BS, MS; Blake Burgher, BS, RN; Felicia L. Lenzo; Mary K. Nesline, MS; Paul DePietro, PhD; Yirong Wang, M.S.; Sean T. Glenn, PhD; Shengle Zhang, MD; Jeffrey Conroy, BS; Sarabjot Pabla, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Gene expression; Immune monitoring; Solid tumors; Tumor antigens |
| 65 | Poster Presentation | PD-L1 by RNA next generation sequencing: Comparison with PD-L1 IHC 22C3 and association with survival benefit from pembrolizumab with or without chemotherapy in non-small cell lung cancer. | Yong Hee Lee; Grace K. Dy; Paul DePietro, PhD; Jeffrey Conroy, BS; Sarabjot Pabla, PhD; Mary K. Nesline, MS | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Chemotherapy; Gene expression; RNA; Solid tumors; Tumor microenvironment |
| 66 | Poster Presentation | Complex markers of survival from pembrolizumab: The potential predictive role of tumor mutational burden (TMB) and KRAS | Yong Hee Lee; Carrie Hoefer; Paul DePietro, PhD; Mary K. Nesline, MS | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Gene expression; Immune monitoring; Solid tumors; Tumor microenvironment |
| 67 | Poster Presentation | B-cell receptor heavy chain repertoire profiling using an augmented transcriptome | Eric Levy, PhD; Pamela Milani, PhD; Gabor Bartha, PhD; Charles Abbott, PhD; Robert Power, MS; Rena McClory, PhD; Robin Li, MS; John S. West, MBA; John Lyle, PhD; Sean M. Boyle, PhD, MS; Richard Chen, MD, MS; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; B cell; Bioinformatics; Biomarkers; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 68 | Poster Presentation | The prognostic and predictive implications of the 12-chemokine score in muslce invasive bladder cancer | Roger Li, MD; Logan Zemp, MD; Anders E. Berglund, PhD; Jasreman Dhillon, MD; Ryan Putney, PhD; Youngchul Kim, PhD; Rohit K. Jain, MD; Daniel Grass, MD; Jingsong Zhang, MD, PhD; Michael A. Poch, MD; Julio M. Pow-Sang, MD; Wade J. Sexton, MD; Scott M. Gilbert, MD; Shari A. Pilon-Thomas, PhD; José Conejo-Garcia, MD, PhD; Colin P. Dinney, MD; James J. Mulé, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Checkpoint blockade; Chemokine; Immune contexture; Tumor microenvironment |
| 69 | Poster Presentation | Automated TRB locus haplotype analysis by long-amplicon TCRB chain sequencing for potential immune-related adverse events biomarker research | Jennifer Burke; Frances Chen; Jiajie Huang; Geoffrey M. Lowman, PhD; Timothy Looney, PhD; Marina Sedova, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Immune monitoring; Immune toxicity; T cell |
| 70 | Poster Presentation | Beyond PD-L1: novel PD-1 biomarkers identified by driving T cell dysfunction in vitro | Simarjot Pabla, PhD; Tenzing Khendu; Simarjot Pabla, PhD; Dhan Chand, PhD; Bulent A. Aksoy, PhD; Benjamin Duckless, BS; Andrew Basinski; Cailin CJ. Joyce, PhD; Thomas Horn, PhD; Lukasz Swiech; Jeremy D. Waight, PhD; David Savitsky, PhD; Jennifer S. Buell, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; T cell; Tumor evasion; Tumor microenvironment |
| 71 | Poster Presentation | Whole Exome Sequencing of individuals presenting extreme phenotypes of high and low-risk of developing tobacco-induced lung adenocarcinoma: relevance of immune and DNA-repair related pathways | Jose Perez-Gracia, MD; Mapi Andueza; Ana Patiño-Garcia, PhD; Alfonso Gurpide; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Carcinogenesis; Epidemiology; Genetic polymorphism; Solid tumors |
| 72 | Poster Presentation | Routine use of comprehensive genomic profiling to assess tumor mutational burden across a community health system | Carlo B. Bifulco, MD; Roshanthi Weerasinghe; Bela Bapat; Alexa K. Dowdell; Shwetha Pindikuri; Sheila Reynolds; Nancy Biery; David Ball; Mary Campbell; Thomas R. Ward; Alisha Stein; Brock E. Schroeder; David A. Eberhard, MD PhD; Brian D. Piening; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring; Solid tumors |
| 73 | Poster Presentation | Orthogonally and functionally validated algorithm for detecting HLA loss of heterozygosity | Rachel M. Pyke, PhD; Dattatreya M. Mellacheruvu, PhD; Charles Abbott, PhD; Eric Levy, PhD; Simo V. Zhang, PhD; Devayani P. Bhave, PhD; Manjula Chinnappa, PhD; Gabor Bartha, PhD; John Lyle, PhD; John S. West, MBA; Richard Chen, MD, MS; Sean M. Boyle, PhD, MS; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Genetic polymorphism; Neoantigens; Tumor antigens; Tumor evasion; Vaccine |
| 74 | Poster Presentation | Novel approach for profiling immune-tumor cell interactions and mutations in the same tumor section by multiplex immunohistochemistry and NGS in immuno-oncology trials | Nathan Riccitelli; Jennifer M. Bordeaux, PhD; Nancy Valencia; Ju Young Kim, PhD; Sarah Johnson; Nathan Roscoe; James Santos; Justin Santos; Jacob Levy; Deepika Asnani; Tracie Cobb; Angela McIntosh; Xun Li, MD; Shabnam Tangri, PhD; Reinhold Pollner, PhD; Naveen Dakappagari, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Immune contexture; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 75 | Poster Presentation | Generalizability of potential biomarkers of response to CTLA-4 and PD-1 blockade therapy in cancer | Dante S. Bortone; Steven Vensko; Sarah Entwistle; Alexandria P. Cogdill, MEng; Anne Monette, PhD; Yana G. Najjar, MD; Randy F. Sweis, MD; Nicholas Tschernia, MD; Erik Wennerberg, PhD; Praveen K. Bommareddy, MS, PhD; Cara Haymaker, PhD; Uqba Khan, MD; Heather M. McGee, MD, PhD; Wungki Park, MD; Houssein A. Sater; Christine Spencer; Maria L. Ascierto, PhD; Valentin Barsan, MD; Vinita Popat, BA; Sara Valpione, MD, PhD; Danny Wells, BA, PhD; Vésteinn Thorsson, PhD; Roberta Zappasodi, Phd; Nils Rudqvist, PhD; Benjamin G. Vincent, MD; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immune contexture; Immune monitoring; RNA; Systems biology; Tumor microenvironment |
| 76 | Poster Presentation | Potential Mechanisms of Resistance Identified Through Analysis of Multiple Biomarkers in Immune Hot Non-Responders With Non-Small Cell Lung Cancer (NSCLC) Treated With Tislelizumab | Jayesh Desai, MBBS FRACP; Qing Zhou; Sanjeev Deva; Jun Zhao; Jie Wang; Wei Tan; Xiaopeng Ma; Yun Zhang; Zhirong Shen; Xikun Wu; Shiangjiin Leaw; Juan Zhang; Yi-Long Wu, MD; | Biomarkers, Immune Monitoring and Novel Technologies | Angiogenesis; Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; Monocyte/Macrophage; Regulatory T cell (Treg cell); Solid tumors; T cell lineages; Tumor microenvironment |
| 77 | Poster Presentation | Association Between Programmed Death-Ligand 1 (PD-L1) Expression and Gene Signatures of Response or Resistance to Tislelizumab Monotherapy in Hepatocellular Carcinoma (HCC) | Ming-Mo Hou; Kun-Ming Rau; Yoon-Koo Kang; Jong-Seok Lee; Hongming Pan; Ying Yuan; Cunjing Yu; Yun Zhang; Xiaopeng Ma; Xikun Wu; Xin Li; Katie Wood; Chia-Jui Yen, MD, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical trial; Tumor microenvironment |
| 78 | Poster Presentation | T-Cell, MHC I, and Tumor Intrinsic Gene Signatures Predict Clinical Benefit and Resistance to Tislelizumab Monotherapy in Pretreated PD-L1+ Urothelial Carcinoma | Dingwei Ye; Aiping Zhou; Qing Zou; Hanzhong Li; Cheng Fu; Hailong Hu; Jian Huang; Wei Shen; Yun Zhang; Xiaopeng Ma; Pei Zhang; Ruiqi Huang; Xiusong Qiu; Lilin Zhang; Feng Bi; | Biomarkers, Immune Monitoring and Novel Technologies | Angiogenesis; Antigen presenting cells; Biomarkers; Checkpoint blockade; Clinical trial; Immune contexture; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 79 | Poster Presentation | Tumor-Immune Signatures Associated With Response or Resistance to Tislelizumab (Anti-PD-1) in Esophageal Squamous Cell Carcinoma (ESCC) | Jianming Xu; Nong Xu; Yuxian Bai; Chia-Chi Lin, MD, PhD; Michael Millward; Jingwen Shi; Yun Zhang; Xiaopeng Ma; Zhirong Shen; Ruiqi Huang; Wei Huang; Lin Shen, MD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical trial; Tumor microenvironment |
| 80 | Poster Presentation | Evaluation of the TruSight Oncology 500 assay for routine clinical testing of tumor mutational burden (TMB) and clinical utility for predicting response to pembrolizumab | Bo Wei, MS; John Kang; Miho Kibukawa, MS; Gladys Arreaza; Maureen Maguire; Lei Chen; Ping Qiu, PhD; Lixin Lang, PhD; Deepti Aurora-Garg, PhD; Razvan Cristescu, PhD; Diane Levitan, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Solid tumors |
| 81 | Poster Presentation | Inclusion of PD-L1-expressing tumor cells in the Combined Positive Score algorithm yields superior identification of positive specimens around diagnostic cut-offs across multiple indications | Jay Milo, MAS; Christopher LaPlaca; Julia Hand; Stephanie Hund; Angeliki Apostolaki; Lindsay Guerrero; Kenneth Emancipator, MD; Jonathan Juco, MD; Bryce Portier; Siena Tabuena-Frolli; Karina Kulangara; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; Antigen presenting cells; Bioinformatics; Biomarkers; Chemotherapy; Solid tumors; T cell |
| 82 | Poster Presentation | SQ3370 is a novel approach that decreases adverse drug exposure and achieves robust injected and non-injected anti-tumor responses | Sangeetha Srinivasan, PhD; Nathan A. Yee, PhD; Kui Wu, PhD; Amir Mahmoodi, MS; Michael Zakharian, MS; Maksim Royzen, PhD; Jose M. Mejia Oneto, MD, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Chemotherapy; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 83 | Poster Presentation | The Prognostic Significance of Peripheral Blood Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab: A Clinical Study | Kira MacDougall, MD; Muhammad Niazi, MD; Jeff Hosry, MD; Sylvester Homsy, MD; Alexander Bershadskiy, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Immune monitoring; Inflammation; Targeted therapy |
| 84 | Poster Presentation | Quantifying pharmacodynamic biomarker changes in immuno-oncology by mass spectrometry | Joseph M. Eckenrode, PhD; Omar F. Laterza, PhD; Michael E. Lassman, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Proteomics; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs) |
| 85 | Poster Presentation | Spatial Heterogeneity of Tumor Associated Macrophages in the Tumor Immune Microenvironment in ccRCC | Nicholas H. Chakiryan, MD; Gregory Kimmel; Youngchul Kim, PhD; Jonathan Nguyen; Jad Chahoud; Philippe Spiess; Jasreman Dhillon, MD; Liang Wang; Carlos Moran-Segura; James J. Mule, PhD; Philipp Altrock; Brandon J. Manley; | Biomarkers, Immune Monitoring and Novel Technologies | Monocyte/Macrophage; Myeloid cells; Solid tumors |
| 86 | Poster Presentation | Co-detection of RNA and protein in FFPE tumor samples by combining RNAscope in situ hybridization and immunohistochemistry assays | Anushka Dikshit, PhD; Xiao-jun Ma, PhD; Emerald Doolittle, PhD; Lydia Hernandez, PhD; Jyoti Sheldon; Siobhan Kernag, PhD; Helly Xiao Yan Pimentel; Hailing Zong, PhD; Bingqing Zhang, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Cytokine; Gene expression; RNA; Tumor microenvironment |
| 87 | Poster Presentation | Transcription factor RUNX1 activates OPN to promote tumor progression via MAPK signaling in head and neck cancer | Kai Liu, Ph.D; Huiying Hu; Zhenkun Yu; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Carcinogenesis; Gene expression; Solid tumors; Tumor evasion |
| 88 | Poster Presentation | Development of a 3D organoid autologous TIL co-culture platform for high throughput immuno-oncology studies | Garima Kaushik, PhD; Bhavna Verma, PhD; Amy K. Wesa, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Checkpoint blockade; Cytokine; Immune suppression; Immune tolerance; NK/NK T cell; Solid tumors; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 89 | Poster Presentation | First-in-human CAR T targets cleaved MUC1, the growth factor receptor form | Benoit J. Smagghe, PhD; Andrew K. Stewart, PhD; Pengyu Huang, PhD; Tyler E. Swanson; Danica M. Page; Mark G. Carter; Trevor J. Grant, PhD; Jennifer Specht, MD; Cynthia C. Bamdad, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; Stem cell/cancer-initiating cell; T cell; Targeted therapy |
| 90 | Oral Presentation | Potentiation of T-cell mediated tumor killing via modulation of the fas/fasL pathway | Jonathan Boiarsky, BA; Ranjan Upadhyay, PhD; Judit Svensson-Arvelund, PhD; Aleksandra Wroblewska, PhD; Sherry Bhalla, PhD; Nathalie Scholler, MD, PhD; Adrian Bot, MD, PhD; John M. Rossi, MS; Samir Parekh, MD; Norah Sadek, BA; Alessia Baccarini, PhD; Miriam Merad, MD, PhD; Brian Brown, PhD; Joshua Brody, MD; | Cellular Therapies | Bispecifics; CAR T cells; Immune tolerance; Leukemia/Lymphoma; T cell; Tumor antigens; Tumor evasion |
| 91 | Poster Presentation | Directly Link T Cell Phenotype and Function to Genotype with the Opto™ Cell Therapy Development 1.0 Workflow | Yelena Bronevetsky, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Cytokine; T cell |
| 92 | Poster Presentation | Adoptive transfer of immature myeloid cells lacking NF-κB p50 (p50-IMC) slows high-risk neuroblastoma tumor growth | Cheng Cui, Ph.D.; Theresa Barberi, PhD; Rahul Suresh, Ph.D.; Ludovic Zimmerlin, Ph.D.; Elias Zambidis, M.D., Ph.D.; Alan D. Friedman, MD; | Cellular Therapies | Adoptive immunotherapy; Monocyte/Macrophage; Myeloid cells; Pediatric tumors |
| 93 | Poster Presentation | Targeting Sirt2 rescues the metabolic fitness and effector functions of tumor-reactive T cells within the metabolically restricted tumor microenvironment | Imene Hamaidi, PhD; Lin Zhang, MD. Ph.D; Nayoung Kim, PhD; Min-Hsuan Wang; Cristina Iclozan, Ph.D.; Bin Fang, PhD; Min Liu, Ph.D.; John M. Koomen, PhD; Anders E. Berglund, PhD; Sean J. Yoder; Jiqiang Yao, PhD; Robert W. Engelman, PhD; Ben C. Creelan, MD, MS; Jose R. Conejo-Garcia, MD, PhD; Scott J. Antonia, MD PhD; James J. Mule, PhD; Sungjune Kim, MD PhD; | Cellular Therapies | Checkpoint blockade; Metabolism; Post-translational modifications; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 94 | Poster Presentation | The T cell Antigen Coupler (TAC) redirects T cell oncolysis while limiting tonic signaling to create a safer engineered T cell product with a higher threshold for activation | Duane Moogk, PhD; Vivian W. Lau; Arya Afsahi, MSc; Anna Dvorkin-Gheva, PhD; Ksenia Bezverbnaya; Joanne A. Hammill, PhD; Jonathan L. Bramson, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Immune toxicity |
| 95 | Poster Presentation | Inhibition of AKT signaling during expansion of TCR-engineered T-cells from patient leukocyte material generates SPEAR T-cells with enhanced functional potential in vitro | Katerina Mardilovich; Lilli Wang; Rachel Kenneil; Gareth Betts, PhD; Natalie Bath, MSc; Will Spinner; Vanessa De Mello; Seint Lwin; Joseph P. Sanderson, PhD; Jonathan D. Silk, PhD; Alex J. Tipping, PhD; Andrew B. Gerry, PhD; Phil Bassett; Karen Miller, PhD; Mark Dudley; Emily Schmidt | Cellular Therapies | Adoptive immunotherapy; T cell; Targeted therapy |
| 96 | Poster Presentation | Decitabine gene modulation sensitizes human non–small cell lung cancer (NSCLC) to NY-ESO-1 TCR immunotherapy (letetresgene autoleucel; GSK3377794) in vivo | Dmitry Pankov; Ioanna S. Eleftheriadou; Anna Domogala; Sara J. Brett, PhD; Lea Patasic; Magdalena A. Kijewska; Gary Thripp; Jack Euesden; Jan Klapwijk; Katrina Soor; Miriam Damm; Mark D. W. Hill; Mirella Georgouli; Aiman Shalabi; Cedrik Britten; | Cellular Therapies | Adoptive immunotherapy; Cytokine; Epigenetics; Gene expression; Solid tumors; T cell; Tumor antigens |
| 97 | Poster Presentation | Polyfunctional activity of GD3CAR T-cells against tumors in Tuberous Sclerosis Complex | Ancy Thomas, PhD; Emilia Dellacecca; Rohan Shivde; Nicola Lanki; Levi Barse; Ancy Thomas, PhD; Agnes Lo; Denise M. M. Scholtens; Daniel F. Dilling; Richard P. Junghans, PhD, MD; Caroline Le Poole; | Cellular Therapies | CAR T cells; Cytokine; Solid tumors; T cell; Targeted therapy |
| 98 | Poster Presentation | ATA3271: An Armored, Next-Generation Off-The-Shelf, Allogeneic, Mesothelin-CAR T Cell Therapy for Solid Tumors | Jiangyue Liu, MS; Xianhui Chen, PhD; Jason Karlen; Alfonso Brito, MS; Tiffany Jheng, MS; Philippe Foubert, PhD; Janani Krishnamurthy, PhD; Yannick Bulliard, PhD; Blake T. Aftab, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Immune suppression; Targeted therapy; Tumor antigens; Tumor microenvironment |
| 99 | Poster Presentation | Structural optimization of anti-CEA-GITR-CAR to reduce tonic signaling and improve antigen-specific reactivity | Yasunori Amaishi; Yu Okubo, PhD; Yizheng Wang; Linan Wang, PhD; Takuma Kato, PhD; Sachiko Okamoto, PhD; Hiroshi Shiku, PhD; Junichi Mineno, PhD; | Cellular Therapies | CAR T cells; Solid tumors; T cell; Tumor antigens |
| 100 | Poster Presentation | Drug-regulatable engineered T cells eliminate CD33+ and CD33ΔE2+ AML | Jacob S. Appelbaum, MD, PhD; Wai-Hang Leung; Unja Martin; Kaori Oda; Giacomo Tampella, PhD; Dong Xia; Joy Zhang; Anne-Rachael Krostag; Rachael Logan; Claudya Evandy; Quennie Vong; Kyle S. Jones; John C. Timmer, PhD; Brendan P. Eckelman, PhD; Jim Rottman; Danielle Montt; Bryan Peguero; Mark Pogson; Alexander Astrakhan; Jordan Jarjour, PhD; Joshua Gustafson, PhD; Michael C. Jensen, MD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; Myeloid cells |
| 101 | Poster Presentation | Engineering gamma/delta T cells with the T-Cell Antigen Coupler receptor effectively induces antigen-specific tumor cytotoxicity in vitro and in vivo | Sarah E. Asbury, BSc; Seung Mi Yoo, PhD; Jonathan L. Bramson, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell |
| 102 | Poster Presentation | Cord-blood derived NK cells, and CAR-T cells, an attractive improved immunotherapy treatment to be considered for hematological malignancies | Mireia Bachiller García, Pharm; Lorena Pérez-Amill; Anthony M. Battram, PhD; Alvaro Urbano-Ispizua; Beatriz Martín-Antonio; Mireia Bachiller García, Pharm; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Myeloid cells; NK/NK T cell; Targeted therapy |
| 103 | Poster Presentation | Inclusion of a Dap10 costimulatory domain enhances anti-tumor efficacy of chimeric PD1-expressing T cells in multiple types of solid tumors | Amorette Barber, Ph.D.; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Solid tumors |
| 104 | Poster Presentation | BCMA-targeting CAR-T cells expanded in IL-15 have an improved phenotype for therapeutic use compared to those grown in IL-2 or IL-15/IL-7 | Anthony M. Battram, PhD; Mireia Bachiller, Pharm; Álvaro Urbano-Ispizua; Beatriz Martin-Antonio, Jr.; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Cytokine; T cell |
| 105 | Poster Presentation | A third-generation human GUCY2C-targeted CAR-T cell for colorectal cancer immunotherapy | Trevor R. Baybutt, BA; Adam E. Snook, PhD; Scott A. Waldman, MD, PhD; Jonathan M. Stem, MD; Ellen Caparosa, MD; Alicja Zalewski, MD; Trevor R. Baybutt, BA; | Cellular Therapies | CAR T cells; Solid tumors; T cell |
| 106 | Poster Presentation | Increasing AMPK activity in human T cells enhances memory subset formation without sacrificing in vitro expansion | Erica Braverman, MD; Andrea Dobbs, MSc; Darlene A. Monlish, PhD; Craig Byersdorfer, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Metabolism; T cell lineages |
| 107 | Poster Presentation | Effects of IL-2 and IL-15 on the proliferative and antitumor capacities of allogeneic CD20 CAR-engineered γδ T cells in a 3D B cell lymphoma spheroid assay | Lu Bai; Kevin Nishimoto; Mustafa Turkoz; Marissa Herrman; Jason Romero; Daulet Satpayev; Stewart Abbot; Sandra M. Hayes; Mary M. Brodey, Ph.D.; | Cellular Therapies | CAR T cells; Cytokine; Leukemia/Lymphoma; Tumor microenvironment |
| 108 | Poster Presentation | MCY-M11, a CAR-PBMC cell product transiently expressing a mesothelin targeted mRNA CAR, exhibits desirable functional and immune phenotype attributed to sustained antitumor immunity in vitro | Sashi Kasimsetty, PhD; Himavanth Gatla, PhD; Dhana Chinnasamy, PhD; | Cellular Therapies | Antigen presenting cells; B cell; CAR T cells; Clinical study; Costimulation; Dendritic cell; Monocyte/Macrophage; NK/NK T cell; RNA; T cell |
| 109 | Poster Presentation | Dominant-negative TGFβ receptor 2 enhances GPC3-targeting CAR-T cell efficacy against hepatocellular carcinoma | Nina J. Chu, PhD; Michael Overstreet, PhD; Ryan Gilbreth; Lori Clarke; Christina Gesse; Eric Tu; Letizia Giardino; Gordon Moody; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Immune suppression; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 110 | Poster Presentation | In-depth characterization of variability in apheresis collections from normal donor populations for allogeneic cell therapy | Shawn P. Fahl, PhD; | Cellular Therapies | B cell; Biomarkers; CAR T cells; Genetic polymorphism; Immune monitoring; NK/NK T cell; T cell; T cell lineages; Targeted therapy |
| 111 | Poster Presentation | Highly efficient multiplexed base editing enables development of universal CD7-targeting CAR-T Cells to treat T-ALL | Jason Gehrke, PhD; Aaron Edwards; Ryan Murray; Angelica Messana; Lindsey Coholan; Henry Poulin; Melissa Le; Alden Ladd; Mark Naniong; Faith Musenge; Adam Camblin; Yeh-Chuin Poh; Sarah Smith; Giuseppe Ciaramella; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; T cell |
| 112 | Poster Presentation | Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy | Letizia Giardino; Ryan Gilbreth; Cui Chen; Erin Sult; Noel Monks; Ravinder Tammali; Jon Chesebrough; Kevin Schifferli; Nina Chu; Jessica Tong; Lori Clarke,; Christina Gesse; Xiao-Tao Yao; Karma DaCosta; Kapil Vashisht; Gordon Moody; Letizia Giardino; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; T cell; Targeted therapy |
| 113 | Poster Presentation | Development of T cell-based immunotherapies to target dormant disseminated breast cancer cells | Erica T. Goddard, PhD; Shivani Srivastava, PhD; Stanley R. Riddell, MD; Cyrus Ghajar, PhD; Erica T. Goddard, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; T cell; Tumor microenvironment |
| 114 | Poster Presentation | Preclinical development of a novel iPSC-derived CAR-MICA/B NK cell immunotherapy to overcome solid tumor escape from NKG2D-mediated mechanisms of recognition and killing | John Goulding, PhD; John Goulding, PhD; Mochtar Pribadi, PhD; Robert Blum, MS; Wen-I Yeh, PhD; Yijia Pan, PhD; Svetlana Gaidarova, MS; Chia-Wei Chang, PhD; Hui-Yi Chu, PhD; Ellen Liu, MS; Shohreh Sikaroodi, PhD; Lucas Ferrari de Andrade, PhD; Lauren Fong, PhD; Janel Huffman, MS; Tom T. Lee, PhD; Ryan Bjordahl, PhD; Kai W. Wucherpfennig, MD, PhD; Bahram Valamehr, PhD; | Cellular Therapies | Adoptive immunotherapy; NK/NK T cell; Solid tumors; Targeted therapy; Tumor antigens; Tumor evasion |
| 115 | Poster Presentation | Engineered T cells directed at tumors with defined allelic loss | Agi Hamburger, PhD; Breanna DiAndreth; Jiajia Cui; Mark Daris, PhD; Melanie Munguia; Kiran Deshmukh; Jee-Young Mock; Grace Asuelime; Emily Lim; Michelle Kreke; Talar Tokatlian; Alexander Kamb, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell |
| 116 | Poster Presentation | Multi-antigen targeting of heterogenous solid tumors using CAR T cells secreting bi-specific T-cell engagers | Martin Hosking, PhD; Bishwas Shrestha; Megan M. Boyett; Soheila Shirinbak; Angela Gentile; Eric Sung; Yijia Pan, PhD; Tom T. Lee, PhD; Jason ORourke; Dan Shoemaker, PhD; Cokey Nguyen; Bahram Valamehr, PhD; | Cellular Therapies | Adoptive immunotherapy; Bispecifics; CAR T cells; Solid tumors; Tumor evasion |
| 117 | Poster Presentation | Rapid point-of-care subcutaneous CAR-T from blood draw to injection in 4 hours with modified LV encoding CARs and synthetic driver elements enables efficient CAR-T expansion and tumor regression | Frederic Vigant, PhD; Qun He, PhD; Wei Zhang, PhD; Hongliang Zong, MD, PhD; Anirban Kundu; Ewa Jaruga-Killeen, PhD; Gregory Schreiber, PhD; Michelle Andraza; Alissa Kerner, PhD; Gregory I. Frost, PhD | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; T cell; Targeted therapy |
| 119 | Poster Presentation | IL-6 is critical for memory responses elicited by Th17 cells to tumors | Hannah M. Knochelmann, BS; Connor J. Dwyer, PhD; Aubrey S. Smith, BS; Megan Wyatt, MS; Guillermo O. Rangel RIvera, B.S.; Gregory B. Lesinski, PhD; Zihai Li, MD, PhD; Mark P. Rubinstein, PhD; Chrystal M. Paulos, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Cytokine; Immune toxicity; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| 120 | Poster Presentation | P-MUC1C-ALLO1: An Allogeneic CAR-T for Multiple Solid Tumor Indications | Anna K. Kozlowska, PhD; Yan Zhang, PhD; Jacqueline Fritz, BS; Steven Wang, PhD; Rebecca A. Codde, BS; Elvira Argus, PhD; Samad A. Ibitokou, PhD; Vanitra Richardson, MS; Sumiti Jain, PhD; Maximilian Richter, PhD; Deepak Patil, PhD; Yening Tan, MS; Min Tong, MS; Lu Yao, PhD; Majid Ghoddusi, PhD; Eric M. Ostertag, MD, PhD; Julia Coronella, PhD; Devon J. Shedlock, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; T cell |
| 122 | Oral Presentation | Guanylyl cyclase C as a target for CAR-T cell therapy in a metastatic gastric cancer model | Amanda N. Lisby, MS; Trevor R. Baybutt, BA; Megan Weindorfer, BS; Robert Carlson, BS; Alicja Zalewski, MD; Scott A. Waldman, MD, PhD; Adam E. Snook, PhD; | Cellular Therapies | Adoptive immunotherapy; Antibody; Biomarkers; CAR T cells; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| 123 | Poster Presentation | Natural killer cells engineered with an inducible, responsive genetic construct targeting TIGIT and CD73 to relieve immunosuppression within the GBM microenvironment | Kyle B. Lupo, BS; Sandro Matosevic, PhD; | Cellular Therapies | Adoptive immunotherapy; NK/NKT cell; Solid tumors; Targeted therapy; Tumor microenvironment |
| 124 | Poster Presentation | Optimizing the Generation from Umbilical Cord Blood of “Off-the-Shelf” CD19-Chimeric Antigen Receptor (CAR) expressing T cells | Cristina Maccalli, PhD; Asma Al Sulaiti, Bachelor; Moza Al Khulaifi; Shilpa Ravindran, MSc; Mohammed El-Anbari; Mohammed Toufiq; Rebecca Mathew; Chiara Bonini; Monica Casucci, PhD; Chiara Cugno, MD; Suruchi Mohan; Sara Deola; Damien Chaussabel; Sara Tomei, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Cytokine; Gene expression; Leukemia/Lymphoma; T cell; T cell lineages |
| 125 | Poster Presentation | Reexamination of MAGE-A3 as a T-cell Therapeutic Target | Aaron D. Martin, M.A.; Xueyin Wang, PhD; Han Xu, PhD; Alexander S. Kamb; Mark Sandberg, PhD; Kathleen Negri; Ming Wu; Dora Toledo Warshaviak, PhD; Grant Gabrelow; Michele Mcelvain; Mark Daris, PhD; Bella Lee; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell; Targeted therapy |
| 126 | Poster Presentation | Early-phenotype Lewis Y CAR-T cells persist better in vivo and induce solid tumor regression in combination with anti-PD1. | Deborah Meyran, MD; Joe Zhu; Jeanne Butler; Sean Macdonald; Daniela Tantalo; Niko Thio; Kevin Sek; Paul Ekert; Michael H. Kershaw, PhD; Joe Trapani; Phillip K. Darcy; Paul J. Neeson, PhD; | Cellular Therapies | CAR T cells; Checkpoint blockade |
| 127 | Poster Presentation | Preclinical evaluation of NKX019, a CD19-targeting CAR NK Cell | Nadege Morisot; Sarah Wadsworth; Tina Davis; Nicole Dailey; Kyle Hansen; Denise Gonzalez; Nafees Rahman; Alex Aronov; Y Fan; Chao Guo; Luxuan Buren; Anmol Vohra, MS; Kate Jamboretz; H Leman; Sasha Lazetic, BA; Ivan Chan, PhD; James T. Trager, PhD; Joanne BT. Tan; | Cellular Therapies | Adoptive immunotherapy; Leukemia/Lymphoma; NK/NK T cell |
| 128 | Poster Presentation | Development of an M1-polarized, non-viral chimeric antigen receptor macrophage (CAR-M) platform for cancer immunotherapy | Yumi Ohtani, PhD; Kayleigh Ross; Aditya Dandekar; Rashid Gabbasov, PhD; Michael Klichinsky, PharmD, PhD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Gene expression; Monocyte/Macrophage; Myeloid cells; Solid tumors; TLR; Tumor microenvironment |
| 129 | Poster Presentation | A novel CAR conducting antigen-specific JAK-STAT signals demonstrates superior antitumor effects with minimal undesired non-specific activation | Sachiko Okamoto, PhD; Sachiko Okamoto, PhD; Yasunori Amaishi; Mitsuki Shigeta, PhD; Yu Okubo, PhD; Yota Ohashi; Naoto Hirano, MD, PhD; Junichi Mineno, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Costimulation; Leukemia/Lymphoma; Solid tumors; T cell; Tumor antigens |
| 130 | Poster Presentation | Immunogenic potential of chimeric antigen receptor (CAR)-engineered T cells expressing inducible nuclease-deactivated SpCas9 (dCas9) | Dharmeshkumar Patel, PhD, MS; Angshumala Goswami; Vitaly Balan; Zhifen Yang, Dr.; Lingyu Li, PhD; Sowndharya Rajavel, Sr.; Alper Kearney, PhD; Rona Harari-Steinfeld; Maggie Bobbin; Bing C. Wang, PhD; Alessandra Cesano, MD, PhD; Stanley L. Qi, Ph.D.; Francesco M. Marincola, MD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; CAR T cells; Immune monitoring; Immune toxicity; Solid tumors; T cell; Targeted therapy |
| 131 | Poster Presentation | CoupledCAR® Technology Strengthens Adoptive T Cell Therapy by Promoting Rapid Expansion | Zhiyuan Cao; Chengfei Pu; Xianyang Jiang; Xiaogang Shen; Ruihong Zhu; Yuzhe Peng; Xi Huang; Zhao Wu; Lei Xiao, Ph.D.; | Cellular Therapies | Adoptive immunotherapy; Biomarkers; CAR T cells; Clinical study; Gene expression; Inflammation; Solid tumors; T cell; Tumor antigens |
| 132 | Poster Presentation | CAR macrophages (CAR-M) elicit a systemic anti-tumor immune response and synergize with PD1 blockade in immunocompetent mouse models of HER2+ solid tumors | Stefano Pierini, PhD; Rashid Gabbasov, PhD; Linara Gabitova, PhD; Yumi Ohtani, PhD; Michael Klichinsky, PharmD, PhD; | Cellular Therapies | Monocyte/Macrophage; Myeloid cells; Solid tumors |
| 133 | Poster Presentation | Development of novel cellular therapeutics for metastatic and primary CNS malignancies | Paul D. Rennert, PhD; Alyssa Birt; Lihe Su, PhD; Lan Wu, PhD; Fay J. Dufort, PhD; Roy R. Lobb, PhD; Christine Ambrose, PhD; | Cellular Therapies | Adoptive immunotherapy; Antibody; Bispecifics; CAR T cells; Pediatric tumors; Solid tumors; Tumor antigens |
| 134 | Poster Presentation | Tumor-responsive, multi-functional genetically-engineered natural killer cells for immunotherapy of glioblastoma | Jiao Wang, PhD; Yeonhee I. Yun; Karen E Pollok; Anthony L. Sinn; Randy R Brutkiewicz; Michael C Veronesi; Sandro Matosevic, PhD; Jiao Wang, PhD; | Cellular Therapies | Adoptive immunotherapy; Chemokine; Immune suppression; Metabolism; NK/NKT cell; Solid tumors; Tumor antigens; Tumor evasion; Tumor microenvironment; Tumor stroma |
| 136 | Poster Presentation | Targeting MET with Chimeric Antigen Receptor T cells in Hepatocellular Carcinoma | Yuan Qin; Anna Qin; Anna Musket; Joseph Lee; Zhi Q. Yao; Giedre Krenciute, PhD; Qian Xie; Qian Xie | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; Targeted therapy |
| 137 | Poster Presentation | Genomics of multiple myeloma influences the expression of CAR T-cell targets | Christina Y. Yu, BSc; Brian A. Walker, PhD; G. David Roodman, MD, PhD; Kun Huang, PhD; Michel Sadelain, MD PhD; Fabiana Perna, MD, PhD; | Cellular Therapies | B cell; Bioinformatics; CAR T cells; Gene expression; Targeted therapy |
| 138 | Poster Presentation | In vivo localization of genetically engineered natural killer cells against glioblastoma using PET imaging | Yeonhee I. Yun; Jiao Wang, PhD; Karen Pollok; Tony Sinn; Randy Brutkiewicz; Sandro Matosevic, PhD; Michael Veronesi; | Cellular Therapies | Chemokine; Immune suppression; Metabolism; NK/NKT cell; Radiotherapy; Solid tumors; Tumor antigens; Tumor evasion |
| 139 | Poster Presentation | Establishment of canine CAR T cells treatment model for solid tumor immunotherapy development | Shihong Zhang, Ph.D; Karan Kohli, Ph.D; R. Graeme Black; Brian J. Hayes, Ph.D; Cassandra Miller, DVM; Mari Maeda-Whitaker, PhD; Brett A. Schroeder, MD; Kraig Abrams; Bernard Seguin, DVM; Stephen Gottschalk, MD; Peter F. Moore, DVM, Ph.D.; Beverly J. Torok-Storb, Ph.D; Seth M. Pollack, MD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; Tumor antigens |
| 140 | Poster Presentation | Adoptive transfer of T cells surface-tethered with IL-12 promote antigen spreading for enhanced anti-tumor efficacy | Ditte E. Jaehger, PhD; Kate L. Stokes, PhD; Hólmfridur R. Halldórsdóttir, MSc; Alvin Pratama, PhD; Gulzar Ahmad, PhD; Jonathan D. Nardozzi, PhD.; Katharine Sackton, PhD; Douglas Jones, PhD; Thomas L. Andresen, PhD; | Cellular Therapies | Adoptive immunotherapy; Dendritic cell; Immune adjuvant; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 141 | Poster Presentation | PBMC-based cancer vaccines generated with microfluidics squeezing demonstrate synergistic and durable tumor reduction in combination with PD1 checkpoint and FAP targeted IL-2 variants | Matthew G. Booty, PhD; Adam Stockmann; Olivia Pryor; Melissa Myint, PhD; Christine Trumpfheller, PhD; Valeria G. Nicolini; Christian Klein, Dr rer nat; Laura Codarri, Dr.; Pablo Umana, PhD; Armon Sharei, PhD; Howard Bernstein, MD, PhD; Katherine Seidl, PhD; Scott M. Loughhead, PhD; | Cellular Therapies | Adoptive immunotherapy; Antibody; Bispecifics; Checkpoint blockade; Cytokine; Tumor microenvironment; Vaccine |
| 142 | Poster Presentation | Contextual reprogramming of CAR T cells for the treatment of HER2-expressing cancers | Zhifen Yang, Dr.; Lingyu Li, PhD; Ahu Turkoz, Ph.D.; Pohan Chen, MS; Hana Choi, MS; Damla Inel, MS; Stanley L. Qi, Ph.D.; Francesco M. Marincola, MD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Costimulation; Immune contexture; Solid tumors; T cell lineages; Tumor microenvironment |
| 144 | Poster Presentation | RTX-240, an Allogeneic Engineered Red Blood Cell Expressing 4-1BBL and IL-15TP, Promotes NK Cell Functionality In Vitro and In Vivo | Anne-Sophie Dugast; Shannon L. McArdel; Enping Hong; Arjun Bollampalli; Maegan E. Hoover; Sneha Pawar; Viral Amin; Kangjian Qiao; Christopher Ta; Laurence A. Turka; Thomas J. Wickham, PhD; Sivan Elloul; | Cellular Therapies | Costimulation; Cytokine; Immune monitoring; NK/NK T cell |
| 145 | Poster Presentation | Preclinical Development of EDIT-201, a Multiplexed CRISPR-Cas12a Gene Edited Healthy Donor Derived NK Cells Demonstrating Improved Persistence and Resistance to the Tumor Microenvironment | Karrie K. Wong, Ph.D.; Steven Sexton; Kelly Donahue; Lincy Prem Antony; Kevin Wasko; Jared Nasser, BS; Glenn Leary; Amanda Pfautz; Owen Porth; William Pierce; Patricia Sousa; Sean N. Scott; Aaron C. Wilson; Kai-Hsin Chang, Ph.D.; John A. Zuris, Ph.D.; Christopher J. Wilson, Ph.D.; Richard A. Morgan, Ph.D.; Christopher M. Borges, Ph.D.; | Cellular Therapies | NK/NK T cell; Solid tumors; Tumor microenvironment |
| 146 | Poster Presentation | Alloantigen-specific Tr1 cells designed to prevent GvHD have a distinct molecular identity and suppress through CTLA-4 and PD-1 | Alma-Martina Cepika; Pauline P. Chen; Molly J. Uyeda; Brandon Cieniewicz; Mansi Narula; Laura Amaya; David M. Louis; Liwen Xu; Xuhuai Ji; Alice Bertaina; Rajni Agarwal-Hashmi; Mark M. Davis; Everett Meyer; Rosa Bacchetta; Maria Grazia Roncarolo | Cellular Therapies | Adoptive immunotherapy; Immune suppression; Immune tolerance; Leukemia/Lymphoma; Regulatory T cell (Treg cell); T cell |
| 147 | Poster Presentation | CD155 blockade boosts alloreactive natural killer cell antitumor effects against osteosarcoma | Monica M. Cho, BSE; Monica M. Cho, BSE; Madison F. Phillips; Longzhen Song, Ph.D.; Amy K. Erbe, PhD; Christian M. Capitini, MD; | Cellular Therapies | Adoptive immunotherapy; NK/NKT cell; Pediatric tumors; Solid tumors |
| 148 | Poster Presentation | Identification of prostate-restricted epithelial antigens for transgenic T cell adoptive therapy against prostate cancer | Diana DeLucia, PhD; Tiffany Pariva; Roland Strong; Owen Witte; John Lee; | Cellular Therapies | Adoptive immunotherapy; Solid tumors; T cell; Tumor antigens |
| 149 | Poster Presentation | GEN-011: An ATLASTM-guided peripheral-blood derived neoantigen-specific T cell therapy designed to improve on TIL approaches | Pranay D. Khare, PhD; Harshal Zope; James Perry; Victoria L. DeVault, PhD; Mercay R. Reuter; Adrienne Li, PhD; Daniel B. DeOliveira, PhD; Hubert Lam, PhD; Manish Jain, PhD; Jessica B. Flechtner, PhD; Pranay D. Khare, PhD; | Cellular Therapies | Adoptive immunotherapy; Neoantigens; Solid tumors; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs) |
| 150 | Poster Presentation | GAIA-102: a new class off-the-shelf allogeneic NK-like cells that can eliminate solid tumors | Yui Harada, PhD; Yoshikazu Yonemitsu, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; NK/NK T cell; Solid tumors |
| 151 | Poster Presentation | Combination NK-92MICD64 cell therapy approach with therapeutic antibodies to treat metastatic prostate cancer | Hallie Hintz, BA; Bruce Walcheck; Aaron LeBeau; | Cellular Therapies | Antibody; NK/NKT cell; Solid tumors; Targeted therapy; Tumor antigens; Tumor microenvironment |
| 152 | Oral Presentation | Adoptive T cell therapy targeting somatic p53 mutations | Peter Kim, PhD; Parisa Malekzadeh, MD; Nolan Vale; Elizabeth Hedges; Nikolaos Zacharakis, PhD, MS; Steven A. Rosenberg, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; Neoantigens; T cell; Tumor infiltrating lymphocytes (TILs) |
| 153 | Poster Presentation | NEO-PTC-01 (BNT-221), an autologous neoantigen-specific T-cell product for adoptive cell therapy of metastatic melanoma | Divya R. Lenkala, MS; Jessica Kohler, PhD; Brian McCarthy; Michael Nelson; Jonathan McGee; Daniel Kallin; Janani Sridar; Paul Turcott; Dewi Harjanto; Cynthia Nijenhuis; Joost H. Van Den Berg, PharmD; Richard B. Gaynor, MD; Marit M. Van Buuren, PhD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Bioinformatics; Dendritic cell; Neoantigens; T cell |
| 154 | Poster Presentation | Marrow-infiltrating Lymphocytes (MILs): A Novel Adoptive Immunotherapy for Hematological and Solid Tumors | Eric R. Lutz, PhD; Lakshmi Rudraraju, MS; Elizabeth DeOliveira; Amanda L. Seiz; Monil Shah, PharmD; Celine Colmenares; Beverly Dan Fu; Daniela Bota, MD, PhD; Collin Brummel; Chad Brenner, PhD; Paul Swiecicki, MD; Nicole E. Fredrich; David B. Page, MD; Eleni Efstatihiou, MD, PhD; Ivan M. Borrello, MD; Kimberly A. Noonan, PhD, MPH; | Cellular Therapies | Adoptive immunotherapy; Solid tumors; T cell |
| 155 | Poster Presentation | iPSC-derived NK cells mediate robust anti-tumor activity against glioblastoma | Jeff S. Miller, MD; Frank S. Cichocki, PhD; Jianfang Ning; Ryan Bjordahl, PhD; Zachary B. Davis, PhD; Katie Tuininga; Hongbo Wang; Paul Rogers; Moyar Ge; Tom T. Lee; Bob Valamehr, PhD; Clark C. Chen; | Cellular Therapies | Adoptive immunotherapy; NK/NK T cell; Solid tumors |
| 156 | Poster Presentation | Discovery of TSC-100: A Natural HA-1-specific TCR to Treat Leukemia Following Hematopoietic Stem Cell Transplant Therapy | Ribhu Nayar, Ph.D.; Sonal Jangalwe; Mollie M. Jurewicz; Antoine J. Boudot; Andrew S. Basinski; Robert Prenovitz; Elizabeth A. Olesin; Daniel C. Pollacksmith; Qikai Xu; Yifan Wang; Amy Virbasius; Jeffery Li; Holly Whitton; Garrett S. Dunlap; Alexander Cristofaro; Nancy Nabilsi; Ruan Zhang; Candace Perullo; Sida Liao; Kenneth L. Jahan; Kenneth Olivier; Gavin MacBeath, Ph.D.; | Cellular Therapies | Adoptive immunotherapy; Genetic polymorphism; Inflammation; Leukemia/Lymphoma; T cell; Targeted therapy; Tumor antigens |
| 157 | Poster Presentation | A critical role of CD40 and CD70 signaling in cDC1s in expansion and antitumor efficacy of adoptively transferred tumor-specific T cells | Takaaki Oba, MD,PhD; Toshifumi Hoki, MD,PhD; Takayoshi Yamauchi; Tibor Keler, PhD; Henry C. Marsh; Xuefang Cao; Fumito Ito; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Costimulation; Dendritic cell |
| 158 | Poster Presentation | Inhibition of PI3Kδ improves tumor specific T cell immunity and metabolic fitness | Guillermo O. Rangel RIvera, B.S.; Guillermo O. Rangel RIvera, B.S.; Connor J. Dwyer, PhD; Dimitrios C. Arhontoulis; Hannah M. Knochelmann, BS; Aubrey S. Smith, BS; Megan M. Wyatt, MS; Amalia M. Rivera Reyes, BS; Chrystal M. Paulos, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Metabolism; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs) |
| 159 | Poster Presentation | Adoptively transferred CD8+ T cells that target neoantigen persist and regress melanomas to a greater extent than those that target self/tumor-antigen | Amalia M. Rivera Reyes, BS; Megan M. Wyatt, MS; Connor J. Dwyer, PhD; Hannah M. Knochelmann, BS; Aubrey S. Smith, BS; Guillermo O. Rangel RIvera, B.S.; Chrystal M. Paulos, PhD; | Cellular Therapies | Adoptive immunotherapy; Neoantigens; Solid tumors |
| 160 | Poster Presentation | TLR9-activated B cells imprint adoptively transferred CD8+ T cells with potent tumor immunity and persistence in vivo | Aubrey S. Smith, BS; Hannah M. Knochelmann, BS; Connor J. Dwyer, PhD; Megan M. Wyatt, MS; Guillermo O. Rangel RIvera, B.S.; Amalia M. Rivera Reyes, BS; Jessica E. Thaxton, PhD, MS; Eric C. Bartee, PhD; Mark P. Rubinstein, PhD; Bei Liu, MD MPH; Chrystal M. Paulos, PhD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; B cell; Proteomics; T cell; TLR; Tumor infiltrating lymphocytes (TILs) |
| 161 | Poster Presentation | Development of a CD8 co-receptor independent T cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T cell-based immunotherapy | Kathrin Davari, PHD; Tristan Holland; Laura Prassmayer; Giulia Longinotti; Kenneth Ganley; Lisa J. Pechilis; Iulia Diaconu; Prashant R. Nambiar; Mike S. Magee; Dolores J. Schendel, PhD; Daniel Sommermeyer, PhD; Christian Ellinger, Dr. Rer. Nat.; | Cellular Therapies | Adoptive immunotherapy; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| 163 | Poster Presentation | NICE: Neoantigen-Cytokine-Chemokine Multifunctional Engager for NK cell immunotherapy of solid tumors | Xue Yao, MS; Sandro Matosevic, PhD; | Cellular Therapies | Adoptive immunotherapy; Bispecifics; Chemokine; Cytokine; Neoantigens; NK/NK T cell; Solid tumors; Tumor antigens; Tumor microenvironment |
| 164 | Poster Presentation | AgenT-797, a novel allogenic and “off-the shelf” iNKT cell therapy promotes effective tumor killing | Burcu Yigit, PhD; Xavier Michelet, PhD; Shalu S. Kharkwal; Eleni Chantzoura, PhD; Jan Bergmann; Alvaro Sebastian Yague, Ph.D; Simon Yue; Darrian Moskowitz; Benjamin Wolf, PhD; Mark A. Exley, PhD; Dhan Chand, PhD; Marc A. Van Dijk, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; NK/NK T cell |
| 165 | Poster Presentation | Activating antigen carriers generated with microfluidics cell squeezing drive effective anti-tumor responses | Katarina Blagovic, PhD; Katarina Blagovic, PhD; Katarina Blagovic, PhD; Amritha K. Ramakrishnan, PhD; Armon Sharei, PhD; Howard Bernstein, MD, PhD; Katherine J. Seidl, PhD; Defne Yarar, PhD; | Cellular Therapies | Adoptive immunotherapy; Immune adjuvant; Solid tumors; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Vaccine |
| 166 | Poster Presentation | Mucosal-associated invariant T-cells (MAIT) in pancreatic cancer | Jéssica O. Kamiki, Master's student; Patrícia A. António; Pedro Noronha; Carolina Condeço; Georgia Paraschoudi, M.Sc. in Cell and Molecular Biology, Sweden; Eric De Sousa; Andreia Maia, PhD student; Mireia Castillo-Martin, MD, PhD; Antonio Beltran; Carlos Carvalho, MD; Joana Lérias, DVM; Markus J. Maeurer, MD, PhD, FRCP(London); | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Microbiome; T cell; T cell lineages; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| 167 | Poster Presentation | B-cell-based vaccination elicit potent immunity against glioblastoma | Catalina Lee-Chang, PhD; Jason Miska, PhD; David Hou; Aida Rashidi, MD; Peng Zhang, PhD; Rachel A. Burga, PhD; Crag M. Horbinski, MD, PhD; Roger Stupp, MD; Maciej S. Lesniak, MD; | Cellular Therapies | Adoptive immunotherapy; Antibody; Antigen presenting cells; B cell; Checkpoint blockade; Costimulation; Solid tumors; Tumor microenvironment; Vaccine |
| 168 | Poster Presentation | A Novel Prostate-Restricted Tumor-Associated Antigen: A Potential Therapeutic Target | Zoila (Areli) A. Lopez Bujanda, MS; Aleksandar Obradovic; Thomas Nirschl; Timothy O’Donnell; Uri Laserson; Rodney Macedo-Gonzales; Ran Reshef, MD, MSc; Tiezheng Yuan; Mithil Soni; Emmanuel S. Antonarakis, MD; Benjamin Larman; Pawel Muranski; Charles G. Drake, MD, PhD; | Cellular Therapies | Antigen presenting cells; Dendritic cell; Neoantigens; Targeted therapy; Tumor antigens |
| 169 | Poster Presentation | Microfluidics cell squeezing enables human PBMCs as drivers of antigen-specific CD8 T responses across broad range of antigens for diverse clinical applications | Michael F. Maloney, PhD; Scott M. Loughhead, PhD; Amritha K. Ramakrishnan, PhD; Carolyne Smith, PhD; Anita Venkitaraman; Christian Yee; Miye Jacques, MSc; Defne Yarar, PhD; Armon Sharei, PhD; Howard Bernstein, MD, PhD; Kelan A. Hlavaty, PhD; Melissa Myint, PhD; Katherine J. Seidl, PhD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Cytokine; T cell; Targeted therapy; Tumor antigens; Vaccine |
| 170 | Poster Presentation | Microfluidics Cell Squeezing Enables Potent Cellular Vaccines in Murine Models Through Direct Cytosolic Loading and Direct CD8 T Cell Priming | Emrah I. Ozay, PhD; Matthew G. Booty; Katarina Blagovic, PhD; David Soto; Olivia Pryor; Adam Stockmann; Disha Subramanya; Kelly Volk; Armon Sharei, PhD; Howard Bernstein, MD, PhD; Defne Yarar, PhD; Katherine J. Seidl, PhD; Scott M. Loughhead, PhD; | Cellular Therapies | Antigen presenting cells; Chemotherapy; Immune adjuvant; Inflammation; Solid tumors; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| 171 | Poster Presentation | Preclinical studies support therapeutic application of the leukemic cell-based cancer relapse vaccine DCP-001 in ovarian cancer | Maho Nagasawa; Remco Bos; Haoxiao Zuo; Kiave Yune Ho Wang Yin, PhD; Marie-José van Lierop; Sebastien Tabruyn, PhD; Erik Manting; Marco de Bruyn; Hans Nijman; Satwinder Kaur SK. Singh, PhD; | Cellular Therapies | Dendritic cell; Solid tumors; T cell; Tumor antigens; Vaccine |
| 172 | Poster Presentation | Increasing activation of human tumor-reactive T cells (CD39+CD103+CD8+) by gene silencing of PD1 with self-delivering RNAi INTASYL(TM) | Colin J. Thalhofer, PhD; Ryan D. Montler, MBA; Melissa Maxwell, MS; Dingxue Yan, PhD; James Cardia, PhD; Simon P. Fricker, PhD; Jacob Moses, B.S.; Joshua Rios, B.S.; Tarsem L. Moudgil, MS; Bernard A. Fox, PhD; Nick P. Morris, PhD; B R. Bell, M.D., DDS; Andrew D. Weinberg, PhD; | Cellular Therapies | Biomarkers; Immune contexture; Immune tolerance; Solid tumors; T cell; T cell lineages; Tumor antigens; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 173 | Poster Presentation | An In Vivo CRISPR/Cas9 Screening Platform to Identify T Cell Enhancing Edits in Distinct Solid Tumor Microenvironments | Amy Becker, PhD; Troy Luster; Ishina Balwani; Nachiket Shevale; Jingwei Sun, PhD; Erica Del Aguila; Jeff Jones; Srijani Sridhar; Nishit Patel; Daniel O'Connell; Reynald Lescarbeau; Birgit C. Schultes; | Cellular Therapies | Adoptive immunotherapy; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 174 | Poster Presentation | An ex vivo tumoroid model of fresh patient tumors (3D-ACT) to assess efficacy of cellular therapy in immuno-oncology | Stephen Iwanowycz, PhD; Jared C. Ehrhart, PhD; Mibel Pabon, PhD; Tina Pastoor; Jenny Kreahling, PhD; Soner Altiok, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; Antibody; CAR T cells; Cytokine; Gene expression; Immune monitoring; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 175 | Poster Presentation | A Fas-4-1BB immunomodulatory fusion protein converts a pro-death to a pro-survival signal, enhancing T cell function and efficacy of adoptive cell therapy in murine models of AML and pancreatic cancer | Shannon K. Oda, PhD; Shannon K. Oda, PhD; Kristin G. Anderson, PhD; Philip D. Greenberg, MD; Nicolas Garcia, BS; Pranali Ravikumar; Patrick Bonson; Cody Jenkins; Summer Zhuang; Andrew W. Daman; Shannon K. Oda, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Costimulation; Immune suppression; Leukemia/Lymphoma; Metabolism; Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
| 176 | Poster Presentation | Evaluating the safety of Tumor Treating Fields (TTFields) application to the torso – in vivo studies | Shiri Davidi; Roni Blat; Mijal Munster; Anna Shteingauz; Shay Cahal; Moshe Giladi; Uri Weinberg, MD PhD; Yoram Palti; Moshe Giladi, PhD; | Cellular Therapies | Solid tumors |
| 177 | Poster Presentation | A severe cytokine release syndrome with respiratory failure in recurrent mesothelioma induced by EpCAM CAR-T cells infusion: a case report | Sitong Wang, PG; Sitong Wang, PG; Juemin Fang; Hui Wang; Qing Xu; | Cellular Therapies | CAR T cells |
| 179 | Poster Presentation | Immunotherapy trials lack a biomarker for inclusion: implications for drug development | Jacob J. Adashek, DO; Alexey Goloubev; Shumei Kato, MD; Razelle Kurzrock, MD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Clinical study |
| 180 | Poster Presentation | The effect of packed red blood cell transfusions on the clinical efficacy of immunotherapy | Christopher D'Avella, MD; Karthik Devarajan, PhD; Martin Edelman, MD; Daniel M. Geynisman, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Solid tumors |
| 181 | Poster Presentation | Anlyasis of Therapeutic effect and safty of PD-1 Inhibitors in Clinical treatment of Oral and Maxillofacial malignant tumors | Haochuan Liu; Yaqiong Jie; Xinguang Han; | Checkpoint Blockade Therapy | Angiogenesis; Antibody; Antigen presenting cells; Checkpoint blockade; Clinical study; Clinical trial; Immune contexture; Immune suppression; Surgery; T cell |
| 182 | Poster Presentation | Highly Potent Fully Human Anti-VISTA Antibodies – A New Target Checkpoint Inhibitor against Immunosuppressive Myeloid Cells. | Thierry Guillaudeux; Eric Tarcha; Robert Bader; Benjamin Dutzar; Nathan Eyde; Emily Frazier; David Jurchen; Remington Lance; Cristina Loomis; Kurt Lustig; Yulia Ovechkina; David Peckham; Shaarwari Sridhar; Mei Xu; Shawn Iadonato; Jeff Posakony; | Checkpoint Blockade Therapy | Antibody; Antigen presenting cells; Checkpoint blockade; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Regulatory T cell (Treg cell); Targeted therapy; Tumor microenvironment |
| 183 | Poster Presentation | Overcoming immunotherapy resistance in T cell-inflamed lung cancer | Brendan L. Horton, PhD; Duncan Morgan; Noor Momin; Vidit Bhandarkar; Dane Wittrup, PhD; Chris Love, PhD; Stefani Spranger, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Cytokine; Immune contexture; Immune suppression; Immune tolerance; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| 184 | Poster Presentation | Two types of anti-TIGIT antibodies with distinct binding epitope and functional activities | Tingting Zhong, MS; Xinghua Pang, BSc; Zhaoliang Huang, BSc; na chen, MD; Xiaoping Jin, PhD; Yu Xia, PhD; Maxwell Zhongmin Wang, PhD; Baiyong Li, PhD; Yu Xia, PhD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade |
| 185 | Poster Presentation | Camrelizumab monotherapy or combination therapy in patients with recurrent or metastatic cervical and endometrial carcinoma：a retrospective study | Hong Liu, MD; Hong Liu, MD; Shuhuai Niu; Zhaohui Fang; Xi Chen; Qianying Zhang; | Checkpoint Blockade Therapy | Antibody; Biomarkers; Checkpoint blockade; Chemotherapy; Clinical study; Cytokine; Immune toxicity; Radiotherapy; Solid tumors; T cell |
| 186 | Poster Presentation | Distinct immune signatures predicting clinical response to PD-1 blockade therapy in gynecological cancers revealed by high-dimensional immune profiling. | Yuki Muroyama, MD, PhD; Sasikanth Manne; Alexandar C. Huang, MD; Divij Mathew, PhD; Lakshmi Chilukuri; Allison R. Greenplate, PhD; Takuya Ohtani, PhD; Dmitriy Zamarin, MD, PhD; Claire F. Friedman, MD; John Wherry, PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 187 | Poster Presentation | Real-world treatment patterns and clinical predictors of overall survival among anti-PD-1 exposed advanced melanoma patients with documented evidence of disease progression. | Cathy Anne Pinto, Ph.D.; Xinyue Liu; Xiaoyun Li; Emilie Scherrer; Mizuho Kalabis; Cathy Anne Pinto, Ph.D.; | Checkpoint Blockade Therapy | Checkpoint blockade; Epidemiology |
| 188 | Poster Presentation | Novel Anti-SIRPalpha Antibodies with Differentiated Characteristics as Promising Cancer Therapeutics | Minu K. Srivastava, PhD; Swati Jalgaonkar; George Huang; Erin L. Filbert, PhD; Christine Tan; Ryan Alvarado; Sushma Krishnan, MSc in Biology; Rena Bahjat; Xiaodong Yang, MD, PhD; | Checkpoint Blockade Therapy | Antibody; Antigen presenting cells; Checkpoint blockade; Dendritic cell; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor microenvironment |
| 189 | Poster Presentation | A clear increase in TILs and modest tumor growth inhibition by pembrolizumab in prostate cancer tumors growing in bone of CD34+ engrafted NOG mice | Suominen I. Suominen, PhD; Justyna Zdrojewska, PhD; Jenni Mäki-Jouppila, PhD; Philip Dube, PhD; Ivan Gladwyn-Ng, PhD; Paul Volden, PhD; Jukka Rissanen, PhD; Mari I. Suominen, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 190 | Poster Presentation | Timing of steroid doses and response rates to immune-checkpoint inhibitors in metastatic cancer | Karine Tawagi, MD; Diana V. Maslov, MD, MS; Victoria Simenson, MD; Helen Yuan; Cameron Parent; Adi Bamnolker; Richa Goel; Zoe Blake; Madhav KC; Marc Matrana; Karine Tawagi, MD; Daniel Johnson, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune toxicity; Solid tumors |
| 191 | Poster Presentation | Association of immune related adverse events with the efficacy of immune checkpoint inhibitors in metastatic renal cell carcinoma | Vasilii Bushunow, MD; Leonard J. Appleman, MD, PhD; Roby Thomas, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune toxicity; Solid tumors |
| 192 | Poster Presentation | 'Immune-Brain': A case series of cognitive dysfunction/decline in cancer patients on immunotherapy | Sarah R. Gillett, MD, PhD; Ximena Jordan-Bruno, MD; Hibba Rehman, MD; Alissa Thomas, MD; Sarah R. Gillett, MD, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune toxicity; Solid tumors |
| 193 | Poster Presentation | Differences In Thyroid Immune-Related Adverse Events Between Lung Cancer Types, A Retrospective Analysis | Rahim A. Jiwani, MD; Heather Brody; Yuxuan Mao, MD, MS; Elisabeth Lee, PhD; Rita Rehana, MD; Cynthia Cherry; Hui Bian, PhD; Praveen Namireddy, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune toxicity |
| 194 | Poster Presentation | A multicenter characterization of chronic toxicities following adjuvant anti-PD-1 therapy for high risk resected melanoma | James R. Patrinely, Jr., BA; Rebecca Johnson, B.HlthSc, M.N; Aleigha R. Lawless, B.S.; Prachi Bhave, M.D.; Amelia Sawyers, B.S.; Maya Dimitrova, M.D.; Hui L. Yeoh, M.B.B.S., B.Med.Sc.; Marisa Palmeri, B.S.; Elizabeth J. Davis, M.D.; Suthee Rapisuwon, M.D.; Georgina V. Long, M.D., Ph.D.; Andrew Haydon, M.D., Ph.D.; Iman Osman, M.D.; Janice M. Mehnert, M.D.; Matteo S. Carlino, M.D., Ph.D.; Ryan J. Sullivan, M.D.; Alexander M. Menzies, M.D., Ph.D.; Douglas B. Johnson, M.D.; | Checkpoint Blockade Therapy | Checkpoint blockade; Clinical study; Immune adjuvant; Immune toxicity; Targeted therapy |
| 195 | Poster Presentation | Avelumab internalization and lysosomal degradation by circulating immune cells in human is mediated by both Fc gamma Receptor (FcgR) and PD-L1 binding | Hulin Jin, Ph.D; Vittorio D'Urso; Berend Neuteboom; Sean D. McKenna; Rene Schweickhardt; Alec W. Gross; Yves Fomekong Nanfack; Lars Toleikis; Markus Fluck; Juergen Scheuenpflug, PhD; Ti Cai; | Checkpoint Blockade Therapy | Antibody; Biomarkers; Checkpoint blockade |
| 196 | Poster Presentation | Checkpoint blockade therapy for brain-metastatic non-small cell lung cancer: a comparative effectiveness analysis of national data | Nayan Lamba, MD; Bryan Iorgulescu, MD; | Checkpoint Blockade Therapy | Checkpoint blockade |
| 197 | Poster Presentation | Survival outcomes and toxicity among patients treated with concomitant radiotherapy and immunotherapy for advanced melanoma: two faces of the abscopal effect? | Nikolaos Andreatos, MD; Joanna Roopkumar, MBBS, MPH; Alok A. Khorana, MD; Neil M. Woody, MD, MS; Brian R. Gastman, MD; Pauline Funchain, MD; | Checkpoint Blockade Therapy | Autoimmunity; Checkpoint blockade; Immune toxicity; Radiotherapy; Solid tumors; Tumor antigens |
| 198 | Poster Presentation | Combination intratumoral treatment with INTASYL™ self-delivering RNAi targeting TIGIT and PD-1/PD-L1 improves tumor control compared to monotherapy in a CT26 model of murine colorectal cancer | Benjamin Cuiffo, PhD; Melissa Maxwell, MS; Dingxue Yan; Andrej Jedinak, PhD; James Cardia, PhD; Simon P. Fricker, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Coinhibition; Gene expression; RNA; T cell; Targeted therapy; Tumor microenvironment |
| 199 | Poster Presentation | Enhanced immune responses in human breast and colon cancer following checkpoint therapy in a CD34+ stem cell humanized NCG (HuCD34NCG) mouse model | Christoph S. Eberle, PhD; Jenny Rowe, PhD; Ann Fiore, BS; Robert Mihalek, PhD; Stephen Festin, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 200 | Oral Presentation | NBTXR3 nanoparticle with immunoradiation improves survival and generates long-term anti-tumor memory in an anti-PD1 resistant Murine Lung Cancer Model | Yun Hu, PhD; James W. Welsh, MD; Sebastien Paris, PhD; Hampartsoum Barsoumian, PhD; Chike O. Abana; Saumil Gandhi; Quynh N. Nguyen; Maria A. Cortez, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 201 | Poster Presentation | Carboplatin, paclitaxel and pembrolizumab for the first line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma | Angelica Valadez; Madeleine Welsh; Christine Kim; Angela Johns; Alain P. Algazi, MD; Hyunseok Kang, MD, MPH; Hyunseok Kang, MD, MPH; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemotherapy; Clinical study; Solid tumors |
| 202 | Poster Presentation | In vitro and in vivo combination therapy of Low Molecular Weight Heparins, chemotherapy and immunotherapy, induce antitumor activity in Pancreatic Cancer | Michalis Karamouzis; Panagiotis Sarantis, MD, PhD; Evangelos Koustas; Adriana Papadimitropoulou; Pavlos Papakotoulas; Alexandros Bokas; Dimitrios Schizas; Alexandros Papalampros; Evangelos Felekouras; Theodoros Liakakos; Athanasios Papavassiliou; | Checkpoint Blockade Therapy | Checkpoint blockade; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 203 | Poster Presentation | Preclinical characterization and development of MG1124, a Novel Immune Checkpoint inhibitor targeting CEACAM1 for NSCLC patients | Jae-Chul Lee, MS; Woo Seok Yang; Hye-Young Park; Hye-mi Nam; Hyun-Jung Cho; Mi-Young Oh; Eun-Young Kwak; Jinhyun Park; Myeng Eun Jung; Hawook Chung; Minju Kim; Jae-Hwan Kim, PhD; Byoung Chul c. Cho, MD, PhD; | Checkpoint Blockade Therapy | Antibody; Biomarkers; Checkpoint blockade; Immune suppression; NK/NK T cell; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 204 | Poster Presentation | The role of immune checkpoint inhibitor as a single agent or combination therapy in advanced thyroid cancer | Ju Young Lee; Ju Young Lee, MD; Inae Park; Myungwoo Nam, MD; Christmann Low; Eugene Kim; Hansol Choi; Elena Vagia; Chan Mi Jung; Young Kwang Chae, MD, MPH, MBA; | Checkpoint Blockade Therapy | Checkpoint blockade; Clinical study; Clinical trial |
| 205 | Poster Presentation | PD-1/PD-L1/CTLA-4 inhibitor therapy following progression on a different PD-1/PD-L1 inhibitor: a case series | Suresh Mukkamala, MD; Suresh Mukkamala, MD; Suresh Mukkamala, MD; Karine Tawagi, MD; Marc R. Matrana, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Clinical study; Immune toxicity; Tumor microenvironment |
| 206 | Oral Presentation | An immune-competent tumor organoid platform to test novel immune checkpoint combinations targeting the receptor CD47 in triple negative breast cancer | Elizabeth R. Stirling, MS; Ethan Willey-Shelkey; Adam Wilson; Aleksander Skardal, PhD; Pierre L. Triozzi, MD; Masaki Terabe, PhD; Lance D. Miller, MS, PhD; Shay Soker, PhD; David R. Soto-Pantoja, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Metabolism; Solid tumors; T cell; Tumor microenvironment |
| 207 | Poster Presentation | Small molecule inhibitors of Sec61 cotranslational translocation regulate the phagocytosis checkpoint molecule CD47 | Jennifer A. Whang, PhD; Jennifer A. Whang, PhD; Andrea Fan, PhD; Christopher J. Kirk, PhD; Eric Lowe, BS; Dustin McMinn, PhD; Beatriz Millare, BS; Meera Rao, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Monocyte/Macrophage; Tumor evasion; Tumor microenvironment |
| 208 | Poster Presentation | E7777 (denileukin diftitox) enhances anti-tumor activity and significantly extends survival benefit of anti-PD-1 in syngeneic solid tumor models | Mary Woodall-Jappe, Ph.D.; A. Raghav Chari; Anil N. Namboodiripad; Chandrasekhar Goda; | Checkpoint Blockade Therapy | Regulatory T cell (Treg cell); Solid tumors; T cell |
| 209 | Oral Presentation | Preclinical mechanistic and clinical evaluation of the corticosteroid dexamethasone’s detrimental effects on immune checkpoint blockade in glioblastoma cancer | Bryan Iorgulescu, MD; Prafulla C. Gokhale, PhD; Maria Speranza, PhD; Benjamin Eschle; Michael Poitras; Margaret Wilkens; Kara Soroko; Chhayheng Chhoeu; Aine Knott; Yan Gao; Mary Jane Lim-Fat; Gregory Baker; Dennis Bonal; Quang-Dé Nguyen; Gareth Grant; Keith Ligon; Peter K. Sorger; E Chiocca, MD; Ana C. Anderson, PhD; Paul T. Kirschmeier, PhD; Arlene H. Sharpe, MD, PhD; Gordon J. Freeman, PhD; David A. Reardon, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Clinical study; Immune suppression; Tumor infiltrating lymphocytes (TILs) |
| 210 | Poster Presentation | Regulation of TIM-3 by phosphatidylserine | Courtney M. Smith, BS; Alice Li; Nithya Krishnamurthy; Mark A. Lemmon, PhD, FRS; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Coinhibition; T cell |
| 211 | Poster Presentation | Targeting BTN2A1 modulates anti-tumor activity of Vg9Vd2 T Cells | Carla E. Cano, Ph.D.; Aude de Gassart, PhD; Christine Pasero, PhD; Melanie Gabriac; Marie Fullana; Emilie Granarolo; Rene Hoet; Caroline Imbert; Laurent Gorvel; Antoine Briantais; Anne-Charlotte Le Floch; Daniel Olive, Md, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; T cell; T cell lineages; Targeted therapy; Tumor microenvironment |
| 212 | Poster Presentation | CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and synergizing with tumor-targeted antibodies. | Vanessa Gauttier; Marion Drouin; Sabrina Pengam; Javier Saenz; Bérangère Evrard; Caroline Mary; Géraldine Teppaz; Ariane Desselle; Virginie Thépénier; Emmanuelle Wilhelm; Elise Chiffoleau; Nicolas Poirier, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Dendritic cell; Myeloid cells; Tumor microenvironment |
| 213 | Poster Presentation | Use of A novel peptide ligand targeting multiple immune checkpoints: A novel approach to immunotherapy against Central Nervous System Tumors | Christopher Moertel; Zhengming Xiong; Michael Olin, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Solid tumors |
| 214 | Poster Presentation | The effect of Anti-PD-1 therapy on median Overall Survival and Progression Free Survival in Glioblastoma Multiforme Patients with certain tumor markers | Awais Paracha, BA; Jian L. Campian, MD, PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Targeted therapy |
| 215 | Poster Presentation | AO-176, a highly differentiated clinical stage anti-CD47 antibody, preferentially binds tumor versus normal cell CD47 when complexed to β1 integrin | Robyn J. Puro, Ph.D; Prabir Chakraborty, Ph.D; John O. Richards, Ph.D; Ronald R. Hiebsch; Michael J. Donio, MS; W. Casey Wilson, Ph.D; Benjamin J. Capoccia, Ph.D; Carrie B. Brachmann, Ph.D; Vicki Sung, Ph.D; Arun K. Kashyap, Ph.D; Daniel S. Pereira, Ph.D; | Checkpoint Blockade Therapy | Antibody; Monocyte/Macrophage; Solid tumors; Targeted therapy; Tumor microenvironment |
| 216 | Poster Presentation | Anti-tumor activity of iosH2 by blocking LILRB2 receptor signalling | Osiris Marroquin Belaunzaran; Anahita Rafiei; Anil Kumar; Julia Kolibaba; Lorenz Vogt; Sean Smith; Christoph Renner; | Checkpoint Blockade Therapy | Checkpoint blockade; MDSC; Solid tumors; T cell |
| 217 | Poster Presentation | Evaluating biomarkers of JTX-8064 (anti-LILRB2/ILT4 monoclonal antibody) in an ex vivo human tumor histoculture system to inform clinical development | Yasmin L. Hashambhoy-Ramsay, PhD; Vikki Spaulding; Michelle Priess; Kristin O'Malley; Monica Gostissa, PhD; Edward C. Stack, PhD; Jeff Smith; Margaret Willer; Ben Umiker; Donald Shaffer, PhD; | Checkpoint Blockade Therapy | Antigen presenting cells; Biomarkers; Monocyte/Macrophage; Myeloid cells; RNA; Tumor evasion; Tumor microenvironment; Tumor stroma |
| 218 | Poster Presentation | A preclinical study of IMC-002, a fully human therapeutic antibody safely targeting CD47 in cancer | Hyeonseok Yoo, Ph.D.; Jeong Kook Kim, Ph.D.; Ji Yea Choi; Sun Kwang Song; Jihyun Park, Ph.D; Ara Jeon; Ji Hye Lee, MD; Sook Kyung Chang, Ph.D; Yun J. Song; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Monocyte/Macrophage; Myeloid cells; Solid tumors |
| 219 | Poster Presentation | Long-term clinical outcomes associated with sequential treatment of BRAF mutant advanced melanoma patients | Ahmad A. Tarhini, MD, PhD, MS; David F. McDermott, MD; Apoorva Ambavane, MPH; Agnes Benedict, MSc, MA; Cho-Han Lee; Corey Ritchings, PharmD; Brian Stwalley, PharmD; Meredith M. Regan, PhD; Michael B. Atkins, MD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Targeted therapy |
| 220 | Poster Presentation | Real-world outcomes of patients with resected stage IIIA melanoma treated with adjuvant nivolumab | Wolfram Samlowski, MD; Robert Nicholas, MD; Tayla Poretta, PharmD, MPH; Andriy Moshyk, MSc, MD; Jonathan Rajkumar, MPH; Anthony Salvatore, PharmD; Brian Stwalley, PharmD; Esmond D. Nwokeji, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Epidemiology; Immune adjuvant; Solid tumors |
| 221 | Poster Presentation | Poor performance status negatively affects survival benefit of immunotherapy in non-small cell lung cancer | Hameem I. Kawsar, MD, PhD; Pramod I. Gaudel, MD; Nahid Suleiman, MD, PharmaD; Mohammed Al-Jumayli, MD; Chao Huang, MD; Prakash Neupane, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune toxicity; Solid tumors |
| 222 | Poster Presentation | Increased PD-L1 Tumor Expression Correlates with High Rate of Response to PD-1 Inhibitors in Patients with Unresectable, Recurrent, and Metastatic Cutaneous Squamous Cell Carcinoma | Nate Bowers, MD, PhD; Kimberly Burcher, MD; Jess Savas, MD; Phillip Williford, MD; Laura Doerfler, MD; Hafiz Shabbir Patwa, PharmD, MD; Joshua Waltonen, MD; Christopher Sullivan, MD; James Brown, MD; Mercedes Porosnicu, MD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Gene expression |
| 223 | Poster Presentation | Racial differences in outcomes for metastatic Renal Cell Carcinoma (mRCC) patients managed on Immune-Checkpoint Inhibitor (ICI) therapy. | T. Anders Olsen, BA; Dylan J. Martini, BA; Subir Goyal, Ph.D; Yuan Liu, Ph.D; Sean T. Evans, BS; Benjamin L. Magod, BS; Jacqueline T. Brown, MD; Lauren Yantorni, NP; Greta A. Russler, MSN, FNP-BC; Sarah Caulfield, PharmD, BCOP; Jamie M. Goldman, MD; Bassel Nazha, MD; Wayne B. Harris, MD; Viraj A. Master, MD Ph.D; Omer Kucuk, MD; Bradley C. Carthon, MD Ph.D; Mehmet A. Bilen, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Clinical study; Immune toxicity; Solid tumors |
| 224 | Poster Presentation | Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis | Tamara A. Sussman, MD; Wei Wei, MS; Pauline Funchain, MD; Brian R. Gastman, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Solid tumors; T cell |
| 226 | Poster Presentation | Checkpoint blockade hastens a switch from an NKT dominant, TNF-alpha-driven to a CD4+/CD8+ IFN-gamma-driven immune response within MC-38 tumor-infiltrating lymphocytes | Shota Aoyama, MD; Ryosuke Nakagawa, MD; Satoshi Nemoto, MD; Patricio Perez Villarroel; James J. Mulé; Adam W. Mailloux, PhD; | Checkpoint Blockade Therapy | Tumor infiltrating lymphocytes (TILs) |
| 227 | Poster Presentation | Using 3D spheroid cultures towards personalized ex vivo profiling of immune checkpoint inhibitor efficacy in melanoma and non-small cell lung cancer | Kathryn Appleton, PhD; Katy A. Lassahn, MS; Ashley K. Elrod; Tessa DesRochers, PhD; | Checkpoint Blockade Therapy | Antibody; Biomarkers; Checkpoint blockade; Chemokine; Chemotherapy; T cell; T cell lineages; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 228 | Poster Presentation | Radiological dynamics and resistance types in patients with advanced melanoma treated with anti-PD-1 monotherapy | Xue Bai, MD; Michelle Kim; Gyulnara Kasumova; Lu Si; Bixia Tang; Chuanliang Cui; Xiaoling Yang; Xiaoting Wei; Justine V. Cohen, DO; Donald P. Lawrence, MD; Christine Freedman, RN; Riley Fadden, NP; Krista M. Rubin, NP, MS; Tatyana Sharova; Dennie Frederick; Keith Flaherty, MD; Ryan J. Sullivan, MD; Jun Guo; Genevieve M. Boland, MD, PhD; | Checkpoint Blockade Therapy | Clinical study |
| 229 | Poster Presentation | Discovery of ganglioside GM2 activator as a novel proteomic biomarker associated with response to treatment in first-line melanoma subjects treated with PD-1 immunotherapy | Kristina Beeler, Dr.; Jakob Vowinckel, PhD; Martin Soste; Domenico Mallardo, MD; Mariaelena Capone, MD; Madonna Gabriele, MD; Antonio Sorrentino, MD; Vito Vanella, MD; Kamil Sklodowski, PhD; Daniel Heinzmann, MSc; Paolo A. Ascierto, MD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Immune monitoring; Immune suppression; Metabolism; Proteomics; Tumor microenvironment |
| 230 | Poster Presentation | Single cell PIK3 gene expression patterns support duvelisib (PI3K-delta, gamma inhibitor) treatment of melanoma and other tumors after checkpoint inhibitor therapy | Samantha Hidy; David Weaver, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Gene expression; Targeted therapy |
| 231 | Poster Presentation | A novel discovery pipeline identifies melanoma-specific antibodies in patients responding to immune checkpoint inhibitors | Daniel Delitto, MD, PhD; Evan J. Lipson, MD; Daniel Delitto, MD, PhD; Laura Cappelli, MD; Klaus J. Busam, MD; Antony Rosen, MBChB, MS; Suzanne L. Topalian, MD; Livia Casciola-Rosen, PhD; | Checkpoint Blockade Therapy | Antibody; B cell; Biomarkers; Checkpoint blockade; Immune monitoring; Immune toxicity; Solid tumors; Tumor antigens |
| 232 | Poster Presentation | The Epithelial-to-Mesenchymal Transition (EMT) contributes to Immunosuppression in Breast Carcinomas and regulates their response to Immune Checkpoint Blockade | Anushka Dongre, PhD; Robert A. Weinberg, PhD; Mohammad Rashidian, PhD; Elinor Ng. Eaton; Ferenc Reinhardt; Prat Thiru; Maria Zagorulya; Sunita Nepal; Tuba Banaz; Anna Martner; Stefani Spranger, PhD; | Checkpoint Blockade Therapy | Biomarkers; Carcinogenesis; Checkpoint blockade; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| 233 | Poster Presentation | Gene expression analysis of immune checkpoint therapy in mouse tumor models reveals similarities and differences in immune cell populations and functional processes that reflect response to treatment | Dominic Pearce; Daniel Halligan; Patrick Fadden, PhD; Chassidy Hall; Amber Blackwell; Edgar R. Wood, Ph.D.; | Checkpoint Blockade Therapy | B cell; Gene expression; Monocyte/Macrophage; NK/NK T cell; Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 235 | Poster Presentation | Antigen presentation pathways prime melanoma patients for more durable response to anti–PD-1 checkpoint blockade therapy | Saurabh Garg, PhD; Eric A. Welsh; Bin Fang, PhD; Yuliana I. Hernandez; Trevor Rose; Jhanelle Gray; John M. Koomen, PhD; Anders E. Berglund, PhD; James J. Mule, PhD; Joseph Markowitz, MD, PhD; | Checkpoint Blockade Therapy | Antigen presenting cells; Biomarkers; Checkpoint blockade; Gene expression; Proteomics; RNA; Tumor microenvironment |
| 236 | Poster Presentation | Evaluation of PD-L1 Expression in Primary Lung Tumor and Metastatic Lymph Nodes in the Presence of Immune Cells | Chris Hansis; Xiaomei Wang, MD, PhD; Tao Wang; Gerald Feldman; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune contexture; Solid tumors; Targeted therapy |
| 237 | Poster Presentation | In vitro potency assays for immune checkpoint blockade using human primary cells, murine huGEMM immune cells and patient-derived tumor organoids | Xuefei Yan, PhD; Hongjuan Zhang, PhD; Jun Zhou; Jia Zheng; Shuang Zhu; Rui Zhang; Mingfa Zang; Annie Xiaoyu An; Xiaoxi Xu; Shuzong Wang; Kevin Qijin Xu; Davy Xuesong Ouang; Henry Q. Li; Yujun Huang; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Costimulation; T cell |
| 238 | Poster Presentation | Molecular dissection of tumor-immune microenvironment factors associated with response to checkpoint inhibitor therapy in non-small cell lung cancer patients using Nanostring Digital Spatial Profiling | Omar J. Jabado, PhD; Suzana Couto, PhD, DVM pathologist; Jordan Blum, PhD; Patrick Franken; Patricia Coutinho de Souza, PhD; Maria N. Jure-Kunkel, PhD, DVM; Nora Pencheva, PhD; Brandon W. Higgs, PhD; Kate Sasser, PhD; Mark Fereshteh, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemotherapy; Gene expression; Immune contexture; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 239 | Poster Presentation | Decr2 loss promotes resistance of tumor cells to immunotherapy by affecting CD8+ T cell-regulated tumor ferroptosis | Thomas F. Gajewski, MD, PhD; Emily Higgs, BA; Shuyin Li, PhD; Shuyin Li, PhD; Blake Flood, BS; Ken Hatogai; | Checkpoint Blockade Therapy | Checkpoint blockade; Metabolism |
| 240 | Poster Presentation | Identification of lung cancer mutational signatures and tumor drivers associated with specific bimodal PD-L1/TMB status. | Fernando J. Lopez-Diaz, PhD.; Lauryn Keeler; Sally Agersborg, MD.; Lawrence Weiss, MD.; Vincent Funari, PhD (CGMBS); | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Immune monitoring; Neoantigens; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 241 | Poster Presentation | Clinical Outcomes of Metastatic Melanoma Patients with Liver Metastases Treated with Anti-PD-1 Monotherapy Versus Combination Ipilimumab/Nivolumab | Vincent T. Ma, MD; Kent A. Griffith, MPH, MS; Jessica J. Waninger, BS; Stephanie Daignault-Newton, MS; Leslie A. Fecher, MD; Ajjai S. Alva, MBBS; Christopher D. Lao, MD, MPH; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Clinical study; Immune tolerance; Solid tumors |
| 242 | Poster Presentation | Monitoring MDSC – A Hurdle to Immune Checkpoints Inhibitors | Damien Montamat-Sicotte, PhD; Laetitia Cortes; Virginia Litwin; Henry Hepburne-Scott, PhD; Phoebe Bonner; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; MDSC |
| 243 | Poster Presentation | Real world exposure survival relationship of pembrolizumab in metastatic melanoma | Vishal Navani, MA (Oxon) MBBS (Lon) MRCP (UK); Moira C. Graves, PhD; Giovana Marchett, MD, FRACP; Hiren Mandaliya, MD, FRACP; Nikola Bowden, BSc, PhD; Andre Van der Westhuizen, MBChB, MMed (Internal Medicine), FRACP, MSc (Med); | Checkpoint Blockade Therapy | Antibody; Biomarkers; Checkpoint blockade; Solid tumors |
| 244 | Poster Presentation | Novel Respirable Antisense Oligonucleotide (RASON) approach to primary and metastatic human lung cancer: Preliminary results in a model system employing spontaneous lung tumors in dogs | Jonathan W. Nyce, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Epigenetics; NK/NK T cell; Solid tumors; Tumor evasion |
| 245 | Poster Presentation | Human TLR8 knock-in mice potentiate immunotherapy responses of MC38 syngeneic tumors | Shanshan Qi, PhD; Hongjuan Zhang, PhD; Ruilin Sun; Annie X. An; Henry Q. Li; Davy X. Ouyang, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Dendritic cell; T cell; TLR |
| 246 | Poster Presentation | Clinicopathologic and genomic correlates of tumor mutational burden and its impact on PD-(L)1 inhibition efficacy in non-small cell lung cancer according to different PD-L1 expression subgroups | Biagio Ricciuti, MD; Navin R. Mahadevan; Renato Umeton; Joao V. Alessi; Andrew Polio; Natalie Vokes; Giulia C. Leonardi; Elizabeth J. Aguilar; Gonzalo Recondo, MD; Giuseppe Lamberti, MD; Marissa Lawrence; Pasi A. Janne, MD PhD; Eliezer Van Allen, MD; Lynette M. Sholl, MD; Mark Awad, MD, PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade |
| 247 | Poster Presentation | Assessment of sensitivity to a PD-1 check point inhibitor and cisplatin in bladder cancer patient-derived xenografts with various levels of PD-L1 expression in HuCD34NCG mice | Simon Tarpinian, BS; Jenny Rowe, PhD; Ruziboy Husanov, MS; Uma Saha, MS; Prabal Banerjee, PhD; Rukiye Eraslan, PhD; Beverly Jones, PhD; Stephen Festin, PhD; Vladimir Khazak, PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Chemotherapy; Solid tumors; Stem cell/cancer-initiating cell |
| 248 | Oral Presentation | Immunotherapy persister cells uncovered by dynamic single-cell RNA-sequencing | Kartik Sehgal, MD; Andrew Portell; Elena Ivanova; Patrick Lizotte, PhD; Navin R. Mahadevan; Jonathan R. Greene; Amir Vadji; Carino Gurjao; Tyler Teceno; Luke J. Taus; Tran C. Thai; Shunsuke Kitajima; Derek Liu; Tetsuo Tani; Moataz Noureddine; Christie J. Lau; Paul T. Kirschmeier, PhD; David Liu, MD, MPH, MS; Marios Giannakis, MD, PhD; Russell W. Jenkins; Prafulla C. Gokhale, PhD; Silvia Goldoni; Maria Pinzon-Ortiz, BS; William D. Hastings; Peter Hammerman; Juan Miret; Cloud P. Paweletz, Ph.D.; David A. Barbie, MD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Gene expression; Stem cell/cancer-initiating cell; Targeted therapy; Tumor evasion |
| 249 | Poster Presentation | Targeting IFNβ-regulated secretory profiles to overcome acquired anti-PD-L1 resistance | Yuhao Shi, B.S.; Melissa Dolan; Michalis Mastri, PhD; Kevin H. Eng, PhD; John ML. Ebos, PhD; | Checkpoint Blockade Therapy | Bioinformatics; Biomarkers; Checkpoint blockade; Cytokine; Gene expression; Immune suppression; Inflammation; Tumor microenvironment; Tumor stroma |
| 250 | Poster Presentation | SEA-TGT is a nonfucosylated antibody with distinct and amplified effector function activity that leverages the dependencies of anti-TIGIT anti-tumor activity upon Fc?R engagement | Alyson J. Smith, PhD; Weiping Zeng; William Siegall; Bryan Grogan; Jane Haass; Amber Blackmarr; Robert Thurman; Scott Peterson; Shyra J. Gardai, PhD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; NK/NK T cell; Regulatory T cell (Treg cell); T cell; Targeted therapy |
| 251 | Poster Presentation | Factors evaluated as predictors of exceptional response to PD-1 inhibitors in patients with head and neck squamous cell cancer | Alexander H. Song, MD; Ron Ng, MD; John Heller, MD; Robin Petro; Ralph B. D’Agostino, PhD; Thomas W. Lycan, Jr., DO; Mercedes Porosnicu, MD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade |
| 252 | Poster Presentation | Immune-related adverse events associated with immune checkpoint inhibitor therapy are associated with enhanced survival and disease-specific incidence | Eric J. Vick, MD, PhD; Inas Abuali, MD; Andrew Kelleher, MD; Sarah Ludvigsen, DO; Nathanael D. Moore, MD; Nicholas Arias; Shuchi Gulati, MD, FACP; Trisha M. Wise-Draper, MD, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune toxicity; Solid tumors |
| 253 | Poster Presentation | Anti-TIGIT antibodies require enhanced FcγR co-engagement for optimal T and NK cell-dependent anti-tumor immunity | Rebecca Ward, MSc; Elena Paltrinieri, PhD; Marilyn Marques; Priyadarshini Iyer, MSc; Sylvia Dietrich, PhD; Jeremy D. Waight, PhD; Mark Bushell, PhD; Nicholas Wilson, PhD; Jennifer S. Buell, PhD; David Savitsky, PhD; Dhan Chand, PhD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; NK/NK T cell; T cell |
| 254 | Oral Presentation | CTLA-4 blockade promotes Treg glucose metabolism and reduces Treg functional stability in glycolysis-defective tumors. | Roberta Zappasodi, PhD; Inna Serganova; Ivan Cohen; Masatomo Maeda; Yasin Senbabaoglu; Masahiro Shindo; Rachana Maniyar, PhD; Mayuresh Mane; Avigdor Leftin; McLane Watson, BS; Svena Verma, BS; Matthew Lubin; Myat Kyaw Ko; Arnab Ghosh, MD, PhD; Mohsen Abu-Akeel, BS; Ellen Ackerstaff; Jason Koutcher; Ping-Chih Ho, PhD; Greg M. Delgoffe, PhD; Ronald Blasberg; Jedd D. Wolchok, MD, PhD; Taha Merghoub, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Immune tolerance; Metabolism; Regulatory T cell (Treg cell); T cell; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 255 | Poster Presentation | Efficacy of sequential immune checkpoint inhibition (ICI) in patients with genitourinary malignancies | Sean T. Evans, BS; Dylan J. Martini, BA; Benjamin L. Magod, BS; Timothy A. Olsen, BA; Jacqueline T. Brown, MD; Lauren Yantorni, NP; Deepak Ravindranathan, MD, MS; Greta A. Russler, MSN, FNP-BC; Sarah Caulfield, PharmD, BCOP; Jamie M. Goldman, MD; Bassel Nazha, MD; Wayne B. Harris, MD; Viraj A. Master, MD Ph.D; Omer Kucuk, MD; Bradley C. Carthon, MD Ph.D; Mehmet A. Bilen, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Targeted therapy |
| 256 | Poster Presentation | Single-agent Zalifrelimab (anti-CTLA-4) Shows Clinical Benefit in Rare Tumors - Case Report from Phase 2 Study (NCT03104699). | Cesar A. Perez, MD; Robert Wesolowski, MD; Breelyn A. Wilky, MD; Waldo Ortuzar Feliu, MD; Hong Zhang; irina shapiro, PhD; Anna Wijatyk, MD; Remigiusz Kaleta, MD; Jonathan C. Trent, MD; | Checkpoint Blockade Therapy | Solid tumors |
| 257 | Poster Presentation | Development of a Diagnostic Platform Which Matches Therapies to the Tumor Microenvironment Dominant Biology | Kristen Strand-Tibbitts, PhD; | Completed Clinical Trials | Angiogenesis; Bioinformatics; Tumor microenvironment; Tumor stroma |
| 258 | Poster Presentation | Scientific correlatives from LCCC 1525: A Phase II Study of a Priming Dose of Cyclophosphamide Prior to Pembrolizumab to Treat Metastatic Triple Negative Breast Cancer | Mark G. Woodcock, MD; Carey K. Anders, MD; Amanda E. Van Swearingen; Dominic T. Moore; Maria J. Sambade; Luz A. Cuaboy; Amy L. Garrett; Karen McKinnon; Kristen Cowens; Dante S. Bortone; Benjamin C. Calhoun; Lisa Carey; Claire Dees; Trevor Jolly; Hyman Muss; Katherine Reeder-Hayes; Rebecca Kaltman; Rachel Jankowitz; Vinay Gudena; Oludamilola Olajide; Charles M. Perou; Benjamin G. Vincent, MD; Jonathan S. Serody, MD; | Completed Clinical Trials | B cell; Checkpoint blockade; Clinical trial; Gene expression; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor microenvironment |
| 259 | Poster Presentation | Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + selicrelumab (seli) + gemcitabine+nab-paclitaxel (gem+nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC | Gulam A. Manji, MD PhD; Nathan Bahary, MD PhD; Vincent Chung, MD; Florence Dalenc; Michel Ducreux; Carlos A. Gomez-Roca, MD; Seock-Ah Im; Jeremy Kortmansky; Jill Lacy, MD; Neil H. Segal, MD; Olivier Tredan; Olivera Cirovic, MD, PhD; Kelly DuPree; Christelle Lenain; Danny Lu; Lidia Robert; Jeffrey Xu; Xiaosong Zhang, MD PhD; Sung-Bae Kim; | Completed Clinical Trials | Checkpoint blockade; Chemotherapy; Clinical trial |
| 260 | Poster Presentation | T Cell Infiltrating Repertoire Diversity is Associated with Enhanced Survival Following Neoadjuvant Therapy in Patients with Resectable Pancreatic Cancer | Pranav Murthy, BS; Pragosh Saini; Kira L. Russell, BS; Wenjing Pan, PhD; Daniel Weber, BS; Miranda L. Byrne-Steele, PhD; Jian Han, MD PhD; Viginia Espina, PhD; Lance Liotta, MD, PhD; Herbert J. Zeh III, MD; Nathan Bahary, MD PhD; Aatur D. Singhi, MD PhD; Tullia C. Bruno, PhD; Amer H. Zureikat, MD; Michael T. Lotze, MD; | Completed Clinical Trials | B cell; Bioinformatics; Biomarkers; Chemotherapy; Immune contexture; Inflammation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 261 | Poster Presentation | Association of T-cell–inflamed gene expression profile and PD-L1 status with efficacy of pembrolizumab in patients with esophageal cancer from KEYNOTE-180 | Manish A. Shah, MD; Takashi Kojima; Daniel Hochhauser; Peter M. Enzinger, MD; Judith Raimbourg; Antoine Hollebecque, MD; Florian Lordick; Sung-Bae Kim; Masahiro Tajika; Heung Tae Kim; A. Craig Lockhart; Hendrick-Tobias Arkenau; Farid El-Hajbi; Per Pfeiffer; Pooja Bhagia, MBBS, MD; Z. Alexander Cao; Jared Lunceford; Shailaja Suryawanshi; Mark Ayers, PhD; Matt Marton; Ken Kato, MD, PhD; | Completed Clinical Trials | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Gene expression; Solid tumors; Tumor microenvironment |
| 262 | Poster Presentation | Tumoral DKK1 expression correlates with better clinical outcomes in patients with advanced esophagogastric cancer (EGC) treated with DKN-01 | Samuel J. Klempner, MD; Michael Kagey, PhD; Cynthia Sirard, MD; Cynthia Sirard, MD; | Completed Clinical Trials | Antibody; Biomarkers; Clinical trial; RNA; Targeted therapy |
| 263 | Poster Presentation | Pleiotropic effects of IL-7 in prostate cancer patients receiving Sipuleucel-T vaccination | Caroline Duault, PharmD, PhD; Nirasha Ramchurren, PhD; Russell Pachynski, MD; Lawrence Fong, MD; Sean C. Bendall, PhD; Mina Pichavant; Bita Sahaf, PhD; Chihiro Morishima, MD; Leonard D'Amico, PhD; Martin A. Cheever, MD; Steven P. Fling, PhD; Holden T. Maecker, PhD; | Completed Clinical Trials | Antigen presenting cells; Clinical trial; Costimulation; Cytokine; Immune adjuvant; Immune monitoring; Solid tumors; Vaccine |
| 264 | Poster Presentation | Correlation of virus-specific CD8+ T cells to clinical response following treatment with Pexa-Vec and Cemiplimab in patients with advanced renal cell carcinoma | Myles Dillon, PhD; Lianjie Li, MD PhD; Jeongsook Bang, MS; Nicholas Gaspar, PhD; Jessica Kuhnert, BS; Nathalie M. Fiaschi, PhD; Vladimir Jankovic, MD; Israel Lowy, MD, PhD; Gavin Thurston, PhD; Glenn Kroog, MD; Kyoung Soo Ha, MD; Raquel Deering, PhD; Raquel Deering, PhD; | Completed Clinical Trials | Biomarkers; Checkpoint blockade; Clinical trial; Cytokine; T cell; Tumor microenvironment; Vaccine |
| 265 | Poster Presentation | Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort | Jean-Laurent Deville; Alain Ravaud; Marco Maruzzo; Theodore S. Gourdin, MD; Michele Maio, MD; Luc Dirix, MD; XiaoZhe Wang; Yulia Vugmeyster; Frank Beier; Jeorg Seebeck; Sarah Chennoufi, MD, PhD; James L. Gulley, MD, PhD; James L. Gulley, MD, PhD; | Completed Clinical Trials | Antibody; Checkpoint blockade; Clinical trial; Cytokine; Solid tumors |
| 266 | Poster Presentation | Tumour mutation burden (TMB) and efficacy outcomes in the phase III DANUBE study of advanced urothelial carcinoma (UC) | Sophie Wildsmith; Jill Walker, PhD; Anne L’Hernault; Weimin Li; Hannah Bye; Philip He; Feng Xiao; Qu Zhang; Ross Stewart; Melissa de los Reyes, MS; Rajiv G. Raja, PhD; Wendy Levin; Ashok K. Gupta, MD, PhD; Thomas Powles, MBBS, MD, MRCP; Joaquim Bellmunt; Matthew D. Galsky, MD; Alexandra Drakaki, MD,PHD; Michiel van der Heijden, MD; | Completed Clinical Trials | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| 267 | Poster Presentation | Pseudoprogression patterns: Analysis from 2 independent phase-2 studies with immunotherapy for recurrent cervical cancer | David M. O'Malley, MD; Waldo Ortuzar Feliu, MD; Isabelle Ray-Coquard, MDPhD; Michael O'Neal; Jerome Alexandre, MD; Julie Cole, MD; Robert Ludwig, MD; Madhavi Nallewar; Jennifer S. Buell, PhD; Remigiusz Kaleta, MD; Anna Wijatyk, MD; Victoria Borisovskaya; | Completed Clinical Trials | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Immune toxicity; Solid tumors |
| 268 | Poster Presentation | A phase 1 study of retifanlimab (INCMGA00012), a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results in recurrent MSI-high or dMMR endometrial cancer (POD1UM-101) | Dominique Berton-Rigaud; Ignace Vergote; Patricia Pautier; Anna Kryzhanivska, MD; Antoine Angelergues; Deanna Kornacki, PhD; Monika Dudzisz-Sledz; Chuan Tian, PhD; Nawel Bourayou, MD; Frederic Selle; | Completed Clinical Trials | Antibody; Checkpoint blockade; Clinical trial; Solid tumors |
| 269 | Poster Presentation | Tumoral and peripheral landscape of Viral- versus Carcinogen-Driven Head and Neck Cancer | Tze Heng Tan; Sriram Sridhar; Helen K. Angell, PhD, BSc; Emma Jones; Amelia Raymond; Sophie Willis; Dimitris Polychronopoulos; Alejandro Yovine; Nassim Morsli; Patricia McCoon, PhD; Carl Barrett; Maria L. Ascierto, PhD; | Completed Clinical Trials | Biomarkers; Cytokine; Gene expression; Immune contexture; Immune monitoring; Tumor microenvironment |
| 270 | Poster Presentation | A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the thyroid tumor cohort | Young Kwang Chae, MD, MPH, MBA; Megan Othus; Sandip P. Patel, MD; Sarah E. Fenton, MD PhD; Ding Wang, MD; Cristina Rodriguez; Adedayo Onitilo; Ahmad H. Mattour, MD; Igor Rybkin, MD, PhD; Jourdain Hayward; Christine M. McLeod; Helen Chen, MD; Elad Sharon, MD, MPH; Edward Mayerson; Christopher W. Ryan; Melissa Plets, M.S.; Charles D. Blanke; Razelle Kurzrock, MD; Young Kwang Chae, MD, MPH, MBA; | Completed Clinical Trials | Checkpoint blockade; Clinical trial; Solid tumors |
| 271 | Poster Presentation | Consistent high-quality dendritic cell vaccines produced post-chemotherapy in patients with acute myeloid leukemia for use in a Phase I/II trial | Frauke Schnorfeil; Christiane Geiger, PhD; Iris Bigalke; Dag Josefsen; Yngvar Floisand; Gunnar Kvalheim, MD, PhD; Dolores J. Schendel, PhD; Anna Tafuri; Kai Pinkernell; | Completed Clinical Trials | Antigen presenting cells; Dendritic cell; Leukemia/Lymphoma; Targeted therapy; Tumor antigens; Vaccine |
| 272 | Poster Presentation | Use of LioCyx-M, Autologous Hepatitis B Virus (HBV)-Specific T cell receptor (TCR) T-cells, in Advanced HBV-related Hepatocellular Carcinoma (HCC) | Fu-Sheng Wang, MD, PhD; Fanping Meng, MD, PhD; Jiehua Jin, PhD; Yuanyuan Li, MD, PhD; Regina Wanju Wong, PhD; Anthony Tanoto Tan, PhD; Tingting Wang, MD, PhD; Antonio Bertoletti, MD; | Completed Clinical Trials | Adoptive immunotherapy; Clinical trial; T cell |
| 273 | Poster Presentation | Phase I Study of LioCyx-M, Autologous Hepatitis B Virus (HBV)-Specific T cell receptor (TCR) T-cells, in Recurrent HBV-Related Hepatocellular Carcinoma (HCC) Post-Liver Transplantation | Wenjie Chen, MD, PhD; Jintao Cheng, MD; Xiaofang Zheng, BSc; Fan Yang, MD, PhD; Royce Fam, BSc; Sarene Koh, PhD; Lu-En Wai, PhD; Tingting Wang, MD, PhD; Antonio Bertoletti, MD; Qi Zhang, MD, PhD; | Completed Clinical Trials | Adoptive immunotherapy; Clinical trial; T cell |
| 274 | Oral Presentation | Tumoral and peripheral immunophenotype of refractory vs relapse to PD-(L)1 blockade in patients with advanced Non-Small Cell Lung Cancer | Maria L. Ascierto, PhD; Matthew D. Hellmann, MD; Nathan Standifer; Song L. Wu; Han Si; Chris Morehouse; Marlon C. Rebelatto, DVM, PhD, DACVP; Shaad E. Abedin, MD, FACP; Rajiv G. Raja, PhD; Jean-Charles Soria, MD, PhD; Caroline Germa; Carl Barrett; | Completed Clinical Trials | B cell; Biomarkers; Checkpoint blockade; Tumor microenvironment |
| 275 | Poster Presentation | Translational endpoints associated with STK11 mutations in patients with non-squamous NSCLC | Song Wu; Nathan Standifer, PhD; Melissa de los Reyes, MS; Micheal Oberst; Rajv Raja; Carl Barrett; Maria L. Ascierto, PhD; Maria L. Ascierto, PhD; | Completed Clinical Trials | Biomarkers; Checkpoint blockade; Immune suppression; Tumor microenvironment |
| 276 | Poster Presentation | Prognostic value of tumor size varies by treatment in a meta-analysis of 15 randomized clinical trials in advanced non-small cell lung cancer across immunotherapy, TKI, and chemotherapy regimens | Jacqueline Buros, BA; Krzysztof Sakrejda, PhD; Daniel Lee, MS; Eric Novik, MS; Jacqueline Buros, BA; Philip Jewsbury, PhD; | Completed Clinical Trials | Biomarkers; Checkpoint blockade; Clinical trial |
| 277 | Oral Presentation | Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy | Boris Sepesi, MD; Erin M. Corsini; Annikka Weissferdt; Apar Pataer; Mehmet Altan, MD; Mara B. Antonoff, MD; George R. Blumenschein, Jr., MD; Yasir Y. Elamin; Frank Fossella; Bonnie S. Glisson, MD; Wayne Hofstetter; Jonathan Kurie; Xiuning Le, MD, PhD; Cheuk Hong Leung, MS; Heather Lin, MS, PhD; Charles Lu; Reza Mehran; Frank Mott; David Rice; Jack Roth; Ferdinandos Skoulidis; Stephen G. Swisher, MD; Anne Tsao, MD; Ara A. Vaporciyan, MD; Garret Walsh; Jianjun Zhang, MD, PhD; Don L. Gibbons, MD, PhD; John V. Heymach, MD, PhD; Tina Cascone, MD, PhD; | Completed Clinical Trials | Checkpoint blockade; Chemotherapy; Clinical trial; Solid tumors; Surgery; Targeted therapy |
| 278 | Poster Presentation | Phase I clinical trial evaluating the safety of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ advanced non-small cell lung cancer | George R. Blumenschein, Jr., MD; Siddhartha Devarakonda, MD; Melissa L. Johnson, MD; Victor Moreno, PhD, MD; Justin F. Gainor, MD; Martin Edelman, MD; John V. Heymach, MD, PhD; Ramaswamy Govindan, MD; Carlos Bachier, MD; Bernard Doger de Spéville; Matthew J. Frigault, MD, MSc; Anthony J. Olszanski, MD, RPh; Vincent K. Lam; Natalie Hyland; Jean-Marc Navenot, PhD; Svetlana Fayngerts, PhD; Jane Bai; Elliot Norry, MD; Paula M. Fracasso, MD, PhD | Completed Clinical Trials | Adoptive immunotherapy; Targeted therapy |
| 279 | Poster Presentation | Durvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC impacts local-regional control and overall survival | MD; Lukas Kaesmann, MD; Julian Taugner; Chukwuka Eze; Claus Belka; Farkhad Manapov; | Completed Clinical Trials | Checkpoint blockade; Clinical trial; Radiotherapy; Solid tumors |
| 280 | Poster Presentation | Both tumor intrinsic and extrinsic factors contribute to TIL resistance in lung cancer patients | Chao Wang, PhD; Jamie Teer; Jiqiang Yao, PhD; Carmen Anadon; David Noyes; Ana Landin; Xiaoqing Yu; Dongliang Du; Zachary Thompson; Bin Fang, PhD; John M. Koomen, PhD; Sungjune Kim, MD PhD; Shari A. Pilon-Thomas, PhD; Dung-Tsa Chen; Jose R. Conejo-Garcia, MD, PhD; Scott J. Antonia, MD PhD; Eric Haura, MD; Ben C. Creelan, MD, MS; | Completed Clinical Trials | Adoptive immunotherapy; Neoantigens; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| 281 | Poster Presentation | JAVELIN Medley VEGF: phase 2 study of avelumab + axitinib in patients with previously treated non-small cell lung cancer (NSCLC) or treatment naive, cisplatin-ineligible urothelial cancer (UC) | Gabriella Galffy, MD; Iwona Lugowska; Elena Poddubskaya; Byoung Chul c. Cho, MD, PhD; Myung-Ju Ahn; Ji-Youn Han, MD, PhD; Wu-Chou Su; Ralph J. Hauke, MD; Stephen Dyar; Dae Ho Lee; Piotr Serwatowski; David Lorente Estelles; Viran Holden; Yu Jung Kim; Vladimir Vladimirov; Zsolt Horvath; Abhimanyu Ghose; Allison Goldman; Alessandra di Pietro; Jing Wang; Danielle Murphy; Mikhail Laskov | Completed Clinical Trials | Angiogenesis; Antibody; Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| 282 | Poster Presentation | Pan-tumor analysis of the association between PD-L1 combined positive score and response to pembrolizumab monotherapy | Lingkang Huang; Jared Lunceford, PhD; Junshui Ma; Kenneth Emancipator, MD; | Completed Clinical Trials | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| 283 | Poster Presentation | Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs) | Shubham Pant, MD; Amishi Shah; Pavlos Msaouel, MD, PhD; Matthew T. Campbell, MD; Shi-Ming Tu; Jianjun Gao, MD PhD; George R. Blumenschein, Jr., MD; Frank Mott; Xiuning Le, MD, PhD; Mehmet Altan, MD; Funda Meric-Bernstam, MD; Timothy A. Yap, MD, PhD; Vivek Subbiah, MD; Jordi Rodon; Axel Glasmacher; Imke Mulder; Michael J. Chisamore, PhD; Alexander Stevenson, PhD; Nizar M. Tannir, MD, FACP; | Completed Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Microbiome; Solid tumors; TLR |
| 284 | Poster Presentation | Real World Data of Sequencing Immune Checkpoint Inhibitors (ICI) after Initial ICI | Krishna S. Gunturu, MD; Muhammad A. Awidi, MD; Rojer Ranjit, NP; Brendan Connell, MD; Rachel Carrasquillo; Brigitte Gil; Natalie Dalbo, MD; Lewena Maher; Seanna Reilly; Stephanie McDonald, NP; Philip Tsoukas, MD; Linda Voner, RN; | Completed Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Immune tolerance; Solid tumors |
| 285 | Poster Presentation | Phase I clinical trial evaluating the safety of ADP-A2M10 in patients with MAGE-A10+ head and neck, melanoma, or urothelial tumors | David S. Hong, MD; Marcus O. Butler, MD; Russell Pachynski, MD; Ryan J. Sullivan, MD; Partow Kebriaei; Sarah Boross-Harmer; Matthew J. Frigault, MD, MSc; Ecaterina I. Dumbrava, MD; Amy Sauer; Francine Brophy; Jean-Marc Navenot, PhD; Svetlana Fayngerts, PhD; Jane Bai; Elliot Norry, MD; Paula G. Fracasso | Completed Clinical Trials | Adoptive immunotherapy; Targeted therapy |
| 286 | Poster Presentation | Tumor targeting and tissue biodistribution of RO7122290, a novel FAP-targeted 4-1BB (CD137) agonist, in patients with advanced solid tumors, using [89Zr]-RO7122290 as a PET tracer | Maria Jose Garcia Velloso; Ivan Penuelas; Mariano Ponz-Sarvise; Miguel Sanmamed; Maria E. Rodriguez-Ruiz, MD, PhD; Ignacio J. Melero, Dr., MD, PhD; Danielle Vugts; Ronald Boellaard; Marc Huisman; Guus van Dongen; Ernesto Guarin; Florian Heil; Maurizio Ceppi, PhD; Marta Canamero, MD, PhD; Camilla Matheisen; Francois Iglesias; Radoiane Helbaj; Oliver Krieter; Michael Hettich; | Completed Clinical Trials | Bispecifics; Clinical study; Clinical trial; Solid tumors; T cell; Tumor microenvironment; Tumor stroma |
| 287 | Poster Presentation | Safety and antitumor activity of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor KHK2455 in combination with anti-CCR4 monoclonal antibody mogamulizumab in patients with advanced solid tumors | Solmaz Sahebjam, MD; Jameel Muzaffar, MD; Timothy A. Yap, MD, PhD; David S. Hong, MD; Olivier Rixe, MD, PhD; Ursa Brown-Glaberman, MD; Andreea Varga, MD; Christophe Massard, MD; Capucine Baldini, MD; Sergey Efuni, MD, PhD; Barbara Kapelan, BS; Yi Liu, PhD; Eniola Ogunmefun, MD; Tomonori Tayama, MS; Henry Zhao, PhD; Denis J. Healy, MBA; Robert Latek, PhD; Daisuke Nakashima, MS; Emrullah Yilmaz, MD, PhD | Completed Clinical Trials | Antibody; Biomarkers; Clinical study; Clinical trial; Regulatory T cell (Treg cell); Solid tumors |
| 288 | Poster Presentation | A Phase 1 Study of IMC-001, a PD-L1 Blocker, in Patients with Metastatic or Locally Advanced Solid Tumors | Bhumsuk Keam, MD, PhD; Tae Min Kim, MD, PhD; Do-Youn Oh, MD, PhD; Chan-Young Ock, MD, PhD; Won Ki Kang, MD, PhD; Yeon Hee Park, MD, PhD; Jeeyun Lee, MD, PhD; Ji Hye Lee, MD; Yun Jeong Song, MD; Young Suk Park, MD, PhD; | Completed Clinical Trials | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; T cell |
| 289 | Poster Presentation | PGV-001: A Phase 1 Trial of a Personalized Neoantigen Peptide Vaccine for the Treatment of Malignancies in the Adjuvant Setting. | Thomas U. Marron, MD, PhD; Julia Kodysh, PhD; Alex Rubinsteyn, PhD; John Finnigan, MD PhD; Ana Blazquez, PhD; Mansi Saxena, PhD; Marcia Meseck; Timothy O’Donnell; Daniela Delbeau, RN; Matthew Galsky, MD; Deborah , Doroshow, MD PhD; Brett Miles, MD; Krysztof Misiukiewicz, MD; Hanna Irie, MD PhD; Amy Tiersten, MD; Samir Parekh, MD; Marshall Posner, MD; Andrea Wolf, MD MPH; John Mandeli, PhD; Jeffrey Hammerbacher, PhD; Michael Donovan, MD PhD; Rachel Brody, MD PhD; Sacha Gnjatic, PhD; Eric Schadt, PhD; Philip Friedlander, MD PhD; Nina Bhardwaj, MD PhD; | Completed Clinical Trials | Clinical trial; Immune monitoring; Neoantigens; Solid tumors; Vaccine |
| 290 | Poster Presentation | Cytokine and immune subset signatures in patients with various solid and hematological malignancies treated with oncolytic vaccinia virus delivered by autologous stromal vascular fraction cells | Dobrin Draganov, PhD; Antonio F. Santidrian; Ivelina Minev, MSc; Duong H. Nguyen, PhD; Dmitriy Zamarin, MD, PhD; Francesco M. Marincola, MD; Boris Minev, MD; | Completed Clinical Trials | Adoptive immunotherapy; Antigen presenting cells; Clinical study; Immune monitoring; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; Stem cell/cancer-initiating cell; T cell; T cell lineages |
| 291 | Poster Presentation | Phase Ib Study of Selicrelumab (CD40 agonist) in Combination with Atezolizumab (anti-PD-L1) in Patients with Advanced Solid Tumors | Fabrice Barlesi, Prof, MD, PhD; Martijn Lolkema, MD, PhD; Kristoffer Staal Rohrberg, MD, PhD; Cinta Hierro, MD; Aurelien Marabelle, MD, PhD; Albiruni Abdul Razak, MD; Luis Teixeira, MD, PhD; Valentina Boni, MD, PhD; Wilson H. Miller, Jr, MD, PhD; Charu Aggarwal, MD, MPH; Martin Stern, MD; Olivera Cirovic, MD, PhD; Olivera Cirovic, MD, PhD; Barbara Romagnoli, PhD; Randolph Christen, MD; Raksha Dodia, PhD; Kevin Smart, PhD; Bernhard Reis, PhD; Nicolas Staedler, PhD; Carl Watson; Neeltje Steeghs, MD, PhD; | Completed Clinical Trials | Antigen presenting cells; Checkpoint blockade; Clinical study; Solid tumors |
| 292 | Poster Presentation | Immune checkpoint inhibitor induced overlapping cardiac and neuromuscular toxicities: Highlight of early diagnosis, early initiation of immunosuppressive therapy and multidisciplinary management | HoWai D. Siu, MBBS, MMed; Robert S. O'Neill, MedSci MBBS; Matthew H. Tong, MD; JunHee Hong, Bmed, MD; Carole A. Harris, MBBS (Hons) MMed BPharm FRACP; Morteza Aghmesheh, MD, GradDipSC, PhD, FRACP; Hussein S. Hussein, Dr; | Completed Clinical Trials | Checkpoint blockade; Immune suppression; Immune toxicity; Inflammation |
| 293 | Poster Presentation | Results of the first-in-human clinical trial with personalized multi-target adoptive cell therapy (ACTolog IMA101) | Apostolia M. Tsimberidou, MD, PhD; Apostolia M. Tsimberidou, MD, PhD; Apostolia M. Tsimberidou, MD, PhD; Kerstin Guenther; Amir Alpert; Borje Andersson, MD, PhD; Zoe Coughlin; Jens Fritsche, PhD; Norbert Hilf; Patrick M. Hwu, MD; Mamta Kalra, PhD; Sabrina Kuttruff-Coqui, PhD; Dominik Maurer, PhD; Regina Mendrzyk; Ali Mohamed; Becky Norris; Anna Nowak; Rita Ort; Carsten Reinhardt, MD, PhD; Fabian Richter; Arun Satelli; Oliver Schoor, PhD; Kerry A. Sieger; Harpreet Singh, PhD; David Vining, MD; Claudia Wagner; Toni Weinschenk, PhD; Cassian Yee, MD; Steffen Walter, PhD; | Completed Clinical Trials | Adoptive immunotherapy; Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| 294 | Oral Presentation | CD8 PET imaging of tumor infiltrating T cells in advanced solid tumors: a phase I first-in-human study of 89Zr-IAB22M2C, a radiolabeled anti-CD8 minibody | Michael D. Farwell, MD; Raymond F. Gamache, PhD; Neeta Pandit-Taskar, MD; Mike Postow, MD; Michael S. Gordon; Ian A. Wilson, PhD; Alessandro Mascioni, PhD; Anna M. Wu, PhD; William Le; Avital Weiss; Ronald Korn, MD PhD; | Completed Clinical Trials | Biomarkers; Clinical study; Clinical trial; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 295 | Poster Presentation | First-in-human Phase I trial of IBI188, an anti-CD47 targeting monoclonal antibody, in patients with advanced solid tumors and lymphomas | Nehal Lakhani, MD, PhD; Marlana Orloff, MD; Siqing Fu, MD, PhD; Ying Liu; Yan Wang; Hui Zhou; Kedan Lin, PhD; Fang Liu; Shuling Yan; Amita Patnaik, MD FRCP(C) | Completed Clinical Trials | Autoimmunity; Clinical trial; Immune toxicity |
| 296 | Poster Presentation | Immune correlates of clinical response to Avelumab in patients with advanced thymic epithelial tumors | Yo-Ting Tsai, PhD; Arun Rajan, MD; James L. Gulley, MD, PhD; Jeffrey Schlom, PhD; Renee N. Donahue, PhD; | Completed Clinical Trials | Autoimmunity; B cell; Biomarkers; Checkpoint blockade; Immune monitoring; Solid tumors |
| 297 | Poster Presentation | Modeling the efficacy of NY-ESO-1 TCR T cells (letetresgene autoleucel; GSK3377794) in patients with synovial sarcoma: correlations of response with transduced cell kinetics and biomarkers | Alexandra Gyurdieva; Stefan Zajic; Ya-Fang Chang; E. Andres Houseman; Shan Zhong; Jaegil Kim; David C. Turner; Laura A. Johnson; Ioanna S. Eleftheriadou; Jenna Tress; Aisha N. Hasan, MBBS MD; Victoria L. Chiou; Naimish Pandya; John Glod, MD; Dejka Araujo, MD; Warren Chow; Mihaela Druta; George D. Demetri; Brian A. Van Tine, MD, PhD; Sandra P. D’Angelo; | Completed Clinical Trials | Adoptive immunotherapy; Biomarkers; Chemokine; Cytokine; Gene expression; Immune monitoring; Pediatric tumors; Solid tumors; T cell; Targeted therapy |
| 298 | Poster Presentation | Final analysis of the Phase 1 trial of NY-ESO-1–specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS) | Sandra P. D'Angelo, MD; George D. Demetri; Brian A. Van Tine, MD, PhD; Mihaela Druta; John Glod, MD; Warren Chow; Naimish Pandya; Aisha N. Hasan, MBBS MD; Victoria L. Chiou; Jenna Tress; Julie Edwards; Tim Young; Mary Woessner; Alexandra Gyuerdieva; Stefan Zajic; Sophia Goodison; Dejka Araujo, MD; | Completed Clinical Trials | Adoptive immunotherapy; Clinical trial; Solid tumors; T cell; Tumor antigens |
| 299 | Poster Presentation | Immuno-Metabolic Signatures of Dendritic Cells Associate With T-cell Responses in Melanoma Patients | Juraj Adamik, PhD; Deena M. Maurer, MS; Paul Munson, PhD; Alexis J. Combes, PhD; Philippe Pierre, PhD; Matthew F. Krummel, PhD; Rafael J. Argüello, PhD; Lisa H. Butterfield, PhD; | Completed Clinical Trials | Antigen presenting cells; Dendritic cell; Gene expression; Metabolism; Vaccine |
| 300 | Poster Presentation | Final analysis of a prospective, randomized, double-blind, placebo-controlled phase IIb trial of tumor lysate, particle-loaded, dendritic cell vaccine in stage III/IV melanoma: 36-month analysis | Lexy M. Adams, MD, MPH; Robert C. Chick, M.D.; Guy T. Clifton, MD; Timothy J. Vreeland, BS MD; Patrick M. McCarthy, MD; Anne E. O'Shea, MD; Phil M. Kemp Bohan, MD; Annelies T. Hickeron, MD; John W. Myers, MD; Jessica L. Cindass, MD; Diane F. Hale, MD; Mark B. Faries, MD; John Hyngstrom, MD; Adam C. Berger, FACS, MD; James W. Jakub, MD; Jeffrey J. Sussman, MD; Montaser F. Shaheen, MD; Thomas E. Wagner, BS, MD; George E. Peoples, MD, FACS; | Completed Clinical Trials | Clinical trial; Dendritic cell; Solid tumors; Tumor antigens; Vaccine |
| 301 | Poster Presentation | Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study | Paolo A. Ascierto, MD; Karl D. Lewis, MD; Caroline Robert, MD, PhD; Daniil Stroyakovskiy, MD, PhD; Helen Gogas, MD, PhD; Svetlana Protsenko, MD, DSc; Rodrigo P. Pereira, MD; Thomas Eigentler, MD; Piotr Rutkowski, MD; Lev Demidov, MD, DSc; Georgy Moiseevich Manikhas, MD, PhD; Haocheng Li, PhD; Qian Zhu, PhD; Edward McKenna, PharmD, BCOP; Virginia McNally, PhD; Ralf Gutzmer, MD; Grant A. McArthur, MBBS (Hons), PhD, FRACP, FAHMS; | Completed Clinical Trials | Checkpoint blockade; Clinical study; Solid tumors; Targeted therapy |
| 302 | Poster Presentation | A phase I trial of intratumoral PVSRIPO in patients with unresectable treatment refractory melanoma | Georgia M. Beasley, MD, MHs; Nellie E. Farrow, MD; Karenia Landa, MD; Maria Angelica Selim, MD; Sin-Ho Jung, PhD; Darell D. Bigner, MD, PhD; Andrea True Kelly, PhD; Smita Nair, PhD; Matthias Gromeier, MD; April Salama, MD; | Completed Clinical Trials | Clinical trial; Solid tumors; Vaccine |
| 303 | Oral Presentation | Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (IT) CMP-001 in High-Risk Resectable Melanoma (Neo-C-Nivo): Final Results. | Diwakar Davar, MD; Arivarasan Karunamurthy; Douglas Hartman; Richelle DeBlasio, B.Sc.; Joe-Marc JM. Chauvin, PhD; Quanquan Ding; Ornella Pagliano; Amy Rose, RN; John M. Kirkwood, MD; Hassane M. Zarour, MD; | Completed Clinical Trials | Checkpoint blockade; Clinical trial; Immune contexture; TLR |
| 304 | Poster Presentation | Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma | Mohammed M. Milhem, MBBS; Yousef Zakharia, MD; Diwakar Davar, MD; Elizabeth I. Buchbinder, MD; Theresa Medina, MD; Adil Daud, MD; Antoni Ribas, MD, PhD; Jiaxin Niu, MD, PhD; Geoffrey T. Gibney, MD; Kim A. Margolin, MD; Anthony J. Olszanski, MD, RPh; Inderjit Mehmi, MD; Takami Sato, MD; Montaser Shaheen, MD; Aaron J. Morris, PhD; David Mauro, MD, PhD; Katie Campbell, PhD; Heather Kelley, MA; Riyue Bao, PhD; George J. Weiner, MD; Jason J. Luke, MD; Arthur M. Krieg, MD; James E. Wooldridge, MD; John M. Kirkwood, MD; | Completed Clinical Trials | Checkpoint blockade; Clinical study; Dendritic cell; T cell; TLR; Tumor microenvironment |
| 305 | Poster Presentation | Technical considerations for normalizing digital spatial profiling data with multiple within-patient samples | Tyler D. Hether; Tim Howes, PhD; Christine N. Spencer, PhD; Travis Hollman, PhD, MD; Jason W. Reeves; Danny Wells, BA, PhD; Claire F. Friedman, MD; Theresa LaVallee; Jedd D. Wolchok, MD, PhD; Sarah E. Warren, PhD; | Completed Clinical Trials | Antibody; Bioinformatics; Biomarkers; Clinical trial; Gene expression; RNA; Solid tumors; Tumor microenvironment; Tumor stroma |
| 306 | Poster Presentation | Predictors of immunotherapy benefit in Merkel cell carcinoma | Alec J. Kacew, BA; Harita Dharaneeswaran; Gabriel J. Starrett; Manisha Thakuria; Nicole R. LeBoeuf, MD, MPH; Ann W. Silk, MD, MS; James A. DeCaprio; Glenn J. Hanna, MD; | Completed Clinical Trials | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| 307 | Poster Presentation | Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study | Karl D. Lewis, MD; Paolo A. Ascierto, MD; Caroline Robert, MD, PhD; Rodrigo Munhoz, MD; Gabriella Liszkay, MD; Luis De La Cruz Marino, MD; Judit Olah, MD; Paola Queirolo, MD; Jacek Mackiewicz, MD, PhD; Kalpit Shah, PhD; Harper Forbes, MSc; Christian Hertig, PhD; Yibing Yan, PhD; Ralf Gutzmer, MD; Grant A. McArthur, MBBS (Hons), PhD, FRACP, FAHMS; | Completed Clinical Trials | Checkpoint blockade; Clinical study |
| 308 | Poster Presentation | Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for melanoma | Jeffrey S. Weber, MD, PhD; Paolo A. Ascierto, MD; Mark R. Middleton, MD, PhD; Delphine Hennicken; Roberto Zoffoli; Anne Pieters; Adenike Amadi; Katrin Kupas; Srividya Kotapati; Andriy Moshyk, MSc, MD; Dirk Schadendorf, MD; | Completed Clinical Trials | Checkpoint blockade; Immune adjuvant; Solid tumors |
| 309 | Poster Presentation | The role of tumor-draining lymph nodes in the tuning of systemic T cell immunity by CTLA-4 blockade is revealed by local delivery of tremelimumab in early-stage melanoma: data from a Phase-I trial | Jessica C. Notohardjo, MD; Kim M. van Pul, MD; Anita G. Stam; Dafni Chondronasiou; Sinead Lougheed; Petrousjka M. van den Tol; Karin Jooss, PhD; Ronald J. Vuylsteke, MD, PhD; Alfons J. van den Eertwegh; Tanja D. de Gruijl, PhD; | Completed Clinical Trials | Checkpoint blockade; Clinical study; Dendritic cell; Immune adjuvant; Immune monitoring; MDSC; T cell; TLR; Tumor microenvironment |
| 310 | Poster Presentation | The effect of pretreatment with G-CSF prior to dendritic cell collection during the phase IIb trial of an autologous DC-based vaccine for advanced, resectable melanoma | Anne E. O'Shea, MD; Robert C. Chick, M.D.; Guy T. Clifton, MD; Timothy J. Vreeland, BS MD; Lexy M. Adams, MD, MPH; Patrick M. McCarthy, MD; Phillip M. Kemp Bohan, MD; Annelies T. Hickeron, MD; John W. Myers, MD; Jessica L. Cindass, MD; Tommy A. Brown, MD; Diane F. Hale, MD; Mark B. Faries, MD; John Hyngstrom, MD; Adam C. Berger, FACS, MD; James W. Jakub, MD; Jeffrey J. Sussman, MD; Montaser F. Shaheen, MD; Thomas E. Wagner, BS, MD; George E. Peoples, MD, FACS; | Completed Clinical Trials | Antigen presenting cells; Clinical trial; Dendritic cell; Solid tumors; Tumor antigens; Vaccine |
| 311 | Poster Presentation | Phase II Trial of Lymphodepletion Plus Adoptive Cell Transfer with or Without Dendritic Cell Vaccination in Patients with Metastatic Melanoma | Chantal Saberian, MD; Rodabe N. Amaria, MD; Cara Haymaker, PhD; Marie Andree Forget, PhD; Roland L. Bassett, BS; Isabella C. Glitza, MD, PhD; Gregory A. Lizee, PhD; Cassian Yee, MD; Jeniffer L. McQuade, MD; Michael K. Wong, MD PhD FRCPC; Hussein A. Tawbi, MD, PhD; Sapna Patel, MD; Adi Diab, MD; Michael A. Davies, MD, PhD; Patrick M. Hwu, MD; Chantale Bernatchez, PhD; | Completed Clinical Trials | Antigen presenting cells; Clinical study; Clinical trial; Dendritic cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| 312 | Poster Presentation | Female sex independently predicts adjuvant immunotherapeutic benefit from CTLA4 immune checkpoint inhibition | Ahmad A. Tarhini, MD, PhD, MS; Ni Kang; Sandra Lee; F. Stephen Hodi, Jr., MD; Gary I. Cohen; Omid Hamid, MD; Laura F. Hutchins; Jeffrey A. Sosman, MD; Harriett M. Kluger; Zeynep Eroglu, MD; Henry Koon, MD; Donald P. Lawrence, MD; Kari L. Kendra; David R. Minor, MD; Carrie Lee, RN, MSN, OCN; Mark R. Albertini, MD; Lawrence E. Flaherty, MD; Teresa Petrella; Howard Striecher; Vernon K. Sondak, MD; John M. Kirkwood, MD; | Completed Clinical Trials | Biomarkers; Checkpoint blockade; Clinical trial; Immune tolerance; Solid tumors |
| 313 | Poster Presentation | A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms | Manish Patel, MD; Jason J. Luke, MD; Erika P. Hamilton, MD; Bartosz Chmielowski, MD, PhD; George R. Blumenschein, Jr., MD; Hedy L. Kindler, MD; Shakeela Bahadur, MD; Cesar A. Santa-Maria, MD, MSCI; Janine Koucheki; Jichao Sun, PhD; Sanjeev Kaul, PhD; Francine Z. Chen, MD; Xiaoyu Zhang; John J. Muth; Patrick Kaminker, PhD; Paul A. Moore, PhD; Bradley J. Sumrow, MD; Susanna Ulahannan, MD, MMED; | In-Progress Clinical Trials | Antibody; Bispecifics; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy |
| 315 | Poster Presentation | W0180 novel anti-VISTA antibody: Rationale for target patient population and first-in-human trial design in monotherapy and in combination with anti-PD1 antibody | Ignacio J. Melero, Dr., MD, PhD; Carlos A. Gomez-Roca, MD; Pierre Ferre, VetMD, PhD; Pierre Ferre, VetMD, PhD; Eric Chetaille; Aurelie Petain; Celine Thuilliez; Isabelle Vandenberghe; Francisco Cruzalegui, PhD; Asmaa Boudribila; Mariya Pavlyuk; Aurelien Marabelle, MD, PhD; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical trial; Immune contexture; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor microenvironment |
| 316 | Poster Presentation | EVICTION Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A | Aurelien Marabelle, MD, PhD; Christiane Jungels, MD; Johann S. De Bono, MD; Norbert Vey, MD; Martin Wermke, MD; Elena Garralda, MD; Aude de Gassart, PhD; Patrick Brune; Emmanuel Valentin, PhD; Marina Iché; Daniel OLIVE, M.D., Ph.D.,; Paul Frohna, MD, PharmD, PhD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Cytokine; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 317 | Poster Presentation | A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors | Leisha A. Emens, MD, PhD; Muralidhar Beeram, MD; Erika P. Hamilton, MD; Sarina A. Piha-Paul, MD; Valerie Odegard, PhD; Sue Hamke; Naomi Hunder, MD; Samuel J. Klempner, MD; | In-Progress Clinical Trials | Antibody; Clinical study; Clinical trial; Dendritic cell; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; TLR; Tumor antigens |
| 318 | Poster Presentation | Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation and/or homologous recombination repair deficiency: KEYLYNK-007 | Timothy A. Yap, MD, PhD; Mallika Dhawan; Andrew E. Hendifar; Michele Maio, MD; Taofeek K. Owonikoko; Miguel Quintela-Fandino; Ronnie Shapira-Frommer, MD; Sanatan Saraf, MD; Ping Qiu, PhD; Fan Jin, MD; Alexander Gozman; Douglas A. Levine; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical trial; Gene expression; Solid tumors; Targeted therapy |
| 319 | Poster Presentation | Phase II trial of immunotherapy in primary glioblastoma: antigens from self-renewing autologous tumor cells presented by autologous dendritic cell vaccine | Daniela Bota, MD, MD., PhD; David E. Piccioni, MD, PhD; Christopher M. Duma, MD; Renato V. LaRocca, MD; Santosh Kesari, MD, PhD; Jose A. Carrillo, MD; Robert O’Donnell; Robert Aiken, MD; Frank Hsu; Xiao-Tang Kong; Thomas H. Taylor, PhD; Gabriel I. Nistor, MD; Robert O. Dillman, MD; Daniela Bota, MD, MD., PhD; | In-Progress Clinical Trials | Clinical trial; Dendritic cell; Immune monitoring; Neoantigens; Stem cell/cancer-initiating cell |
| 320 | Poster Presentation | Phase IIa Study of Alpha-DC1 Vaccine against HER2/HER3, Chemokine Modulation Regimen and Pembrolizumab in Patients with Asymptomatic Brain Metastasis from Triple Negative or HER2+ Breast Cancer | Shipra Gandhi, MD; Peter A. Forsyth, MD; Mateusz Opyrchal, MD, PhD; Kamran A. Ahmed, MD; Hung T. Khong, MD; Kristopher Attwood, PhD; Ellis G. Levine, MD; Tracey L. O'Connor, MD; Amy P. Early, MD; Robert A. Fenstermaker, MD; Dheerendra Prasad, MD; Kazuaki Takabe, MD,PhD; Brian J. Czerniecki, MD,PhD; Pawel Kalinski, MD, PhD; | In-Progress Clinical Trials | Checkpoint blockade; Chemokine; Clinical trial; Vaccine |
| 321 | Poster Presentation | Phase I clinical trial assessing the combination of systemic chemokine modulatory regimen targeting TLR3 with neoadjuvant chemotherapy in triple negative breast cancer | Shipra Gandhi, MD; Mateusz Opyrchal, MD, PhD; Cayla Ford; Victoria Fitzpatrick; Melissa Grimm, PhD; Per H. Basse, MD, PhD; Marie Quinn, MD; Agnieszka Witkiewicz, MD; Kristopher Attwood, PhD; Marc S. Ernstoff, MD; Tracey L. O'Connor, MD; Amy P. Early, MD; Ellis G. Levine, MD; Pawel Kalinski, MD, PhD; | In-Progress Clinical Trials | Chemokine; Chemotherapy; Clinical trial; Immune adjuvant; TLR; Tumor infiltrating lymphocytes (TILs) |
| 322 | Poster Presentation | Efficacy and safety of GX-I7 plus pembrolizumab for heavily pretreated patients with metastatic triple negative breast cancer: The Phase 1b/2 KEYNOTE-899 Study. | Joo H. Sohn, PhD; Joo H. Sohn, PhD; Young Hyuk Im; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Cytokine; Immune adjuvant; T cell |
| 323 | Poster Presentation | Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients | Lajos Pusztai, MD; Hailing Lu, MD, PhD; Christopher Hale, PhD; Anne Grosse-Wilde, PhD; Jennifer Specht, MD; Shanu Modi, MD; Hyo Han, MD; Javier Cortes, MD PhD; Mafalda Oliveira, MD, PhD; Phillip Garfin, MD, PhD; Zejing Wang, MD, PhD; Matthew Onsum, PhD; | In-Progress Clinical Trials | Antibody; Biomarkers; Checkpoint blockade; Immune monitoring; Monocyte/Macrophage; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 324 | Poster Presentation | BDB001, a Toll-Like Receptor 7 and 8 (TLR7/8) Agonist, can be safely administered intravenously and shows clinical responses in advanced solid tumors. | Manish Patel, MD; Drew Rasco, MD; Melissa L. Johnson, MD; Anthony W. Tolcher, MD; Lixin Li, PhD; Adam Zong, PhD; Alexander Chung, PhD; Robert H. Andtbacka, MD, CM; | In-Progress Clinical Trials | COVID and Immunotherapy; Adoptive immunotherapy; Clinical study; Clinical trial; Cytokine; Dendritic cell; Monocyte/Macrophage; Solid tumors; TLR |
| 325 | Poster Presentation | Immunotherapy with B cell activating antibody CPI-006 in patients (pts) with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells and memory T effector cells | Gerard J. Criner, MD; Mehrdad Mobasher, MD, MPH; Craig M. Hill, PhD; Shenshen Hu, PhD; Suresh Mahabhashyam, MD, MPH; Joshua Brody, MD; Thomas U. Marron, MD, PhD; Stephen Willingham, PhD; Richard A. Miller, MD; | In-Progress Clinical Trials | COVID and Immunotherapy; Antibody; B cell; Clinical study; Clinical trial; Immune adjuvant; Vaccine |
| 326 | Poster Presentation | SARS-CoV-2 specific T-cells in TIL from patients with epithelial cancer | Pedro Noronha; Georgia Paraschoudi, M.Sc. in Cell and Molecular Biology, Sweden; Eric D. Sousa; Jéssica O. Kamiki; Patrícia A. António; Carolina Condenço; Inês Silva; Andreia Maia, PhD student; Mireia Castillo-Martin; António Beltran; Carlos Carvalho, MD; Joana R. Lerias, PhD; Alimuddin Zumla; Markus J. Maeurer, MD, PhD, FRCP(London); | In-Progress Clinical Trials | COVID and Immunotherapy; Clinical study; Tumor infiltrating lymphocytes (TILs) |
| 327 | Poster Presentation | Study of anti-PD-1 antibody multimodal combination as first-line treatment on time window of advanced solid tumor | Jian Shi, MD; Baoen Shan; Junyan Wang; Jiayin Liu; Rongfeng Liu; Yujie Shan; | In-Progress Clinical Trials | COVID and Immunotherapy; Angiogenesis; Biomarkers; Checkpoint blockade; Chemotherapy; Clinical trial; Gene expression; Immune toxicity; Solid tumors; Targeted therapy |
| 328 | Poster Presentation | Phase 3 study of olaparib ± bevacizumab versus bevacizumab + fluorouracil in patients with unresectable or metastatic colorectal cancer not progressing on first-line FOLFOX + bevacizumab (LYNK-003) | Carlos A. Mayo, MD; Ellen B. Gurary; Patricia Marinello; | In-Progress Clinical Trials | Angiogenesis; Chemotherapy; Clinical study; Targeted therapy |
| 329 | Poster Presentation | Prolonged overall survival (OS) in patients with metastatic colorectal cancer (mCRC) in SPICE, a phase I study of enadenotucirev in combination with nivolumab | Tom R. Lillie, MD; Andrew Stone; Sarah Lockwood; Richard R. Brown; Andrew Fox; Eirini Bournazou; John W. Beadle, MBBCH; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| 330 | Poster Presentation | Investigating the clinical safety, efficacy, and immune modulation of combined XL888 and pembrolizumab in metastatic gastrointestinal malignancies | Cameron J. Herting, PhD; Yuchen Zhang; Deon B. Doxie, PhD; Matthew R. Farren, Ph.D.; Michael B. Ware; Olatunji B. Alese, MD; Christina Wu, MD; Walid L. Shaib, MD; Mehmet Akce; Mohammad Y. Zaidi, MD, MS; Amanda N. Ruggieri; Madhav Dhodapkar, MD; Kavita M. Dhodapkar, MD; Juan Sarmiento; Rafi Ahmed, PhD; Shishir K. Maithel; Bassel El-rayes, MD; Gregory B. Lesinski, PhD; | In-Progress Clinical Trials | Checkpoint blockade; Chemokine; Clinical trial; Cytokine; Immune monitoring; T cell lineages; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 331 | Poster Presentation | Immunotherapy with Y90-radioembolization for metastatic colorectal cancer (iRE-C) | Pashtoon M. Kasi, MD, MS; Beau M. Toskich, MD; Sandeep T. Laroia, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Inflammation; Neoantigens; Radiotherapy; Solid tumors; Tumor antigens; Tumor microenvironment; Tumor stroma |
| 332 | Oral Presentation | Novel TGF-β signatures in metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab. | Keun-Wook Lee, MD, PhD; Young Suk Park, MD, PhD; Joong Bae Ahn, MD; Jin Kyung Lee, PhD; Jiyeon Ryu, Ph.D; Bitna Oh, MD; Chan-Young Ock, MD, PhD; Sunjin Hwang, MD; Ki Baik Hahm, MD, PhD; Seong-Jin Kim, PhD; Tae Won Kim, MD; Keun-Wook Lee, MD, PhD; | In-Progress Clinical Trials | Biomarkers; Checkpoint blockade; Clinical trial; Tumor microenvironment |
| 333 | Poster Presentation | Targeting the apical intracellular checkpoint CISH unleashes T cell neoantigen reactivity and effector program | Douglas C. Palmer, PhD; Beau R. Webber; Yogin Patel, PhD; Matthew J. Johnson, PhD; Christine M. Kariya; Walker S. Lahr; Maria r. Parkhurst; Jared Gartner, MS; Todd D. Prickett; Frank J. Lowery; Rigel J. Kishton; Devikala Gurusamy; Zulmarie Franco; Suman Vodnala; Miechaleen D. Diers; Natalie K. Wolf; Nicholas J. Slipek; David H. McKenna, Jr., MD; Darin Sumstad; Lydia Viney; Tom Henley; Tilmann Bürckstümmer; Oliver Baker; Ying Hu; Chunhua Yan; Daoud Meerzaman; Kartik Padhan; Winnie Lo; Parisa Malekzadeh; Li Jia; Drew C. Deniger; Shashank J. Patel; Paul F. Robbins; R. Scott McIvor, PhD; Modassir Choudhry; Steven A. Rosenberg; Branden S. Moriarity, PhD; Nicholas P. Restifo; | In-Progress Clinical Trials | Adoptive immunotherapy; Checkpoint blockade; Clinical study; Clinical trial; Neoantigens; Tumor antigens; Tumor infiltrating lymphocytes (TILs) |
| 334 | Poster Presentation | Phase II Study Evaluating a Chemokine-Modulatory (CKM) Regimen in Patients with Colorectal Cancer (CRC) Metastatic to the Liver | Sarbajit Mukherjee, MD, MS; Patrick Boland; Medhavi Gupta; Melissa Grimm, PhD; Kristopher Attwood, PhD; Pawel Kalinski, MD, PhD; | In-Progress Clinical Trials | Chemokine; Clinical trial |
| 335 | Poster Presentation | Novel CoupledCARTM Technology for Treating Colorectal Cancer | Song Li; Chengfei Pu; Zhiyuan Cao; Ning Li; Xinyi Yang; Youli Luo; Haiyan Zhao; Hang Yang; Xi Huang; Xiaogang Shen; Xiuwen Wang; Yongping Song; Junjie Mao; Pengfei Pang; Qun Hu; Zhao Wu; Lei Xiao, Ph.D.; | In-Progress Clinical Trials | Adoptive immunotherapy; Biomarkers; CAR T cells; Clinical study; Gene expression; Inflammation; Solid tumors; T cell; Tumor antigens |
| 337 | Poster Presentation | Pembrolizumab in combination with xelox bevacizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer and a high immune infiltrate: a proof of concept study. FFCD 1703 POCHI | David Tougeron, MD, PhD; Jean Francois Emile; Stephano Kim; Carole Monterymard; marine gilabert; Jérémie BEZ; Astrid Lievre; Laetitia Dahan; Pierre Laurent-puig; Laurent Mineur; ROmain Coriat; Jean Louis Legoux; Vincent Hautefeuille; Jean marc Phelip; Thierry Lecomte; Harry Sokol; Claude Capron; Claire Gallois; Violaine Randrian; Come Lepage; Julien Taieb; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Solid tumors; Tumor infiltrating lymphocytes (TILs) |
| 338 | Poster Presentation | Emerging insights on the association of tumor molecular phenotype with clinical benefit in metastatic colorectal cancer (mCRC) subjects treated with AB928 + Modified FOLFOX-6 (mFOLFOX-6) | Akshata R. Udyavar, Ph.D; Michael Cecchini; Daniel DiRenzo, PhD; Sean Cho, PhD; Lisa Seitz, MS; Kristen Zhang, BS; Stephen W. Young, PhD; Amy E. Anderson, PhD; Kimberline Y. Gerrick; Matthew J. Walters, PhD; Houston N. Gilbert, PhD; Olivia S. Gardner; Cheng Quah, MD; Juan C. Jaen, PhD; William Grossman, MD; | In-Progress Clinical Trials | Bioinformatics; Biomarkers; Chemotherapy; Clinical trial; Gene expression; Immune suppression; Metabolism; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 339 | Poster Presentation | Preliminary Safety, Tolerability and Efficacy Results of KN026 (a HER2-targeted Bispecific Antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in Patients (pts) with HER2 aberrated solid tumors | Jifang Gong, MD; Zhi Dong; Dan Liu; June Xu; Jing Yang; Yue Yang; Yakun Qi; Jie Men; Paul Kong; Ting Xu; Lin Shen, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Targeted therapy |
| 340 | Poster Presentation | Phase 1 study of AMG 160, a half-life extended BiTE® (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer | Lisa Horvath; Tanya Dorff, MD; Matthew Rettig, MD; Jean-Pascal Machiels, MD, PhD; Martijn Lolkema, MD, PhD; Karen Autio, MS, MD; Richard Greil; Sylvie Rottey, MD; Nabil Adra, MD, MSc; Mark E. Salvati, PhD; Shirley Poon, MS, MBA; Daniel Tan, MBBS, MRCP; Gabor Jurida; Hosein Kouros-Mehr; Karim Fizazi; Ben Tran, MD; Lisa Horvath; | In-Progress Clinical Trials | Bispecifics; Clinical study; Clinical trial; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| 341 | Poster Presentation | Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC) | Rahul Aggarwal, MD; Dan Costin, MD; Jingsong Zhang, MD, PhD; Paul Monk, MD; Mark Linch, MD; Lawrence I. Karsh, MD; Diane Healey, MS; Stefani Corsi-Travali; Sreenivas Adurthi, PhD; Adedayo Adedoyin; Vincent O'Neill, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Cytokine; Inflammation; Monocyte/Macrophage; Solid tumors; Tumor microenvironment |
| 342 | Poster Presentation | A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk | Toni K. Choueiri; Laurence Albiges, MD; Thomas Powles, MBBS, MD, MRCP; Nehal Mohamed; Fong Wang; Robert J. Motzer, MD; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Coinhibition; Solid tumors; Targeted therapy |
| 343 | Poster Presentation | Phase 3 Study of Pembrolizumab + Docetaxel and Prednisone/Prednisolone for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Pretreated With Next-Generation Hormonal Agents (NHAs) (KEYNOTE-921) | Daniel P. Petrylak, MD; Neal Shore, MD; Mostefa Bennamoun; Raffaele Ratta; Josep M. Piulats; Ben Li; Charles Schloss; Karim Fizazi; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial |
| 344 | Poster Presentation | Phase 3 Trial of Pembrolizumab and Enzalutamide Versus Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641) | Julie Nicole Graff; Joseph Burgents; Li Wen Liang; Arnulf Stenzl; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial |
| 345 | Poster Presentation | Phase 3 Study of Combination Pembrolizumab + Olaparib Therapy Versus Enzalutamide/Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Progression on Chemotherapy (KEYLYNK-010) | Evan Y. Yu, MD; Se Hoon Park; Yi-Hsiu Huang; Mostefa Bennamoun; Lu Xu; Jeri Kim, MD; Emmanuel S. Antonarakis, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial |
| 346 | Poster Presentation | KEYNOTE-991: Phase 3 Study of Pembrolizumab Plus Enzalutamide and Androgen Deprivation Therapy (ADT) for Patients With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Christian Gratzke; Cuizhen Niu; Christian H. Poehlein, MD; Joseph Burgents; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial |
| 347 | Poster Presentation | Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial | Ira Winer, MD, PhD; Lucy Gilbert, MD; Ulka N. Vaishampayan, MD; Seth Rosen, MD; Christopher J. Hoimes, DO; Jameel Muzaffar, MD; Anna Spreafico, MD PhD; David F. McDermott, MD; Quincy Chu, MD; Olivier Dumas, MD; Aman Chauhan, MD; Arvind Chaudhry, MD; Piotr Tomczak, MD; Valentina Boni, MD, PhD; Debora S. Bruno, MD; Kelly K. Curtis, MD; Yan Wang, PhD; Elizabeth Dorn, PhD; Jessicca Rege, PhD; Yangchun Du, PhD; Ilda Bidollari; Lei Sun, PhD; Emily L. Putiri, PhD; Heather C. Losey, PhD; Bruce Dezube, MD; Marc S. Ernstoff, MD; Vamsidhar Velcheti, MD; James Strauss, MD; | In-Progress Clinical Trials | Clinical study; Clinical trial; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 348 | Poster Presentation | A phase 2 umbrella study of retifanlimab (INCMGA00012) alone or in combination with other therapies in patients with advanced or metastatic endometrial cancer (POD1UM-204, GOG 3038, ENGOT-en12/NOGGO) | Brian M. Slomovitz, MD; Bradley J. Monk; Katherine Moxley; Nadeem Ghali; Justyna Fronczek Sokol; Chuan Tian, PhD; Nawel Bourayou, MD; Jalid Sehouli; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical trial; Coinhibition; Targeted therapy |
| 349 | Poster Presentation | Early Safety and Efficacy of a Phase 1/2 Open-Label, Multi-Center Trial of SNS-301 Added to Pembrolizumab in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Alain P. Algazi, MD; William Smith; Timothy Panella; Dong M. Shin, MD; Marie-Louise H. Fjaellskog; John Celebi; Alice Drumheller; Jean Campbell, PhD; Robert H. Pierce, Jr., MD; Michael Guarino; | In-Progress Clinical Trials | Antigen presenting cells; Biomarkers; Checkpoint blockade; Clinical trial; Monocyte/Macrophage; Solid tumors; T cell; Tumor antigens; Tumor microenvironment; Vaccine |
| 351 | Poster Presentation | Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009 | Kevin Harrington, PhD, FRCP, FRCR; Ezra EW. Cohen, MD; Lilian L. Siu, MD; Danny Rischin, MBBS, MD; Lisa Licitra, MD; Jan Vermorken; Quynh-Thu Le, MD, FACR, FASTRO; Makoto Tahara; Jean-Pascal Machiels, MD, PhD; Natalyn Hawk; Joy Ge; Behzad Bidadi, MD, MS; Ramona F. Swaby, MD; Barbara A. Burtness, MD; | In-Progress Clinical Trials | Angiogenesis; Checkpoint blockade; Clinical trial; Targeted therapy |
| 352 | Oral Presentation | Updated clinical data from the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab | Ezra EW. Cohen, MD; Michael Postow, MD; Ryan J. Sullivan, MD; David S. Hong, MD; Heather Yeckes-Rodin, MD; Jerry McCarter, RN, BSN; Nora Zizlsperger; Jeffery Kutok, MD, PhD; Brenda O'Connell, PhD; Kara Page; Jennifer Roberts; Halle Zhang, PhD; Bartosz Chmielowski, MD, PhD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Immune suppression; Immune tolerance; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; Tumor microenvironment |
| 353 | Poster Presentation | Safety and efficacy of tumor infiltrating lymphocytes (TIL, LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC | Antonio Jimeno, MD, PhD; Sophie Papa, PhD, MBBS, MRCP; Missak Haigentz, MD; Juan F. Rodríguez-Moreno,, MD; Julian Schardt; Maria Fardis, PhD; Friedrich Graf Finckenstein, MD; Rana Fiaz; Guang Chen; Alex Cacovean; Zelanna Goldberg; Ammar Sukari, MD; | In-Progress Clinical Trials | Adoptive immunotherapy; Checkpoint blockade; Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| 354 | Poster Presentation | A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer | Sara I. Pai, MD PhD; Douglas R. Adkins, MD; Lori J. Wirth, MD; Christine H. Chung, MD; Michael K. Gibson, MD PhD; Ammar Sukari, MD; Francis P. Worden, MD; Dimitrios Colevas, MD; Nabil F. Saba, MD; Barbara A. Burtness, MD; Cristina P. Rodriguez, MD; Julie E. Bauman, MD, MPH; Bonnie S. Glisson, MD; Lara A. Dunn, MD; Anish Suri, PhD; Mark Haydock, B.S.; Steven N. Quayle, PhD; Saso Cemerski, PhD; Megan Leader; Jason Brown; Kenneth J. Pienta, MD; Mary C. Simcox, PhD; | In-Progress Clinical Trials | Biomarkers; Clinical trial; Costimulation; Cytokine; Immune monitoring; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor antigens |
| 355 | Poster Presentation | First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies | Nina Shah, MD; Alan Tan, MD; Lihua E. Budde, MD, PhD; Craig C. Hofmeister, MD; Andrew J. Cowan, MD; Hayder Saeed, MD; Jing C. Ye, MD; Mitchell S. Cairo, MD; David A. Rizzieri, MD; Gregory J. Orloff, MD; Xue Snow Ge, PhD; Zachary Lee, PharmD; Neha Dixit, PhD; Wildaliz Nieves, PhD; Mona Vimal, MSc; Haijun Ma, PhD; Takahiro Miyazaki, PhD; Loui Madakamutil, PhD; Mario Q. Marcondes, MD, PhD; Wei Lin, MD; Mary A. Tagliaferri, MD; Jonathan Zalevsky, PhD; Krina K. Patel, MD; | In-Progress Clinical Trials | Biomarkers; Clinical trial; Cytokine; Leukemia/Lymphoma; NK/NK T cell; T cell |
| 356 | Poster Presentation | Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab | Neil L. Berinstein, MD; Isabelle A. Bence-Bruckler; Nick Forward; Pierre Laneuville; Joy Mangel; Douglas Stewart; Irina Amitai; Gail Klein; Nancy Pennell; Iran Rashedi; Kim Roos; Yogesh Bramhecha, PhD; Rebekah Conlon; | In-Progress Clinical Trials | B cell; Checkpoint blockade; Clinical trial; Immune adjuvant; Immune monitoring; Leukemia/Lymphoma; T cell; Targeted therapy; Tumor microenvironment; Vaccine |
| 357 | Poster Presentation | TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma | Sabrina C. Collins, BS; Adarsh Joshi; Lei Shen; Subhasree Das; Kaveri Suryanarayan; Dean C. Bottino; Cheryl Li; Michael Curley; Dannie Wang; Michael Abadier; Ryan Larson; Xavier Parot; | In-Progress Clinical Trials | Biomarkers; Chemokine; Cytokine; Immune contexture; Immune monitoring; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 358 | Poster Presentation | Trial In Progress: A Pilot Study of Combined Immune Checkpoint Inhibition in combination with ablative therapies in subjects with hepatocellular carcinoma (HCC) | Hailey K. Carroll, MD; Umair Aleem, MD; Pooja Varghese; Marie Galligan, PhD; Michèle Bourke; Katherine Hoey; Ronan Ryan, MD; Peter Doran, PhD; Stephen Stewart, MD PhD; Cliona O'Farrelly, PhD; Tim F. Greten, MD; Diarmaid Houlihan, MD; Raymond McDermott, MD; Austin G. Duffy, MD; | In-Progress Clinical Trials | Biomarkers; Checkpoint blockade; Clinical trial; Coinhibition; Immune monitoring; Microbiome; NK/NKT cell; Solid tumors; Targeted therapy; Tumor microenvironment |
| 359 | Oral Presentation | AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results | Hossein Borghaei, MS, DO; Michael Boyer; Melissa L. Johnson, MD; Ramaswamy Govindan, MD; Luis Paz-Ares Rodrigues; Fiona Blackhall; Rene Boosman; Stéphane Champiat; Horst-Dieter Hummel; W. Victoria Lai; Hibiki Udagawa; Anne Chiang; Afshin Dowlati, MD; Christine L. Hann, MD, PhD; Ravi Salgia, MD; Everett E. Vokes, MD; Mukul Minocha; Nooshin Hashemi-Sadraei; Aditya Shetty; Marie-Anne Damiette Smit, MD, MS; Hui Yang; Taofeek K. Owonikoko, MD, PhD; | In-Progress Clinical Trials | Bispecifics; Clinical trial |
| 360 | Poster Presentation | A Phase 1 Study of an Off-the-Shelf, Multi-Neoantigen Vector (ADXS-503) Alone and in Combination with Pembrolizumab in Subjects with Metastatic Non-Small Cell Lung Cancer (NSCLC) | Jonathan W. Goldman, MD; Thomas Stinchcombe, MD; Gregory J. Gerstner, MD; Missak Haigentz Jr., MD; Surya Vangala; Megan Parsi; Victor Kabala; Dinesh Simkhada; Andres A. Gutierrez, MD PhD; Suresh S. Ramalingam, MD; | In-Progress Clinical Trials | Adoptive immunotherapy; Antigen presenting cells; Biomarkers; Checkpoint blockade; Clinical study; Immune tolerance; Neoantigens; Solid tumors; T cell; Tumor antigens |
| 361 | Poster Presentation | A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma - 12 month analysis of biomarkers and clinical outcomes | Magnus Jaderberg, MD; Luis Paz-ares; Susana Cedres; Luis Paz-Ares; Xavier Serres; Charles Ricordel; Nicolas Isambert; Santiago Ponce Aix; Victor Levitsky; Lukasz Kuryk, PhD; Anne-Sophie Moller; Sylvia Vetrhus; | In-Progress Clinical Trials | Clinical study; Gene expression; Immune monitoring; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 362 | Oral Presentation | A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis | James Spicer, PhD, FRCP; Åslaug Helland, MD, PhD; Enric Carcereny, MD; Edurne Arriola, MD, PhD; Manuel Dómine Gomez, MD, PhD; Jose Manuel Trigo Perez, MD, PhD; Jonathan R. Thompson, MD; James Strauss, MD; Ana Laura Ortega Granados, MD; Enriqueta Felip, MD PhD; Emmett V. Schmidt, MD PhD; Michael J. Chisamore, PhD; Noelly Madeleine, PhD; Austin Rayford, MS; Katherine Lorens; Abdul Siddiqui, MD; Hani Gabra, MD, PhD, FRCP; Jaya Nautiyal, PhD; David Micklem, PhD; James B. Lorens, PhD; Matthew G. Krebs, MD, PhD; | In-Progress Clinical Trials | Antigen presenting cells; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Regulatory T cell (Treg cell); Targeted therapy; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 363 | Poster Presentation | Vactosertib and durvalumab as second or later line treatment for PD-L1 positive non-small cell lung cancer: interim result | Byoung Chul c. Cho, MD, PhD; Ki Hyeong Lee, MD, PhD; Ji-Youn Han, MD, PhD; Byoung yong Shim, MD, PhD; Hye Ryun Kim, MD, PhD; Kyoung-Ho Pyo, PhD; Jae-Hwan Kim, PhD; Chung-Feng Xin; Jin Kyung Lee, PhD; Jiyeon Ryu, PhD; Bitna Oh, MD; Sunjin Hwang, MD; Ki Baik Hahm, MD, PhD; Seong-Jin Kim, PhD; | In-Progress Clinical Trials | Biomarkers; Checkpoint blockade; Clinical trial; Coinhibition; Immune monitoring; Solid tumors; Tumor microenvironment |
| 364 | Poster Presentation | A personal neoantigen vaccine NEO-PV-01 in combination with chemotherapy and pembrolizumab induces broad de novo immune responses in first line, non-squamous NSCLC | Mark Awad, MD, PhD; David R. Spigel, MD; Edward B. Garon, MD; Saiama Waqar, MD; Aaron Lisberg, MD; Melissa A. Moles; Jennifer Tepper; April Lamb; Amy Wanamaker; Zakaria Khondker; John Srouji; Jesse Z. Dong; Asaf Poran; Kristen N. Balogh; Meghan Bushway; Mark DeMario, MD; Lakshmi Srinivasan, PhD; Richard B. Gaynor; Ramaswamy Govindan, MD; | In-Progress Clinical Trials | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Neoantigens; T cell; Tumor antigens; Tumor microenvironment; Vaccine |
| 365 | Poster Presentation | Tumor Treating Fields (TTFields, 150 kHz) concurrent with standard of care treatment for stage 4 non-small cell lung cancer (NSCLC) in Phase 3 LUNAR Study | Ticiana A. Leal, MD; Raphael Bueno; Libor Havel; Jeffrey Ward, MD, PhD; Ticiana A. Leal, MD; | In-Progress Clinical Trials | Checkpoint blockade; Chemotherapy; Clinical trial; Targeted therapy |
| 366 | Poster Presentation | A randomized double-blind placebo-controlled phase III study evaluating perioperative toripalimab combined with platinum-based doublet chemotherapy in resectable stage III NSCLC | Wenxiang Wang; Lin Wu, MD; Wei Zhang; Shun Lu; Haohui Fang; Guohua Yu, MD; Ming Zhou; Wenqun Xing; Qixun Chen; Xingya Li; Nong Yang; Minhua Ye; Wentao Fang; Yunchao Huang; Jichun Liu; Lijie Tan; Xiaosheng Hang; Wengang Zhang; Liwei Zhang; Jun Chen; Xun Zhang; Yu Zhang; Jie Jiang; Aihong Zhong; Shanqing Li; Yunpeng Liu; Guowu Wu; Xiaoyan Kang; Ying Tian; Tao Xu; | In-Progress Clinical Trials | Biomarkers; Checkpoint blockade; Chemotherapy; Clinical trial; Immune adjuvant; Solid tumors; Surgery |
| 367 | Poster Presentation | A Phase 1/1b Dose-escalation Study of Intravenously Administered SB 11285 Alone and in Combination with Atezolizumab in Patients with Advanced Solid Tumors | Jason J. Luke, MD; Filip Janku, MD, PhD; Anthony J. Olszanski, MD, RPh; Kevin Leach; Radhakrishnan Iyer; Atif Abbas, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Cytokine; Immune monitoring; T cell; Tumor microenvironment |
| 368 | Oral Presentation | REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors | Adi Diab, MD; Brendan D. Curti, MD; Mehmet A. Bilen, MD; Andrew S. Brohl, MD; Evidio Domingo-Musibay, MD; Erkut H. Borazanci, MD; Christie Fanton, PhD; Cat Haglund; Mona Vimal, MSc; Mann Muhsin, MD; Mario Q. Marcondes, MD, PhD; Anh Nguyen; Mary A. Tagliaferri, MD; Wei Lin, MD; Jonathan Zalevsky, PhD; Sandra P. D'Angelo, MD; | In-Progress Clinical Trials | Biomarkers; Clinical trial; Cytokine; Solid tumors; T cell; TLR; Tumor microenvironment |
| 369 | Poster Presentation | Safety and pharmacodynamic activity of ATOR-1015, a CTLA-4 x OX40 bispecific antibody, in a phase 1 dose escalation study of patients with advanced solid malignancies | Jeffrey Yachnin, MD, PhD; Gustav J. Ullenhag, PhD, MD; Ana Carneiro, MD PhD; Dorte Nielsen, MD, PhD; Kristoffer Staal Rohrberg, MD, PhD; Anne Månsson Kvarnhammar, PhD; Lena Schultz; Erika Bågeman, PhD; Erika Bågeman; Camilla Wennersten, PhD; Charlotte A. Russell, MD, PhD; | In-Progress Clinical Trials | Antibody; Bispecifics; Checkpoint blockade; Clinical trial; Solid tumors |
| 370 | Poster Presentation | Pharmacodynamic assessment of a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab to patients with advanced solid tumors | Victor Moreno, PhD, MD; Tatiana Hernandez; Ignacio J. Melero, Dr., MD, PhD; Miguel Sanmamed; Iben Spanggaard; Kristoffer Staal Rohrberg, MD, PhD; Josep Tabernero, MD, PhD, MSc.; Analia Azaro; Maria Martinez Garcia; Alejo Rodriguez-Vida; Christina Claus; Florian Heil; Oliver Krieter; Oliver Grimm; Marta Canamero, MD, PhD; Jose Duarte; Alexandra-Cristina Nica; Iakov Davydov; Michael Hettich; Chia-Huey Ooi; Christian Heichinger; Ernesto Guarin; Radoiane Helbaj; Tamara Tanos; Eveline Nueesch; Maurizio Ceppi, PhD; Irene Moreno; Emiliano Calvo; | In-Progress Clinical Trials | Biomarkers; Bispecifics; Checkpoint blockade; Clinical trial; Costimulation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 371 | Poster Presentation | The association of the gut microbiota and clinical response to immune checkpoint inhibitors in patients with advanced cancer | Cheng-Hsun Chiu; Chih-Yu Tsai; Yu-Fen Lin; John W. Chang, MD; Chiao-En Wu; Yuan-Ming Yeh; Yung-Chi Shen; Ming-Mo Hou; Jia-Juan Hsieh; John W. Chang, MD; | In-Progress Clinical Trials | Biomarkers; Clinical study; Microbiome; Solid tumors |
| 372 | Poster Presentation | Single-agent anti-tumor activity in relapsed/refractory solid tumors: interim data from the Phase 1 solid tumor trial of AMV564, a novel T-cell engager | Sarina A. Piha-Paul, MD; Alexander N. Starodub, MD; Raghad Karim, MD; Michael Shafique, MD; Gabriel R. Tinoco Suarez, MD; Curtis Ruegg, PhD; Victoria Smith, PhD; Patrick Chun, MD; | In-Progress Clinical Trials | Bispecifics; Clinical study; Clinical trial; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Tumor microenvironment |
| 373 | Poster Presentation | Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2 | John D. Powderly, II, MD; Bradley C. Carthon, MD Ph.D; Marc S. Ernstoff, MD; Anthony J. Olszanski, MD, RPh; John M. Wrangle, MD; Anthony F. Shields, MD PhD; Sarina A. Piha-Paul, MD; Kelly K. Curtis, MD; Ilda Bidollari; Yangchun Du, PhD; Lei Sun, PhD; Emily L. Putiri, PhD; Yan Wang, PhD; Heather C. Losey, PhD; Bruce Dezube, MD; Bruce Dezube, MD; Ulka N. Vaishampayan, MD; | In-Progress Clinical Trials | Clinical study; Clinical trial; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell |
| 374 | Poster Presentation | A first-in-human Phase 1/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors | Devalingam Mahalingam, MBBChBAO; Devalingam Mahalingam, MBBChBAO; Wael A. Harb, MD; Amita Patnaik, MD FRCP(C); Susanna Ulahannan, MD, MMED; Haider Mahdi, MD; Manmeet S. Ahluwalia, MD; Manish Patel, MD; Afshin Dowlati, MD; Andrea Bullock, MD; Patrick Wen, MD; Shubham Pant, MD; Mary Mulcahy, MD; Robert Guttendorf, Rph, PhD; Lou Vaickus, MD; Suming Wang, PhD; Marsha Crochiere, PhD; Melanie Vincent, PhD; Michael Cieslewicz, PhD; Jing Watnick, PhD; | In-Progress Clinical Trials | Angiogenesis; Clinical study; Clinical trial; MDSC; Monocyte/Macrophage; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor microenvironment |
| 375 | Poster Presentation | Expansion of HPV-16 specific T cells in patients with HPV-related cancers treated with bintrafusp alfa | Nicole J. Toney, Ph.D; Yo-Ting Tsai, PhD; Claire S. Rumfield, PhD; Samuel T. Pellom, PhD; Caroline Jochems, MD, PhD; Julius Strauss, MD; James L. Gulley, MD, PhD; Jeffrey Schlom, PhD; Renee N. Donahue, PhD; | In-Progress Clinical Trials | Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; Tumor antigens; Vaccine |
| 376 | Poster Presentation | A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors | Shubham Pant, MD; Amishi Shah; Pavlos Msaouel, MD, PhD; Matthew T. Campbell, MD; Shi-Ming Tu; Jianjun Gao, MD PhD; George R. Blumenschein, Jr., MD; Frank Mott; Xiuning Le, MD, PhD; Mehmet Altan, MD; Funda Meric-Bernstam, MD; Timothy A. Yap, MD, PhD; Vivek Subbiah, MD; Jordi Rodon; Axel Glasmacher; Imke Mulder; Michael J. Chisamore, PhD; Alexander Stevenson, PhD; Nizar M. Tannir, MD, FACP; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Microbiome; Solid tumors; TLR |
| 377 | Poster Presentation | AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects | Claire H. Galand, PhD; Vignesh Venkatraman; Marilyn D. Marques; James Strauss, MD; Richard D. Carvajal, MD; Min Lim; Benjamin Morin, PhD; Olga Ignatovich, PhD; Mark A. Findeis, PhD; Dennis Underwood, PhD; Marc A. Van Dijk, PhD; Irina Shapiro, PhD; Lernik Ohanjanian, MD, MPH; Anna Wijatyk, MD; Nicholas Wilson, PhD; Jennifer S. Buell, PhD; Dhan Chand, PhD; David Savitsky, PhD; Anthony W. Tolcher, MD; | In-Progress Clinical Trials | Antibody; Clinical trial; Immune monitoring; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 378 | Poster Presentation | A first in-human, multicenter, open-label, dose-finding phase 1 study of the immune stimulator antibody conjugate NJH395 in patients with nonbreast HER2+ advanced malignancies | Filip Janku, MD, PhD; Sae-Won Han; Toshihiko Doi, MD, PhD; Jaffer A. Ajani, MD; Yasutoshi Kuboki; Ping Mahling; Kulandayan Subramanian; Marc Pelletier; Vasileios Askoxylakis, MD, PhD; Salvatore Siena; | In-Progress Clinical Trials | Antibody; Clinical study; Clinical trial; Cytokine; T cell; TLR; Tumor infiltrating lymphocytes (TILs) |
| 379 | Poster Presentation | Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor | David S. Hong, MD; David S. Hong, MD; David S. Hong, MD; Jeffrey M. Clarke, MD; Tanner Johanns; Partow Kebriaei; John V. Heymach, MD, PhD; Ahmed Galal; Samuel Saibil; Adrian Sacher, MD, MSc; Francine Brophy; Gareth Betts, PhD; Natalie Bath, MSc; Spinner William; Alex J. Tipping, PhD; Jessica Tucci; Raymond Luke; Trupti Trivedi, MS; Quan Lin; Jean-Marc Navenot, PhD; Paula M. Fracasso, MD, PhD; Karen Miller, PhD; Elliot Norry, MD; Mark Dudley; Marcus O. Butler, MD; | In-Progress Clinical Trials | Adoptive immunotherapy; Targeted therapy |
| 380 | Poster Presentation | Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors | David Hong, MD; Sandip P. Patel, MD; Manish R. Patel, D.O.; Kimberly Musni, BSHA; Marlisa Anderson, MPH; Sarah Cooley, PhD, MS; Bahram Valamehr, PhD; Wayne Chu, MD; | In-Progress Clinical Trials | Adoptive immunotherapy; Checkpoint blockade; Clinical trial; Leukemia/Lymphoma; NK/NK T cell; Solid tumors |
| 381 | Poster Presentation | Role of CT Scans of Abdomen and Pelvis in Management of Patients with Immunotherapy-induced Colitis | Juan J. Ibarra Rovira, MD; Raghunandan Vikram, MD; Selvi Thirumurthi, MD; Bulent Yilmaz, MD; Heather Lin, MS, PhD; Fechukwu O. Akhmedzhanov, MD, MPH; David S. Hong, MD; Abdulrazzak Zarifa; Melissa Tagart, MD; Funda Meric-Bernstam, MD; Aung Naing, MD, FACP; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Immune toxicity; Inflammation; Targeted therapy |
| 382 | Poster Presentation | Targeting Innate Immunity with BXCL701 in Combination with Pembrolizumab in Patients with Advanced Solid Cancers: Phase 2 Basket Study | Filip Janku, MD, PhD; Apostolia M. Tsimberidou, MD, PhD; Veronica R. Holley; Abha Adat, MD; Ozgur Karakuzu, PhD; Greg Call, PhD; Gabriele Urschel; Diane Healey, MS; Vincent O’Neill; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Inflammation; Solid tumors |
| 383 | Poster Presentation | First-in-man clinical trial of intratumoral injection of Clostridium novyi-NT spores in combination with pembrolizumab in patients with treatment-refractory advanced solid tumors | Filip Janku, MD, PhD; Siqing Fu, MD, PhD; Ravi Murthy, MD; Daniel D. Karp, MD; David S. Hong, MD; Apostolia M. Tsimberidou, MD, PhD; Maura L. Gillison, MD PhD; Abha Adat, MD; Anjali Raina; Greg Call, PhD; Brent L. Kreider; David Tung; Mary Varterasian, MD; Khashayarsha Khazaie, PhD, DSc; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Inflammation; Vaccine |
| 384 | Poster Presentation | A Phase 1 study to evaluate the safety, PK, and antitumor activity of AK117, an anti-CD47 monoclonal antibody, in subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas | Amy AP. Prawira, MD; Jermaine Coward; Anna Mislang, MD; Adnan Nagrial, MD; Hui K. Gan, MBBS PhD; Xiaoping Jin, PhD; Baiyong Li, PhD; Zhongmin Maxwell Wang, PhD; Kon Yew Kwek; Dennis Xia; Yu Xia, PhD; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical trial; Leukemia/Lymphoma; Monocyte/Macrophage; Solid tumors; Tumor antigens; Tumor evasion |
| 385 | Poster Presentation | A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results | Jordan Berlin, MD; Wael A. Harb, MD; Alex A. Adjei, MD PhD; Yan Xing, MD, PhD; Paul Swiecicki, MD; Mahesh Seetharam, MD; Lakshminarayanan Nandagopal, MD; Ajay Gopal, MD; Cong Xu, MD, PhD; Cong Xu, MD, PhD; Yuan Meng, MD; Linda Lee, PharmD; Yonggang Zhao, PhD; Zhengyi Wang, PhD; Joan Huaqiong Shen, MD, PhD; | In-Progress Clinical Trials | Antibody; Clinical study; Clinical trial; Monocyte/Macrophage; Solid tumors |
| 386 | Oral Presentation | Phase I/Ib first-in-human study of HEK-NIZ985, a recombinant IL-15/IL-15Rα heterodimer, alone and in combination with spartalizumab, in adults with advanced and metastatic solid tumors | Rom S. Leidner, MD; Andrea Wang-Gillam, MD, PhD; Sumati Gupta, MD; Robert Wesolowski, MD; Douglas G. McNeel, MD, PhD; Kevin C. Conlon, MD; Nehal S. Parikh, MD; Jessica A. O’Keeffe, PhD; Niladri Roy Chowdhury, PhD; Xiaoli Wang, PhD; Ryan Sullivan, PhD; John A. Thompson, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Cytokine; NK/NK T cell; Solid tumors |
| 387 | Poster Presentation | A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies | Chia-Chi Lin, MD, PhD; Elena Garralda, MD; Patrick Schöffski; David S. Hong, MD; Lillian Siu, MD; Miguel Martin, MD; Michela Maur, MD; Rina Hui, MD; Ross Soo, MD; Joanne Chiu, MD; Tian Zhang, MD; Brigette Ma, MD; Chrisann Kyi, MD; Daniel Tan, MBBS, MRCP; Philippe Cassier, MD; John Sarantopoulos, MD; Andrew Weickhardt, MBBS, FRACP, DMedSc; Rich Carvajal, MD; Jennifer Spratlin, MD; Taito Esaki, MD; Fréderic Rolland; Wallace Akerley, MD; Barbara Deschler-Baier; Catherine A. Sabatos-Peyton, PhD; Niladri Roy Chowdhury, PhD; Daniel Gusenleitner, PhD; Eunice Kwak, MD, PhD; Vasileios Askoxylakis, MD, PhD; Filippo De Braud; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical trial; Coinhibition; Solid tumors |
| 388 | Poster Presentation | Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors | Johanna C. Bendell, MD; Wells Messersmith, MD; Drew Rasco, MD; Andrea Wang-Gillam, MD, PhD; Wungki Park, MD; Lei Zhou, MD, MS; Laura L. Carter, PhD; Jean-Marie Bruey, PhD; Jack Li, PhD; Beatrice Ferguson, MS; Jakob Dupont, MD; Marya F. Chaney, PhD; Johann S. De Bono, MD; | In-Progress Clinical Trials | Clinical trial; Gene expression; Immune contexture; Immune monitoring; Inflammation; MDSC; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 389 | Poster Presentation | Combining transcriptomic- and tissue-based immune biomarkers to evaluate GB1275, a CD11b modulator, as a single agent or with pembrolizumab in patients with advanced solid tumors | Wells Messersmith, MD; Drew Rasco, MD; Johann S. De Bono, MD; Andrea Wang-Gillam, MD, PhD; Wungki Park, MD; David Nickle, PhD; Anna Galkin, PhD; Beatrice Ferguson, MS; Laura L. Carter, PhD; Lei Zhou, MD, MS; Jakob Dupont, MD; Marya F. Chaney, PhD; Johanna C. Bendell, MD; Jean-Marie Bruey, PhD; | In-Progress Clinical Trials | Biomarkers; Clinical trial; Gene expression; MDSC; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 390 | Poster Presentation | Emerging safety and activity data from GEN-009-101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors | Maura L. Gillison, MD PhD; Roger B. Cohen, MD; Przemyslaw Twardowski, MD; Ammar Sukari, MD; Melissa L. Johnson, MD; Rudy Lackner, MD; Thomas A. Davis, MD; Thomas A. Davis, MD; Arthur P. DeCillis, MD; Richard Hernandez; Jessica Price; Kevin J. Mancini, MS; Mara G. Shainheit, PhD; Jessica B. Flechtner, PhD; Mark Awad, MD, PhD; Mark Awad, MD, PhD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Tumor antigens; Vaccine |
| 391 | Poster Presentation | A first-in-human study of intratumoral SAR441000, an mRNA mixture encoding IL-12sc, interferon alpha2b, GM-CSF and IL-15sushi as monotherapy and in combination with cemiplimab in advanced solid tumors | Oliver Bechter, MD; Jochen Utikal, MD; Jean-Francois Baurain, MD; Christophe Massard, MD; Ugur Sahin, MD; Evelyna Derhovanessian; Marie-Laure Ozoux, Phd; Rahul Marpadga, MD; Esteban-Rodrigo Imedio, MD; Nicolas P. Acquavella, MD; Carmen Loquai, MD; | In-Progress Clinical Trials | B cell; Checkpoint blockade; Clinical trial; Costimulation; Cytokine; Immune toxicity; RNA; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| 392 | Poster Presentation | Phase 1 Study of CI-8993 anti-VISTA antibody in patients with advanced solid tumor malignancies | Elizabeth Martinez, PhD/DHA, MSN, HCC,; Jason Faris, MD; Reinhard Von Roemeling, MD; Steven Angelides; Melissa L. Johnson, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Monocyte/Macrophage; Solid tumors; T cell; Targeted therapy; Tumor microenvironment; Tumor stroma |
| 393 | Poster Presentation | First-in-human phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: initial phase 1 results | Claire F. Friedman, MD; Paolo A. Ascierto, MD; Diwakar Davar, MD; Mark O'Hara, MD; Ronnie Shapira-Frommer, MD; Matthew Dallos, MD; Vivek Khemka, MD, MBA; Lee James, MD, PhD; Bruce S. Fischer, MD; Shilpa Demes, PhD; Li Li, PhD; Martin Kozicki, MBC; Palanikumar Ravindran, PhD; Ke Xu, PhD; Georgia Kollia, PhD; Jacqueline Shoukry, MBS; Mona Yunan, BA; Ashish Massey, MD, PhD; Martin Gutierrez, MD; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| 394 | Poster Presentation | Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results | Diwakar Davar, MD; Matteo Simonelli, MD; Martin Gutierrez, MD; Emiliano Calvo, MD PhD; Jason Melear, MD; Sarina A. Piha-Paul, MD; Donald Richards, MD, PhD; Matthew Dallos, MD; Janaki Parameswaran, MD; Vinit Kumar, PhD; Xiaochen Zhao, PhD; Santanu Dutta, PhD; Ignacio J. Melero, MD, PhD; | In-Progress Clinical Trials | Antibody; Biomarkers; Checkpoint blockade; Chemokine; Clinical trial; Cytokine; MDSC; Myeloid cells; Solid tumors; Tumor microenvironment |
| 395 | Poster Presentation | A first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, in patients with advanced cancer and resistance to PD-(L)1 therapy | Timothy A. Yap, MD, PhD; Deborah J. Wong, M.D., Ph.D.; Siwen Hu-Lieskovan, PhD, MD; Kyriakos P. Papadopoulos, MD; Michelle Morrow, PhD; Michelle Morrow, PhD; Urszula Grabowska, PhD; Daniel Gliddon, PhD; Josefin-Beate Holz, MD, PhD; Patricia LoRusso, DO; | In-Progress Clinical Trials | Antibody; Bispecifics; Checkpoint blockade; Clinical trial; Coinhibition; T cell |
| 396 | Poster Presentation | Overcoming resistance to anti-PD-1 with tumor agnostic NBTXR3: from bench to bed side | James W. Welsh, MD; Colette Shen; Jessica Frakes, MD; Jiaxin Niu, MD, PhD; Jared Weiss, MD; Jimmy Caudell, MD; Hu Yun, PhD; Hampartsoum Barsoumian, PhD; Juliette Thariat, MD, PhD; Sylvie Bonvalot, MD; Zsusanna Papaï; Maria Angelica Cortez, PhD; Ping Zhang, PhD; Katherine L. Jameson, PhD; Patricia Said; Sébastien Paris; Tanguy Seiwert, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Radiotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 397 | Poster Presentation | Intra-Tumor Immunotherapy Injections utilizing Image guidance in Interventional Radiology: Clinical Trial Experience at a Tertiary care Cancer Center | Ravi Murthy; Rahul A. Sheth, MD; Alda Tam; Sanjay Gupta; Vivek Subbiah, MD; Filip Janku, MD, PhD; Timothy A. Yap, MD, PhD; Adi Diab, MD; Aung Naing, MD, FACP; Sapna Patel, MD; Funda Meric-Bernstam, MD; | In-Progress Clinical Trials | Clinical trial; Solid tumors; Vaccine |
| 398 | Poster Presentation | AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy | Steven J. O'Day, MD; Anthony El khoueiry, MD; Chethan Ramamurthy, MD; Andrea Bullock, MD; Irina Shapiro, PhD; Serina Ng, BS; Haiyong Han, PhD; Lernik Ohanjanian Namagerdi, MD, MPH; Remigiusz Kaleta, MD; Anna Wijatyk, MD; Olivia J. Wijatyk; waldo Ortuzar, MD; Marek Ancukiewicz, PhD; Jennifer S. Buell, PhD; Dhan Chand, PhD; Michael S. Gordon; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Solid tumors |
| 399 | Poster Presentation | Cosibelimab, an anti-PD-L1 antibody: Preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial | Dean L. Harris, MD FRACP; Daniel Brungs; Rahul Ladwah; Andrew Mant, MD; Margaret McGrath; Andrea Tazbirkova; Andrey Akopov; Natalia Fadeeva; Boris Kasparov; Nadezhda V. Kovalenko; Vadim Kozlov; Fedor Moiseenko; Vasiliy Oschepkov; Piotr Koralewski; Dariusz Kowalski; Iwona Lugowska; Chaiyut Charoentumn; Arunee Dechaphunkul; Virote Sriuranpong; James Oliviero; Philip R. Clingan; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| 400 | Poster Presentation | CoupledCARTM Technology for Treating Thyroid Cancer | Xingchen Liu; Keshu Zhou; Yong Huang; Chengfei Pu; Zhiyuan Cao; Ruihong Zhu; Haiyang Tang; Zhipeng Huang; Hang Yang; Xi Huang; Yongping Song; Renbin Liu; Zhao Wu; Lei Xiao, Ph.D.; | In-Progress Clinical Trials | Adoptive immunotherapy; Biomarkers; CAR T cells; Clinical study; Gene expression; Inflammation; Solid tumors; T cell; Tumor antigens |
| 401 | Poster Presentation | Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors | Manish R. Sharma, MD; Ecaterina Ileana Dumbrava, MD; Richard D. Carvajal, MD; Daniel V. Catenacci, MD; Leisha A. Emens, MD, PhD; Glenn J. Hanna, MD; Dejan Juric; Yoon-Koo Kang; Jeeyun Lee, MD, PhD; Keun-Wook Lee, MD, PhD; Bob T. Li; Kathleen N. Moore; Mark D. Pegram; Paula R. Pohlmann; Drew Rasco; Alexander I. Spira, MD, PhD, FACP; Antoinette Tan; Ding Wang, MD; Shelley E. Ackerman, PhD; Heidi N. LeBlanc; David Dornan, PhD; Marcin Kowanetz, Ph.D.; Michael N. Alonso, PhD; Edith A. Perez, MD; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical study; Immune adjuvant; Myeloid cells; Solid tumors; T cell; Targeted therapy; TLR; Tumor microenvironment |
| 402 | Poster Presentation | DRAGON: Phase 1 trial of SRK-181, a latent TGFβ1 inhibitor in combination with anti-PD-(L)1 inhibitors for patients with solid tumors unresponsive to anti-PD-(L)1 therapy alone | Johanna C. Bendell, MD; Lu Gan; Johanna C. Bendell, MD; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical study; Solid tumors |
| 403 | Poster Presentation | Early results from a phase 1 study to evaluate safety, pharmacokinetics, and efficacy of AMG 404, a programmed death-1 (PD-1) antibody, in patients with advanced solid tumors | Timothy J. Price, MBBS, DHlthSc (Medicine), FRACP; Sant P. Chawla, MD; Gerald S. Falchook, MD, MS; Hans Prenen, MD; Iwona Lugowska; Vivek Subbiah, MD; Jose Monzon; Yuichi Ozawa; Tobias Arkenau, MD, PhD; Caio S. Rocha Lima, MD; Yasutoshi Kuboki; Tomohiro Nishina; Mun Hui; Erik Rasmussen, PhD; Hansen Wong; Saltanat Najmi; Nooshin H. Sadraei; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Cytokine; Solid tumors |
| 404 | Poster Presentation | ALX148, a CD47 blocker, in combination with standard chemotherapy and antibody regimens in patients with gastric/gastroesophageal junction (GC) cancer and head and neck squamous cell carcinoma (HNSCC) | Keun-Wook Lee, MD, PhD; Hyun C. Chung, MD, PhD; Won Seog Kim, MD; Laura Q. Chow, MD; Nehal Lakhani, MD, PhD; Wells Messersmith, MD; Yung-Jue Bang, MD PhD; Patricia LoRusso, DO; Philip S. Fanning, PhD; Pierre Squifflet, MSc; Feng Jin, PhD; Alison Forgie, PhD; Hong I. Wan, PhD; Jaume Pons, PhD; Sophia S. Randolph, MD, PhD; Justin F. Gainor, MD; | In-Progress Clinical Trials | Antibody; Antigen presenting cells; Checkpoint blockade; Chemotherapy; Clinical trial; Costimulation; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor microenvironment |
| 405 | Poster Presentation | CDX1140-01, a Phase 1 dose-escalation/expansion study of CDX-1140 alone (Part 1) and in combination with CDX-301 (Part 2) or pembrolizumab (Part 3) | Rachel E. Sanborn, MD; Ralph J. Hauke, MD; Nashat Y. Gabrail, MD; Mark O'Hara, MD; Nina Bhardwaj, MD, PhD; Rodolfo E. Bordoni, MD; Michael S. Gordon; Danny Khalil, MD, PhD; Maen Abdelrahim; Thomas U. Marron, MD, PhD; Thomas Hawthorne; Lawrence J. Thomas, PhD; Tracey Rawls, MA; Mark Rogalski; Diego Alvarado; Laura Vitale, BS; Tibor Keler, PhD; Michael Yellin, MD; | In-Progress Clinical Trials | Antibody; Biomarkers; Clinical trial; Dendritic cell; Leukemia/Lymphoma; Solid tumors; Tumor microenvironment |
| 406 | Poster Presentation | CDX527-01, a phase 1 dose-escalation and expansion study of the PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies | Michael Yellin, MD; Tracey Rawls, MA; Diane C. Young, MD; Philip Golden; Laura Vitale, BS; Li-Zhen He, MD; Lawrence J. Thomas, PhD; Tibor Keler, PhD; | In-Progress Clinical Trials | Antibody; Biomarkers; Bispecifics; Checkpoint blockade; Clinical trial; Costimulation; Solid tumors |
| 407 | Poster Presentation | Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors | Elaine Shum, MD; Adil Daud, MD; Matthew J. Reilley, MD; Yana G. Najjar, MD; John A. Thompson, MD; Joaquina C. Baranda, MD; R. Donald Harvey, PharmD; Rom S. Leidner, MD; Anthony F. Shields, MD PhD; Ezra EW. Cohen, MD; Roger B. Cohen, MD; Alain Mita, MD; Shubham Pant, MD; Mark N. Stein, MD; Bartosz Chmielowski, MD, PhD; Siwen Hu-Lieskovan, MD, PhD; Catherine A. Fleener, MS; Ying Ding, PhD; Sowmya Chollate, MS; Hector Avina; Jolene S. Shorr; Raphael Clynes, MD, PhD; Barbara Hickingbottom, MD; | In-Progress Clinical Trials | Antibody; Biomarkers; Bispecifics; Checkpoint blockade; Clinical study; Clinical trial; Immune toxicity; Solid tumors; T cell |
| 408 | Poster Presentation | Phase I, first-in-human trial evaluating BI 1387446 (stimulator of interferon genes [STING] agonist) alone and combined with BI 754091 (anti-programmed cell death [PD]-1) in solid tumors | Kevin Harrington, PhD, FRCP, FRCR; Eileen Parkes; Jared Weiss, MD; Mathew Ingham; Andrés Cervantes; Emiliano Calvo, MD PhD; Matthew Riese; Ute Klinkhardt; Patricia Sikken; Michael Schmohl; Elena Garralda, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Coinhibition; Solid tumors |
| 409 | Poster Presentation | A Phase I Trial of Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO) | John H. Stewart, IV, MD, MBA; John H. Strickler, MD; Niharika B. Mettu, MD, PhD; Shannon MacLaughlan, MD; Donna Niedzwiecki, PhD; Edward Levine, MD; Daniel Blazer, MD; | In-Progress Clinical Trials | Clinical trial; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 410 | Poster Presentation | Phase I study of intratumoral NBTXR3 in combination with anti-PD-1 in patients with advanced cancers | Colette Shen; Jessica Frakes, MD; Jiaxin Niu, MD; Jared Weiss, MD; Jimmy Caudell, MD; Katherine L. Jameson, PhD; Patricia Said; Tanguy Seiwert, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Radiotherapy; T cell; Tumor infiltrating lymphocytes (TILs) |
| 411 | Poster Presentation | Novel intratumoral agent, INT230-6 induces cancer cell death, increases tumor infiltrates and results in durable benefit alone or in combination with pembrolizumab in refractory patients | Anthony El-Khoueiry, MD; Jacob Thomas, MD; Anthony J. Olszanski, MD, RPh; Nilofer Azad, MD; Lewis H. Bender, MS, MA, MBA; Ian B. Walters, MD, MBA; Ian B. Walters, MD, MBA; Giles F. Whalen, MD; Diana Hanna, MD; Matthew Ingham, MD; Lilian L. Siu, MD; | In-Progress Clinical Trials | Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Neoantigens; Solid tumors; Tumor antigens; Tumor infiltrating lymphocytes (TILs) |
| 412 | Poster Presentation | First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4-1BB (GEN1046) in patients with advanced solid tumors | Elena Garralda, MD; Ravit Geva, MD; Eytan Ben-Ami; Corinne Maurice-Dror; Emiliano Calvo, MD PhD; Patricia LoRusso, DO; Özlem Türeci; Michelle Niewood; Ugur Sahin; Maria Jure-Kunkel; Ulf Forssmann; Tahamtan Ahmadi; Ignacio J. Melero, MD, PhD; | In-Progress Clinical Trials | Antibody; Bispecifics; Checkpoint blockade; Clinical study; Clinical trial; Coinhibition; Costimulation; Solid tumors; Targeted therapy |
| 413 | Poster Presentation | GEN-009, a personalized neoantigen vaccine, elicits robust immune responses in individuals with advanced or metastatic solid tumors | Mara G. Shainheit, PhD; Devin P. Champagne; Gabriella Santone; Syukri Shukor; Ece Bicak; Samuel Tipps; Li Xue; Thomas A. Davis, MD; Jessica B. Flechtner, PhD; Mara G. Shainheit, PhD; | In-Progress Clinical Trials | Biomarkers; Clinical study; Neoantigens; Solid tumors; T cell; Vaccine |
| 414 | Poster Presentation | Enhancing T cell therapy for patients with relapsed/refractory Wilms Tumor | Amy Hont, MD; Conrad R. Cruz; Maja Stanojevic; Robert Ulrey; Madeline Terpilowski; Emily Reynolds; Fahmida Hoq; Maria F. Fortiz; Haili Lang; Jeffrey S. Dome; Patrick J. Hanley; Catherine Bollard, MD; Holly J. Meany; | In-Progress Clinical Trials | Adoptive immunotherapy; Clinical trial; Immune monitoring; Pediatric tumors; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| 415 | Poster Presentation | Toripalimab plus nab-paclitaxel and carboplatin as neoadjuvant therapy for patients with esophageal squamous cell carcinoma at clinical stage T2-T4/N0-N2/M0: a single-arm, single-center clinical study | Kunkun Li, MD; Xiao Yang; Wei Luo; Qiang Ma; Yingjian Wang; Yanli Xiong; Xiaolong Zhao; Xianfeng Lu; Tao Bao; Wei Guo; Mengxia Li; | In-Progress Clinical Trials | Checkpoint blockade; Chemotherapy; Clinical study; Surgery |
| 416 | Poster Presentation | SQ3370-001 is a multi-center open-label phase I dose-escalation study to test a novel intratumoral and systemic approach to treat advanced solid tumors | Vivek Bhadri, MD; Nam Bui, MD; Alexander Guminski, MD; Jose M. Mejia Oneto, MD, PhD; Ravi Murthy, MD; Kamalesh Sankhala, MD; M. Wayne Saville, MD; M. Wayne Saville, MD; M. Wayne Saville, MD; Sangeetha Srinivasan, PhD; Robert Steffner, MD; Vivek Subbiah, MD; Ding Wang, MD; Nathan A. Yee, PhD; | In-Progress Clinical Trials | Chemotherapy; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 417 | Poster Presentation | Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumors | Gregory A. Durm, MD; Sophia Frentzas; Erik Rasmussen; Saltanat Najmi; Nooshin H. Sadraei; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Cytokine; Solid tumors |
| 418 | Poster Presentation | A Phase 1, Dose Escalation and Dose Expansion Study of SQZ PBMC HPV as Monotherapy and in Combination with Atezolizumab in HLA-A*02+ Patients with HPV16+ Recurrent, or Metastatic Solid Tumors. | Cathy Eng, MD; Joaquina C. Baranda, MD; Matthew H. Taylor; Michael S. Gordon; Ursula A. Matulonis, MD; Filip Janku, MD, PhD; Martin Kornacker, MD; Asha Kamat, PhD; Oliver Rosen; Antonio Jimeno, MD, PhD; Cathy Eng, MD; | In-Progress Clinical Trials | Adoptive immunotherapy; Antigen presenting cells; Biomarkers; Clinical study; T cell; Tumor infiltrating lymphocytes (TILs); Vaccine |
| 419 | Poster Presentation | Pharmacodynamic biomarkers demonstrate T-cell activation in patients treated with the oral PD-L1 inhibitor INCB086550 in a phase 1 clinical trial | Sarina A. Piha-Paul, MD; Tara C. Mitchell, MD; Solmaz Sahebjam, MD; Janice M. Mehnert, M.D.; Thomas Karasic; Kevin O’Hayer; Ryan Geschwindt, BS; Susan Spitz, PhD; Hao Liu, PhD; Johanna C. Bendell, MD; Sarina A. Piha-Paul, MD; | In-Progress Clinical Trials | Biomarkers; Checkpoint blockade; Inflammation; Solid tumors; T cell |
| 420 | Oral Presentation | Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study | Adi Diab, MD; Scott S. Tykodi, MD, PhD; Gregory A. Daniels, MD, PhD; Michele Maio, MD; Brendan D. Curti, MD; Karl D. Lewis, MD; Sekwon Jang, MD; Ewa Kalinka, PhD, MD; Igor Puzanov, MD, MSCI; Alexander I. Spira, MD, PhD, FACP; Daniel C. Cho, MD; Shanhong Guan, PhD; Erika Puente, MD; Ute Hoch, PhD; Sue L. Currie, PhD; Tuan Nguyen, PhD; Wei Lin, MD; Mary A. Tagliaferri, MD; Jonathan Zalevsky, PhD; Mario Sznol, MD; Michael E. Hurwitz, MD, PhD; | In-Progress Clinical Trials | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Cytokine; Solid tumors; T cell |
| 421 | Poster Presentation | Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors | Francesca Aroldi, MD; Joseph Sacco, MSc, MBChB, MRCP, Ph; Kevin Harrington, PhD, FRCP, FRCR; Anna C. Olsson-Brown, MD; Pablo Nanclares, MD; Lavita Menezes; Praveen K. Bommareddy, MS, PhD; Suzanne Thomas, PhD; Howard L. Kaufman, MD; Selda Samakoglu, MD, PhD; Mark R. Middleton, MD, PhD; Robert S. Coffin, PhD; | In-Progress Clinical Trials | Antibody; Antigen presenting cells; Checkpoint blockade; Clinical trial; Dendritic cell; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 422 | Poster Presentation | An Open-label, multicenter, Phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: Updated results from the skin cancer cohorts | Mark R. Middleton, MD, PhD; Francesca Aroldi, MD; Joseph Sacco, MSc, MBChB, MRCP, Ph; Mohammed M. Milhem, MBBS; Brendan D. Curti, MD; Ari M. VanderWalde, MD, MPH, MBioeth; Scott Baum, MD; Adel Samson, MBChB, PhD; Anna C. Pavlick, MD, MBA; Jason A. Chesney, MD; Jiaxin Niu, MD; Terence Rhodes, MD, PhD; Tawnya L. Bowles, MD; Robert M. Conry, MD; Anna C. Olsson-Brown, MD; Douglas Earl Laux, MD; Howard L. Kaufman, MD; Praveen K. Bommareddy, MS, PhD; Alex Deterding; Selda Samakoglu, MD, PhD; Robert S. Coffin, PhD; Kevin Harrington, PhD, FRCP, FRCR; | In-Progress Clinical Trials | Clinical trial; Solid tumors; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Vaccine |
| 423 | Poster Presentation | Safety and preliminary efficacy of intratumoral cavrotolimod (AST-008), a spherical nucleic acid TLR9 agonist, in combination with pembrolizumab in patients with advanced solid tumors | Steven J. O'Day, MD; Cesar A. Perez, MD; Trisha M. Wise-Draper, MD, PhD; Glenn J. Hanna, MD; Shailender Bhatia, MD; Ciara Kelly, MD; Theresa Medina, MD; Douglas E. Laux, MD; Adil Daud, MD; Sunandana Chandra, MD; Montaser F. Shaheen, MD; Ling Gao, MD; Melissa Burgess, MD; Leonel Hernandez-Aya, MD; Cecilia CS. Yeung, MD; Kimberly Smythe, PhD; Emil M. DeGoma, MD; Weston L. Daniel, PhD; Douglas E. Feltner, MD; Laurel Sindelar; Robert E. Michel, PhD; Alice S. Bexon, MD; Martin Bexon, MD; Mohammed M. Milhem, MBBS; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; TLR; Tumor microenvironment |
| 425 | Poster Presentation | Investigation of Wnt Ligand Signaling Regulators as a Predictor of Anti-PD-1 Response in Metastatic Melanoma | Nicholas DeVito, MD; Michael Sturdivant, B.S.; Luke P. Wachsmuth, B.S.; John H. Strickler, MD; Georgia M. Beasley, MD, MHs; Rami Al-Rohil; April Salama, MD; Brent A. Hanks, MD, PhD; | In-Progress Clinical Trials | Biomarkers; Checkpoint blockade; Clinical trial; Dendritic cell; Gene expression; Immune suppression; Immune tolerance; Solid tumors; Tumor evasion; RNA |
| 426 | Poster Presentation | MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma | Reinhard Dummer, MD; Georgina V. Long, BSc, PhD, MB, BS, FRACP; Anna Pavlick, DO; Michael Postow, MD; Antoni Ribas, MD, PhD; Caroline Robert, MD, PhD; Richard A. Scolyer, BMedSci, MBBS, MD, FRCPA, FRCPath; Janis M. Taube, MD; Michael Tetzlaff, MD, PhD; Jason Liao, PhD; Sama Ahsan, MD; Scott J. Diede, MD, PhD; Hussein A. Tawbi, MD, PhD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| 427 | Poster Presentation | A Phase 1b/2 Study of Cabozantinib in Combination with Pembrolizumab in Advanced Melanoma | Jayanshu Jain, MD; Melanie Frees; Hesham Yasin; Jaime Bonner; Michele Freesmeier; Rohan Garje; Vyshak Alva Venur, MD; Mohammed M. Milhem, MBBS; Yousef Zakharia, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Targeted therapy |
| 428 | Poster Presentation | Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs) | Karl D. Lewis, MD; Ketty Peris, MD; Alexander J. Stratigos, MD, PhD; Lara A. Dunn, MD; Zeynep Eroglu, MD; Anne Lynn S. Chang, MD; Michael R. Migden, MD; Siyu Li, PhD; Kosalai Mohan, PhD; Ebony Coates, MHA; Emmanuel Okoye, MBBS, MPH; Jean-François Baurain, MD, PhD; Oliver Bechter, MD; Axel Hauschild, MD; Marcus O. Butler, MD; Leonel Hernandez-Aya, MD; Lisa Licitra, MD; Rogerio I. Neves, MD PhD FACS; Emily S. Ruiz, MD; Frank Seebach, MD; David M. Weinreich, MD; George D. Yancopoulos, MD, PhD; Israel Lowy, MD, PhD; Timothy Bowler, MD, PhD; Matthew G. Fury, MD, PhD; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical trial |
| 429 | Poster Presentation | Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma | Georgina V. Long, MBBS, PhD, BSc, FRAC; Reinhard Dummer, MD; Douglas B. Johnson, M.D.; Olivier Michielin, MD PhD; Salvador Martin-Algarra; Sheryl A. Treichel; Edward L. Chan; Scott J. Diede, MD, PhD; Antoni Ribas, MD, PhD; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; Targeted therapy |
| 430 | Poster Presentation | A phase II study of nivolumab + BMS-986016 (relatlimab) in patients with metastatic uveal melanoma(UM) (CA224-094) | Jose Lutzky, MD, FACP; Lynn Feun, MD; William J. Harbour, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Coinhibition; Solid tumors; T cell |
| 431 | Poster Presentation | Prospective, randomized trial of the tumor lysate, particle only vaccine compared to the tumor lysate, particle-loaded, dendritic cell vaccine to prevent recurrence for resected stage III/IV melanoma | Patrick M. McCarthy, MD; Lexy M. Adams, MD, MPH; Robert C. Chick, M.D.; Guy T. Clifton, MD; Timothy J. Vreeland, BS MD; Anne E. O'Shea, MD; Phillip M. Kemp Bohan, MD; Annelies T. Hickeron, MD; Jessica L. Campf, MD; John W. Myers, MD; Tommy A. Brown, MD; Diane F. Hale, MD; Mark B. Faries, MD; John Hyngstrom, MD; Adam C. Berger, FACS, MD; James W. Jakub, MD; Jeffrey J. Sussman, MD; Montaser F. Shaheen, MD; Thomas E. Wagner, BS, MD; George E. Peoples, MD, FACS; | In-Progress Clinical Trials | Antigen presenting cells; Clinical study; Clinical trial; Dendritic cell; Solid tumors; Surgery; Targeted therapy; Vaccine; Extracellular vesicles/exosomes |
| 432 | Poster Presentation | 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma | Reinhard Dummer, MD; David E. Gyorki; John Hyngstrom, MD; Adam C. Berger, FACS, MD; Robert M. Conry, MD; Lev Demidov, MD, DSc; Edward L. Chan; Hoi-Shen Radcliffe; Mark B. Faries, MD; Merrick Ross, MD; | In-Progress Clinical Trials | Clinical trial; Solid tumors; Surgery |
| 433 | Poster Presentation | Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial | Igor Puzanov, MD, MSCI; Jason A. Chesney, MD; Frances A. Collichio, MD; Parminder Singh, MD; Mohammed M. Milhem, MBBS; John Glaspy, MD; Omid Hamid, MD; Merrick Ross, MD; Philip Friedlander, MD PhD; Claus Garbe, MD, PhD; Theodore F. Logan, MD; Axel Hauschild, MD; Celeste Lebbe; Min Yi; Wendy Snyder; Janice M. Mehnert, M.D.; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Solid tumors |
| 434 | Poster Presentation | Updated clinical data from the melanoma expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab | Michael Postow, MD; Ryan J. Sullivan, MD; Ezra EW. Cohen, MD; Martin Gutierrez, MD; David S. Hong, MD; Conor Steuer, MD; Jerry McCarter, RN, BSN; Nora Zizlsperger; Jeff Kutok, MD, PhD; Brenda O'Connell, PhD; Jennifer Roberts; Kara Page; Halle Zhang, PhD; Bartosz Chmielowski, MD, PhD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Immune suppression; Immune tolerance; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; Tumor microenvironment |
| 435 | Poster Presentation | A phase II trial of nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma | Saba S. Shaikh, MD; Yan Zang, MS; Hong Wang, PhD; Xi Yang, BS; Cindy Sander; Amy Rose; Diwakar Davar, MD; Jason J. Luke, MD; Hassane M. Zarour, MD; John M. Kirkwood, MD; Greg M. Delgoffe, PhD; Yana G. Najjar, MD; | In-Progress Clinical Trials | Angiogenesis; Checkpoint blockade; Clinical trial; Metabolism; Solid tumors; Targeted therapy; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 436 | Poster Presentation | Rational Sequencing of Immune-Oncology Therapies Achieves Durable Response and Immunologic Memory | Robert Saddawi-Konefka, MD PhD; Aoife E. O'Farrell; Andrew Sharabi, MD, PhD, FACS; Joseph Califano; J. Silvio Gutkind; | Combination Immunotherapies | Checkpoint blockade; Immune adjuvant; Radiotherapy; Solid tumors; Surgery; T cell; Targeted therapy |
| 437 | Poster Presentation | Adenovirus IL-12 and Docetaxel in Combination with Anti-PD1 as an Effective Treatment Strategy for TNBC | Ann C. Anselme, BS; Wei Qian, BS; Roberto R. Rosato, PhD; Jianying Zhou; Jenny C. Chang, MD; Ann C. Anselme, BS; | Combination Immunotherapies | Checkpoint blockade; Chemotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 438 | Poster Presentation | Synergy Between SEA-CD40 and Chemotherapeutics Drives Curative Antitumor Activity in Preclinical Models | Weiping Zeng; Haley Neff-LaFord; Sahar Ansari; Celine Jacquemont, PhD; Michael Schmitt, MD, PhD; Shyra J. Gardai, PhD; | Combination Immunotherapies | Antibody; Antigen presenting cells; Chemotherapy; Costimulation; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; Tumor microenvironment |
| 439 | Poster Presentation | Dual modes of action for anti-TIM-3 antibody MBG453 in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): preclinical evidence for immune-mediated and anti-leukemic activity | Catherine A. Sabatos-Peyton, PhD; Tyler A. Longmire; Lisa Baker; Nidhi Patel; Anne-Sophie Wavreille; Melanie Verneret; Pushpa Jayaraman, PhD; Xiaomo Jiang; Stephanie Schwartz; Viviana Cremasco; Hongbo Lu; Shumei Qiu; Fiona A. Sharp, PhD; Mikael Rinne; Glenn Dranoff, MD; | Combination Immunotherapies | Antibody; Leukemia/Lymphoma; Monocyte/Macrophage; Myeloid cells; Tumor microenvironment |
| 440 | Poster Presentation | Activity and safety of camrelizumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced non-small-cell lung cancer | Guo Gui Sun; Jing Hao Jia; Peng Gao; Xue Min Yao; Ming Da Chen; Wei Nan Yao; Lu Sun; Wei Wang; | Combination Immunotherapies | COVID and Immunotherapy; Checkpoint blockade; Chemotherapy; Clinical study; Immune monitoring; Immune suppression; Solid tumors; T cell; Tumor evasion; Tumor microenvironment |
| 441 | Poster Presentation | Outcomes of patients with metastatic renal cell carcinoma with intermediate- or poor-risk symptomatic disease who received their first cycle of nivolumab and ipilimumab while being hospitalized | Omar Alhalabi, MD; Elshad Hasanov; John Araujo; Jianbo Wang; Matthew T. Campbell, MD; Sangeeta Goswami, MD, PhD; Amishi Shah; Jianjun Gao, MD PhD; Pavlos Msaouel, MD, PhD; Nizar M. Tannir, MD, FACP; | Combination Immunotherapies | Checkpoint blockade; Clinical study; Solid tumors |
| 442 | Poster Presentation | ICT01, an anti-BTN3A mAb that activates Vg9Vd2 T cells, plus interleukin-2: a potent and promising combination for cancer immunotherapy | Aude de Gassart, PhD; Patrick Brune; Suong LE; Sophie Agaugué; Emmanuel Valentin, PhD; Jennifer Sims; Daniel OLIVE, M.D., Ph.D.,; Paul Frohna, MD, PharmD, PhD; Rene HOET; | Combination Immunotherapies | Antibody; T cell; T cell lineages |
| 443 | Poster Presentation | An Immunotherapy Trio in advanced HNSCC for coordinated B and T cell antigen response | Bernard A. Fox, PhD; Tarsem L. Moudgil, MS; Traci L. Hilton, PhD; Noriko NI. Iwamoto, PhD; Christopher C. Paustian, PhD; Adi Mehta, PhD; Fridtjof Lund-Johansen, MD, PhD; Rachel E. Sanborn, MD; Bryan R. Bell, MD, DDS, FACS; Madeleine Laws, BS; Glenna McDonnell, MS; Yoshinobu Koguchi, MD, PhD; Carlo B. Bifulco, MD; Brian D. Piening, PhD; Carmen Ballesteros Merino, PhD; Shawn M. Jensen, PhD; Takashi Shimada, PhD; Hong-Ming Hu, PhD; Walter J. Urba, MD, PhD; Rom S. Leidner, MD; Marcus A. Couey, MD, DDS; | Combination Immunotherapies | Antibody; Clinical study; Clinical trial; Costimulation; Neoantigens; Solid tumors; Surfaceome; T cell; Tumor antigens; Vaccine |
| 444 | Poster Presentation | MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination | Mathieu Gigoux, PhD; Roberta Zappasodi, PhD; Joseph J. Park; Stephane Pourpe; Arnab Ghosh, MD, PhD; Cansu Cimen Bozkus, PhD; Levi M. Mangarin, BS; David Redmond; Svena Verma, BS; Sara Schad, BS; William Duke; Max Jan; Matthew J. Leventhal; Vincent Ho; Gabriela S. Hobbs; Trine Alma Knudsen; Vibe Skov; Lasse Kjær; Thomas Stauffer Larsen; Dennis Lund Hansen; R. Coleman Lindsley; Hans Hasselbalch; Jacob H. Grauslund; Mads H. Andersen, PhD; Morten O. Holmström; Timothy A. Chan, MD, PhD; Raajit Rampal; Omar Abdel-Wahab, M.D.; Nina Bhardwaj, MD, PhD; Jedd D. Wolchok, MD, PhD; Ann Mullally, M.D.; Taha Merghoub, PhD; Mathieu Gigoux, PhD; | Combination Immunotherapies | Checkpoint blockade; Immune monitoring; Neoantigens; T cell; Tumor antigens; Tumor evasion; Vaccine |
| 445 | Poster Presentation | Blockade of the inhibitory collagen receptor LAIR-1 with NC410, a LAIR2-Fc fusion protein, enhances anti-tumor activity of the bifunctional fusion protein bintrafusp alfa | Lucas A. Horn, PhD; Linjie Tian, PhD; Dallas B. Flies, PhD; Linda N. Liu, PhD; Solomon Langermann, PhD; Jeffrey Schlom, PhD; Claudia M. Palena, PhD; | Combination Immunotherapies | Checkpoint blockade; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 446 | Oral Presentation | Immunopeptidome changes mediated by a novel ERAP1 inhibitor leads to tumor growth inhibition. | Peter I. Joyce, PhD; Lesley Young, PhD; Martin Quibell, PhD; Jason Shiers, PhD; Carmen Tong; Kristopher Clark, PhD; Edd James, PhD; Emma Reeves, PhD; Alihussein Remtulla, PhD; Henry Leonard; Camila de Almeida; Elisa Lori; Nicola Ternette, PhD; Fergus Poynton, PhD; Andrew Leishman; | Combination Immunotherapies | Checkpoint blockade; Neoantigens; Solid tumors; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 447 | Poster Presentation | VISTA targeting remodels the tumor microenvironment to overcome adaptive resistance | Janet L. Lines, Ph.D.; Evelien Schaafsma; Walburga Croteau; Mohamed ElTanbouly; Elizabeth Nowak; Nicole Smits; Cecilia A. Webber; Dina Rabadi; Jie Deng; Chao Cheng; Randolph Noelle; | Combination Immunotherapies | Gene expression; MDSC; Myeloid cells; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 448 | Poster Presentation | Discovery of clinical candidate IK-175, a selective orally active AHR antagonist | KAREN MCGOVERN, PhD; KAREN MCGOVERN, PhD; Alfredo C. Castro; Jill Cavanaugh; Marta Sanchez-Martin; Jeremy H. Tchaicha, PhD; Sakeena Syed; Hyejin Frosch; Prabitha Natarajan; Katie O'Callaghan; Ben Amidon, PhD; X. Michelle Zhang; Jeff Ecsedy; Mark Manfredi, PhD; | Combination Immunotherapies | Immune suppression; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 449 | Oral Presentation | Neoadjuvant cyclic dinucleotides combined with interleukin-2 and anti-PD-1 antibody limit lung metastasis of orthotopic breast tumors through prolonged NK cell activation | Lauren Milling, BS; Darrell J. Irvine, PhD; | Combination Immunotherapies | Checkpoint blockade; Cytokine; NK/NK T cell; Surgery |
| 450 | Poster Presentation | Combination of rhIL-7-hyFc and anti-PD-L1xCD3ε bispecific antibody enhances antitumor response in mice | Sujeong Park, graduate student; Ji-Hae Kim; Yeon-Woo Kang; Kun-Joo Lee; Dain Moon; Nara Tae; Yunji Park; Dae Hee Kim; Byung Ha Lee, PhD; Donghoon Choi, PhD; Se Hwan Yang, PhD; Seung-Woo Lee; | Combination Immunotherapies | Antibody; Bispecifics; Cytokine; Solid tumors; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs) |
| 451 | Poster Presentation | Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity | Annah S. Rolig, Ph. D; Daniel C. Rose, BS in biology; Saul Kivimae, PhD; Werner Rubas, PhD; William L. Redmond, Ph.D.; | Combination Immunotherapies | Cytokine; NK/NK T cell; Radiotherapy; TLR; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 452 | Poster Presentation | Combination treatment using KISIMATM protein-based cancer vaccine and systemic STING agonist results in profound modulation of tumor microenvironment and improved tumor control | Matteo Rossi, PhD; Elodie Belnoue; Susanna Carboni; Wilma Besson-Di Berardino; Erika Riva; Marie-Laure Santiago-Raber; Madiha Derouazi; | Combination Immunotherapies | Immune adjuvant; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| 453 | Poster Presentation | Novel combination immunotherapy for boosting and priming immune responses in pancreatic cancer: strong anti-tumour effects with interleukin-15 and CD40 agonist treatment | Jonas RM. Van Audenaerde, MSc; Elly Marcq; Bianca von Scheidt; Ashleigh S. Davey, PhD; Amanda J. Oliver; Jorrit De Waele; Delphine Quatannens; Jinthe Van Loenhout; Patrick Pauwels; Geert Roeyen; Filip Lardon; Clare Y. Slaney; Marc Peeters, MD, PhD; Michael H. Kershaw, PhD; Phillip K. Darcy; Evelien LJ. Smits; | Combination Immunotherapies | Antibody; Antigen presenting cells; Cytokine; Dendritic cell; NK/NKT cell; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| 454 | Poster Presentation | Oncolytic Parainfluenza Virus 5 Vector Enhances Natural Killer Cell Killing of Lung Tumor Cells in 2D and 3D spheroid cultures | Namita Varudkar, MS, PhD Candidate; Namita Varudkar, MS, PhD Candidate; Jeremiah L. Oyer; Alicja Copik, PhD; Griffith Parks, PhD; | Combination Immunotherapies | Adoptive immunotherapy; NK/NK T cell; Solid tumors; Targeted therapy |
| 455 | Oral Presentation | Impact of EphB4 and PD-1 treatment on immune infiltrate in advanced bladder cancer | Sarmad Sadeghi, MD; Tyler D. Hether; Jason Yeon; Richard Mangio; Jason W. Reeves; Yan Liang, MD PhD; Sarah E. Warren, PhD; Troy McEachron, MD; Parkash S. Gill, MD; | Combination Immunotherapies | Biomarkers; Checkpoint blockade; Clinical trial; Immune adjuvant; Immune tolerance; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 456 | Poster Presentation | Impact of angiotensin II pathway inhibition on tumor response to anti PD(L)1 based therapy | Julius Strauss, MD; Ravi A. Madan, MD; Marijo Bilusic, MD, PhD; Fatima Karzai; Scot Niglio; Jason M. Redman, MD; Houssein Abdul Sater, MD; Charalampos Floudas; Jung-Min Lee; Andrea B. Apolo, MD; Seth M. Steinberg; Jeffrey Schlom, PhD; James L. Gulley, MD, PhD; | Combination Immunotherapies | Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| 457 | Poster Presentation | Intratumoral interleukin-12 administered after cryoablation does not improve survival in multiple bilateral murine models | Maura R. Vrabel; Jake A. Schulman; David A. Zaharoff, PhD; | Combination Immunotherapies | Checkpoint blockade; Immune adjuvant; Solid tumors; Targeted therapy; Tumor antigens; Vaccine |
| 458 | Poster Presentation | Antitumor mechanisms of local radiation and combination immunotherapy in an immunologically cold model of neuroblastoma | Taylor Aiken, MD; Julie S. Voeller, MD; Amy K. Erbe, PhD; Alexander L. Rakhmilevich, MD, PhD; Paul M. Sondel, MD, PhD; | Combination Immunotherapies | NK/NK T cell; Pediatric tumors; Radiotherapy; Regulatory T cell (Treg cell); Tumor microenvironment; Vaccine |
| 459 | Poster Presentation | NK cells activation and recruitment to irradiated tumors is increased in the presence of IL-15. | Maud Charpentier, PhD; Karsten A. Pilones, MD, PhD; Elena Garcia-Martinez, MD, PhD; Sandra Demaria, MD; | Combination Immunotherapies | NK/NKT cell; Radiotherapy |
| 460 | Poster Presentation | The immuno-metabolic enzyme FASN prevents anti-tumor immune responses in irradiated glioblastoma | Mara De Martino, PhD; Camille Daviaud; Claire I. Vanpouille-Box, PhD; | Combination Immunotherapies | Dendritic cell; Immune suppression; Metabolism; Radiotherapy; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| 461 | Poster Presentation | Improving Specific Targeting of Tumors Through Bispecific SNIPER Antibodies | Amy K. Erbe, PhD; Daniel Gerhardt; Reinier Hernandez, PhD; Bonnie Hammer; Mildred A. Felder, BS; Mark Bercher; Jennifer Dennin; Christopher Massey; Sabrina VandenHeuvel; Arika S. Feils, BS; Mackenzie Heck; Jonathan Engle; Todd E. Barnhart; Jacquelyn A. Hank, PhD; Bryan Glaser, PhD; Roland Green, PhD; Paul M. Sondel, MD, PhD; | Combination Immunotherapies | Bispecifics; Cytokine; NK/NK T cell; Pediatric tumors; Radiotherapy |
| 462 | Poster Presentation | Single agent immunotherapy response in patients with head and neck squamous cell carcinoma with prior history of radiation therapy | Moises Harari-Turquie, MD; Shashank Cingam, MD; David Lee; Gregory Gan; Emrullah Yilmaz, MD, PhD; | Combination Immunotherapies | Chemotherapy; Epidemiology; Immune adjuvant; Metabolism; Radiotherapy; Solid tumors; Tumor microenvironment |
| 463 | Poster Presentation | Metastatic gastric cancer patient benefiting from combined radio-immunotherapy treatment displayed sustained anti-NY-ESO-1 specific T cells and expressed important immuno-modulatory markers | Maysaloun Merhi, PhD; Afsheen Raza; Varghese Inchakalody; Siveen Kodappully; Deepak Choubey; Fairooz Sahir; Sarra Mestiri; Shereena Hydrose; Niloofar Allahverdi; Munir D. Jalis; Allan Relecom; Lobna Al-Zaidan; Mohamed Sir Elkhatim Hamid; Mai Mostafa; Abdul Rehman Zar Gul; Shahab Uddin; Mohammed Ussama Al Homsi; Said Dermine; | Combination Immunotherapies | Biomarkers; Checkpoint blockade; Cytokine; Immune monitoring; Radiotherapy; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor antigens |
| 464 | Poster Presentation | Clonal replacement of tumor-infiltrating CD8+ T cells by induction and activation of tumor-residing Batf3-dependent dendritic cells | Takaaki Oba, MD,PhD; Mark Long; Tibor Keler, PhD; Henry Marsh, BS PhD; Hans Minderman; Scott I. Abrams, PhD; Song Liu; Fumito Ito; | Combination Immunotherapies | Costimulation; Dendritic cell; Radiotherapy |
| 465 | Oral Presentation | Radiotherapy and CTLA-4 blockade expand anti-tumor T cells differentiation states and cooperate with CD40 agonist to induce tumor rejection | Nils-Petter Rudqvist; Claire Lhuillier, PhD; Maud Charpentier, PhD; Erik Wennerberg, PhD; Sheila Spada, PhD; Caroline Sheridan; Xi Kathy Zhou; Tuo Zhang, PhD; Jennifer S. Sims, PhD; Alicia Alonso; Sandra Demaria, MD; | Combination Immunotherapies | Bioinformatics; Checkpoint blockade; Costimulation; Gene expression; Radiotherapy; T cell; Tumor infiltrating lymphocytes (TILs) |
| 467 | Poster Presentation | Anti-EGFR antibody added to ongoing anti-PD-1 antibody treatment for metastatic cutaneous squamous cell carcinoma of the face: two case reports | Omar Eton, MD, FACP; Emily Hsu, MD; Akshay V. Patel, DO; Omar Eton, MD, FACP; Richard Cartun, PhD; Jonathan S. Earle, MD; Laila O. Mnayer, PhD; Peter P. Yu, MD, FACP, FASCO; Jennifer Kotowitz, RN BSN; | Combination Immunotherapies | Biomarkers; Checkpoint blockade; Clinical study; Coinhibition; Solid tumors; Surgery; Targeted therapy; Tumor microenvironment |
| 468 | Poster Presentation | Enhancers and repressors of immunotherapy: translational perspectives on gene-mediated cytotoxic immunotherapy in glioblastoma | Sean E. Lawler, PhD; Marilin S. Koch, MD; Mikolay S. Zdioruk, phD; Estuardo Aguilar-Cordova; Laura K. Aguilar, MD, PhD; Brian W. Guzik; Ghazaleh Tabatabai; Michal Nowicki; E Antonio A. Chiocca; | Combination Immunotherapies | Solid tumors; T cell; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 469 | Poster Presentation | Cooperation between checkpoint inhibitors targeting the PD-1 / PD-L1 axis and ATRC-101, a novel clinical-stage candidate for the treatment of solid tissue malignancies | Amy Manning-Bog, PhD; Jeff DeFalco, PhD; Alexander Scholz, PhD; Iraz T. Aydin, PhD; Nikhil Vad, PhD; Cathrin Czupalla, Ph.D.; Felix Chu, MS; Mauricio Velasco-Delgado; Michael Harbell, M.S.; Judevin Lugar-Supagay; Yvonne Leung, Ph.D.; Shaun M. Lippow, Ph.D.; Anne Ye, PhD; Ish Dhawan, PhD; Gilson Baia, PhD; Dai-Chen Wu, PhD; Carl Millward, MD; Mark Whidden, PhD; Jonathan Benjamin, MD, PhD; John Vivian, PhD; Ngan Nguyen, BS PhD; William H. Robinson, MD PhD; Tito A. Serafini, PhD; Daniel Emerling, PhD; Norman M. Greenberg, PhD; | Combination Immunotherapies | Antibody; Checkpoint blockade; Solid tumors; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 470 | Oral Presentation | Targeting Pan-Tumor Associated Antigen B7H3 via Combination of Tri-specific Killer Engager and Off-the-shelf NK Cell Therapy Enhances Specificity and Function Against a Broad Range of Solid Tumors | Jeff S. Miller, MD; Nicholas A. Zorko, MD, PhD; Behiye Kodal; Zachary B. Davis, PhD; Alexander J. Lenvik; Todd R. Lenvik; Joshua S. Walker; Daniel A. Vallera; Svetlana Gaidarova, MS; Alejandro Garcia; Tom T. Lee, PhD; Ryan Bjordahl, PhD; Bahram Valamehr, PhD; Frank S. Cichocki, PhD; Martin S. Felices; | Combination Immunotherapies | Adoptive immunotherapy; Bispecifics; NK/NK T cell |
| 471 | Poster Presentation | Pancreatic cancer therapy based on combination of DNA vaccination and PI3Kgamma inhibition | Francesco Novelli, PhD; Claudia Curcio, PhD; Cecilia Roux; Laura Conti; Roberta Curto; Gianluca Mucciolo; Sara Bulfamante, MS; Silvia Brugiapaglia; Alessandro Scagliotti; Alessandra Ghigo; Paola Cappello, PhD MS; Emilio Hirsch; Francesco Novelli, PhD; | Combination Immunotherapies | Myeloid cells; Solid tumors; Targeted therapy; Tumor antigens; Tumor microenvironment; Vaccine |
| 472 | Oral Presentation | ImmunoPET-informed sequence for focused ultrasound-targeted mCD47 blockade controls glioma | Natasha D. Sheybani, PhD; Soumen Paul, PhD; Katelyenn S. McCauley; Victoria R. Breza; Stuart S. Berr, PhD; G. Wilson Miller, PhD; Kiel D. Neumann, PhD; Richard J. Price, PhD; | Combination Immunotherapies | Antibody; Checkpoint blockade; Immune adjuvant; Monocyte/Macrophage; Solid tumors; Targeted therapy |
| 473 | Poster Presentation | Mavrilimumab, a human monoclonal antibody targeting GM-CSFRα, inhibits polarization to myeloid-derived suppressor cells (MDSCs) that express PD-L1 and restores T-cell proliferation in vitro. | Luis A. Carvajal, PhD.; Luciana Gneo, PhD.; Carmela De Santo, PhD; Matt Perez, B.S; Tracy Garron, B.S; Francis Mussai, M.D; Annalisa D’Andrea, PhD.; | Combination Immunotherapies | Checkpoint blockade; Immune adjuvant; Immune suppression; Immune tolerance; MDSC; Monocyte/Macrophage; Solid tumors; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 474 | Poster Presentation | Multiple combinational strategies of immunotherapy for esophageal squamous cell carcinoma: one institutional experience in Taiwan since 2016 | Jo-Pai Chen, MD; Wei-Chen Lu, M. D.; Ruey-Long Hong, M.D. PhD; | Combination Immunotherapies | Checkpoint blockade; Chemotherapy; Clinical study; Solid tumors; Targeted therapy |
| 475 | Oral Presentation | Incidental finding of colorectal cancer in a COVID-19 patient, followed by deep profiling of SARS-CoV-2-associated immune landscape and tumour microenvironment | Chun Chau Lawrence Cheung, BA, MMedSc; Chun Chau Lawrence Cheung, BA, MMedSc; Xinru Lim; Denise Goh, BBiomedSc (Hons); Tracy Zhijun Tien; Jeffrey Chun Tatt Lim; Thuan Tong Tan; Shirin Kalimuddin; Jia Lin Ng; Jenny Guek-Hong Low; Joe P. Yeong, MD, PhD; Kiat Hon T. Lim; | COVID and Immunotherapy | COVID and Immunotherapy; Biomarkers; Chemokine; Cytokine; Immune contexture; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 476 | Poster Presentation | AK119, a humanized anti-CD73 monoclonal antibody, as Immunotherapy for COVID-19 | Tingting Zhong, MS; Zhaoliang Huang, BSc; Xinghua Pang, BSc; na chen, MD; Konyew Kwek, PhD; Chris Wynne, MB, ChB; Adam Konpa, MS; Xiaoping Jin, PhD; Yu Xia, PhD; Maxwell Zhongmin Wang, PhD; Baiyong Li, PhD; Yu Xia, PhD; | COVID and Immunotherapy | COVID and Immunotherapy; Antibody; B cell |
| 477 | Poster Presentation | Deep Learning to Drive COVID-19 Rapid Drug Repurposing | Sarah Kolitz, PhD; Jason Kim, PhD; Jenny Zhang, PhD; Yoonjeong Cha, PhD; Sailaja Battula, PhD; Rebecca Kusko, PhD; Rajaraman Krishnan, PhD; Benjamin J. Zeskind, PhD, MBA; Howard L. Kaufman, MD; | COVID and Immunotherapy | COVID and Immunotherapy; Bioinformatics; Systems biology |
| 478 | Poster Presentation | Translation of a therapeutic neoantigen vaccine workflow to SARS-CoV-2 vaccine development | Christof C. Smith, PhD; Christof C. Smith, PhD; Sarah Entwistle; Caryn Willis; Steven P. Vensko; Wolfgang Beck, AB; Jason Garness; Maria J. Sambade; Eric Routh; Kelly Olsen; Brandon Carpenter; Kaylee Gentry; Maria Fadri; Misha Fini; Amber Washington; Julia Kodysh, MSc; Timothy O'Donnell; Carsten Haber; Kirsten Heiss; Volker Stadler; Erik Garrison; Oliver C. Grant; Robert J. Woods; Mark Heise; Benjamin G. Vincent, MD; Alexander Rubinsteyn, PhD; | COVID and Immunotherapy | COVID and Immunotherapy; Antibody; B cell; Neoantigens; T cell; Vaccine |
| 479 | Poster Presentation | A lymph-node targeted amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2 | Martin Steinbuck, PhD; Peter C. DeMuth, PhD; Lochana Seenappa, MS; Christopher M. Haqq, MD, PhD; Aniela Jakubowski; Lisa K. McNeil, PhD; | COVID and Immunotherapy | COVID and Immunotherapy; Immune adjuvant; T cell; Vaccine |
| 480 | Oral Presentation | Preliminary evaluation of a novel coronavirus vaccine (CORVax) using electroporation of plasmid DNA encoding a stabilized prefusion SARS-CoV-2 spike protein alone or with transfection of plasmid IL-12 | Shawn M. Jensen, PhD; Christopher G. Twitty, PhD; Christopher C. Paustian, PhD; Madelein Laws; Glenna McDonnell, MS; Keith Wegmann; Tarsem L. Moudgil, MS; Michael E. Afentoulis, MSc; Mia Han; Kellie Malloy Foerter; David A. Canton, PhD; Jack Y. Lee; Bianca A. Nguyen; John Rodriguez; Kim Jaffe, PhD; Brian D. Piening, PhD; Carlo B. Bifulco, MD; Daniel J. O'Connor; Walter J. Urba, MD, PhD; Rom S. Leidner, MD; Traci L. Hilton, PhD; Hong-Ming Hu, PhD; Bernard A. Fox, PhD; | COVID and Immunotherapy | COVID and Immunotherapy; Antibody; B cell; Cytokine; Immune adjuvant; Immune monitoring; T cell; Vaccine |
| 481 | Poster Presentation | Impact of COVID-19 on Cancer Patients Receiving Immune Checkpoint Inhibitors | Kevin Tyan, BA; Ai-Tram N. Bui, BA; Anita Giobbie-Hurder, MS; Isaac A. Klein, MD, PhD; Michael P. Manos, BA; Leyre Zubiri, MD, PhD; Kerry L. Reynolds, MD; Shilpa Grover, MD, MPH; Gerald L. Weinhouse, MD; Patrick A. Ott, MD, PhD; Nicole R. LeBoeuf, MD, MPH; Osama E. Rahma, MD; | COVID and Immunotherapy | COVID and Immunotherapy; Checkpoint blockade; Immune toxicity |
| 482 | Poster Presentation | COVID-19 in patients with lung cancer receiving immunotherapy. A report from an spanish academic center. | David Viñal; Laura Gutierrez; Julia Villamayor; Oliver Higuera; Dario Sanchez Cabrero; Javier De Castro; | COVID and Immunotherapy | COVID and Immunotherapy; Clinical study; Solid tumors |
| 483 | Poster Presentation | Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis | Olivier OD. Demaria, PhD; Julien Carvelli, MD; Nassima Chouaki Benmansour, MD; Joanna Fares, PhD; Luciana Batista, PhD; Marie-Laure Thibult, PhD; Ariane Morel, PhD; Sabrina Carpentier, PhD; Romain Remark, PhD; Agnes Represa; Frederic Vely, PhD; Mikael Ebbo, MD; Nicolas Schleinitz, MD; Robert Zerbib, MSc; Yannis Morel, PhD; Eric Vivier, PhD; Olivier OD. Demaria, PhD; | COVID and Immunotherapy | COVID and Immunotherapy; Antibody; Biomarkers; Cytokine; Inflammation; MDSC; Monocyte/Macrophage; Myeloid cells |
| 484 | Poster Presentation | BioTuring Browser: Interactively explore public single cell sequencing data | Son K. Pham; Tri Le, BSc; Tan Phan; Minh Pham; Huy Nguyen; Loc Lam; Nam Phung; Tuan Tran; Duy Phung; Thang Tran; Hoa Pham; Khoa Nguyen; Ha-An Nguyen; Trang Nguyen; Tam Luu; Hao Tran; | Data Sharing, Handling and Access | Checkpoint blockade; Gene expression; RNA; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 485 | Poster Presentation | RAFT: A framework to support rapid and reproducible immuno-oncology analyses | Steven P. Vensko, II, Ph.D.; Benjamin G. Vincent, MD; Dante S. Bortone; Steven P. Vensko; | Data Sharing, Handling and Access | Bioinformatics |
| 486 | Poster Presentation | iReceptor Plus: a data integration platform to share, compare and analyze Adaptive Immune Receptor Repertoire (AIRR-seq) data from antibody/B- and T-cell repertoires | Felix Breden, PhD; | Data Sharing, Handling and Access | Antibody; B cell; Bioinformatics; Biomarkers; Genetic polymorphism; Immune monitoring; Leukemia/Lymphoma; Systems biology; T cell; T cell lineages |
| 487 | Poster Presentation | Reasons for not testing for biomarkers in non-small cell lung cancer: A regional comparison of patients in the US and Europe | Nikita Sharma; Mahaletchumy Krishnam; Ayse Levent, MSc; Ayse Levent, MSc; Ayse Levent, MSc; | Education and Treatment Management | Biomarkers; Solid tumors |
| 488 | Poster Presentation | The impact of education on novel concepts in metastatic melanoma: triplet therapy | Kinjal Parikh, PharmD, BCOP; Kinjal Parikh, PharmD, BCOP; Kinjal Parikh, PharmD, BCOP; Sara Fagerlie, PhD; Patrick Kugel, MBA; Richard Caracio, MBA; Ryan J. Sullivan, MD; | Education and Treatment Management | Checkpoint blockade; Targeted therapy |
| 489 | Poster Presentation | The impact of education on novel concepts in adjuvant melanoma: a closer look at high risk stage II disease | Kinjal Parikh, PharmD, BCOP; Kinjal Parikh, PharmD, BCOP; Kinjal Parikh, PharmD, BCOP; Charlotte Warren; Emily Van Laar, MS; Jason J. Luke, MD; | Education and Treatment Management | Checkpoint blockade |
| 490 | Poster Presentation | An immuno-oncology census: assessment of clinician knowledge and educational needs in 2020 | Janelle Schrag, MPH; Fitzgerald Draper, MS; Monique Dawkins, EdD, MPA; Lorna Lucas, MSM; Leigh Boehmer, Pharm.D, BCOP; Janelle Schrag, MPH; | Education and Treatment Management | Bispecifics; CAR T cells; Checkpoint blockade |
| 491 | Poster Presentation | Developing Educational Materials about Immunotherapy for Patients and Their Caregivers | Maria B. Gonzalo; Claire Saxton, MBA; Kirstin Fearnley, MALS; Jenny Karubian, MA; Nick Power, BS; Alyssa Jaisle, PhD; | Education and Treatment Management | Immune adjuvant; Targeted therapy |
| 492 | Poster Presentation | Integration of high dimensional datasets in an immunocompetent mammary mouse model reveals pathways of tolerance and resistance to immune checkpoint blockade | Jade Moore, PhD; Lin Ma, PhD; Jian-Hua Mao, PhD; Mary Helen Barcellos-Hoff, PhD; | Immune Cell Biology | Checkpoint blockade; Gene expression; Immune monitoring; Inflammation; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 493 | Poster Presentation | Tired and Hungry: A potential role for CD47 in T cell exhaustion | Chien-Huan Weng, PhD; Levi M. Mangarin, BS; Cailian Liu, MD; Roberta Zappasodi, PhD; Pamela M. Holland, PhD; Jedd D. Wolchok, MD, PhD; Taha Merghoub, PhD; David Schroder, MD; | Immune Cell Biology | Adoptive immunotherapy; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 494 | Poster Presentation | Bias in Cross-Presentation by Dendritic Cells Impacts anti-tumor T cell Responses | Timothy B. Fessenden, PhD; Lauren Stopfer; Therese Cordero-Dumit; Forest White; Stefani Spranger, PhD; | Immune Cell Biology | Dendritic cell; Neoantigens; Tumor antigens; Vaccine |
| 495 | Poster Presentation | Basal Cell Carcinoma demonstrates a T-cell exclusion immune phenotype in contrast to other anti-PD-1 therapy responsive cutaneous malignancies | Geoffrey T. Gibney, MD; Joanne Xiu; Gino K. In, MD, MPH; Steven J. O'Day, MD; Jose Lutzky, MD, FACP; Joseph J. Drabick, MD, FACP, FIDSA; Ari M. VanderWalde, MD, MPH, MBioeth; Kelsey Poorman; W. M. Korn; Michael B. Atkins, MD; | Immune Cell Biology | Angiogenesis; Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 496 | Poster Presentation | Immune cell profiling across solid tumor types by mass cytometry reveals tumor enrichment of PD-1+/LAG-3+ CD8 memory T cells that exhibit tumor-reactive yet dysfunctional features | Bradley Garman, MSc; Laurence Menard, PhD; Can Jiang, MSc; Sherif Daouti, MSc; Priyanka Mehta, MSc; Miye Jacques, MSc; Mohan Bolisetty, PhD; Christos Hatzis, PhD; Nataly Manjarrez Orduno, PhD; Michaela Bowden, PhD; Justin M. David, PhD; Justin M. David, PhD; Justin M. David, PhD; | Immune Cell Biology | Immune contexture; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 497 | Poster Presentation | Longitudinal immune profiling reveals unique myeloid and T cell phenotypes associated with spontaneous immunoediting in a novel prostate tumor model | Casey R. Ager, PhD; Aleksander Obradovic; Juan M. Arriaga, PhD; Matthew G. Chaimowitz; Cory Abate-Shen, PhD; Andrea Califano, PhD; Charles G. Drake, MD, PhD; | Immune Cell Biology | Dendritic cell; Granulocyte; Immune contexture; Immune monitoring; Monocyte/Macrophage; Myeloid cells; Regulatory T cell (Treg cell); T cell; Tumor evasion; Tumor microenvironment |
| 498 | Poster Presentation | Downregulation of CD5 in CD8+ T tumour-infiltrating lymphocytes associates with increased level of activation and exhaustion | Faizah Alotaibi; Mark D. Vincent, MD, FRCPC, MRCPUK; Weiping Min; James Koropatnick; | Immune Cell Biology | Checkpoint blockade; Immune suppression; Immune tolerance; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 499 | Poster Presentation | AT1636, a colon cancer survivor-derived antibody recognizes a previously unidentified truncated, O-mannosylated 70kDa variant of E-cadherin. | Tim Beaumont, PhD; Martijn Kedde, PhD; Sabrina J. Merat, MSc; Mark J. Kwakkenbos, PhD; Lina Bartels; Dorien van der Berg; Koen Wagner, PhD; Arjen Q. bakker; Kelly Maijoor; Martino Bohne; Camille Bru; Veronika Kattler; Yvonne Claassen; Gemma Moiset, PhD; Hans Van Eenennaam, PhD; Victorine Roos; Frank Kallenberg; Jan P. Medema; Paul J. Hensbergen; Pauline M. van Helden, PhD; Evelien Dekker; Hergen Spits, PhD; | Immune Cell Biology | Antibody; B cell; Bispecifics; Post-translational modifications; Solid tumors; Targeted therapy; Tumor antigens |
| 500 | Poster Presentation | P2RX7 agonist treatment boosts the ability of IL-12-activated CD8+ T cells to infiltrate and control murine melanoma | Kelsey M. Wanhainen; Stephen C. Jameson; Henrique Borges Da Silva, PhD; | Immune Cell Biology | Adoptive immunotherapy; Immune adjuvant; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs) |
| 501 | Poster Presentation | VISTA regulates the differentiation and suppressive function of myeloid-derived suppressor cells | Juan Dong, MD; Cassandra Gilmore; Hieu M. Ta, PhD; Keman Zhang; Sarah Stone; Li Wang, PhD; | Immune Cell Biology | Antibody; Immune suppression; MDSC; Myeloid cells; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 502 | Poster Presentation | The co-expression of two immune complex molecules, VISTA and TIGIT, define a dysfunctional cytotoxic T cell subset | Cassandra K. Gilmour, BS; Li Wang, PhD; Juan Dong, MD; Hieu M. Ta, PhD; | Immune Cell Biology | Biomarkers; Checkpoint blockade; Costimulation; Immune suppression; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 503 | Poster Presentation | Tumor infiltrating lymphocytes in soft tissue sarcomas upregulate the exhaustion marker TIGIT and are reinvigorated by IL-15 stimulation and TIGIT blockade | Sean J. Judge, MD, MS; Morgan A. Darrow, MD; Steven W. Thorpe, MD; Alicia A. Gingrich, MD; Edmond F. O'Donnell, MD; Alyssa R. Bellini, MD; Ian R. Sturgill; Logan V. Vick; Cordelia M. Dunai, MS; Kevin M. Stoffel, MS; Yue M. Lyu; Shuai M. Chen, PhD; May M. Cho, MD; Robert M. Rebhun, DVM PhD; Arta M. Monjazeb, MD, PhD; William J. Murphy, PhD; Robert J. Canter, MD, MAS, FACS; | Immune Cell Biology | NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 504 | Poster Presentation | Using multiplexed immunofluorescence to quantitatively analyze myeloid derived suppressor cells (MDSCs) in relation to tertiary lymphoid structures (TLS) in bladder cancer | Anna Juncker-Jensen, PhD; Gang Huang; Mate L. Nagy; Xin Lu; Anna Juncker-Jensen, PhD; Anna Juncker-Jensen, PhD; | Immune Cell Biology | Adoptive immunotherapy; B cell; Immune contexture; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 505 | Poster Presentation | Activation of NK T cells promote the inflammatory tumor microenvironment and control the growth of solid tumor | Sourav Paul, PhD; Amrita Mishra, MSc; Sushanta Chhatar; Girdhari Lal, PhD; Girdhari Lal, PhD; | Immune Cell Biology | Chemotherapy; Costimulation; Cytokine; Immune adjuvant; Inflammation; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 506 | Poster Presentation | The tumor immune microenvironment of metastatic osteosarcoma is marked by lymphocyte exclusion and impacts patient progression-free survival | John A. Ligon, MD; Woonyoung Choi; Gady Cojocaru; Wei Fu; Emily H. Hsiue, MD; Teniola F. Oke; Carol D. Morris; Adam Levin; Daniel S. Rhee; David J. McConkey; Robert A. Anders, MD, PhD; Drew M. Pardoll, MD, PhD; Nicolas J. Llosa, MD; | Immune Cell Biology | Checkpoint blockade; Chemokine; Cytokine; Myeloid cells; MDSC; Solid tumors; Tumor microenvironment |
| 507 | Poster Presentation | High dimensional flow cytometry analysis in newly diagnosed acute myeloid leukemia predicts patients outcomes | Francesco Mazziotta, MD; Rupkatha Mukhopadhyay; Hanna A. Knaus; Anish Chowdhury; Amanda Blackford; Ivana Gojo, MD; Leo Luznik, MD; | Immune Cell Biology | Bioinformatics; Chemotherapy; Immune contexture; Immune monitoring; Leukemia/Lymphoma; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 508 | Poster Presentation | Different neoantigen expression patterns impact the strength of anti-tumor immune responses | Kim B. Nguyen, B.A.; Stefani Spranger, PhD; Christopher J. Copeland, B.S.; | Immune Cell Biology | Immune suppression; Neoantigens; T cell; Tumor infiltrating lymphocytes (TILs) |
| 509 | Poster Presentation | Potent And Selective Inhibition Of AXL Receptor Tyrosine Kinase For The Treatment of Cancer | Susan L. Paprcka, PhD; Akshata R. Udyavar, Ph.D; Subhasree Sridhar; Dillon H. Miles, PhD; Yu Chen, PhD; Sean Cho, PhD; Corinne N. Foley, PhD; Rebecca Grange, PhD; Manmohan R. Leleti, PhD; Sharon Zhao, PhD; Lixia Jin, PhD; Stephen W. Young, PhD; Jay P. Powers, PhD; Matthew J. Walters, PhD; | Immune Cell Biology | Dendritic cell; Gene expression; Immune suppression; Immune tolerance; Monocyte/Macrophage; Myeloid cells; NK/NK T cell; Solid tumors; Targeted therapy; Tumor microenvironment |
| 510 | Poster Presentation | Helping the killers: innovative cancer immunotherapy harnessing quasi-universal tumor antigen-specific CD4 T cells | Margaux Saillard; Amelie Cachot; Georg Alexander Rockinger; Philippe Guillaume; Julien Schmidt, PhD; Alexandre Harari, PhD; Camilla Jandus, MD, PhD; Pedro J. Romero, MD; | Immune Cell Biology | Antigen presenting cells; T cell; Tumor antigens; Vaccine |
| 511 | Poster Presentation | Tumor immune microenvironment in adult mice asynchronously cross-fostered as pups | Vianca Vianzon, BS; Ishita Garg; Kara G. Greenfield; Kathryn A. Knoop, PhD; Laura M. Rogers, PhD; | Immune Cell Biology | Immune tolerance; Microbiome; Tumor infiltrating lymphocytes (TILs) |
| 512 | Oral Presentation | Terminally exhausted CD8+ T cells potentiate the tolerogenic tumor microenvironment as functional suppressors | Paolo DA. Vignali, BA; Kristin DePeaux, BS; McLane Watson, BS; Ashley Menk, MS; Nicole E. Scharping, PhD; Greg M. Delgoffe, PhD; | Immune Cell Biology | Immune suppression; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 513 | Poster Presentation | CD26 enzymatic activity modulates efficient migration of adoptively transferred T cells to solid tumors | Megan M. Wyatt, MS; Michelle H. Nelson, PhD; Stefanie R. Bailey, PhD; Hannah M. Knochelmann, BS; Aubrey S. Smith, BS; Guillermo O. Rangel RIvera, B.S.; Amalia M. Rivera Reyes, BS; Chrystal M. Paulos, PhD; | Immune Cell Biology | Adoptive immunotherapy; Chemokine; Costimulation; Solid tumors; T cell |
| 514 | Poster Presentation | Disturbed Mitochondrial Dynamics Rewire the Epigenetic Program for CD8+ TIL Exhaustion | Yi-Ru Yu, PhD; Haiping Wang; Fabien Franco; Ping-Chih Ho, PhD; | Immune Cell Biology | Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 515 | Oral Presentation | Metabolic reprogramming of antitumor CD8+ T cell immunity | Alison Jaccard, MS; Mathias Wenes, PhD; Gábor Gyülvészi; Ping-Chih Ho, PhD; Pedro J. Romero, MD; | Immune Cell Biology | Adoptive immunotherapy; Epigenetics; Immune monitoring; Metabolism; Post-translational modifications; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 516 | Poster Presentation | Caspase-8 regulated senescence as an immune checkpoint in T lymphocytes for adoptive cell therapy | Valérie Janelle, PhD; Mathieu Neault, PhD; Marie-Eve Lebel, PhD; Dave De Sousa, MSc; Salix Boulet, PhD; Ludovic Durrieu, PhD; Cedric Carli, PhD; Sebastien Lemieux, PhD; Nathalie Labrecque, PhD; Heather J. Melichar, PhD; Frederick A. Mallette, PhD; Jean-Sebastien Delisle, PhD, MD; | Immune Cell Biology | Adoptive immunotherapy; Bioinformatics; CAR T cells; Gene expression; Leukemia/Lymphoma; Metabolism; T cell; Targeted therapy |
| 517 | Oral Presentation | Regulatory T cell functional identity is sustained by a glucose:lactate axis that is exploited in the tumor microenvironment | McLane Watson, BS; Paolo DA. Vignali, BA; Steven Mullet; Abigail E. Overacre-Delgoffe, PhD; Ronal M. Peralta; Stephanie Grebinoski; Ashley Menk, MS; Natalie Rittenhouse; Kristin DePeaux, BS; Ryan D. Whetstone, MS, PhD; Dario A. Vignali, PhD; Timothy W. Hand, PhD; Amanda Poholek; Brett Morrison, MD, PhD; Jeffrey Rothstein; Stacy Wendell, PhD; Greg M. Delgoffe, PhD; | Immune Cell Biology | Metabolism; Regulatory T cell (Treg cell); Tumor evasion; Tumor microenvironment |
| 518 | Poster Presentation | Epigenetic dysfunction of terminally exhausted tumor infiltrating T cells | Rhodes Ford, BSc; Paolo DA. Vignali, BA; Natalie Rittenhouse; Nicole Scharping; Andrew Frisch; Greg M. Delgoffe, PhD; Amanda Poholek; | Immune Cell Biology | Bioinformatics; Epigenetics; Gene expression; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 519 | Poster Presentation | Diacylglycerol kinase ζ limits IL-2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes | Javier Arranz-Nicolas, PhD; Cristina Rodríguez-Rodríguez; Rosa Liébana; Judith Leitner; Antonia Ávila-Flores; Peter Steinberger; Isabel Mérida; | Immune Cell Biology | Antibody; Biomarkers; Checkpoint blockade; Costimulation; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs) |
| 520 | Poster Presentation | The immune landscape of pediatric tumors | Shimaa M. Sherif, MSc.; Jessica Roelands, Master; William Mifsud; Blessing Dason; Darawan Rinchai, PhD; Adrian Charles; Ayman Saleh; Chiara Cugno, MD; Khalid Fakhro; Borbala Mifsud; Davide Bedognetti, MD, PhD; Wouter RL. Hendrickx, PhD; | Immune Cell Biology | Bioinformatics; Biomarkers; Gene expression; Immunoscore; Pediatric tumors; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; RNA |
| 521 | Poster Presentation | Immune Regulatory Metabolites in Human Ovarian Cancer | Julian J. Lum, PhD; Marisa Kilgour, BSc; Sarah MacPherson; Lauren Zacharias; Sarah Keyes; Bertrand Allard, PhD; Julian Smazynski; Peter Watson; John Stagg, PhD; Bradley Nelson, PhD; Ralph Deberardinis; Phineas Hamilton; Julian J. Lum, PhD; | Immune Cell Biology | Immune suppression; Metabolism; Tumor infiltrating lymphocytes (TILs) |
| 522 | Poster Presentation | Metabolic requisites for T cell protein translation in tumors | Katie E. Hurst; Megan Tennant; Megan Tennant; Alex M. Andrews, PhD; Lee Leddy, MD, MsCR; David M. Neskey, MD; Lauren Ball, PhD; Jessica E. Thaxton, PhD, MS; | Immune Cell Biology | Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 523 | Poster Presentation | A subset of mature neutrophils contains the strongest PMN-MDSC activity in blood and tissue of patients with head and neck cancer | Yu Si; Kirsten Bruderek; Simon Merz; Philip Jansen; Stephan Lang; Matthias Gunzer; Joachim Klode; Anthony Squire; Sven Brandau, PhD; | Immune Cell Biology | Biomarkers; Granulocyte; Immune monitoring; Inflammation; MDSC; Myeloid cells; Solid tumors; Tumor microenvironment; Tumor stroma |
| 524 | Poster Presentation | Tim-4+ Resident Macrophages Impair Anti-Tumor Immunity In the Serous Body Cavities By Sequestering Viable and Cytotoxic CD8+ T cells Expressing High Levels of Phosphatidylserine | Andrew Chow, MD, PhD; Sara Schad, BS; Michael D. Green, MD, PhD; Matthew D. Hellmann, MD; Nicholas Ceglia, PhD; Viola Allaj; Giulia Zago, PhD; Nisarg Shah; Sai K. Sharma, PhD; Marissa Mattar; Joseph Chan, MD, PhD; Hira Rizvi; Hong Zhong, BS; Cailian Liu, MD; Yonina Bykov; Dmitriy Zamarin, MD, PhD; Hongyu Shi; Sadna Budhu, PhD; Corrin Wohlhieter; Fathema Uddin; Aditi Gupta, MD; Inna Khodos; Jessica J. Waninger, BS; Angel Qin; Vinod Balachandran, MD; Weiping Zou, MD, PhD; Sohrab Shah, PhD; Andrew McPherson, PhD; Katherine S. Panageas, PhD; Jason S. Lewis, PhD; Justin Perry, PhD; Elisa de Stanchina, PhD; Triparna Sen, PhD; John T. Poirier, PhD; Jedd D. Wolchok, MD, PhD; Charles M. Rudin, MD, PhD; Taha Merghoub, PhD; | Immune Cell Biology | Checkpoint blockade; Gene expression; Immune contexture; Immune suppression; Monocyte/Macrophage; Solid tumors; T cell; Tumor evasion; Tumor microenvironment |
| 525 | Poster Presentation | KIT mutation with a low MS4A1/CD20 expression is associated with poor prognosis in melanoma | Shashank Cingam, MD; Moises Harari-Turquie, MD; Dulcinea Quintana, MD; Leslie Andritsos, MD; Emrullah Yilmaz, MD, PhD; | Immune Cell Biology | B cell; Checkpoint blockade; Targeted therapy; Tumor microenvironment |
| 526 | Poster Presentation | InhibigenTM-specific responses suppress anti-tumor immunity and promote tumor growth | Victoria L. DeVault, PhD; Tulin Dadali, PhD; Hanna Starobinets, PhD; Kevin Lema; Stephanie Rinaldi; Osaruese Odeh; Julie N. Arnold; Dylan Sheehan; Cindy K. Nguyen; Louisa Dowal, PhD; Jessica B. Flechtner, PhD; Alberto Visintin, PhD; Hubert Lam, PhD; | Immune Cell Biology | Antigen presenting cells; Checkpoint blockade; Immune suppression; Neoantigens; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment |
| 527 | Poster Presentation | Tumor organoid and immune cell co-culture system potentiates Immuno-Oncology drug development | Hongjuan Zhang, PhD; Jun Zhou; Shuang Zhu; Jia Zheng; Limei Shang; Chunmei Li; Xuefei Yan, PhD; Rui Zhang; Mingfa Zang; Annie Xiaoyu An; Xiaoxi Xu; Shuzong Wang; Henry Q. Li; Yujun Huang; | Immune Cell Biology | Bispecifics; CAR T cells; Checkpoint blockade; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 528 | Oral Presentation | Sexual dimorphism in myeloid-derived suppressor cells promote GBM progression in females via IL-1b | Defne Bayik, PhD; Yadi Zhou; Chihyun Park; Chngjin Hong; Danielle Silver, PhD; Dionysios C. Watson, MD; Alice Lo; Tae Hyun Hwang; Feixiong Cheng; Peter A. Sims; Antonio Iavarone; Justin D. Lathia, PhD; | Immune Cell Biology | Cytokine; Granulocyte; Immune suppression; Myeloid cells; MDSC; Tumor microenvironment |
| 529 | Poster Presentation | Cancer cells educate natural killer cells to a metastasis promoting cell state | Isaac S. Chan, MD, PhD; Hildur Knu´tsdo´ttir, PhD; Gayathri Ramakrishnan; Veena Padmanaban; Manisha Warrier; Juan Carlos Ramirez; Joel S. Bader; Elizabeth M. Jaffee, MD; Isaac S. Chan, MD, PhD; Andrew Ewald; | Immune Cell Biology | NK/NKT cell; Tumor evasion; Tumor microenvironment |
| 530 | Poster Presentation | T-cell immunoglobulin– and mucin domain–containing (TIM)–3 downregulation in response to ex vivo activation and cancer targets correlates to NK cell functionality. | Tram N. Dao, BS; Sandro Matosevic, PhD; Sagar Utturkar, PhD; Nadia A. Lanman, PhD; Sandro Matosevic, PhD; | Immune Cell Biology | Cytokine; NK/NK T cell; Solid tumors; Tumor infiltrating lymphocytes (TILs) |
| 531 | Oral Presentation | AFM13-targeted blood and cord-blood-derived memory-like NK cells as therapy for CD30+ malignancies | Lucila Kerbauy; Nancy D. Marin, PhD; Mecit Kaplan; Pinaki Banerjee; Melissa Berrien-Elliott; Michelle Becker-Hapak; Rafet Basar; Mark Foster; Luciana Garcia Melo; Carly Neal; Ethan McClain; May Daher, MD; Ana Karen Nunez Cortes; Sweta Desai; Francesca Wei Inng Lim; Mayela Carolina Mendt; Timothy Schappe; Li Li; Hila Shaim; Mayra Hernandez Sanabria; Pamela Wong; Enli Liu; Sonny Ang; Rong Cai; Vandana Nandivada; Vakul Mohanty; Yifei Shen; Natalia Baran; Natalie Fowlkes; Ken Chen; Luis Muniz-Feliciano; Joachim Koch, PhD; Martin Treder; Wolfgang Fischer; Oswaldo Keith Okamoto; Yago Nieto, MD PhD; Richard E. Champlin, MD; Elizabeth J. Shpall, MD; Todd A. Fehniger; Katy Rezvani, MD, PhD; | Immune Cell Biology | Antibody; Bispecifics; NK/NK T cell; Targeted therapy |
| 532 | Poster Presentation | SOCS3 deficiency blocked autophagy-dependent myeloid differentiation of early-stage myeloid-derived suppressor cells via the miR-155/C/EBPß/Wnt axis | Jinpu Yu, Ph.D.; Wenwen Zhang; | Immune Cell Biology | Carcinogenesis; Immune suppression; MDSC; Tumor evasion; Tumor microenvironment |
| 533 | Poster Presentation | Cross-species immunogenomic analysis identifies pathways of canine natural killer cell response to cytokine therapy, and reveals convergence of activated dog and human natural killer transcriptomes | Alicia A. Gingrich, MD; Taylor Reiter; Sean J. Judge, MD, MS; Daniel York; Mio Yanagisawa, MD; Ian R. Sturgill; Rachel Brady; Kevin M. Stoffel, MS; Arta M. Monjazeb, MD, PhD; Robert M. Rebhun, DVM PhD; C. Titus Brown, PhD; Robert J. Canter, MD, MAS, FACS; | Immune Cell Types | Bioinformatics; Cytokine; Gene expression; NK/NK T cell |
| 534 | Poster Presentation | Better Immune Profiles on Elderly Colorectal Cancer Patients Correlated With 1 Year Diseases Free Survival (DFS) | Budhi Ida Bagus, MD; Metria Ida Bagus; Mastini Ida Ayu Kade; | Immune Cell Types | Chemotherapy; Immune monitoring; Solid tumors; Surgery |
| 535 | Poster Presentation | Electroporation of B cells is correlated with cell size change during B cell expansion | Jian Chen, PhD; George Sun; Jian Chen, PhD; | Immune Cell Types | B cell; Gene expression |
| 536 | Poster Presentation | Divergent cancer etiologies drive distinct B cell signatures and tertiary lymphoid structures in head and neck cancer | Ayana Ruffin, MS; Anthony R. Cillo, PhD; Tracy Tabib; Angen Liu; Sayali Onkar; Sheryl R. Kunning; Caleb Lampenfeld, B.S.; Irina Abecassis; Zengbiao Qi; Ryan Soose, MD; Umamaheswar Duvvuri; Seungwon Kim, MD; Steffi Oesterrich; Robert Lafyatis; Robert L. Ferris, MD, PhD; Dario A. Vignali, PhD; Tullia C. Bruno, PhD; | Immune Cell Types | B cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 537 | Poster Presentation | Conventional type 1 dendritic cells and natural killer cells demonstrate strong correlation to T lymphocyte infiltration in cervical cancer tumors | Anushka Dikshit, PhD; Xiao-jun Ma, PhD; Bingqing Zhang, PhD; Anushka Dikshit, PhD; | Immune Cell Types | Dendritic cell; NK/NK T cell; RNA; Tumor infiltrating lymphocytes (TILs) |
| 538 | Poster Presentation | Harnessing cross-dressing dendritic cells to strengthen anti-tumor immunity | Ellen Duong, Sc.B.; Timothy B. Fessenden, PhD; Arjun Bhutkar; Stefani Spranger, PhD; | Immune Cell Types | Antigen presenting cells; Dendritic cell; Myeloid cells; Tumor microenvironment |
| 539 | Oral Presentation | High dimensional analysis of the human lymph node during melanoma progression reveals shifts in myeloid content that relate to differential T cell content | Anastasia Prokopi, PhD; Marta Lopez-Gonzalez; Jan Verhoeff; Rieneke R. Van de Ven, PhD; Juan J. Garcia-Vallejo, PhD; Patrizia Stoitzner, PhD; Tanja D. de Gruijl, PhD; | Immune Cell Types | Dendritic cell; Immune suppression; Myeloid cells; Regulatory T cell (Treg cell); T cell |
| 540 | Poster Presentation | Transcriptionally defined immune landscape in human gliomas | Pravesh Gupta, PhD; Minghao Dang, PhD; Krishna Bojja; Huma Shehwana, PhD; Tuan M. Tran; Linghua Wang, PhD; Krishna P. Bhat, PhD; Pravesh Gupta, PhD; | Immune Cell Types | Antigen presenting cells; Dendritic cell; Immune contexture; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor microenvironment |
| 541 | Poster Presentation | Investigating myeloid derived suppressor cells (MDSCs) and Oligonucleotide based targeting of STAT3 in Renal Cell Carcinoma | Marice Alcantara; Dayson F. Moreira, PhD; Chia-Yang Hung, PhD; Chunsong Yu; Dongfang Wang, PhD; JoAnn Hsu, BS; Sumanta K. Pal, MD; Marcin Kortylewski, PhD; Marice Alcantara; | Immune Cell Types | Checkpoint blockade; Immune monitoring; Immune suppression; MDSC; Myeloid cells; T cell; Tumor microenvironment |
| 542 | Poster Presentation | Expansion of cytotoxic NK Cells from PBMCs using individualized cytokine combination | Andreia Maia, PhD student; Joana R. Lerias, PhD; Markus J. Maeurer, MD, PhD, FRCP(London); Mireia Castillo-Martin, MD, PhD; Andreia Maia, PhD student; | Immune Cell Types | Adoptive immunotherapy; Cytokine; NK/NK T cell; Tumor evasion |
| 543 | Poster Presentation | Natural killer cells restrict the growth of liver metastases in nude hosts | Alexandra Quackenbush, BS; Pepper Schedin; | Immune Cell Types | NK/NK T cell; Solid tumors |
| 544 | Poster Presentation | Multiomic characterization of T-cell populations at the single-cell level utilizing sensitive dextramers and BD® AbSeq on the BD RhapsodyTM Single-Cell Analysis system | Kivin Jacobsen, PhD; Cynthia Sakofsky, PhD; Vadir Lopez-Salmeron, PhD; Margaret Nakamoto, PhD; Liselotte Brix, PhD; Stefanie Mortimer; Cynthia Sakofsky, PhD; | Immune Cell Types | Bioinformatics; Biomarkers; Gene expression; Immune monitoring; Neoantigens; T cell |
| 545 | Oral Presentation | TUMOR-SPECIFIC CYTOLYTIC CD4 T CELLS MEDIATE PROTECTIVE IMMUNITY AGAINST HUMAN CANCER | Amélie Cachot; Mariia Bilous; Yen-Cheng Liu; Xiaokang Li; Alexander Rockinger; Margaux Saillard; Tania Wyss; Philippe Guillaume; Julien Schmidt, PhD; Raphael Genolet; Maria Pia Protti; Walter Reith; Laurence De Leval; Kalliopi Ioannidou; George Coukos, MD, PhD; Alexandre Harari, PhD; Daniel E. Speiser, MD; Alexander Mathis; David Gfeller; Hatice Altug; Pedro J. Romero, MD; Camilla Jandus, MD, PhD; | Immune Cell Types | Adoptive immunotherapy; Solid tumors; T cell; T cell lineages; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 546 | Poster Presentation | The Differentiation status of Systemic PD1+ CD8 T Cells is Associated with Favorable Outcome to PD1 Blockade Therapy in Non Small Cell Lung Cancer | Asma Khanniche, PhD; Ying Wang; | Immune Cell Types | Biomarkers; Checkpoint blockade; T cell |
| 547 | Oral Presentation | Identification of the immune landscape in penile squamous cell carcinoma using multiplex immunofluorescence and spatial image analysis | Rossana N. Lazcano Segura, MD; Santhoshi N. Krishnan; Morgan D. Oneka; Federico Netto; Xin Lu; Priya Rao, MD; Renganayaki K. Pandurengan; Curtis R. Pickering; Curtis A. Pettaway, MD; Jad Chahoud; Edwin R. Parra, MD, PhD; Edwin R. Parra, MD, PhD; | Immune Cell Types | Immune contexture; Immune suppression; Solid tumors; T cell; Tumor microenvironment |
| 548 | Poster Presentation | CD8+ Tissue-resident memory T cells are tumour reactive and increase after immunotherapy in a case of metastatic mucosal melanoma | Angela Pizzolla, PhD; Simon P. Keam, PhD; Ismael Vergara; Franco Caramia; Minyu Wang; Nikolce Kocovski; ThuNgoc Nguyen; Sean Macdonald; Daniela Tantalo; Pasquale Petrone; Han Xian Aw Yeang; David E. Gyorki; Alison Weppler, MD; George Au-Yeung; Shahneen Sandhu, MBBS FRACP; Maurizio Perdicchio, PhD; Grant A. McArthur, MBBS (Hons), PhD, FRACP, FAHMS; Tony Papenfuss; Paul J. Neeson, PhD; | Immune Cell Types | Checkpoint blockade; Neoantigens; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 549 | Oral Presentation | Characterizing Double Positive T cells in the Tumor Microenvironment: a tale of promiscuous cell fates | Sara Schad, BS; Sara Schad, BS; Andrew Chow, MD, PhD; Heng Pan; Levi M. Mangarin, BS; Roberta Zappasodi, PhD; Mathieu Gigoux, PhD; David Redmond; Daniel Hirschhorn-Cymerman, PhD; Sadna Budhu, PhD; Hong Zhong, BS; Xia Yang; Olivier Elemento, PhD; Jedd D. Wolchok, MD, PhD; Taha Merghoub, PhD; | Immune Cell Types | Adoptive immunotherapy; CAR T cells; Gene expression; Regulatory T cell (Treg cell); Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 550 | Poster Presentation | An Axl-targeting monoclonal antibody that inhibits Axl activity and potently stimulates the innate immune response | Diego Alvarado; Laura Vitale, BS; Mike Murphy; Thomas O'Neill, BA; Edward J. Natoli; Jay Lillquist; Linda Crew; Anna Wasiuk; Jeffrey Weidlick, BS; Crystal Sisson; Jenifer Widger, BA; Laura Mills-Chen; Andrea Crocker, BS; Colleen Patterson; James M. Boyer; Eric Forsberg; April R. Baronas; Taylor M. Mathieu; Amelia C. Fields; Russell Hammond; Li-Zhen He, MD; Joel Goldstein, PhD; Lawrence J. Thomas, PhD; Henry C. March; Tibor Keler, PhD; | Immune-stimulants and immune modulators | Antibody; Bispecifics; Checkpoint blockade; Coinhibition; Dendritic cell; Immune suppression; Monocyte/Macrophage; Myeloid cells; Targeted therapy; Tumor microenvironment |
| 552 | Poster Presentation | SUMOylation inhibitor TAK-981 activates NK cells and macrophages via Type I interferon signaling and shows synergistic activity in combination with rituximab and daratumumab in preclinical models | Akito Nakamura, PharmD; Keli Song, PhD; Stephen Grossman, PhD; Kristina Xega; Yuhong Zhang; Allison J. Berger, PhD; Allison J. Berger, PhD; Gary S. Shapiro, PhD; Dennis Huszar, PhD; | Immune-stimulants and immune modulators | Antibody; Leukemia/Lymphoma; Monocyte/Macrophage; NK/NK T cell; Post-translational modifications |
| 553 | Poster Presentation | CUE-100 series Immuno-STATs from concept to the clinic: Leveraging protein engineering to stimulate and selectively deliver affinity-attenuated IL-2 to antigen-specific T cells | Alex Histed, MSc; Natasha Girgis, PhD; Miguel Moreta; Jonathan Soriano, MSc; Luke Witt, B.S.; Zohra Merazga, MSc; Fulvio Diaz; Fan Zhao, PhD; Melissa Kemp, PhD; Paige Ruthardt, MSc; Dharma Thapa, PhD; Anish Suri, PhD; Ronald D. Seidel, PhD; Kenneth J. Pienta, MD; Mary C. Simcox, PhD; Steven N. Quayle, PhD; John F. Ross, Ph.D.; Saso Cemerski, PhD; Saso Cemerski, PhD; Saso Cemerski, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Clinical trial; Cytokine; T cell; Tumor infiltrating lymphocytes (TILs); Vaccine |
| 555 | Poster Presentation | Inhibition of FOXP3 by stapled alpha-helical peptides alters Regulatory T Cell function | Katrina M. Hawley, AB; Rachel J. Eclov, PhD; Marie Fefferman, MD; Gregory H. Bird, PhD; Mathew R. Schnorenberg; Ravand Samaeekia, MD; Loren D. Walensky, MD, PhD; Matthew V. Tirrell, PhD; James L. LaBelle, MD, PhD; | Immune-stimulants and immune modulators | Regulatory T cell (Treg cell); Targeted therapy |
| 557 | Poster Presentation | Determining the efficacy of ADCC by the 3D-EX ex vivo platform utilizing tumoroids of fresh patient tumor samples with intact tumor microenvironment | Jenny Kreahling, PhD; Jared C. Ehrhart, PhD; Stephen Iwanowycz, PhD; Mibel Pabon, PhD; Tina Pastoor; Soner Altiok, MD, PhD; | Immune-stimulants and immune modulators | Antibody; Checkpoint blockade; Cytokine; Gene expression; Immune monitoring; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 558 | Poster Presentation | Programmed death (PD)-1 and PD-ligand-1 inhibitors in the treatment of non-small cell lung cancer: a systematic review of their efficacy and safety | Melissa Lingohr-Smith; Chelsea Deitelzweig; Grace Lin; Jay Lin; | Immune-stimulants and immune modulators | Checkpoint blockade; Clinical trial; Targeted therapy |
| 559 | Poster Presentation | Fostriecin potentiates genome instability and anti-tumor immunity in ovarian cancer | Remya Raja, PhD; Christopher Wu; Kristina A. Butler, M.D., MS; Marion Curtis, Ph.D.; | Immune-stimulants and immune modulators | Chemotherapy; Cytokine; Inflammation; Solid tumors; T cell |
| 560 | Poster Presentation | Alpha-tocopheryloxyacetic acid induces apoptosis of murine rhabdomyosarcoma in vitro while modulating innate and adaptive immune responses in vivo | Fernanda Szewc, MSc; Longzhen Song, Ph.D.; Sean P. Rinella, MPH, CCRP; Christopher Dubay, Ph.D.; Emmanuel T. Akporiaye, Ph.D.; William L. Redmond, Ph.D.; Christian M. Capitini, MD; | Immune-stimulants and immune modulators | Gene expression; Immune suppression; Myeloid cells; Pediatric tumors; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Epigenetics; RNA |
| 561 | Poster Presentation | DuoBody®-PD-L1×4-1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4-1BB co-stimulation | Alexander Muik, PhD; Isil Altintas, PhD; Friederike Gieseke; Rachelle Kosoff, PhD; Kristina Schödel; Theodora Salcedo; Saskia Burm, PhD; Aras Toker; Lena M. Kranz, PhD; Mathias Vormehr; David Eisel; Mark Fereshteh, PhD; Özlem Türeci; Esther Breij, PhD; Tahamtan Ahmadi; Ugur Sahin, MD; Maria Jure-Kunkel; | Immune-stimulants and immune modulators | Antibody; Bispecifics; Checkpoint blockade; Coinhibition; Costimulation; Targeted therapy |
| 562 | Poster Presentation | SO-C101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity | Zuzana Antosova, PhD; Nada Podzimkova, MSc; Marketa Jiratova, MSc; Eva Nedvedova, PhD; Guy de Martynoff, PhD, CMO; David Bechard, PhD, CEO; Ulrich Moebius, PhD,CSO; Radek Spisek, MD,PhD,CEO; Irena Adkins, PhD; | Immune-stimulants and immune modulators | Antibody; Cytokine; Immune adjuvant; Leukemia/Lymphoma; Solid tumors; T cell |
| 563 | Poster Presentation | Pharmacodynamics and pharmacokinetics of SO-C101 in cynomolgus monkeys | Nada Podzimkova, MSc; Irena Adkins, PhD; Irena Adkins, PhD; Guy de Martynoff, PhD, CMO; David Bechard, PhD, CEO; Radek Spisek, MD,PhD,CEO; Ulrich Moebius, PhD,CSO; | Immune-stimulants and immune modulators | Cytokine; Immune adjuvant; NK/NK T cell; Regulatory T cell (Treg cell); T cell |
| 564 | Poster Presentation | Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents | Matthew J. Bernett, PhD; Rajat Varma, PhD; Ke Liu, PhD; Christine Bonzon, PhD; Rumana Rashid, PhD; Nicole Rodriguez, PhD; Nargess Hassanzadeh-Kiabi, PhD; Connie Ardila; Seung Chu, PhD; Umesh Muchhal, PhD; John R. Desjarlais, PhD; | Immune-stimulants and immune modulators | Bispecifics; Cytokine; Solid tumors; Tumor microenvironment |
| 565 | Poster Presentation | A novel long-acting interleukin-7 agonist, NT-I7, increases cytotoxic CD8+ T cells and enhances survival in mouse glioma models | Subhajit Ghosh, PhD; Ran Yan, PhD; Sukrutha Thotala; Arijita Jash, PhD; Anita Mahadevan, BS; Tong Hu, BS; Byung H. Lee, PhD; Se Hwan Yang, PhD; Dennis Hallahan, MD, PhD; Milan Chheda, MD; Dinesh Thotala, PhD; Jian L. Campian, MD, PhD; Jian L. Campian, MD, PhD; | Immune-stimulants and immune modulators | Cytokine; Radiotherapy; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 566 | Poster Presentation | MDK-202: An empirically-designed peptidyl agonist of the IL-2/15βγc receptor, devoid of Rα interaction, unrelated to IL-2 or IL-15, and fused to an Fc-domain for PK enhancement | William J. Dower, PhD; Steven E. Cwirla; Blake M. Williams, MS; Praechompoo Pongtornpipat, MS; Prarthana Joshi, ME; Sandra M. Wang, BSc; Alice V. Bakker, BA; Michael C. Needels, PhD; Ronald W. Barrett, PhD; | Immune-stimulants and immune modulators | Cytokine; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 567 | Poster Presentation | MDK1319/MDK-701: A potent fully efficacious peptidyl agonist of IL-7Rαγc, designed with no reference to cytokine or receptor structure and unrelated to IL-7, fused to an Fc-domain for PK enhancement | William J. Dower, PhD; Alice V. Bakker, BA; Steven E. Cwirla; Prarthana Joshi, ME; Praechompoo Pongtornpipat, MS; Blake M. Williams, MS; Sandra M. Wang, BSc; Michael C. Needels, PhD; Ronald W. Barrett, PhD; | Immune-stimulants and immune modulators | COVID and Immunotherapy; CAR T cells; Cytokine; Immune adjuvant; T cell; T cell lineages; Vaccine |
| 568 | Poster Presentation | XTX201, a protein-engineered IL-2, exhibits tumor-selective activity in mice without peripheral toxicities in non-human primates | Minjie Zhang; Wilson Guzman; Parker Johnson; Megan McLaughlin; Kurt Jenkins, PhD; Hsin-Jung Wu; Hanumantha Rao Madala; Caitlin O'Toole; Magali Pederzoli-Ribeil; Raphael Rozenfeld; Huawei Qiu; Margaret L. Karow, PhD; Tim Clackson; Ronan O'Hagan; Jennifer O'Neil; Ugur Eskiocak, PhD; | Immune-stimulants and immune modulators | Cytokine |
| 569 | Poster Presentation | Targeting IL-15 delivery to PD-L1 Expressing Tumors with an Anti-PD-L1-IL-15 Cytokine Fusion IgM to Enhance T Cell and NK Cell Mediated Tumor Cytotoxicity | Angus M. Sinclair, PhD; Thierry D. Giffon; Dean Ng, Ph.D.; Poonam Yakkundi, Ph.D.; Hope Lancero, Ph.D.; Marigold Manlusoc; Rodnie Rosete; Avneesh Saini, Ph.D.; Madeline Tran; Kevin Carlin, Ph.D.; Chitra Saraiya; Ramesh Baliga, Ph.D.; Bruce Keyt, Ph.D.; | Immune-stimulants and immune modulators | Antibody; Bispecifics; Checkpoint blockade; Cytokine; NK/NK T cell; T cell; Tumor infiltrating lymphocytes (TILs) |
| 570 | Poster Presentation | IL-15/IL-15Rα heterodimeric complex as cancer immunotherapy in murine breast cancer models | Siqi Guo; Ronald Smeltz B. Smeltz, PhD; Anthony Nanajian; Richard Heller; Siqi Guo; | Immune-stimulants and immune modulators | Cytokine; Solid tumors; T cell |
| 571 | Poster Presentation | ANV419 is a novel CD122-selective IL-2/anti-IL-2 antibody fusion protein with potent CD8 T cell and NK cell stimulatory function in vitro and in vivo | Christoph Huber, PhD; Andreas Katopodis, PhD; Barbara Branetti; Jean-Michel Rondeau; Simone Popp; Catherine Regnier; Daniel Kaiser; | Immune-stimulants and immune modulators | Antibody; Cytokine; Immune adjuvant; Immune toxicity; NK/NK T cell; Regulatory T cell (Treg cell); T cell |
| 572 | Poster Presentation | Fibroblast activating protein (FAP)-targeting IL-12 (anti-FAP/IL-12) TMEkine™ potentiates anti-cancer effects in preclinical cancer models | Donggeon Kim, DVM,PhD; Donggeon Kim, DVM,PhD; Dahea Lee; Soomin Ryu; Yeongseon Byeon, PhD; Kyoung-Ho Pyo, PhD; Jae-Hwan Kim, PhD; Seul Lee; Dong Kwon Kim; Eun Ji Lee; Seung Yeon Oh; Byoung Chul c. Cho, MD, PhD; | Immune-stimulants and immune modulators | Antibody; Bispecifics; Cytokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 573 | Poster Presentation | A novel human anti-PD1/IL15 bi-functional protein with robust anti-tumor activity and low systemic toxicity | Dan Lu, MS; Zhanna Polonskaya; Tzu-Pei Chang, PhD; Stella Martomo, PhD; Xenia Luna; zhikai zhang; Stanley Ng; Faical Miyara, PhD; Jeegar Patel; | Immune-stimulants and immune modulators | Antibody; Bispecifics; Checkpoint blockade; Cytokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| 574 | Poster Presentation | ONM-400, a Novel Approach for Interleukin-2 Therapy Using a pH-Activated Nanoparticle Targeting Metabolic Acidosis in Solid Cancers | Xinliang Ding, PhD; Jason B. Miller, PhD; Qingtai Su, PhD; Qingtai Su, PhD; Stephen Gutowski; Ashley Campbell; Drew Robinson; Tian Zhao, PhD; | Immune-stimulants and immune modulators | Cytokine; Solid tumors; Targeted therapy; Tumor microenvironment |
| 575 | Poster Presentation | Regression by hetIL-15 monotherapy in different mouse breast cancer models correlates with intratumoral infiltration of a novel population of dendritic cells | Sevasti Karaliota; Dimitris Stellas; Vasiliki Stravokefalou, MSc.; Bethany Nagy, BS; Cristina Bergamaschi, PhD; Barbara K. Felber, PhD; George N. Pavlakis, M.D., Ph.D.; | Immune-stimulants and immune modulators | Antigen presenting cells; Cytokine; Dendritic cell; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 576 | Poster Presentation | NL-201, a de novo IL-2 and IL-15 agonist, demonstrates enhanced in vivo antitumor activity in combination with multiple cancer immunotherapies | Carl Walkey, PhD; Ryan Swanson, BS; Umut Ulge, MD, PhD; Daniel Adriano Silva Manzano, PhD; Jonathan G. Drachman, MD; | Immune-stimulants and immune modulators | Antibody; Bispecifics; Checkpoint blockade; Costimulation; Cytokine; Inflammation; NK/NK T cell; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 577 | Poster Presentation | Engineered non-pathogenic synthetic biotic producing L-arginine synergize with PD-1-based cancer immunotherapy | Fernando P. Canale; Camilla Basso; Ning W. Li, PhD; Anna Sokolovska, PhD; Michela Perotti; Michael J. James, BS; Wenjie Jin; Jean-Philippe Theurillat; Daniel Leventhal; Kip A. West, PhD; Jose Lora; Federica Sallusto; Roger Geiger, PhD; | Immune-stimulants and immune modulators | Checkpoint blockade; Immune adjuvant; Immune suppression; Metabolism; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 578 | Poster Presentation | Tumor selective immune responses of STA551, a novel anti-CD137 agonist antibody activated by extracellular ATP | Yoshinori Narita, Ph.D.; Mika Kamata-Sakurai, PhD; | Immune-stimulants and immune modulators | Antibody; Checkpoint blockade; Costimulation; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 579 | Poster Presentation | Lactate Dehydrogenase C-associated molecular networks predict enhanced tumor growth and impaired immune response in breast cancer. | Julie Decock, PhD; Adviti N. Jana; Julie Decock, PhD; | Immune-stimulants and immune modulators | Carcinogenesis; Immune contexture; Immune suppression; Tumor antigens; Tumor evasion; Tumor microenvironment |
| 580 | Poster Presentation | High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot | Simon P. Keam, PhD; Heloise Halse; ThuNgoc Nguyen; Minyu Wang; Nicolas Van Kooten Losio; Catherine Mitchell; Franco Caramia; David J. Byrne; Sue Haupt; Georgina Ryland; Phillip K. Darcy; Shahneen Sandhu, MBBS FRACP; Piers Blombery; Ygal Haupt; Scott G. Williams; Paul J. Neeson, PhD; | Immune-stimulants and immune modulators | Bioinformatics; Clinical study; Gene expression; Immune contexture; Immune suppression; Inflammation; Radiotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 581 | Poster Presentation | Effects of Acoustic Immune Priming with Low-Intensity Focused Ultrasound (LOFU) and Trabectedin on a Murine Model of Osteosarcoma | Shannon Keisling; | Immune-stimulants and immune modulators | Immune tolerance; Radiotherapy; Solid tumors; Tumor antigens |
| 582 | Poster Presentation | Modulation of TCR repertoire by radiotherapy-activated NBTXR3 nanoparticles | Audrey Darmon, BS; Ping Zhang, PhD; Sebastien Paris, PhD; | Immune-stimulants and immune modulators | Radiotherapy; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs) |
| 583 | Poster Presentation | Novel, potent, and selective inhibitors of Hypoxia-Inducible Factor (HIF)-2α reverse pro-tumorigenic transcriptional programming in cancer, stromal, and immune cells | Kelsey E. Sivick Gauthier, PhD; Dana Piovesan, MSc; Kenneth V. Lawson; Soonweng Cho; Akshata R. Udyavar, Ph.D; Jean Chan; Ada Chen, BS; Jennie Au; Cesar Meleza; Xiaoning Zhao; Anh T. Tran; Samuel L. Drew; Balint Gal; Brandon R. Rosen, PhD; Manmohan R. Leleti, PhD; Elaine Ginn; Lixia Jin, PhD; Stephen W. Young; Jay P. Powers, PhD; Matthew J. Walters, PhD; | Immune-stimulants and immune modulators | Angiogenesis; Chemokine; Gene expression; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
| 584 | Poster Presentation | Therapeutic vascular normalization to promote tumor-associated tertiary lymphoid structures | Jessica Filderman, BS; Manoj Chelvanambi; Walter J. Storkus, PhD; | Immune-stimulants and immune modulators | Angiogenesis; Chemokine; Dendritic cell; Inflammation; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 585 | Poster Presentation | Intralesional injection of rose bengal improves the efficacy of gemcitabine chemotherapy against pancreatic cancer. | Patrick Innamarato, B.S.; Shari A. Pilon-Thomas, PhD; Jennifer Morse, MS; Sarah Asby; Amy Mackay; Matthew Beatty, PhD; Jaime Blauvelt; Scott Kidd; John E. Mullinax, MD; | Immune-stimulants and immune modulators | Chemotherapy; Inflammation; Solid tumors; T cell |
| 586 | Poster Presentation | Intratumoral DNA-based gene transfer as an efficient delivery approach to combine checkpoint-inhibiting antibodies with interleukin 12 | Liesl Jacobs, MPharm; Elien De Smidt; Nick Geukens, PhD; Kevin Hollevoet, PhD; Paul Declerck, PhD; | Immune-stimulants and immune modulators | Antibody; Checkpoint blockade; Costimulation; Cytokine; Gene expression |
| 587 | Oral Presentation | Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models | Kurt Jenkins, PhD; Kurt Jenkins, PhD; Kurt Jenkins, PhD; Parker Johnson; Minjie Zhang; Wilson Guzman; Ugur Eskiocak, PhD; Megan McLaughlin; Caitlin O'Toole; Magali Pederzoli-Ribeil; Miso Park, PhD; John Williams, PhD; Margaret L. Karow, PhD; Jennifer O'Neil; Timothy Clackson; Ronan O'Hagan; | Immune-stimulants and immune modulators | Antibody; Checkpoint blockade; Immune toxicity; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 588 | Oral Presentation | Targeting GITR enhances human tumour-infiltrating T cell functionality in mismatch repair proficient primary colorectal carcinoma and liver metastases | Yannick S. Rakké, MD, MSc; Yannick S. Rakké, MD, MSc; Lucia Campos Carrascosa, PhD; Adriaan A. van Beek, PhD; Valeska de Ruiter, MSc; Michael Doukas, MD, PhD; Susan ter Borg, MD; Pascal G. Doornebosch, MD, PhD; Maarten Vermaas, MD, PhD; Erwin van der Harst, MD, PhD; Peter Paul LO. Coene, MD, PhD; Dirk J. Grünhagen, MD, PhD; Cornelis Verhoef, MD, PhD; Jan NM. IJzermans, MD, PhD; Dave Sprengers, MD, PhD; Jaap Kwekkeboom, PhD; | Immune-stimulants and immune modulators | Checkpoint blockade; Costimulation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 589 | Poster Presentation | Efficacy of oncolytic vaccinia virus requires infection of suppressive immune cells in the tumor microenvironment leading to their reprogramming and deletion | Kristin DePeaux, BS; Paolo DA. Vignali, BA; Saumendra Sarkar, PhD; Greg M. Delgoffe, PhD; | Immune-stimulants and immune modulators | Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 590 | Poster Presentation | Pre-conditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy | Christianne Groeneveldt, MSc; Priscilla Kinderman; Diana J.M. van den Wollenberg; Ruben L. van den Oever; Jim Middelburg; Dana A.M. Mustafa; Rob C. Hoeben; Sjoerd H. van der Burg, PhD; Thorbald van Hall, PhD; Nadine Van Montfoort; | Immune-stimulants and immune modulators | Antibody; Immune adjuvant; Inflammation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Bispecifics |
| 591 | Oral Presentation | Comparison of Two oHSV Vectors for the Treatment of Glioblastoma | Joseph Jackson, PhD; Joseph Jackson, PhD; Bonnie Hall, PhD; Lisa Bailey; E Chiocca, MD; Justus Cohen, PhD; Joseph C. Glorioso, III, PhD; | Immune-stimulants and immune modulators | Immune adjuvant; MDSC; Monocyte/Macrophage; Myeloid cells; Tumor microenvironment; Vaccine |
| 592 | Poster Presentation | Enhancing the therapeutic potential of oncolytic adenoviruses with vSENSᵀᴹ technology | Goo-Young Kim, Ph.D.; Ji Yeon Son; So Jin Lee; Sang Woo Jo; Changhoon In; Sang Hoon Kim; Joon Young Park; So-Young Kim; Gyu-Young Moon; Ji-Hye Choi; Suk-Hwan Kim; Minhyuk Yun; Hye Yeong Nam; Helen Cho; | Immune-stimulants and immune modulators | Immune contexture; Immune monitoring; Immune tolerance; Solid tumors; Systems biology; Targeted therapy; Tumor microenvironment |
| 593 | Poster Presentation | Tumoral Melanosis Mimicking Residual Melanoma After T-VEC Treatment | Song Y. Park, MD; Ata S. Moshiri, MD, MPH; Rouba Hadi, MD; Austin R. Green, MD; Jennifer Gardner, MD; Coley Doolittle-Amieva, PA-C; Song Y. Park, MD; | Immune-stimulants and immune modulators | Clinical study; Inflammation; Solid tumors; Tumor microenvironment; Vaccine |
| 594 | Poster Presentation | BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment | Monika Semmrich, PhD; Jean-Baptiste j. Marchand, PhD; Laetitia Fend, PhD; Matilda Rehn, PhD; Nathalie Silvestre, PhD; Linda Mårtensson, PhD; Johann Foloppe, PhD; Ingrid Teige, PhD; Eric Quéméneur, PhD; Björn Frendeus, PhD; | Immune-stimulants and immune modulators | Antibody; Checkpoint blockade; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Vaccine |
| 595 | Poster Presentation | Armed Myxoma virus demonstrates efficacy in syngeneic tumor models alone and in combination with immune checkpoint inhibitors | Lina S. Franco, PhD; Lino E. Torres-Dominguez, PhD; Joseph Mamola; Ana L. de Matos, PhD; Mario Abrantes; Benjamin S. Walker; Zachary Tacner; Cassandra Kien; Natalie M. Elliott; Grant McFadden, PhD; Leslie L. Sharp, PhD; | Immune-stimulants and immune modulators | Checkpoint blockade; Cytokine; Immune adjuvant; Myeloid cells; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| 596 | Poster Presentation | Armed Myxoma virus demonstrates therapeutic activity in xenograft models | Lino E. Torres-Dominguez, PhD; Lina S. Franco, PhD; Mario Abrantes; Benjamin S. Walker; Zachary Tacner; Cassandra Kien; Natalie M. Elliott; Anna K. Waters; Grant McFadden, PhD; Steven J. Potts, PhD; Leslie L. Sharp, PhD; | Immune-stimulants and immune modulators | Checkpoint blockade; Costimulation; Gene expression; Immune adjuvant; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 597 | Poster Presentation | In situ vaccination with oncolytic vesicular stomatitis virus improves anti-tumor immune response and outcome in bladder cancer | Coby Rangsitratkul, BSc; Christine Lawson, PhD; Lee-Hwa Tai, PhD; Lee-Hwa Tai, PhD; | Immune-stimulants and immune modulators | Immune suppression; MDSC; Solid tumors; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| 598 | Oral Presentation | Reversal of epigenetic silencing of cGAS and STING in melanoma enhances the activity of tumor infiltrating lymphocytes | Rana Falahat, PhD; James Mulé, PhD; Anders E. Berglund, PhD; Patricio Perez- Villarroel; Ryan Putney, PhD; Shari A. Pilon-Thomas, PhD; Glen N. Barber, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Bioinformatics; Chemokine; Epigenetics; Immune adjuvant; Tumor antigens; Tumor evasion; Tumor infiltrating lymphocytes (TILs) |
| 599 | Poster Presentation | New checkpoints controlling function of cytotoxic lymphocytes infiltrating human carcinoma | Anna S. Herbstritt, MS; Elfriede Noessner, Prof. Dr.; Petra U. Prinz, Dr.; Mani D. Kadiyala, BS; Melissa Maxwell, MS; Dingxue Yan, PhD; James Cardia, PhD; Simon P. Fricker, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; NK/NK T cell; RNA; Solid tumors; T cell; Tumor evasion |
| 600 | Poster Presentation | In Vitro Anticancer and Immunomodulatory Activities of NBT-167, a Dimer of Resveratrol | Jeffrey Zhang; Everett Henry; L. Harris Zhang; Wanying Zhang; | Immune-stimulants and immune modulators | Costimulation; Cytokine; NK/NK T cell; T cell |
| 601 | Poster Presentation | Development of improved small molecule STING agonists suitable for systemic administration | Maciej K. Rogacki; Stefan Chmielewski, PhD; Magdalena Zawadzka; Jolanta Mazurek; Katarzyna Wnuk-Lipinska; Kamil Kus; Karolina Gluza; Katarzyna Wójcik-Jaszczynska; Aleksandra Poczkaj; Lukasz Dudek; Wojciech Schonemann; Urszula Glowniak-Kwitek; Marcin Les; Marek Wronowski; Tushar Mahajan; Urszula Kulesza; David Synak; Karol Zuchowicz; Katarzyna Banaszak; Karolina Wiatrowska; Izabela Strojny; Miroslawa Gladysz; Justyna Jablonska; Ewelina Gabor-Worwa; Raghuram Tangirala; Luigi Stasi; Peter Littlewood; Krzysztof Brzózka; Monika Dobrzanska; | Immune-stimulants and immune modulators | Antigen presenting cells; Costimulation; Cytokine; Inflammation |
| 602 | Poster Presentation | STING Agonist-Based Treatment Promotes Vascular Normalization and Tertiary Lymphoid Structure Formation in the Therapeutic Melanoma Microenvironment | Manoj Chelvanambi, BS; Ronald Fecek, PhD; Jennifer L. Taylor, Ph.D.; Walter J. Storkus, PhD; | Immune-stimulants and immune modulators | Angiogenesis; Antigen presenting cells; Chemokine; Dendritic cell; Immune adjuvant; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 603 | Poster Presentation | Covalent attachment of a TLR7/8 agonist to tumor-targeting antibodies drives potent anti-tumor efficacy by synergistically activating FcgR- and TLR- signaling and enables safe systemic administration | Shelley E. Ackerman, PhD; Felix J. Hartmann, PhD; Cecelia I. Pearson, PhD; Joseph C. Gonzalez; Po Yi Ho; Samuel C. Kimmey; Andrew Luo; Benjamin Ackerman, PhD; Arthur Lee; Richard P. Laura, PhD; Jason C. Paik, MD, PhD; Karla A. Henning, PhD; David Y. Jackson, PhD; Steven J. Chapin, PhD; Bruce H. Devens, PhD; David Dornan, PhD; Sean C. Bendall, PhD; Edgar G. Engleman, MD; Michael N. Alonso, PhD; | Immune-stimulants and immune modulators | Antibody; Antigen presenting cells; Dendritic cell; Immune adjuvant; Monocyte/Macrophage; Myeloid cells; TLR; Tumor microenvironment |
| 604 | Poster Presentation | Intravenous CMP-001, a CpG-A Toll-like receptor 9 (TLR9) agonist delivered via a virus-like particle, causes tumor regression in syngeneic Hepa1-6 mouse models of hepatocellular carcinoma | Aaron J. Morris, PhD; Evan D. Walters; Bassel Akache; Michael J. McCluskie; Arthur M. Krieg, MD; | Immune-stimulants and immune modulators | Dendritic cell; TLR |
| 605 | Poster Presentation | Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models | Heidi N. LeBlanc; Cecelia I. Pearson, PhD; Justin A. Kenkel; LIsa Blum; Po Y. Ho; Angela Luo; Richard P. Laura, PhD; Matthew Zhou; Joshua Gregorio; Andrew Luo; Shelley E. Ackerman, PhD; Brian S. Safina; David Dornan, PhD; Michael N. Alonso, PhD; Marcin Kowanetz, Ph.D.; | Immune-stimulants and immune modulators | Antibody; Antigen presenting cells; Biomarkers; Cytokine; Gene expression; Monocyte/Macrophage; Myeloid cells; Solid tumors; TLR |
| 606 | Poster Presentation | Epidermal growth factor modulation of CXCL10 in keratinocytes and cutaneous cancers | Myles R. McCrary, PhD; David Gibbs, PhD; Carlos S. Moreno, PhD; Brian P. Pollack, MD/PhD; Myles R. McCrary, PhD; | Immune-stimulants and immune modulators | Carcinogenesis; Chemokine; Cytokine; Gene expression; Immune toxicity; Inflammation |
| 607 | Oral Presentation | TJ210 (MOR210), A Differentiated Anti-C5aR Antibody for Anti-Cancer Therapy | Jane Meng, PhD; Jane Meng, PhD; Zhengyi Wang, PhD; Wei Cao; Chan Chen; Joan Huaqiong Shen, MD, PhD; Christian Augsberger; Julia Neugebauer; Stefan Haertle; | Immune-stimulants and immune modulators | Antibody; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 608 | Poster Presentation | Immunodominant Listeria Epitopes Compete with Vaccine-Directed CD8+ T-cell Responses Rescued By Peptide-MHC Stabilizing Modifications | John C. Flickinger, Jr., BS; Jagmohan Singh, PhD; Yanki Yarman; Robert Carlson, BS; Scott A. Waldman, MD, PhD; Adam E. Snook, PhD; | Immune-stimulants and immune modulators | Immune adjuvant; Solid tumors; Tumor antigens; Vaccine |
| 610 | Poster Presentation | Technical challenges in monocyte-derived dendritic cell vaccine manufacturing; a QI project | Opal Reddy, MD; Sandhya Panch, MD; Chauha Pham; Mame Thioye Sall; Minh T. Tran, RN; Steven L. Highfill, PhD; Kamille A. West, MD; Ping Jin, PhD; Haksong Jin, PharmD, MSc; Malcolm K. Brenner, MD, PhD,FRCP,FRCPath; Jay A. Berzofsky, MD, PhD; David F. Stroncek, MD; Hoyoung M. Maeng, MD; | Immune-stimulants and immune modulators | Antigen presenting cells; Dendritic cell; Solid tumors; Targeted therapy; Tumor antigens; Vaccine |
| 611 | Poster Presentation | RNA-sequencing reveals a unique immune transcriptional landscape in the vaccine sites of patients with circulating T-cell responses to cancer immunization | Max O. Meneveau, MD; Pankaj Kumar, PhD; Kevin Lynch, MD; Karlyn E. Pollack, MD; Craig L. Slingluff, Jr., MD; Max O. Meneveau, MD; | Immune-stimulants and immune modulators | Antigen presenting cells; Dendritic cell; Immune adjuvant; Inflammation; T cell; TLR; Vaccine |
| 612 | Oral Presentation | Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+ T cells | Kelly-Anne Masterman; Oscar Haigh; Kirsteen Tullett; Ingrid Leal-Rojas; Carina Walpole; Frances Pearson; Jonathon Cebon; Christopher Schmidt; Liam O’Brien; Nikita Rosendahl; Ghazal Daraj; Irina Caminschi; Eric Gschweng; Roger Hollis; Donald Kohn; Mireille Lahoud; Kristen J. Radford, PhD; | Immune-stimulants and immune modulators | Antibody; Antigen presenting cells; Dendritic cell; Solid tumors; T cell; Tumor antigens; Vaccine |
| 613 | Poster Presentation | HER2-XPAT, A Novel Protease-Activatable Prodrug T Cell Engager (TCE), with Potent T-Cell Activation and Efficacy in Solid Tumors and Large Predicted Safety Margins in Non-Human Primate (NHP) | Fiore Cattaruzza, PharmD, PhD; Ayesha Nazeer; Zachary Lange; Caitlin Koski, PhD; Mikhail Hammond; Trang Dao-Pick; Angela Henkensiefken; Mika K. Derynck, MD; Volker Schellenberger, PhD; Bryan A. Irving, PhD; | Immuno-conjugates and chimeric molecules | Bispecifics; Clinical trial; Immune toxicity; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor stroma |
| 614 | Poster Presentation | Co-stimulation via PD1-41BB chimeric switch receptor enhances function of TCR-T cells in an immune-suppressive milieu and under chronic antigen stimulation | Melanie Salvermoser; Maria Gerget; Franziska Hasselmann; Elfriede Noessner, Prof. Dr.; Christian Ellinger, Dr. Rer. Nat.; Monika Braun; Dolores J. Schendel, PhD; Daniel Sommermeyer, PhD; Nadja Sailer, Dr. rer. nat.; | Immuno-conjugates and chimeric molecules | Adoptive immunotherapy; Checkpoint blockade; Costimulation; Solid tumors; T cell; Tumor microenvironment |
| 615 | Poster Presentation | Targeted Immune Cell Activation by Systemic Delivery of Toll-Like Receptor 9 Agonist Antibody Conjugates Induce Potent Anti-Tumor Immunity | Ons Harrabi, BA; Amy Chen; Emma Sangalang; Laura Doyle; Danielle Fontaine; Bora Han, PhD; Curt W. Bradshaw, PhD; Jaume Pons, PhD; Janet Sim, PhD; Tracy C. Kuo, PhD; Hong I. Wan, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Antigen presenting cells; B cell; Dendritic cell; Myeloid cells; TLR |
| 616 | Poster Presentation | A novel non-covalent linker peptide with nanomolar affinity for clinical IgG1 antibodies preserves antibody-antigen affinity and drug potency against PDL1+ melanoma when conjugated with DM1 | John T. Butterfield, BS; Shari L. Sutor, BS; Wendy K. Nevala, MS; Svetomir N. Markovic, MD, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Chemotherapy; Targeted therapy |
| 617 | Poster Presentation | Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death | Elizabeth Gray, PhD; Kelly Hensley; Sean Allred; Esther Trueblood; John Gosink; Robert Thurman; Kaleb Smith; Celine Jacquemont, PhD; Mark Bieda; Jason Gow; Jeffrey R. Harris; Lauren K. Brady; Ibrahima Soumaoro; Shweta Jain; Leonardo Nicacio; Shyra J. Gardai, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Antigen presenting cells; Solid tumors; Tumor microenvironment |
| 618 | Poster Presentation | Vedotin ADCs induce ER stress and elicit hallmarks of ICD across multiple cancer indications | Kerry Klussman, B.S.; Elena-Marie Tenn; Shaylin Higgins; Rebecca Mazahreh; Katie Snead; Joseph Z. Hamilton; Bryan M. Grogan, MS; Johann Sigurjonsson; Anthony Cao; Shyra J. Gardai, PhD; Bernard A. Liu; | Immuno-conjugates and chimeric molecules | Antibody; Antigen presenting cells; Targeted therapy |
| 619 | Poster Presentation | Evaluating the effectiveness of targeted ADC therapy in a patient-derived ex vivo tumoroid model, 3D-EX, for quantitative tumor cell killing | Jenny Kreahling, PhD; Jared C. Ehrhart, PhD; Mibel Pabon, PhD; Stephen Iwanowycz, PhD; Tina Pastoor; Soner Altiok, MD, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Checkpoint blockade; Cytokine; Gene expression; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 620 | Poster Presentation | Tumor cell-intrinsic STING pathway is activated in the presence of cues from immune cells and contributes to the anti-tumor activity of tumor cell-targeted STING agonist antibody-drug conjugates | Naniye Malli Cetinbas, PhD; Travis Monnell; Winnie Lee; Kalli C. Catcott, PhD; Chen-Ni Chin, PhD; Pamela Shaw; Kelly Slocum; LiuLiang Qin; Kenneth Avocetien; Keith Bentley, PhD; Susan Clardy, PhD; Brian Jones, PhD; Eugene Kelleher; Joshua D. Thomas; Rebecca Mosher, MD; Dorin Toader, PhD; Jeremy Duvall, PhD; Raghida A. Bukhalid, PhD; Marc Damelin, PhD; Timothy B. Lowinger, PhD; | Immuno-conjugates and chimeric molecules | Chemokine; Cytokine; Monocyte/Macrophage; Myeloid cells; Targeted therapy; Tumor microenvironment |
| 621 | Poster Presentation | A Tregs depleting, CD25-targeted antibody-drug conjugate synergizes with tumor-targeted radiotherapy and systemic interleukin-2 in pre-clinical models of solid cancers | Patrick H. van Berkel, Ph.D; Francesca Zammarchi, PhD; Francesca Zammarchi, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Radiotherapy; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 622 | Poster Presentation | PD-L1 is a potential predictive biomarker for response to RM-1929 treatment in recurrent head and neck squamous cell carcinoma patients | C. Daniel De Magalhaes Filho; Chung-Wein Lee; Nikolai Suslov; Jerry Fong, PhD; Miguel Garcia-Guzman; | Immuno-conjugates and chimeric molecules | Antibody; Biomarkers; Checkpoint blockade; Solid tumors; Targeted therapy |
| 623 | Poster Presentation | Immuno-STATs: Leveraging protein engineering to expand and track antigen-specific T cells in vivo | Stad H. Zeigler; Andrew W. Woodham, PhD; Mengyan Li, PhD; Ella L. Zeyang, PhD; Stephen C. Kolifrath; Mohammad Rashidian, PhD; Kaitlyn E. O’Connor; Rodolfo J. Chaparro, PhD; Ronald D. Seidel, PhD; Maia Mesyngier; Ross W. Cheloha, PhD; Jason L. Dearling, PhD; Phaneendra K. Duddempudi, PhD; Alev Celikgil, MD; Scott J. Garforth, PhD; Alan Packard, PhD; Harris Goldstein, MD; Hidde L. Ploegh, PhD; Steven C. Almo, PhD; | Immuno-conjugates and chimeric molecules | Bispecifics; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 624 | Poster Presentation | IFNγ secreted by tebentafusp (IMCgp100)-redirected T cells inhibits expression of melanin synthesis pathway genes in healthy melanocytes | Mariantonella Vardeu, PhD; David Depoil, PhD; Camille Britton-Rivet, PhD; Jane Houghton; Jane Harper, PhD; Gabrielle Le Provost, PhD; Laura Collins, PhD; Koustubh Ranade, PhD; Adel Benlahrech, PhD; | Immuno-conjugates and chimeric molecules | Bispecifics; T cell; Targeted therapy |
| 625 | Poster Presentation | Bispecific Personalized Aptamer for the Treatment of Solid Tumors | Erez Lavi; Nir Skalka; Neta Zilony Hanin; Zohar Pode; Anastasia Paz; Yeela Scharff; Neria Reiss; Omer Levy; Elinor Debby; Liron Levy- Efrati; Vitaliy Buravenkov; Itay Liron; Yaniv Amir; Raanan Berger, MD; Ido Bachelet; Guy Neev; Irit Carmi Levy, PhD; | Immuno-conjugates and chimeric molecules | Bispecifics; Solid tumors; Targeted therapy |
| 626 | Poster Presentation | Improving the yeast transformation efficiency for yeast display in antibody development | Jian Chen, PhD; George Sun; Jian Chen, PhD; | Immuno-conjugates and chimeric molecules | Antibody |
| 627 | Poster Presentation | The DLL3-targeted Half-life Extended Bispecific T Cell Engager (HLE BiTE®) immune-oncology therapy AMG 757 has potent antitumor activity in neuroendocrine cancer | Keegan Cooke, BS; Juan Estrada; Jinghui Zhan; Jonathan Werner; Fei Lee; Aditya Shetty; Marie-Anne Damiette Smit, MD, MS; Mark E. Salvati, PhD; Julie M. Bailis, PhD; | Immuno-conjugates and chimeric molecules | Bispecifics; Solid tumors; Targeted therapy; Tumor microenvironment |
| 628 | Poster Presentation | IL-2 augments ImmTAC-dependent T cell activation and tumour cell killing | Duncan M. Gascoyne, PhD; Kristina Petrovic, PhD; Koustubh Ranade, PhD; David Depoil, PhD; | Immuno-conjugates and chimeric molecules | Bispecifics; Cytokine; T cell; Targeted therapy |
| 629 | Oral Presentation | Targeting a shared TP53 neoantigen with bispecific T cell retargeting antibody | Emily H. Hsiue, MD; Katharine M. Wright, PhD; Jacqueline Douglass, MS; Michael Hwang; Brian J. Mog; Alexander H. Pearlman, BS; Annika Schaefer; P. Aitana Azurmendi; Qing Wang; Drew M. Pardoll, MD, PhD; Nickolas Papadopoulos; Kenneth W. Kinzler, PhD; Bert Vogelstein, MD; Sandra B. Gabelli; Shibin Zhou; Emily H. Hsiue, MD; | Immuno-conjugates and chimeric molecules | Antibody; Neoantigens; Bispecifics |
| 630 | Poster Presentation | PD-L1/CD47 tumor directed B-BodyTM bispecific antibodies demonstrating significant anti-tumor activity with no toxicity in preclinical models | Seema Kantak, PhD, MS, M.Sc.; Bryan Glaser, PhD; Justin Wetter; Bee-Cheng Sim; Jeff Higaki; Jacob Beal; Sara Ollerman; Dileep Pulukkunat; Mandar Bawadekar; Charles Kaplan; Peter Lamb; Bonnie Hammer; | Immuno-conjugates and chimeric molecules | Antibody; Bispecifics; Checkpoint blockade |
| 631 | Poster Presentation | Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platform | Dahea Lee; Donggeon Kim, DVM,PhD; Soomin Ryu; Byoung Chul Lee, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Bispecifics; Cytokine; Leukemia/Lymphoma; Targeted therapy; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 632 | Oral Presentation | HPN601 is a protease-activated EpCAM-targeting T cell engager with an improved safety profile for the treatment of solid tumors | Jack Lin, Ph.D.; Sony S. Rocha; Kathryn Kwant, Ph.D.; Maria R. Dayao; Tessie M. Ng, Ph.D.; Wade Aaron, BS; Evan Callihan; Maria Gamez-Guerrero; Golzar Hemmati; Kevin J. Wright, Ph.D.; Manasi Barath; Yinghua Xiao, Master Degree; Timothy Yu; Patrick Chew; Thomas Evans; Jessica O'Rear; Scott Gatto; Michael Cremin; Stephen Yu; Purbasa Patnaik; Avneel Hundal; Richard Austin, Ph.D.; Bryan Lemon, Ph.D.; Holger Wesche, Ph.D.; | Immuno-conjugates and chimeric molecules | Antibody; Bispecifics; Immune toxicity; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment; Tumor stroma |
| 633 | Oral Presentation | Dual-targeting of 4-1BB and OX40 with an ADAPTIR™ bispecific antibody enhances anti-tumor responses to solid tumor | Michelle Nelson; Robert Miller; Gabriele Blahnik-Fagan; Lauren Loh; Danielle Van Citters; Lynda Misher; Megan Sprague; Maria Dasovich; Irene Barber; Kathy Maggiora; Franz Gruswitz; Brian Woodruff; Kelsey Huntington; Aelish Guinn; Megan Aguilar; Mollie Daugherty; Elizabeth Haglin; Jane Gross; Peter Pavlik; Catherine McMahan; David Bienvenue; Gabriela Hernandez-Hoyos, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Bispecifics; Costimulation; NK/NK T cell; T cell |
| 634 | Poster Presentation | Production and testing of a novel bispecific nanobody construct targeting NK cells and EGFR expressing malignancies | Elisa C. Toffoli, MD; Abdolkarim Sheikhi; Roeland Lameris; Lisa A. King; Jurriaan Tuynman; Jan Spanholtz; Henk Verheul; Tanja D. de Gruijl, PhD; Hans J. Van der Vliet, MD, PhD; Elisa C. Toffoli, MD; | Immuno-conjugates and chimeric molecules | Antibody; Bispecifics; NK/NK T cell |
| 635 | Poster Presentation | A novel site-directed chemical conjugation technology confers antitumor activity via native Fc receptor to plasma immunoglobulin by attaching tumor binders | Christian M. Vidal, PhD; Michael Cukan, PhD; Rajat Varma, PhD; Lawrence Iben, MA; Tanya Berbasova, PhD; Ada Vaill, MS; Anna Bunin, PhD; Ann Marie Rossi, MS; David Trinh, BS; Katy McGrath, BS; Enrique Alvarez, DVM; Matthew Welsch, PhD; Luca Rastelli, PhD; | Immuno-conjugates and chimeric molecules | Antibody; B cell; Leukemia/Lymphoma; Monocyte/Macrophage; NK/NK T cell; Targeted therapy; Tumor antigens |
| 637 | Poster Presentation | Immune-related adverse events (irAEs) may indicate a favorable prognosis in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI) | Dylan J. Martini, BA; Sean T. Evans, BS; Subir Goyal, Ph.D; Yuan Liu, Ph.D; T. Anders Olsen, BA; Benjamin L. Magod, BS; Jacqueline T. Brown, MD; Lauren Yantorni, NP; Greta A. Russler, MSN, FNP-BC; Sarah Caulfield, PharmD, BCOP; Jamie M. Goldman, MD; Bassel Nazha, MD; Wayne B. Harris, MD; Viraj A. Master, MD Ph.D; Omer Kucuk, MD; Bradley C. Carthon, MD Ph.D; Mehmet A. Bilen, MD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Clinical study; Immune toxicity; Solid tumors |
| 638 | Poster Presentation | Plasma Proteome Analysis in Patients with Immune Checkpoint Inhibitors Related Arthritis and Pneumonitis | Noha Abdel-Wahab, MD, PhD; Adi Diab, MD; Hiroyuki Katayama, PhD; Sang Kim, MD, PhD; Samir M. Hanash, MD, PhD; Maria Suarez-Almazor, MD, PhD; | Immunotherapy Toxicities | Checkpoint blockade; Immune toxicity; Proteomics |
| 639 | Poster Presentation | Immune-Related Thyroid Dysfunction in Patients with Existing Thyroid Dysfunction | Francois Kaleta, MD; Heather Brody, MD; Praveen Namireddy, MD; | Immunotherapy Toxicities | Checkpoint blockade; Immune monitoring; Immune toxicity; Solid tumors |
| 640 | Poster Presentation | Characterizing severe acute kidney injury in patients treated with immune checkpoint inhibitors | Chung-Jiah Chen, MD; Lisa Kim, M.S.; Ashley Weaver; Sandip P. Patel, MD; | Immunotherapy Toxicities | Immune toxicity |
| 641 | Poster Presentation | Incidence and risk factors for stroke associated with immune checkpoint inhibitor therapy in cancer patients using real-world clinical data | Prantesh Jain, MD FACP; Jahir Gutierrez, PhD; Avirup Guha, MD; Chhavi Jain, PhD; Nirav Patil; Tingke Shen; Ilya Stanevich; Ankit Mangla, MD; Marcos De Lima, MD; Jill Barnholtz-Sloan, PhD; Afshin Dowlati, MD; | Immunotherapy Toxicities | Checkpoint blockade; Chemotherapy; Immune monitoring; Immune toxicity; Solid tumors; Targeted therapy |
| 642 | Poster Presentation | Retrospective Review of Pulmonary Pathology Associated with Chimeric Antigen Receptor T Cell Therapy | Jing Du, MD; David W. Woolston; Kimberly E. Costas, MD; Alexandre Hirayama, MD; Cameron J. Turtle, MBBS, PhD; Cecilia CS. Yeung, MD; | Immunotherapy Toxicities | CAR T cells; Clinical study; Granulocyte; Immune toxicity; Leukemia/Lymphoma; Monocyte/Macrophage |
| 643 | Poster Presentation | Autopsy Review of Chimeric-Antigen Receptor T Cell Therapy: A Single Institution Experience | KiBeom Kwon; David W. Woolston; Alexandre Hirayama, MD; Damian Green, MD; David G. Maloney, MD, PhD; Cameron J. Turtle, MBBS, PhD; Cecilia CS. Yeung, MD; | Immunotherapy Toxicities | B cell; Biomarkers; CAR T cells; Clinical study; Cytokine; Immune toxicity; Leukemia/Lymphoma; T cell |
| 644 | Poster Presentation | Ocular adverse events associated with Programmed Death-1 and Programmed Death Ligand-1 immunotherapy | LeAnne H. Young, BS; Shanda Finnigan, MPH, RN; Howard Streicher, MD; Helen Chen, MD; James Murray, PhD; H. Nida Sen, MD, MHSc; Elad Sharon, MD, MPH; | Immunotherapy Toxicities | Checkpoint blockade; Immune toxicity; Inflammation |
| 645 | Oral Presentation | Preclinical development of a novel colon-targeted therapeutic for the treatment of Immune Checkpoint Inhibitor (ICI)-colitis | Nazli Dizman, MD; Milton L. Greenberg, PhD; Andrew C. Newman, PhD; Jonathan Skupsky, MD, PhD; JoAnn Hsu, BS; Zeynep B. Zengin, MD; Nicholas Salgia, BS; Luis Meza, MD; Neal Chawla, MD; Sabrina Salgia; Jasnoor Kaur; Sumanta K. Pal, MD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Cytokine; Immune toxicity; Inflammation; Regulatory T cell (Treg cell); T cell |
| 646 | Poster Presentation | Evaluating a preclinical model of contact hypersensitivity for skin immune checkpoint toxicity | Barbara Ma, MD, MS; Abhinav Jaiswal, B.S.; K Sanjana P. Devi, PhD; Qingrong Huang, PhD; Joy Hsu, B.A.; Yong Liu, PhD; Niroshana Anandasabapathy, MD, PhD, MS; | Immunotherapy Toxicities | Checkpoint blockade; Immune toxicity; Inflammation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| 647 | Poster Presentation | Evaluation of efficacy and toxicity of CD137 immunotherapy with urelumab-mIgG1 chimeric antibody in CD137 HuGEMM™ | Hongjuan Zhang, PhD; Daniel X. He; Mingkun Zhang; Xinhe Feng; Annie X. An; Cunxiang Ju; Henry Q. Li; Davy X. Ouyang, PhD; | Immunotherapy Toxicities | Antibody; Immune toxicity; T cell |
| 648 | Poster Presentation | Cytokine changes during immune-related adverse events and steroid treatment in melanoma patients receiving immune checkpoint inhibitors | Kevin Tyan, BA; Joanna Baginska, PhD; Martha Brainard; Anita Giobbie-Hurder, MS; Mariano Severgnini, MSc; Michael P. Manos, BA; Rizwan Haq, MD, PhD; Elizabeth I. Buchbinder, MD; Patrick A. Ott, MD, PhD; F. Stephen Hodi, Jr., MD; Osama E. Rahma, MD; | Immunotherapy Toxicities | Biomarkers; Checkpoint blockade; Chemokine; Cytokine; Immune toxicity; Inflammation |
| 649 | Poster Presentation | Incidence of thromboembolism (TE) in patients with melanoma receiving immune checkpoint inhibitor (ICI) therapy and its adverse impact on survival | Tamara A. Sussman, MD; Joanna Roopkumar, MBBS, MPH; Hong Li, MS; Keith R. McCrae, MD; Pauline Funchain, MD; Alok A. Khorana, MD; | Immunotherapy Toxicities | Checkpoint blockade; Immune toxicity; Inflammation; Solid tumors |
| 651 | Poster Presentation | NEUROLOGICAL ADVERSE EVENTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS: OUR EXPERIENCE IN A TERTIARY CARE CENTER | Pablo Alvarez-Ballesteros; Javier Buisan-Catevilla; Alvaro Beltrán-Corbellini; Iñigo Corral-Corral; Javier Pozas-Perez; Victor Albarran-Fernandez; Lucia Sanz-Gomez; Jorge Esteban-Villarrubia; Javier Torres-Jimenez; Jesús Chamorro-Perez; Diana Rosero-Rodriguez; María San Román-Gil; Ainara Soria-Rivas; | Immunotherapy Toxicities | Clinical study; Immune toxicity |
| 652 | Poster Presentation | Early Outcomes of an APP Acute Checkpoint Inhibitor (CPI) Care Clinic | Lisa Kottschade, NP, MS, RN; Casey Fazer; Anna Schwecke; | Immunotherapy Toxicities | Checkpoint blockade; Immune toxicity |
| 653 | Oral Presentation | Dasatinib as a rapid pharmacological ON/OFF switch for T cell bispecific antibody-induced T cell activation and cytokine release | Gabrielle Leclercq, M. Sc. Eng.; Helene Haegel, PhD; Anneliese Schneider, PhD; Estelle Marrer Berger, PhD; Antje Walz, PhD; Christophe Boetsch, PhD; Vesna Pulko, PhD; Cristiano Ferlini, MD; Christian Klein, Dr rer nat; | Immunotherapy Toxicities | Antibody; Bispecifics; Cytokine; Immune suppression; Immune toxicity; Inflammation; T cell; Targeted therapy |
| 654 | Poster Presentation | Real world incidence of grade III and higher adverse effects, emergency room utilization and hospital admissions during treatment with commonly used PD-1/PDL-1 targeting immune check point inhibitors. | Nerea Lopetegui Lia, M.D.; Syed Imran Jafri; Khalid Shalaby; Dimitrios Drekolias; James Vredenburgh, M.D.; Nerea Lopetegui Lia, M.D.; | Immunotherapy Toxicities | Checkpoint blockade; Immune monitoring; Immune toxicity; Targeted therapy |
| 655 | Poster Presentation | Concordance Between Healthcare Providers and Expert Consensus Recommendations in the Management, Monitoring, and Mitigation of Adverse Events Associated with CAR T-Cell Therapy: An Updated Analysis | Matthew J. Frigault, MD, MSc; Megan Cartwright, PhD; Krista Marcello, BA; Timothy A. Quill, PhD; Daniel J. DeAngelo, MD, PhD; Ilene A. Galinsky, NP; Shilpa Paul, PharmD, BCOP; Jae H. Park, MD; Matthew J. Frigault, MD, MSc; | Immunotherapy Toxicities | CAR T cells; Cytokine; Immune toxicity; Leukemia/Lymphoma |
| 656 | Poster Presentation | Time to diagnostic clarity for suspected checkpoint-inhibitor pneumonitis in patients with lung cancer | Eric Olson, MD; Andrew Faucheux, MD; JiaHao Liang, MD; Janardhana Ponnatapura, MD; Jeffrey Lantz, DO; Nathan Roberts, MD; Andy Dothard, MD; Thomas W. Lycan, Jr., DO; Eric Olson, MD; | Immunotherapy Toxicities | Checkpoint blockade; Immune toxicity; Solid tumors |
| 657 | Poster Presentation | Interleukin-6 Receptor Blockade for Management of Immune Checkpoint Inhibitor Related Adverse Events in Patients with Melanoma | Chantal Saberian, MD; Faisal Fa'ak; Jean H. Tayar, MD; Maryam Buni, MD; Sang Kim, MD, PhD; Huifang Lu, MD, PhD; Maria Suarez-Almazor, MD, PhD; Stephen Gruschkus, PhD; May Daher, MD; Kaysia Ludford; Daniel Johnson, MD; Noha Abdel-Wahab, MD, PhD; Adi Diab, MD; | Immunotherapy Toxicities | Autoimmunity; Cytokine; Immune toxicity; Inflammation |
| 658 | Poster Presentation | Toxicities of single agent and combination immune checkpoint inhibitors in patients with pre-existing autoimmune diseases. | Sabina Sandigursky; Safa Houssein; Xerxes Pundole, MD, PhD; Elizaveta Efuni; Samuel Cytryn; Maryam Buni, MD; Anna C. Pavlick, MD, MBA; Michelle Krogsgaard, PhD; Chantal Saberian, MD; Mehmet Altan, MD; Maria Suarez-Almazor, MD, PhD; Jeffrey S. Weber, MD, PhD; Adi Diab, MD; Noha Abdel-Wahab, MD, PhD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Immune toxicity |
| 659 | Poster Presentation | Blocking Cytokine IL-1 with Anakinra for the Prevention of Cytokine Release Syndrome in COVID-19 | Erik R. Soule; Jason R. Williams, MD; Matthias Piesche; | Immunotherapy Toxicities | Clinical study; Cytokine; Immune toxicity; Targeted therapy |
| 660 | Poster Presentation | Developing generalizable deep learning models for tumor segmentation in pathology images to enable the identification of predictive biomarkers for immunotherapies | Qinle Ba, PhD; Qinle Ba, PhD; Peng Yang; Jennifer Yearley, PhD; | Machine Learning, Artificial Intelligence and Computational Modeling | Biomarkers; Tumor microenvironment; Tumor stroma |
| 661 | Poster Presentation | Five immunotypic signatures identified in human glioblastoma correlate with tumor contact with the lateral ventricle, immune suppression, and patient outcome. | Todd Bartkowiak, MS, PhD; Sierra M. Barone, BS; Madeline J. Hayes, BS; Allison R. Greenplate, Ph.D; Justine Sinnaeve, Ph.D.; Nalin Leelatian, M.D., Ph.D.; Akshitkumar M. Mistry, M.D.; Caroline E. Roe, MLS; Bret C. Mobley, M.D.; Lola B. Chambless, MD; Reid C. Thompson, M.D.; Kyle D. Weaver, M.D.; Rebecca A. Ihrie, Ph.D.; Jonathan M. Irish, Ph.D.; Todd Bartkowiak, MS, PhD; | Machine Learning, Artificial Intelligence, and Computational Modeling | Bioinformatics; Coinhibition; Cytokine; Immune contexture; Immune suppression; Myeloid cells; Solid tumors; Systems biology; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 662 | Poster Presentation | Statistical learning from clinical and immunogenomic variables to predict response and survival with PD-L1 inhibition in advanced urothelial cancer | Wolfgang Beck, AB; Tracy L. Rose, MD; Matthew I. Milowsky, MD; William Y. Kim, MD; Jeff Klomp, PhD; Benjamin G. Vincent, MD; | Machine Learning, Artificial Intelligence and Computational Modeling | Biomarkers; Checkpoint blockade; Immune suppression; Inflammation; Neoantigens; Solid tumors; T cell; Tumor antigens; Tumor microenvironment |
| 663 | Poster Presentation | Correlation between early endpoints and overall survival in non-small-cell lung cancer: a trial-level meta-analysis | Shameer Khader; Youyi Zhang; Daniel Jackson; Kirsty Rhodes; Imran Khan Anwer Neelufer; Sreenath Nampally; Andrzej Prokop; Emmette Hutchison; Jiabu Ye; Feng Liu; Antony Sabin; James Weatherall; Cristina Duran; Renee Iacona; Faisal Khan; Pralay Mukhopadhyay, PhD; | Machine Learning, Artificial Intelligence and Computational Modeling | Bioinformatics |
| 664 | Poster Presentation | Applying Advanced Data Analysis to Immunotherapy Drug Discovery for Uveal Melanoma | Sarah Kolitz, PhD; Yoonjeong Cha, PhD; Sailaja Battula, PhD; Rebecca Kusko, PhD; Benjamin J. Zeskind, PhD, MBA; Howard L. Kaufman, MD; | Machine Learning, Artificial Intelligence and Computational Modeling | Gene expression; Solid tumors; Systems biology; Targeted therapy |
| 665 | Poster Presentation | Spatial single-cell analysis of colorectal cancer tumour using multiplexed imaging mass cytometry | Minh Tran; Andrew Su; HoJoon Lee, Ph.D.; Richard Cruz, Ph.D.; Lance Pflieger, PhD; Ashely Dean; Quan Nguyen, Ph.D; Hanlee P. Ji, MD; Terence Rhodes, MD, PhD; | Machine Learning, Artificial Intelligence and Computational Modeling | Antibody; Bioinformatics; Biomarkers; Immune contexture; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 666 | Poster Presentation | Analyzing regulatory requirements in the development of immune checkpoint inhibitors using Artificial Intelligence | Krish Perumal; Amin Osmani; Amin Osmani; | Machine Learning, Artificial Intelligence and Computational Modeling | Antibody; Bispecifics; Checkpoint blockade; Clinical study; Clinical trial; T cell |
| 667 | Poster Presentation | Integrated molecular characterization and therapeutic vulnerabilities of neurally programmed tumors across 33 human indications | Yasin Senbabaoglu, PhD; Aslihan K. Calviello; Guadalupe O. Munoz; Richard Bourgon, BS, PhD; Shannon J. Turley, PhD; Christine Moussion; | Machine Learning, Artificial Intelligence and Computational Modeling | Bioinformatics; Checkpoint blockade; Epigenetics; Immune contexture; Immune suppression; Metabolism; Stem cell/cancer-initiating cell; Systems biology; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 668 | Poster Presentation | A toolkit for the quantitative analysis of the spatial distribution of cells of the tumor immune microenvironment | Anna S. Trigos, PhD; Tianpei Yang; Yuzhou Feng; Volkan Ozcoban; Maria Doyle; Anu Pasam; Nikolce Kocovski; Angela Pizzolla, PhD; Yu-Kuan Huang; Greg Bass; Simon P. Keam, PhD; Terrence P. Speed; Paul J. Neeson, PhD; Shahneen Sandhu, MBBS FRACP; David Goode; | Machine Learning, Artificial Intelligence and Computational Modeling | Bioinformatics; Biomarkers; Solid tumors; Systems biology; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 669 | Poster Presentation | Computational analysis of mutual feedback regulations between IDO1 and PD-L1 | Jian Zhu, PhD; Rebecca L. Zhu; | Machine Learning, Artificial Intelligence and Computational Modeling | Checkpoint blockade; MDSC; NK/NK T cell; Regulatory T cell (Treg cell); Systems biology |
| 670 | Poster Presentation | Develop a Multiplex Immunofluorescence Panel to Identification of distinct complex immune landscapes in pleural effusion liquids from patients with metastatic lung adenocarcinoma | Caddie Laberiano, MD; Luisa Solis, MD; Sinchita Roy Chowdhuri; Edwin R. Parra, MD, PhD; Caddie Laberiano, MD; | Microbiome and other environmental factors | Antibody; Biomarkers; Immune contexture; Tumor microenvironment |
| 671 | Poster Presentation | Update of a systematic review and meta-analysis studying the association between antibiotic use and clinical outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors | Pierre-Alain Bandinelli, MSc; Julie Cervesi; Clément Le Bescop; Renaud Buffet; Jean De Gunzburg; Gérard Zalcman; Pierre-Alain Bandinelli; | Microbiome and other environmental factors | Autoimmunity; Checkpoint blockade; Microbiome; Solid tumors |
| 672 | Oral Presentation | Identification of microbial-derived HLA-bound peptides in melanoma | Adi Nagler, MSc; Shelly Kalaora; Deborah Gitta Rosenberg; Michal Alon; Eilon Barnea; Ronen Levy; Kevin Vervier; Sophie Trabish; Tali Dadosh; Smadar Zaidman; Leore Geller; Polina Greenberg; Neerupma Bhardwaj; Alexandre Reuben; Reetakshi Arora; Michal Lotem; Arie Admon; Yishai Levin; Trevor Lawley; David Adams; Naama Geva-Zatorsky; Jennifer A. Wargo, MD, MMSc; Ravid Straussman; Yardena Samuels; | Microbiome and other environmental factors | Antigen presenting cells; Bioinformatics; Checkpoint blockade; Microbiome; Neoantigens; Proteomics; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Vaccine |
| 673 | Poster Presentation | Precision microbiome mapping identifies a microbiome signature predictive of Immune Checkpoint Inhibitor response across multiple research study cohorts | Matthew J. Robinson, PhD; Kevin Vervier; Simon R. Harris; David Adams; Doreen Milne; Catherine Booth; Emily Barker; Christine Parkinson; David Bruce; Sarah Welesh; Pippa Corrie, PhD, BMBCh, FRCP; Trevor D. Lawley; | Microbiome and other environmental factors | Bioinformatics; Biomarkers; Checkpoint blockade; Microbiome |
| 674 | Poster Presentation | Late antibiotic administration during durvalumab treatment may be associated with clinical benefit | Siddharth Sheth, DO MPH; Christopher A. Morehouse, MD; Elizabeth A. Dozier; Chen Gao; Paul Warrener; Vancheswaran Gopalakrishnan, PhD, MPH, BDS; Scott Hammond, PhD; Taylor Cohen; Bret Sellman; | Microbiome and other environmental factors | Checkpoint blockade; Microbiome; Solid tumors |
| 675 | Poster Presentation | Oxygen concentration alters Natural Killer cell phenotype and function in the solid tumor microenvironment | Upasana Sunil Arvindam, MSc; Phillipa Kennedy; Brianna Ettestad; Peter Hinderlie; Gwen Phung; James Lim; Jeff S. Miller, MD; Martin S. Felices; | Microbiome and other environmental factors | Adoptive immunotherapy; Immune suppression; Metabolism; NK/NK T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 676 | Poster Presentation | PD-L1 is induced by the periodontal pathogen Porphyromonas gingivalis and can be blocked by small molecule gingipain inhibitors, including atuzaginstat | Shirin Arastu-Kapur; Mai Nguyen; Sean Broce; Joseph P. Vacca; Kirk Ehmsen; Florian Ermini; Ursula L. Haditsch; Aurora Martinez-Horta; Debasish Raha; Leonardo Rodriguez; Casey Lynch; Stephen S. Dominy; Leslie J. Holsinger; | Microbiome and other environmental factors | Checkpoint blockade; Coinhibition; Immune suppression; Inflammation; Microbiome; Monocyte/Macrophage; Solid tumors; Targeted therapy; Tumor evasion; Tumor microenvironment |
| 677 | Poster Presentation | Evaluation of anti-PD1 efficacy in germ-free and antibiotic-treated SPF mice bearing MC38 tumors | Ying Jin; Xue Liang; Frieda Z. Zhang; Guangmao Mu; Wei Zhou; Annie X. An; Marvin Y. Ouyang; Cai Li; Andy Liaw; Henry Q. Li; Davy X. Ouyang, PhD; | Microbiome and other environmental factors | Checkpoint blockade; Microbiome |
| 678 | Poster Presentation | Addition of a single bacteria facilitates anti-tumor immunity and long-term survival in colorectal cancer. | Abigail E. Overacre-Delgoffe, PhD; Anthony R. Cillo, PhD; Hannah J. Bumgarner, BS; Ansen Burr; Justin Tometich; Amrita Bhattacharjee; Tullia C. Bruno, PhD; Dario A. Vignali, PhD; Timothy W. Hand; | Microbiome and other environmental factors | Dendritic cell; Microbiome; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 679 | Poster Presentation | High fiber diet modifies gut microbiome, propionate production, intratumor immune response and is associated with outcome in patients with lung cancer treated with immune checkpoint inhibitors | Corentin Richard, PhD; Myriam Benlaifaoui; Omar El Ouarzadi; Khoudia Diop; Antoine Desilets; Julie Malo; Wiam Belkaid; Andréanne Leblanc; Julien Lamontagne; Meriem Messaoudene; Arielle Elkrief; Bertrand Routy; | Microbiome and other environmental factors | Bioinformatics; Checkpoint blockade; Gene expression; Microbiome; Tumor microenvironment |
| 680 | Poster Presentation | Automated Ion Torrent based solution enables accurate gut microbiome quantification of bacterial species relevant to research in cancer and its response to immunotherapy | Shrutii Sarda, PhD; David Merrill, PhD; Heesun Shin; Anna McGeachy, PhD; Birgit Drews; Wing Lee; Rajesh K. Gottimukkala, MS; Janice K. Au-Young, PhD; Fiona Hyland; Shrutii Sarda, PhD; | Microbiome and other environmental factors | Autoimmunity; Bioinformatics; Microbiome |
| 681 | Poster Presentation | Single pipeline re-analysis revises microbiome associations with anti-tumor response to checkpoint inhibitors | Fyza Y. Shaikh, MD, PhD; James R. White, PhD; Joell J. Gills, PhD; Taiki Hakozaki; Richard Corentin; Bertrand Routy; Yusuke Okuma; Mykhaylo Usyk; Abhishek Pandey; Jeffrey S. Weber, MD, PhD; Jiyoung Ahn; Jarushka Naidoo, MB BCH MHS; Evan J. Lipson, MD; Drew M. Pardoll, MD, PhD; Cynthia Sears; | Microbiome and other environmental factors | Bioinformatics; Biomarkers; Checkpoint blockade; Microbiome; Solid tumors |
| 682 | Poster Presentation | Antibody-mediated Blockade of Interleukin-10 Receptor-alpha Promotes the Activation of Immune Cells from in vitro Dissociated Tumor Samples | Alexey Berezhnoy, PhD, DVM; Kalpana Shah, BS; Daorong Liu; Peter Lung, BS, HT (ASCP); Vatana Long; Kurt Stahl, BS; Douglas Smith, PhD; Francine Z. Chen, MD; Hua Li, MS; Jonathan Li, PhD; Ralph F. Alderson, PhD; Valentina Ciccarone, PhD; James K. Tamura, PhD; Ezio Bonvini, MD; Gundo Diedrich, PhD; Paul A. Moore, PhD; | Novel Single-Agent Immunotherapies | Antigen presenting cells; Checkpoint blockade; Immune suppression; Immune tolerance; Monocyte/Macrophage; Myeloid cells; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 683 | Poster Presentation | A novel mechanism of Neuropilin-1 inhibition results in improved tumor growth inhibition in vivo | Daniel Blom; Shalini Sethumadhavan; Chengfeng Merriman; Katherine Molloy; alexandria Fink; Shan Lou; andrew rogantino; Ameya Apte; Mandana abbassi; Tiffany Liao; Hongyue Dai; aaron fulgham; Jonathan Hurov; Pearl Huang; | Novel Single-Agent Immunotherapies | Angiogenesis; Antibody; MDSC; Monocyte/Macrophage; Regulatory T cell (Treg cell); Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 684 | Poster Presentation | A low affinity bivalent mesothelin-binding MATCH4 multispecific T cell engager increases cytotoxic selectivity for high mesothelin expressing cells | Bithi Chatterjee, PhD; Alexandre Simonin, PhD; Daniel Snell, PhD; Tea Gunde, PhD; Christian Hess, PhD; Matthias Brock, PhD; Stefan Warmuth, PhD; Christopher Weinert, PhD; Niels Kirk; Dania Diem; Naomi Flückiger; Robin Heiz; Benjamin Küttner; Dana Mahler; Diego Morenzoni; Sandro Wagen; Julia Zeberer; David Urech, PhD; | Novel Single-Agent Immunotherapies | Antibody; Bispecifics; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| 685 | Poster Presentation | A Highly Selective and Potent HPK1 Inhibitor Enhances Immune Cell Activation and Induces Robust Tumor Growth Inhibition in a Murine Syngeneic Tumor Model | David Ciccone, PhD; Vad Lazari; Ian Linney; Michael Briggs; Samantha Carreiro; Joshua McElwee; Ian Waddell; Chris Hill; Christine Loh; Peter Tummino; Alan Collis; Neelu Kaila; | Novel Single-Agent Immunotherapies | Antigen presenting cells; B cell; Checkpoint blockade; Cytokine; Dendritic cell; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs) |
| 686 | Poster Presentation | Preclinical characterization of a novel therapeutic antibody targeting LILRB2 | Maria Jose Costa, PhD; Ryan Stafford, PhD; Zhiqiang Ku, PhD; Jing-Tyan Ma; Krista McCutcheon; Xiaoye Liu, PhD; Heyu Chen, PhD; Kyu Hong; Tao Huang, PhD; Ningyan Zhang, PhD; Zhiqiang An, PhD; Cheng Cheng Zhang, PhD; X. Charlene Liao, PhD; An Song, PhD; | Novel Single-Agent Immunotherapies | Antibody; Antigen presenting cells; Checkpoint blockade; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor evasion; Tumor microenvironment |
| 687 | Poster Presentation | Enhancement of anti-tumor immunity by ICT01: a novel g9d2 T cell-activating antibody targeting Butyrophilin-3A (BTN3A) | Aude de Gassart, PhD; Patrick Brune; Suong LE; Sophie Agaugue; Emmanuel Valentin, PhD; Remy Castellano; Jennifer Sims; Alem Truneh; Daniel Olive, M.D., Ph.D.; Rene Hoet; | Novel Single-Agent Immunotherapies | Antibody; T cell; T cell lineages |
| 688 | Poster Presentation | In vivo expansion of gamma delta T cells by a CD19-targeted butyrophilin heterodimer leads to elimination of peripheral B cells | Suresh De Silva, Ph.D.; George J. Fromm, Jr., Ph.D.; Louis E. Gonzalez, Ph.D.; Arpita Patel, BSc; Kyung J. Yoon; Zachery Opheim; Robert Farmer; Dean Chamberlain, Ph.D.; Taylor H. Schreiber, MD, PhD; | Novel Single-Agent Immunotherapies | B cell; Bispecifics; T cell |
| 689 | Poster Presentation | ATRC-101 Drives Potent Single-Agent Activity in Mouse Syngeneic Tumor Models via a Novel Cellular Mechanism of Action | Yvonne Leung, Ph.D.; Nikhil Vad, PhD; Anne Ye, PhD; Daniel R. Santos, MS; Wei Cao; Cathrin Czupalla, Ph.D.; John Vivian, PhD; Carlene Williams; Judevin Sapugay, BS; Michael Harbell, M.S.; Shaun M. Lippow, Ph.D.; Chantia Carroll, BS; Lance Kates, BS; Benjamin Haugen, BS; Gary Bolton, BS; Mark Armanini, BS; Iraz T. Aydin, PhD; Mark Whidden, PhD; Mauricio Velasco-Delgado, MS; Felix Chu, MS; Erin Wechsler, PhD; Ngan A. Nguyen, PhD; William H. Robinson, MD PhD; Tito A. Serafini, PhD; Daniel Emerling, PhD; Norman M. Greenberg, PhD; Amy Manning-Bog, PhD; Alexander Scholz, PhD; | Novel Single-Agent Immunotherapies | Chemokine; Cytokine; Dendritic cell; Myeloid cells; RNA; T cell; T cell lineages; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 690 | Poster Presentation | CD122-selective IL-2 complexes treat ovarian carcinomas, induce Treg fragility and promote T cell stem cells | Yilun Deng, MD, PhD; Justin M. Drerup; Xinyue Zhang; Ryan M. Reyes, BS; Jenny A. Mendez; Aravind Kancharla, MS; Myrna G. Garcia, BS; Haiyan Bai; Alvaro S. Padron, PhD; Harshita B. Gupta, PhD; Tyler J. Curiel, MD, MPH; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Cytokine; Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs) |
| 691 | Poster Presentation | MDK-271: A dual function molecule consisting of empirically-designed peptidyl agonists of IL-2/15Rβγc and IL-7Rαγc, unrelated to IL-2, IL-15, or IL-7, incorporated into a bispecific Fc fusion protein | William J. Dower, PhD; Steven E. Cwirla; Alice V. Bakker, BA; Praechompoo Pongtornpipat, MS; Blake M. Williams, MS; Prarthana Joshi, ME; Sandra M. Wang, BSc; Michael C. Needels, PhD; Ronald W. Barrett, PhD; | Novel Single-Agent Immunotherapies | Bispecifics; Cytokine; NK/NK T cell; Regulatory T cell (Treg cell); T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 692 | Poster Presentation | AMV564, a clinically active T cell engager, induces a target-dependent adaptive immune response | Sterling C. Eckard, PhD; Aurelien Sarde; Li Mei; Curtis Ruegg, PhD; Patrick Chun, MD; Victoria Smith, PhD; | Novel Single-Agent Immunotherapies | Clinical trial; Immune suppression; MDSC; Myeloid cells; Solid tumors; T cell; Targeted therapy |
| 693 | Poster Presentation | APX601, a Novel TNFR2 Antagonist Antibody for Cancer Immunotherapy | Erin L. Filbert, PhD; Sushma Krishnan, MSc in Biology; Ryan Alvarado; George Huang; Francis R. Bahjat; Xiaodong Yang, MD, PhD; | Novel Single-Agent Immunotherapies | Antibody; Immune suppression; MDSC; Myeloid cells; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 694 | Poster Presentation | NC410 is a Novel Immunomedicine for the Treatment of Solid Tumors | Linjie Tian, PhD; M. Ines Pascoal Ramos, PhD; Emma de Ruiter; Ana Paucarmayta; Eline Elshof; Stefan Willems, MD, PhD; Chang Song, PhD; Zachary Cusumano, PhD; Jason Bosiacki; Linda N. Liu, PhD; Solomon Langermann, PhD; Linde Meyaard, PhD; Dallas B. Flies, PhD; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Solid tumors; T cell; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 695 | Poster Presentation | Oral delivery of a microbial extracellular vesicle induces potent anti-tumor immunity in mice | Loise Francisco-Anderson, PhD; Mary Abdou, BS; Michael Goldberg, PhD; Erin Troy, PhD; Alicia Ballok, PhD; Fabian Romano Chernac, PhD; Maria Sizova, PhD; Krutika Invally, PhD; Shubhra Kashyap, MS; Audrey McBride, BS; Jessica Tsang, BS; Shannon Argueta, PhD; Kristie Barth, PhD; Valeria Kravitz, MS; Holly Ponichtera, PhD; Tyler Rommel, MS; Kevin Huynh, MS; Tanmoy Ganguly, PhD; Mark Bodmer, PhD; | Novel Single-Agent Immunotherapies | Antigen presenting cells; Extracellular vesicles/exosomes; TLR; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 696 | Poster Presentation | Brentuximab vedotin, a CD30-directed antibody-drug conjugate, selectively depletes activated Tregs in vitro and in vivo | Bryan M. Grogan, MS; Reice D. James, BS; Michelle Ulrich, BS; Shyra J. Gardai, PhD; Ryan Heiser, PhD; | Novel Single-Agent Immunotherapies | Antibody; Biomarkers; Immune suppression; Leukemia/Lymphoma; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor microenvironment |
| 697 | Poster Presentation | Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors | Michael Hedvat, PhD; Veronica Zeng, PhD; Juan Diaz, PhD; Christine Bonzon, PhD; Kendra N. Avery, PhD; Rumana Rashid, PhD; Irene Leung, PhD; Norm Bartlow, PhD; Charles Bakhit; Matthew Dragovich, PhD; Liz Bogart, PhD; Umesh Muchhal, PhD; John R. Desjarlais, PhD; Gregory L. Moore, PhD; | Novel Single-Agent Immunotherapies | Antibody; Bispecifics; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 698 | Poster Presentation | Targeting HLA-G-mediated immunosuppression with a first-in-class antagonist antibody | Douglas Hodges; Christina M. Kochel, PhD; Michael Totagrande; Jeffrey Jones; Megan Welch; Bradley N. Spatola, PhD; Shelby Joe; John A. Corbin, PhD; Vanessa B. Soros, PhD; Courtney Beers, PhD; Achim K. Moesta, PhD; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Immune suppression; Immune tolerance; Solid tumors; Tumor evasion; Tumor microenvironment |
| 699 | Poster Presentation | A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models | Ye Liu, Ph.D; Beibei Jiang; Tong Zhang; Zuobai Wang; Yingcai Feng; Haiying Li; Wenfeng Gong; Xing Wang; Yajuan Gao; Xiaosui Zhou; Bo Zhang; Yuan Hong; Jing Wang; Zilin Wang; Hongjia Hou; Hanzi Sun; Xiaomin Song, PhD; Kang Li; Xuesong Liu; | Novel Single-Agent Immunotherapies | Antibody; Costimulation; T cell |
| 700 | Poster Presentation | EphA2/CD137 Bicycle tumor-targeted immune cell agonists (TICAsTM) induce tumor regressions, immunogenic memory, and reprogramming of the tumor immune microenvironment | Kristen E. Hurov, PhD; Johanna lahdenranta, PhD; Gemma Mudd, .; Punit Upadhyaya, PhD; Elizabeth M. Repash, MSc; Jun Ma, MSc; Julia Kristensson, .; Marianna Kleyman; Jessica Kublin; Liuhong Chen; Eric Haines, PhD; Sailaja Battula; Kevin McDonnell, PhD; Philip E. Brandish; Nicholas Keen, PhD; | Novel Single-Agent Immunotherapies | Bispecifics; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 701 | Poster Presentation | Nanoparticulate monobenzone (MBEH) as a potential drug candidate for melanoma | Dinesh Jaishankar, PhD; Steven Henning; Anqi Zhang, PhD; Basar Bilgicer, PhD; SonBinh Nhuyen, PhD; I. Caroline Le Poole, PhD; | Novel Single-Agent Immunotherapies | Neoantigens; Solid tumors; T cell |
| 702 | Poster Presentation | Dual blockade of the PD-1 checkpoint pathway and the adenosinergic negative feedback signaling pathway with a PD-1/CD73 bispecific antibody for cancer immune therapy | Tingting Zhong, MS; Zhaoliang Huang, BSc; Xinghua Pang, BSc; na chen, MD; Xiaoping Jin, PhD; Yu Xia, PhD; Zhongmin Maxwell Wang, PhD; Baiyong Li, PhD; Yu Xia, PhD; | Novel Single-Agent Immunotherapies | Antibody; Bispecifics; Checkpoint blockade; Immune monitoring; Immune suppression |
| 703 | Poster Presentation | Engineered exosomes with altered cellular tropism achieve targeted STING agonist delivery and single-agent tumor control in vivo | Monique Kauke, PhD; Nikki Ross, PhD; Dalia Burzyn; Shelly Martin; Ke Xu; Nuruddeen Lewis; Charan Leng; Su Chul Jang, PhD; Christine McCoy; Stephanie Yu; Kevin Dooley; Sriram Sathyanarayanan, PhD; Jonathan Finn; | Novel Single-Agent Immunotherapies | Antibody; Antigen presenting cells; Dendritic cell; Extracellular vesicles/exosomes; Monocyte/Macrophage; Myeloid cells; Proteomics; Solid tumors |
| 704 | Poster Presentation | Preclinical mechanism of action and pharmacodynamic biomarker studies of DuoBody®-CD3x5T4 in vitro and in vivo in solid cancer models | Kristel Kemper, PhD; Ellis Gielen; Mischa Houtkamp, PhD; Peter Boross; Saskia Burm, PhD; Stefanie A. De Poot; Patrick Engelberts; Bart E. de Goeij; David Satijn, PhD; Kate Sasser, PhD; Esther Breij, PhD; | Novel Single-Agent Immunotherapies | Antibody; Biomarkers; Bispecifics; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| 705 | Poster Presentation | Anti-tumor activity of CB-668, a potent, selective and orally bioavailable small-molecule inhibitor of the immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1) | Andrew MacKinnon, PhD; Deepthi Bhupathi; Jason Chen; Tony Huang; Weiqun Li, PhD; Yong Ma; Natalija Sotirovska, MS; Susanne Steggerda, PhD; Winter Zhang; Francesco Parlati, PhD; | Novel Single-Agent Immunotherapies | Immune suppression; Metabolism; Solid tumors; T cell; Tumor microenvironment |
| 706 | Poster Presentation | BT7480, a fully synthetic tumor-targeted immune cell agonist (TICA™) induces tumor localized CD137 agonism and modulation of tumor immune microenvironment | Punit Upadhyaya, PhD; Kristen E. Hurov, PhD; Jessica Kublin; Jun Ma, MSc; Elizabeth M. Repash, MSc; Marianna Kleyman; Julia Kristensson, .; Drasti Kanakia; Fanglei You; Liuhong Chen; Eric Haines, PhD; Sailaja Battula; Kevin McDonnell, PhD; Philip E. Brandish; Johanna lahdenranta, PhD; Nicholas Keen, PhD; | Novel Single-Agent Immunotherapies | Bispecifics; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 707 | Poster Presentation | Discovery of a novel EP2 and EP4 dual antagonist | Yeri Lee; Hyun Jin Kim; Donggeon Kim, DVM,PhD; Joo Youn Lee; Chang Soo Yun; Hyuk Lee; Young Sook Shin; Soo Bong Han; Sang Kyun Lim; | Novel Single-Agent Immunotherapies | Coinhibition; Dendritic cell; Immune suppression; Inflammation; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; Tumor microenvironment |
| 708 | Poster Presentation | Application of a novel mSENS drug delivery technology for mRNA therapeutics | Sojin Lee, Dr.; Joon Young Park; Goo-Young Kim, Ph.D.; Sang Woo Jo; Minhyuk Yun; Hye Yeong Nam; Helen Cho; | Novel Single-Agent Immunotherapies | RNA; Solid tumors; T cell; Tumor antigens; Vaccine |
| 709 | Poster Presentation | Exosome surface display of IL-12 results in tumor-retained pharmacology with superior potency and limited systemic exposure | Nuruddeen Lewis, PhD; Katherine Kirwin; Sonya Haupt; Gauri Mahimkar; Tong Zi; Ke Xu; Kevin Dooley; Su Chul Jang, PhD; Bryan Choi; Andrew Grube; Christine McCoy; Jorge Sanchez-Salazar; Michael Doherty; Scott Estes; Kyriakos Economides; Douglas E. Williams; Sriram Sathyanaryanan, PhD; | Novel Single-Agent Immunotherapies | Cytokine; Extracellular vesicles/exosomes; Immune adjuvant; NK/NK T cell; T cell |
| 710 | Poster Presentation | Development of IL-33 as a novel immunotherapy of cancer | Joshua Zhong; Runzi Sun; Binfeng Lu, PhD; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Cytokine; NK/NK T cell; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 711 | Poster Presentation | HBM1022, a Novel Anti-CCR8 Antibody Depletes Tumor-infiltrating Regulatory T cells via Enhanced ADCC Activity, Mediates Potent Anti-Tumor Activity with Keytruda | Shuang Lu, MS; Shaoping Hu; Xin Gan; Yongqiang Wang; Chuchu Zhao; Yi Ding; Jinqiu He; Qing Du; Xiaocheng Lv; Beibei Qin; Yun He; Lei Niu; Yuntao Wu; Fei Chen; Yuandong Wang; Yunxing Yang; Yang Cao; Musheng Bao; Jason Noon; Wenhao Yu; Juan Liu; Joe Zhao, PhD; Yiping Rong; Shuang Lu, MS; | Novel Single-Agent Immunotherapies | Antibody; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 712 | Poster Presentation | SBT6290, a systemically administered Nectin-4-directed TLR8 ImmunoTAC (TM) therapeutic, is a potent human myeloid cell agonist for the treatment of Nectin-4-expressing tumors | Heather Metz, PhD; Ty Brender; Brenda Stevens; Damion Winship; Jamie Brevik; Michael Comeau; Monica Childs; Jenny R. Chang; Li-Qun Fan; Hengyu Xu; Jonathan Grey; Jeffrey Adamo; Ben Setter; Ray Carrillo; Sean W. Smith; Phil Tan; Robert E. DuBose; Yvette Latchman, PhD; Peter Baum; Valerie Odegard, PhD; | Novel Single-Agent Immunotherapies | Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; TLR; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 713 | Poster Presentation | Antibody-based approach of MT1-MMP metalloprotease inhibition results in decreased invasive properties of pancreatic cancer cells | Nikita A. Mitkin, PhD; Alisa M. Gorbacheva; Alina S. Ustiugova; Aksinya N. Uvarova; Kirill V. Korneev; Vsevolod V. Pavshintsev, PhD; Nikita A. Mitkin, PhD; | Novel Single-Agent Immunotherapies | Antibody; B cell; Immune adjuvant; Inflammation; Tumor microenvironment |
| 714 | Poster Presentation | PD1 x TGFβR2 bispecifics selectively block TGFβR2 on PD1-positive T cells, promote T cell activation, and elicit an anti-tumor response in solid tumors | Gregory L. Moore, PhD; Suzanne Schubbert, PhD; Christine Bonzon, PhD; Kendra N. Avery, PhD; Rumana Rashid, PhD; Erik Pong, BS; Lukasz J. Ochyl, PhD; Alex Nisthal, PhD; Seung Chu, PhD; James Ernst, PhD; John R. Desjarlais, PhD; | Novel Single-Agent Immunotherapies | Antibody; Bispecifics; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| 715 | Poster Presentation | FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, induces LAG-3 shedding resulting in receptor downregulation by T cells via a novel mechanism of action | Michelle Morrow, PhD; Mustapha Faroudi, PhD; Krishnendu Chakraborty, PhD; Wenjia Liao, BSc; Julia Winnewisser, PhD; Claire Seal, PhD; Daniel Gliddon, PhD; Neil Brewis, PhD, DSc; | Novel Single-Agent Immunotherapies | Antibody; Bispecifics; Checkpoint blockade; Coinhibition; T cell |
| 716 | Poster Presentation | CELL-BASED VIROTHERAPY FOR TARGETING CANCERS | Duong H. Nguyen; Alberto Gomez; Forrest Neuharth; Ashley Alamillo; Thomas Herrmann; Barbara Härtl; Laura Schneider; Ivelina Minev; Boris Minev, MD; Dobrin Draganov, PhD; Antonio F. Santidrian; | Novel Single-Agent Immunotherapies | Solid tumors; Stem cell/cancer-initiating cell; Tumor infiltrating lymphocytes (TILs); Vaccine |
| 717 | Poster Presentation | AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy | Katharina Lueckerath, Dr.; Julie M. Bailis, PhD; Kyle Current, BA; Mark E. Salvati, PhD; Caius Radu, MD; Johannes Czernin, MD; | Novel Single-Agent Immunotherapies | Bispecifics; Clinical trial; Solid tumors; T cell; Tumor antigens |
| 718 | Poster Presentation | AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells | Cong Li, PhD; Madeline Fort, PhD; Lingming Liang, MS; Gregory L. Moore, PhD; Matthew J. Bernett, PhD; Umesh Muchhal, PhD; Tao Osgood, BS; Rodolfo Yabut, BA; Sarav Kaliyaperumal, MPH, PhD; John Harrold, PhD; Jude Canon, PhD; Anna Rogojina, PhD; Raushan Kurmasheva, PhD; John R. Desjarlais, PhD; Peter Houghton, PhD; Olivier Nolan-Stevaux, PhD; | Novel Single-Agent Immunotherapies | Antibody; Bispecifics; Chemotherapy; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| 719 | Poster Presentation | CD122-directed interleukin-2 complexes and αPD-L1 differentially require innate and adaptive immunity to treat local and metastatic bladder cancer | Ryan M. Reyes, BS; Yilun Deng, MD, PhD; Deyi Zhang, PhD; Niannian Ji, PhD; Neelam Mukherjee, PhD; Karen Wheeler, MD PhD; Harshita B. Gupta, PhD; Aravind Kancharla, MS; Myrna G. Garcia, BS; Anand VR. Kornepati, BS; Robert S. Svatek, MD MSCI; Tyler J. Curiel, MD, MPH; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Cytokine; NK/NKT cell; T cell; Tumor microenvironment |
| 720 | Poster Presentation | Targeting MARCO and IL-37R on anti-inflammatory macrophages in lung cancer blocks regulatory T cells and shift balance to support cytotoxic lymphocyte function | Linnéa La Fleur; Johan Botling; Fei He; Catarina Pelicano; Giorgia Palano; Artur Mezheyeuski; Patrick Micke; Jeffrey V. Ravetch, MD, PhD; Mikael Karlsson; Dhifaf Sarhan, PhD; | Novel Single-Agent Immunotherapies | Immune suppression; Myeloid cells; Solid tumors; Targeted therapy; Tumor microenvironment |
| 721 | Poster Presentation | AT1412, a patient-derived CD9 antibody in preclinical development promoting tumor immune infiltration and inducing tumor rejection | Remko Schotte, PhD; Julien Villaudy, PhD; Martijn Kedde, PhD; Wouter Pos, PhD; Daniel Go; Christien Fatmawati; Gemma Moiset, PhD; Etsuko Yasuda; Madalina Cercel; Esmay Frankin; Susan van Hal; Pauline M. van Helden, PhD; Els Verdegaal, PhD; Sjoerd H. van der Burg, PhD; Hergen Spits, PhD; Hans van Eenennaam, PhD; | Novel Single-Agent Immunotherapies | Antibody; B cell; Extracellular vesicles/exosomes; Monocyte/Macrophage; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 722 | Poster Presentation | Inhibition of Integrin avß8-Mediated TGF-ß Activation with C6D4 Provides Improved Potency and Selectivity vs General TGF-ß Inhibitors for Cancer Immunotherapy | Robert Seed, PhD; Stephen Nishimura, MD; Robert Seed, PhD; | Novel Single-Agent Immunotherapies | Antibody; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 723 | Poster Presentation | Lymph node-targeted AMP-vaccine enables tumor-directed mKRAS-specific immune responses with potent polyfunctional and cytolytic activity | Martin Steinbuck, PhD; Peter C. DeMuth, PhD; Lochana Seenappa, MS; | Novel Single-Agent Immunotherapies | Immune adjuvant; T cell; Vaccine |
| 724 | Poster Presentation | STAT3 inhibition in acute myeloid leukemia cells allows for TLR9-driven differentiation to immunogenic monocytic cells and induction of T-cell mediated immune responses | Yu-Lin Su, PhD; Marcin Kortylewski, PhD; Priyanka Duttagupta, PhD; | Novel Single-Agent Immunotherapies | Antigen presenting cells; Bispecifics; Immune suppression; Leukemia/Lymphoma; MDSC; Monocyte/Macrophage; Myeloid cells; RNA; Targeted therapy; TLR |
| 725 | Poster Presentation | Pre-clinical development of TNFR2 ligand-blocking BI-1808 for cancer immunotherapy | Linda Mårtensson, PhD; Mathilda Kovacek; Petra Holmkvist, PhD; Monika Semmrich, PhD; Carolin Svensson; Therese Blidberg; Carl Roos, PhD; Andres McAllister, MD, PhD; Mimoza Demiri, PhD; Marie Borggren, PhD; Ingrid Karlsson, PhD; Björn Frendeus, PhD; Ingrid Teige, PhD; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 726 | Poster Presentation | SRF114 is a fully human, CCR8 selective IgG1 antibody that induces destruction of tumor Tregs through ADCC | Andrew C. Lake, PhD; Michael C. Warren, MS; Sonia G. Das, PhD; Christopher C. Wells, BS; Maria Scrivens, BA; Ernest S. Smith, PhD; Vito J. Palombella, PhD; Bijan Etemad-Gilbertson, PhD; Pamela M. Holland, PhD; Austin Dulak, PhD; | Novel Single-Agent Immunotherapies | Antibody; Regulatory T cell (Treg cell); T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs) |
| 727 | Poster Presentation | Increased serum levels of EBI3 are associated with poor outcome in hepatocellular carcinoma patients and SRF388, a first-in-class IL-27 blocking antibody, inhibits the growth of murine liver tumors | Matthew P. Rausch, PhD; Devapregasan Moodley, PhD; Marisa O. Peluso, MS; Secil Koseoglu, PhD; Jing Hua, MD, MS; Gege Tan, MA; Ricard Masia, MD PhD; Benjamin H. Lee, MD PhD; Isabelle Cousineau, PhD; Simon Turcotte, MD MSc; John Stagg, PhD; Vito J. Palombella, PhD; Pamela M. Holland, PhD; Jonathan A. Hill, PhD; | Novel Single-Agent Immunotherapies | Antibody; Cytokine; Immune suppression; Myeloid cells; Tumor evasion |
| 728 | Poster Presentation | Antibiotics and response to immunotherapy: Real-world experience | Yasar Ahmed, MD, FRCP; Paula Calvert; Yasar Ahmed, MD, FRCP; | Other | Microbiome; Solid tumors |
| 729 | Poster Presentation | The impact of immune and targeted therapies for Melanoma in Asian populations: A National Cancer Database analysis 2004-2016 | Lifen Cao, MD PhD; Lifen Cao, MD PhD; Kavin Sugumar, MD; Ankit Mangla, MD; Megan E. Miller, MD; Luke D. Rothermel, MD MPH; | Other | Epidemiology |
| 730 | Poster Presentation | Histotripsy focused ultrasound ablation induces immunological cell death in treated and distant untreated tumors | Anutosh Ganguly, Ph.D; Ashley A. Pepple, MS; Reliza McGinnis; Ryan Hubbard; Amy E. Felsted, MD; Tejaswi Worlikar; Hannah Garavaglia; Joe Dib; Joe Guy; Michal Olszewski; Zhen Xu; Clifford S. Cho, MD, FACS; | Other | Inflammation; Solid tumors; Surgery; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 731 | Poster Presentation | Costs of care for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): a real-world claims analysis | Jonathan Kish; Jonathan Kish; Dhruv Chopra; Djibril Liassou; Solomon J. Lubinga, PhD; John Hartman; Bruce Feinberg; | Regulatory - Financial - and Access Considerations | Checkpoint blockade; Chemotherapy |
| 732 | Poster Presentation | Chemerin reactivates PTEN and suppresses PD-L1 in tumor cells via a novel CMKRL1-mediated pathway | Russell Pachynski, MD; Keith R. Rennier, PhD; Woo Jae Shin; Ethan Krug; Gurpal Virdi, BS; Russell Pachynski, MD; | Tumor and Stromal Cell Biology | Chemokine; Cytokine; Gene expression; Solid tumors; Tumor evasion |
| 733 | Poster Presentation | Integrative molecular profiling of high-grade primary prostate cancer identifies patients with a biomarker profile that favors the combination of standard of care (SOC) therapy with immunotherapy | Evisa Gjini, PhD; Jimena Trillo-tinoco; Andrew Browne; Ryan Powles; Tai Wang; Christine Tauras; Ana Lako; Ruben Ferrer-Luna; Zoe Bleicher; timothy consedine; Chensheng Zhou; Evan Kelemen; anne lewin; Catherine King; sumit bhattacharya; harris bell-temin; ashok dongre; David Nelson; Christos Hatzis, PhD; Kenzie Macisaac; Fadi Towfic; Benjamin Chen, MD, PhD; Michaela Bowden, PhD; Evisa Gjini, PhD; | Tumor and Stromal Cell Biology | Biomarkers; Gene expression; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 734 | Poster Presentation | A novel NQO1 specific anti-tumor agent, SBSC-S3001, selectively regresses the growth of tumors with high NQO1 expression. | Minhyuk Yun; Goo-Young Kim, Ph.D.; Sang Woo Jo; Changhoon In; Gyu-Young Moon; In Seok Ko; Eun Ju Lee; Yong Rae Hong; Whee Seong Lee; Helen Cho; | Tumor and Stromal Cell Biology | Chemotherapy; Gene expression; Immune monitoring; Metabolism |
| 735 | Poster Presentation | Impact of reversing an epithelial-to-mesenchymal transition program on tumor metabolism and immune suppression | Michelle M. Williams, Ph.D.; Jessica L. Christenson, Ph.D.; Kathleen I. O'Neill; Sabrina A. Hafeez; Nicole S. Spoelstra; Jill E. Slansky, PhD; Jennifer K. Richer, Ph.D.; | Tumor and Stromal Cell Biology | Immune suppression; Monocyte/Macrophage; Metabolism; Solid tumors; Tumor evasion |
| 736 | Poster Presentation | MicroRNA expression patterns in melanomas originating from gynecologic sites | Mallory J. DiVincenzo, DVM; Lorena Suarez-Kelly, MD; Maribelle Moufawad; Casey Ren; Zoe Barricklow; Paolo Fadda, PharmD; Lianbo Yu, PhD; Sarah Peters, MD; Alejandro A. Gru, MD; William E. Carson, III, MD, FACS; | Tumor and Stromal Cell Biology | Bioinformatics; Biomarkers; Cytokine; Epigenetics; Gene expression; RNA |
| 737 | Poster Presentation | A novel humanized murine model to identify neoantigen-specific T cells in pediatric acute megakaryoblastic leukemia. | Elizabeth A. Garfinkle, BS; Anthony E. Zamora, PhD; Jeremy C. Crawford, PhD; Paul G. Thomas, PhD; Tanja A. Gruber, MD, PhD; | Tumor and Stromal Cell Biology | Adoptive immunotherapy; Bioinformatics; Cytokine; Leukemia/Lymphoma; Neoantigens; T cell; Tumor infiltrating lymphocytes (TILs) |
| 738 | Poster Presentation | Establishment and application of a series of genetically engineered mouse derived breast cancer homograft models | Yanrui Song; Jessie J. Wang; Likun Zhang; Annie X. An; Henry Q. Li; Davy X. Ouyang, PhD; | Tumor and Stromal Cell Biology | Carcinogenesis; Immune monitoring; Solid tumors; Tumor microenvironment |
| 739 | Poster Presentation | Development of Patient-Derived Models of Esophageal Cancer for GUCY2C-Directed Immunotherapeutic Testing | Megan Weindorfer, BS; Amanda N. Lisby, MS; Alicja Zalewski, MD; Trevor R. Baybutt, BA; Robert Carlson, BS; Madison Crutcher, MD; David Loren, MD; Ernest Rosato, MD; Nathaniel Evans III, MD; Scott A. Waldman, MD, PhD; Adam E. Snook, PhD; | Tumor and Stromal Cell Biology | Adoptive immunotherapy; CAR T cells; Carcinogenesis; Targeted therapy |
| 740 | Poster Presentation | Biomarkers Diverging between Tumor Mutation Burden and Microsatellite Instability | Jason Ding; Nihir Patel; | Tumor and Stromal Cell Biology | Bioinformatics; Biomarkers; Carcinogenesis; Epigenetics; Gene expression; Systems biology |
| 741 | Poster Presentation | High-grade sinonasal carcinomas and surveillance of differential expression in immune related transcriptome | Diana Bell; Achim Bell, PhD; Renata Ferrarotto, MD; Ehab Hanna; Diana Bell; | Tumor and Stromal Cell Biology | Inflammation; Solid tumors; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 742 | Poster Presentation | Phosphopeptides are Increased in the MHC-I Immunopeptidome of Irradiated Human Breast Cancer Cells | Samantha J. Van Nest, PhD, MS; Tomer M. Yaron; Martin G. Klatt; Noah Dephoure; Gad Getz, PhD; Laura Santambrogio; Olivier Elemento, PhD; David A. Scheinberg; Sandra Demaria, MD; Lewis C. Cantley; | Tumor and Stromal Cell Biology | Proteomics; Radiotherapy; Tumor antigens; Post-translational modifications |
| 743 | Poster Presentation | High levels of stromal tumor infiltrating lymphocytes, CD3, CD8 cells & Immunoscore® are associated with pathological CR and time to progression in TNBC patients undergoing neo-adjuvant chemotherapy. | Bernardo L. Rapoport, MD, MMed; Jérôme Galon; Simon Nayler; Aurelie Fugon; Isabelle Boquet; Marine Martel; Mlecnik B; Teresa Smit; Carol Ann Benn; Farhana Moosa; Liezl Heyman; Ronald Anderson, Prof; | Tumor and Stromal Cell Biology | Biomarkers; Chemotherapy; Immune monitoring; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 744 | Oral Presentation | Single cell profiling of acute myeloid leukemia (AML) and its microenvironment reveals a CD8 continuum and adaptable T cell plasticity in response to PD-1 blockade-based therapy | Hussein Abbas; Dapeng Hao, Ph.D.; Katarzyna J. Tomczak; Praveen Barrodia; Jin Seon Im; Patrick Reville; Zoe Alaniz; Wei Wang; Ruiping Wang; Feng Wang, PhD; Gheath Al-Atrash; Koichi Takahashi, MD; Jing Ning; Maomao Ding; Jairo Matthews; Latasha Little, BS; Jianhua Zhang; Sreyashi Basu; Marina Konopleva; Guillermo Garcia-Manero, MD; Michael R. Green, PhD; Padmanee Sharma, MD, PhD; James P. Allison, PhD; Steven M. Kornblau, MD; Kunal Rai; Linghua Wang, PhD; Naval Daver, MD; Andrew Futreal; | Tumor and Stromal Cell Biology | Bioinformatics; Checkpoint blockade; Immune contexture; Immune monitoring; Immune tolerance; Leukemia/Lymphoma; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 745 | Poster Presentation | High throughput tissue imaging and phenotyping by streamlined 8-plex staining and analysis of complex TMA samples | Amanda J. Bares, PhD; Marie Cumberbatch; Lorcan Sherry, PhD; Christopher Womack; Milan Bhagat; Angela Vasaturo, PhD; Mael Manesse, PhD; | Tumor and Stromal Cell Biology | Antibody; Biomarkers; Immune contexture; Immune monitoring; Solid tumors; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 746 | Poster Presentation | Non Small-Cell Lung Cancer cells and cancer-associated fibroblasts drive macrophage polarization in a novel co-culture model | Josiah Flaming, B.S.; Raghav Chandra; Luc Girard, Ph.D.; Debolina Ganguly, M.S.; Jason Toombs, B.S.; John D. Minna, M.D.; Rolf A. Brekken, Ph.D.; | Tumor and Stromal Cell Biology | Cytokine; Gene expression; Immune suppression; Immune tolerance; Inflammation; Monocyte/Macrophage; Solid tumors; Tumor evasion; Tumor microenvironment; Tumor stroma |
| 747 | Poster Presentation | Evaluation of immune microenvironment of primary lung cancer and synchronous liver metastasis with multispectral imaging system | Hyeonbin Cho; Jae-Hwan Kim, PhD; Ji-Hyun Kim; | Tumor and Stromal Cell Biology | Biomarkers; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Tumor stroma |
| 748 | Poster Presentation | Myeloid Cell Infiltration Correlates with Prognosis and Varies Based on Tumor Location in Cholangiocarcinoma | Sean C. Dougherty, MD; Paul R. Kunk, MD; Sean C. Dougherty, MD; | Tumor and Stromal Cell Biology | Antigen presenting cells; Dendritic cell; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 749 | Poster Presentation | Spatial profiling of the tumour microenvironment in head and neck cancer to identify biomarkers of response to therapy | Arutha J. Kulasinghe, PhD; | Tumor and Stromal Cell Biology | Biomarkers; Checkpoint blockade; Solid tumors; T cell; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 750 | Poster Presentation | Malat1 lncRNA Controls Metastatic Reactivation of Dormant Breast Cancer by Immune Evasion | Dhiraj Kumar, PhD; Sreeharsha Gurrapu, PhD; Hyunho Han, MD, PhD; Yan Wang, MD, PhD; Seongyeon Bae, PhD; Hong Chen, PhD; Chang-Jiun Wu, PhD; Filippo Giancotti, MD, PhD; | Tumor and Stromal Cell Biology | Immune monitoring; Immune toxicity; Inflammation; MDSC; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; RNA |
| 752 | Poster Presentation | The impact of grade of differentiation and BRAF mutation status on neoantigen and immune landscape in papillary thyroid cancer | Myungwoo Nam, MD; Woojung Yang; Ju Young Lee, MD; Jaeyoun Choi, M.D.; Hansol Choi; Emma Yu; Eugene Kim; Jin Young Hwang; William H. Bae; Chan Mi Jung; Victor Wang; Jeffrey Chuang; Young Kwang Chae; | Tumor and Stromal Cell Biology | Gene expression; Neoantigens; Regulatory T cell (Treg cell); T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 753 | Poster Presentation | The immune landscape of papillary thyroid cancer and its association with neoantigen landscape and DNA repair gene mutations | Myungwoo Nam, MD; Woojung Yang; Ju Young Lee, MD; Jaeyoun Choi, M.D.; Hansol Choi; Eugene Kim; Emma Yu; Jin Young Hwang; William H. Bae; Chan Mi Jung; Victor Wang; Jeffrey Chuang; Young Kwang Chae; | Tumor and Stromal Cell Biology | Gene expression; Neoantigens; Regulatory T cell (Treg cell); T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 754 | Poster Presentation | Dysregulation of soluble immune checkpoint proteins in newly - diagnosed early breast cancer patients. | Bernardo L. Rapoport, MD, MMed; Helen Steel; Simon Nayler; Teresa Smit; Liezl Heyman; Annette Theron; Nomsa Hlatswayo; Luyanda Kwofie; Carol Ann Benn; Lidia jooste; Ronald Anderson, Prof; | Tumor and Stromal Cell Biology | Biomarkers; Chemokine; Chemotherapy; Costimulation; Cytokine; Immune suppression; Solid tumors; Tumor microenvironment |
| 755 | Oral Presentation | CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity | Alvaro Teijeira; Saray Garasa, BS; Itziar Migueliz; Assunta Cirella; Ignacio J. Melero, Dr., MD, PhD; Alvaro Teijeira; | Tumor and Stromal Cell Biology | Chemokine; Granulocyte; Myeloid cells; MDSC; Tumor microenvironment |
| 756 | Poster Presentation | Assessment of the immune checkpoint landscape in head and neck squamous cell carcinoma by single-cell RNA sequencing and multispectral imaging | Lazar Vujanovic, PhD; Aditi Kulkarni; Cornelius Kürten, MD; Anthony R. Cillo, PhD; Patricia M. Santos, PhD; Stephan Lang; Uma Duvvuri, MD PhD.; Seungwon Kim, MD; Heath Skinner; Tullia C. Bruno, PhD; Dario A. Vignali, PhD; Riyue Bao, PhD; Robert L. Ferris, MD, PhD; | Tumor and Stromal Cell Biology | Gene expression; Immune contexture; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
Late-Breaking | |||||
| 757 | Poster Presentation | Intratumoral delivery CD40 agonist antibody via novel nanofluidic drug-eluting seed reduced tumor burden of murine pancreatic ductal adenocarcinoma | Hsuan-Chen Liu, PhD; Dixita I. Viswanath; Robin Vander Pol; Corrine Chua; Alessandro Grattoni, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Radiotherapy; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 758 | Oral Presentation | Identification of tumor antigen-specific T cells in the peripheral blood of colorectal cancer patients | Emilie Picard, PhD; Alexandrine L. Martel; Alain Simard; Hoang-Thanh Le; Chris P. Verschoor; Grace W. Ma; Graham P. Pawelec, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Clinical study; Immune contexture; Immune monitoring; Solid tumors; T cell; Tumor antigens |
| 759 | Poster Presentation | Development of an implantable artificial lymph node as a therapeutic cancer vaccine | Dixita I. Viswanath, N/A; Hsuan-Chen Liu, PhD; Corrine Ying Xuan Chua, PhD; Alessandro Grattoni, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Cytokine; Dendritic cell; Immune adjuvant; Neoantigens; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Vaccine |
| 760 | Poster Presentation | Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab | Yoshinobu Koguchi, MD, PhD; Noriko NI. Iwamoto, PhD; Takashi Shimada, PhD; Shu-Ching Chang, PhD; John Cha; Brian D. Piening, PhD; Brendan D. Curti, MD; Walter J. Urba, MD, PhD; William L. Redmond, Ph.D.; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Biomarkers; Checkpoint blockade; Chemokine; Clinical study; Immune monitoring; Proteomics |
| 761 | Poster Presentation | Potential predictive biomarkers of rapid progression and response to anti-PD1 treatment by gene profiling analysis in metastatic melanoma patients. | Maria Grazia Vitale, MD; Domenico Mallardo, MD; Antonio M. Grimaldi, MD; Ncholas Bayless; Mariaelena Capone, MD; Gabriele Madonna, MS; Vito Vanella, MD; Lucia Festino; Claudia Trojaniello; Marcello Curvietto; Luigi Scarpato; Sarah E. Warren, PhD; SuFey Ong; Ernesta Cavalcanti; Corrado Caracò; Alessandra Cesaro; Ester Simeone, MD; Paolo A. Ascierto, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Gene expression; Immune contexture; Immune suppression; Solid tumors; Tumor evasion |
| 762 | Oral Presentation | A combination of functional biomarkers improves identification of the tumor-specific reactive T cell repertoire | Arianna Draghi, MD; Katja Harbst; Inge Svane, MD; Marco Donia, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Tumor infiltrating lymphocytes (TILs) |
| 763 | Poster Presentation | Expanded and activated TILs kill tumor cells enabling IO compound assays | Paula Comune Pennacchi, PhD; Paloma Navarro; Verónica García Navas; Arántzazu Barquín García; Elena Sevillano Fernández; Sergio Ruiz Llorente; Juan Francisco Rodriguez; Monica Yagüe; Joan Ballesteros, PhD; Daniel Primo; Jesus Garcia Donas Jimenez; | Biomarkers, Immune Monitoring, and Novel Technologies | Bispecifics; Biomarkers; Checkpoint blockade; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 764 | Poster Presentation | Expansion with IL-15 increases cytotoxicity of Vγ9Vδ2 T cells and is associated with higher levels of cytotoxic molecules and T-bet | Pia Aehnlich, M.Sc.; Per Thor Straten, PhD; Ana Micaela M. Carnaz Simoes, MSc; Signe K. Skadborg, MSc; Gitte H. Olofsson, BA, MSc; | Cellular Therapies | Adoptive immunotherapy; Cytokine; T cell |
| 765 | Poster Presentation | Contextual secretion of nanoscale interleukin (IL)-12 by CAR T cells for the treatment of cancer | Zhifen Yang, Dr.; Maggie Bobbins, Dr.; Hana Choi; Ofir Stefanson; Jin Yang, Dr.; Khristina Magallanes; Bing C. Wang, PhD; Lei Stanley Qi, Dr.; Francesco M. Marincola, MD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Costimulation; Immune contexture; Immune suppression; Monocyte/Macrophage; Solid tumors; T cell; Tumor microenvironment; Tumor stroma |
| 766 | Poster Presentation | Novel bioluminescent bioassays for the discovery and development of T cell redirecting Cancer Therapies | Vanessa Ott, PhD; Julia Gilden, Ph.D.; Jamison J. Grailer, PhD; Michael Slater; Pete Stecha, BS; Jim Hartnett, BS; Dan Lazar; Frank Fan, PhD; Mei Cong, PhD; Zhijie Jey Cheng; | Cellular Therapies | Bispecifics; Adoptive immunotherapy; Antibody; CAR T cells; NK/NK T cell; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 767 | Poster Presentation | Interferon gamma reduces CAR-T exhaustion and toxicity without compromising therapeutic efficacy in hematologic malignancies | Stefanie R. Bailey; Sonika Vatsa; Amanda Bouffard; Rebecca Larson; Irene Scarfo; Michael Kann; Andrea Schmidts; Marcela V. Maus, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; B cell; CAR T cells; Chemokine; Cytokine; Immune toxicity; Inflammation; Leukemia/Lymphoma; Monocyte/Macrophage; T cell |
| 768 | Poster Presentation | Re-directed T cell therapy to control invasive aspergillosis | Karishma Bavisi, PhD; Sebastian Wurster; Nathaniel Albert; Sattva S. Neelapu, MD; Dimitrios P. Kontoyiannis, MD; Pappanaicke Kumaresan; Kumaresan Pappanaicken; | Cellular Therapies | CAR T cells; Leukemia/Lymphoma |
| 769 | Poster Presentation | CAR T cells undergoing epigenetic reprogramming by low-dose decitabine enhances persistent anti-tumor efficacy in vivo. | Yao Wang, Ph.D; Weidong Han; Chuan Tong; Zhiqianag Wu; Hanren Dai; | Cellular Therapies | Epigenetics; CAR T cells; Leukemia/Lymphoma; T cell |
| 770 | Poster Presentation | Analysis of gut microbiome in patients receiving adoptive T-cell therapy (ACT) across different solid tumour types | Arantzazu Barquin Garcia, MD; Sergio Ruiz; Paloma Navarro; Juan Francisco Rodriguez-Moreno; Elena Sevillano, MD; Monica Yague; Sandra Amarilla; Jesus Garcia-Donas; | Cellular Therapies | Adoptive immunotherapy; Microbiome; Solid tumors; Tumor infiltrating lymphocytes (TILs) |
| 771 | Poster Presentation | Characterization of tumor infiltrating immune cells from adult soft tissue sarcomas | Jacky H. Chen, HBSc; Jay S. Wunder, MD, MSc, FRCSC; Nalan Gokgoz, PhD; Irene L. Andrulis, PhD; | Cellular Therapies | Adoptive immunotherapy; Coinhibition; Costimulation; Cytokine; Regulatory T cell (Treg cell); Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 772 | Poster Presentation | A potent and off-the-shelf oNK cell therapy product targets HER2+ cancer cells and resists suppressive tumor microenvironment | Hao-Kang Li, Ph.D; Ching-Wen Hsiao; Sen-Han Yang; Hsiu-Ping Yang; Tai-Sheng Wu; Zih-Fei Cheng; Chia-Yun Lee; Yan-Liang Lin; Yan-Da Lai; Sai-Wen Tang; Janet Pan; Wei-Lun Lo; Shih-Chia Hsiao; | Cellular Therapies | Adoptive immunotherapy; Antibody; NK/NK T cell; Solid tumors; Targeted therapy; Tumor antigens; Tumor microenvironment |
| 773 | Oral Presentation | Adoptive Cell Therapy Response in Melanoma is Mediated by Stem-like CD8 T cells | Sri Krishna, PhD; Frank J. Lowery; Amy R. Copeland; Stephanie L. Goff, MD, FACS; Grégoire Altan-Bonnet; Paul F. Robbins, PhD; Steven A. Rosenberg, MD, PhD; | Cellular Therapies | Biomarkers; Checkpoint blockade; Neoantigens; Solid tumors; Systems biology; T cell |
| 774 | Poster Presentation | Antibiotic Administration Prior to Immunotherapy Leads to Poor Overall Survival Across Multiple Malignancies | Eric J. Vick, MD, PhD; Inas Abuali, MD; Sarah Ludvigsen, DO; Andrew Kelleher, MD; Nathanael D. Moore, MD; Nicholas Arias; Shuchi Gulati, MD, FACP; Trisha M. Wise-Draper, MD, PhD; | Checkpoint Blockade Therapy | Surfaceome; Bioinformatics; Checkpoint blockade; Clinical study |
| 775 | Poster Presentation | Rare case reports on thymic carcinoma patients treated with pembrolizumab | Evelyn Paszkan; Erna Ganofszky; Zsolt Megyesfalvi; Aron Ghimessy; Balazs Dome; Laszlo Agocs; Erika Toth; Ferenc Renyi-Vamos; Gabor Rubovszky; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Chemotherapy; Immune tolerance; Solid tumors |
| 776 | Poster Presentation | A role for immune checkpoint blockade to enhance T cell-mediated responses in combination with chemotherapy in oesophageal adenocarcinoma | Maria D. Davern, PhD; Joanne Lysaght; Andrew D. Sheppard; Stephen G. Maher; Noel E. Donlon, MRCS; John V. Reynolds, FRCS; Fiona O. Connell; Conall Hayes; Ross King; Anshul Bhardwaj; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Chemotherapy; Coinhibition; Costimulation; Immune tolerance; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 778 | Poster Presentation | Preclinical Study Using a Glutamatergic Signaling and Immune-Checkpoint Inhibitors in a Spontaneous Melanoma Prone Mouse Model | Kevinn Eddy, B.A; Christina Marinaro, B.S; Maryam Rasheed, B.A; Joseph Campagnolo; Xiaoxuan Zhong; Mohamad Na. Eddin; Raj Shah, PhD; Kajal Gupta, Ph.D; Jesus Diaz, M.S; Andrew Zloza, MD, PhD; Suzie Chen, PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Chemokine; Cytokine; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 779 | Poster Presentation | Immune checkpoint blockade impacts the suppressive phenotype and function of regulatory T cells in an endogenous mouse lymphoma model | Vera Bauer, Doctoral candidate; Fatima Ahmetlic; Martin Roecken; Ralph Mocikat; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Leukemia/Lymphoma; Regulatory T cell (Treg cell); Tumor microenvironment |
| 780 | Poster Presentation | Quantitative Cell-Based Bioassays to Advance Immunotherapy Programs Targeting Immune Checkpoint Receptors | Jamison J. Grailer, PhD; Julia Gilden, Ph.D.; Pete Stecha, BS; Denise Garvin, BS; Jun Wang; Michael Beck, MS; Jim Hartnett, BS; Gopal B. Krishnan; Frank Fan, PhD; Mei Cong, PhD; Zhi-jie J. Cheng, PhD; | Checkpoint Blockade Therapy | Adoptive immunotherapy; Antibody; Antigen presenting cells; Checkpoint blockade; T cell; Targeted therapy; Vaccine |
| 781 | Poster Presentation | Validation of the Combinatorial Effect of Blinatumomab and Nivolumab in Cancer Therapy | Tienan Wang, PhD; Qing Lin; Jie Zhang; | Checkpoint Blockade Therapy | Bispecifics; Adoptive immunotherapy; Antibody; Checkpoint blockade; Clinical trial; T cell; Tumor antigens |
| 782 | Poster Presentation | ALDH1A inhibition as adjuvant to ovarian cancer immunotherapy | Bingsi Gao; Mainpal Rana, PhD; Dongli Yang, PhD; Edward Grimley; Stacy McGonigal; Ronald P. Buckanovich, MD.PhD; Anda M. Vlad, MD, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune adjuvant; Monocyte/Macrophage; Regulatory T cell (Treg cell); T cell |
| 785 | Poster Presentation | Estrogen-deprivation promotes Th1 polarization of tumor-associated T cells in a mouse model of high grade serous ovarian cancer | Daniel M. Falcon, PhD; Marina D. Miller, MD; Chelsea D. Goff; Ichiko Kinjyo, MD PhD; Sarah F. Adams, MD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Chemotherapy; Coinhibition; Immune suppression; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 786 | Poster Presentation | Distinct efficacy and immunological responses to aPD-1, aPD-L1 and aPD-L2 immunotherapy in B16 melanoma in aged versus young hosts includes T-cell stem cell effects and PD-L2 expression differences | Myrna G. Garcia, BS; Alvaro S. Padron; Yilun Deng, MD, PhD; Aravind Kancharla, MS; Ryan M. Reyes, BS; Harshita B. Gupta, PhD; Tyler J. Curiel, MD, MPH; | Checkpoint Blockade Therapy | Checkpoint blockade; Cytokine; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 788 | Oral Presentation | Pembrolizumab for Patients with Leptomeningeal Metastasis from Solid Tumors: Efficacy, Safety and Cerebrospinal Fluid Biomarkers | Jarushka Naidoo, MB BCH MHS; Karisa C. Schreck; Wei Fu; Chen Hu; Roisin M. Connolly, MD; Cesar A. Santa-Maria, MD, MSCI; Evan J. Lipson, MD; Matthias Holdhoff; Patrick Forde, MD; Joanne Riemer, RN BSN; Amanda Barnes; Nafi Aygun; Lawrence Kleinberg; Kristin Redmond; Christopher Douville; Chetan Bettegowda; Arun Venkatesan; Stuart Grossman; Julie R. Brahmer, MD, MS; | Completed Clinical Trials | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Cytokine |
| 789 | Poster Presentation | Intratumoral plasmid IL-12 expands CD8+ T cells and induces a clinically validated CXCR3 signature in triple-negative breast cancer | Erika J. Crosby, Ph.D.; Hiroshi Nagata; Melinda Telli; Chaitanya R. Acharya; Irene Wapnir; Kaitlin Zablotsky; Erica Browning, BS; Reneta Hermiz; Lauren Svenson; Donna Bannavong; Kellie Malloy; David A. Canton, PhD; Christopher G. Twitty, PhD; Takuya Osada; Herbert K. Lyerly, MD; | Completed Clinical Trials | Biomarkers; Checkpoint blockade; Chemokine; Clinical study; Immune tolerance; MDSC; T cell; Tumor microenvironment |
| 790 | Poster Presentation | A Phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC) | Matthew G. Krebs, MD, PhD; Margarita Majem; Enriqueta Felip, MD PhD; Martin Forster; Bernard Doger; Tim Clay; Enric Carcereny, MD; Julio A. Peguero, MD; Leora Horn; Pawan Bajaj; Patricia Roxburgh; Chrystelle Brignone; Christian Mueller, MSc; Frederic Triebel; | Completed Clinical Trials | Antigen presenting cells; Checkpoint blockade; Clinical study; Clinical trial; Dendritic cell |
| 791 | Poster Presentation | A Phase II Study of the Anti-Programmed Cell Death-1 (PD-1) Antibody Penpulimab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) | Yuqin Song, MD; Keshu Zhou, MD; Chuan Jin, MD; Zhengzi Qian, MD; Ming Hou, MD; Lei Fan, MD; Fei Li, MD; Kaiyang Ding, MD; Hui Zhou, MD; Xiaoling Li, MD; Bing Chen, MD; Xiuhua Sun, MD; Xianmin Song, MD; Ming Jiang, MD; Qingyuan Zhang, MD; Lihong Liu, MD; Guohua Yu, MD; Yu Hu, MD; Zheng Zhao, MD; Ligen Liu, MD; Hongwei Xue, MD; Jun Luo, MD; Bai He, MD; Xiaoping Jin, PhD; Maxwell Wang, PhD; Baiyong Li, PhD; Yu Xia, PhD; Jun Zhu, MD; | Completed Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial |
| 793 | Poster Presentation | TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity | Christophe Le Tourneau, MD, PhD; Philippe Cassier, MD; Frederic Rolland; Sébastien Salas; Jean Marc Limacher, MD, MSc; Olivier Capitain; Olivier Lantz; Ana Lalanne; Christina Ekwegbara; Annette Tavernaro; Hakim Makhloufi; Kaidre Bendjama; Jean-Pierre Delord, MD; | Completed Clinical Trials | Antibody; Checkpoint blockade; Clinical trial; Immune contexture; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment; Vaccine |
| 794 | Poster Presentation | Safety and efficacy results from a phase 1/1b study of intratumoral MK-4621, a retinoic acid-inducible gene I (RIG-I) agonist, plus intravenous pembrolizumab in patients with advanced solid tumors | Victor Moreno, PhD, MD; Caroline Gaudy-Marqueste; Martin Wermke, MD; Antoine Italiano, MD; Emanuela Romano, MD, PhD; Aurelien Marabelle, MD, PhD; Emilee Connors, PhD; Heng Zhou; Konstantin Dobrenkov, MD; Elliot Chartash, MD; Emiliano Calvo, MD PhD; | Completed Clinical Trials | Checkpoint blockade; Clinical trial; Solid tumors |
| 795 | Oral Presentation | A multicenter phase II trial (SWOG S1609, Cohort 51) of Ipilimumab and Nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) | Michael J. Wagner, M.D.; Megan Othus; Sandip P. Patel, M.D.; Christopher W. Ryan; Ashish Sangal; Benjamin Powers; George T. Budd; Adrienne I. Victor; Chung-Tsen Hsueh; Rashmi Chugh; Suresh Nair; Kirsten M. Leu; Mark Agulnik, MD; Elad Sharon, MD, MPH; Edward Mayerson; Melissa Plets, M.S.; Charles D. Blanke; Howard Streicher, MD; Young Kwang Chae, MD, MPH, MBA; Razelle Kurzrock; | Completed Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Coinhibition; Solid tumors |
| 796 | Poster Presentation | A phase I/II trial combining Avelumab and Trabectedin for advanced liposarcoma and leiomyosarcoma | Michael J. Wagner, M.D.; Qianchuan He; Yuzheng Zhang; Lee Cranmer; Elizabeth T. Loggers; Sabrina McDonnell; Shannon Maxwell; Seth M. Pollack, MD; | Completed Clinical Trials | Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Monocyte/Macrophage; T cell |
| 797 | Poster Presentation | Significant anti-tumor activity of HBI-8000, a class I histone deacetylase inhibitor (HDACi) in combination with nivolumab (NIVO) in anti-PD1 therapy-naïve advanced melanoma (TN-Mel) | Nikhil I. Khushalani, MD; Andrew S. Brohl, MD; Joseph Markowitz, MD, PhD; Lyudmila Bazhenova, MD; Gregory A. Daniels, MD, PhD; Heather Yeckes-Rodin, MD; Siqing Fu, MD, PhD; Lori M. McCormick, RN; Michael Kurman, MD; Mireille Gillings, PhD, Hon DSc; Gloria Lee, MD, PhD; Zeynep Eroglu, MD; | Completed Clinical Trials | Epigenetics; Checkpoint blockade; Clinical study; Clinical trial |
| 798 | Poster Presentation | Safety, Tolerability, and Immunogenicity of mRNA-4157 in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603): an Update | Julie E. Bauman, MD, MPH; Manish Patel, MD; Daniel C. Cho, MD; Martin Gutierrez, MD; Ricklie A. Julian; Aaron Scott, MD; Pamela S. Cohen, MD; Joshua Frederick, PhD; Celine Robert-Tissot; Honghong Zhou, PhD; Kinjal Mody; Karen Keating; Robert S. Meehan, MD; Justin F. Gainor, MD; | In-Progress Clinical Trials | RNA; Clinical study; Clinical trial; Neoantigens; Solid tumors; Tumor antigens; Vaccine |
| 799 | Poster Presentation | Durable responses and immune activation with intratumoral electroporation of pIL-12 plus pembrolizumab in actively progressing anti-PD-1 refractory advanced melanoma: KEYNOTE 695 interim data | Pablo Fernandez-Penas, MD, PhD; Matteo S. Carlino, M.D., Ph.D.; Katy K. Tsai, MD; Victoria G. Atkinson, MD; Monaster Shaheen, MD; Sajeve Thomas, MD; Catalin Mihalcioiu, MD, FRCP; Tom Van Hagen, MD; Rachel Roberts-Thomson, MD; Andrew Haydon, M.D., Ph.D.; Andrew Mant, MD; Marcus O. Butler, MD; Gregory A. Daniels, MD, PhD; Elizabeth I. Buchbinder, MD; John Hyngstrom, MD; Mecker Moller, MD, FACS; Igor Puzanov, MD, MSCI; C. Lance Cowey, MD; Eric D. Whitman, MD, FACS; Carmen Ballesteros-Merino, PhD; Shawn M. Jensen, PhD; Bernard A. Fox, PhD; Emmett V. Schmidt, MD PhD; Clemens Krepler, MD; Scott J. Diede, MD, PhD; Erica Browning; Reneta Hermiz; Lauren Svenson; Jon Salazar; Jack Lee, BS, MS; Christopher Baker; Donna Bannavong; Jendy Sell; Kellie Malloy Foerter; David A. Canton, PhD; Sandra Aung, PhD; Christopher G. Twitty, PhD; Alain P. Algazi, MD; Adil Daud, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Cytokine; Gene expression; Immune adjuvant; Immune monitoring; T cell; Tumor microenvironment |
| 800 | Poster Presentation | A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors | Thomas Eigentler, MD; Lucie Heinzerling; Jürgen Krauss; Carsten Weishaupt; Peter Mohr; Sebastian Ochsenreither; Patrick Terheyden; Juan Martin-Liberal; Marc Oliva; Céleste Lebbe; Michael Fluck; Peter Brossart; Jose Manuel Trigo Perez, MD, PhD; Franz-Georg Bauernfeind, Dr; Sarah-Katharina Kays; Tobias Seibel, II; Oliver Schönborn-Kellenberger; Claudia Stosnach; Angelika Daehling; Beate Schmitt-Bormann; Ulrike Gnad-Vogt, MD; | In-Progress Clinical Trials | RNA; Clinical study; Clinical trial; Solid tumors; TLR |
| 801 | Poster Presentation | PRIME™ IL-15 (RPTR-147): Preliminary clinical results and biomarker analysis from a first-in-human Phase 1 study of IL-15 loaded peripherally-derived autologous T cell therapy in solid tumor patients | Erika P. Hamilton, MD; Sarah Nikiforow; Philip D. Bardwell, PhD; Christine M. McInnis, PhD; Jeffrey Zhang; George R. Blumenschein, Jr., MD; Mihaela Cristea, MD; Keren Osman; Anthony F. Shields, MD PhD; Marlyane Motta; Sanela Bilic; Oliver Schoenborn-Kellenberger; James A. Rakestraw; Shawn P. Carey, PhD; Elena Geretti, PhD; Karsten Sauer; Tim Harris, PhD, D.Sc; Tap Maniar, MD; Becker Hewes, MD; Thomas Andresen, PhD; Jonathan B. Fitzgerald, PhD; Harriet Kluger, MD; | In-Progress Clinical Trials | Adoptive immunotherapy; Biomarkers; Clinical study; Clinical trial; Cytokine; Solid tumors; T cell; Tumor antigens |
| 802 | Poster Presentation | Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint blockade | Brett H. Herzog, MD, PhD; Saiama Waqar, MD; Siddhartha Devarakonda, MD; Jeffrey Ward, MD, PhD; Ramaswamy Govindan, MD; Daniel Morgensztern, MD; | In-Progress Clinical Trials | Angiogenesis; Checkpoint blockade; Clinical trial; Immune contexture; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 803 | Poster Presentation | Phase 1/2 study using ENB-003, a first-in-class selective ETBRi, in combination with pembrolizumab in subjects with advanced refractory solid tumors | Adnan Nagrial, MD; Sumayah Jamal, MD-PhD; Anthony M. Joshua, MD; Richard W. Eek, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 804 | Poster Presentation | A Phase II study of the anti-programmed cell death-1 (PD-1) antibody Penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy | Xiaozhong Chen; Wei Wang; Qingfeng Zou; Jingao Li; Chaosu Hu, MD; Chaosu Hu, MD; Qin Lin; Xiaodong Zhu; Yi Jiang; Yan Sun; Liangfang Shen; Lin Wang; Guorong Zou; Xiaoyan Lin; Ying Wang; Shaojun Lin; Minying Li; Rui Ao; Ruilian Xu; Haifeng Lin; Rensheng Wang; Jiacheng Yang; Weifeng Song; Max Wang; Baiyong Li, PhD; Yu Xia, PhD; | In-Progress Clinical Trials | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune toxicity; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| 805 | Poster Presentation | Safety and emerging evidence of immune modulation of the live biotherapeutic MRx0518 in the neoadjuvant setting for patients awaiting surgical removal of solid tumours | Mark Lythgoe, MBBS, MRPharmS; Justin Stebbing; Emily Pickford; Axel Glasmacher; Marsilio Adriani, PhD; Gayle L. Fyvie; Adam Frampton; Alex Stevenson; Jonathan Krell, PhD, MRCP, MBChB, BSc; | In-Progress Clinical Trials | Clinical study; Clinical trial; Microbiome; Solid tumors; Tumor infiltrating lymphocytes (TILs); TLR |
| 806 | Poster Presentation | Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer | Luis Manso; Patricia Villagrasa, PhD; Nuria Chic; Begoña Bermejo; Juan M. Cejalvo; Yann Izarzugaza; Blanca Cantos; Salvador Blanch; Mireia Margeli; Jose L. Alonso; Alejandro Martínez; Rafael Villanueva; Juan Guerra; Raquel Andrés; Pilar Zamora; Esteban Nogales; Manel A. Juan; Blanca Gonzalez-Farre; Thomas C. Heineman; Gerard Nuovo; Grey A. Wilkinson, PhD; Matt Coffey, PhD; Azucena Gonzalez; Débora Martínez; Laia Paré; Fernando Salvador; Xavier Gonzalez; Aleix Prat, MD PhD; Joaquín Gavilá; | In-Progress Clinical Trials | Biomarkers; Checkpoint blockade; Clinical trial; Immune adjuvant; Inflammation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 807 | Poster Presentation | A multicenter open-label phase I/lb study of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors | Aurelien Marabelle, MD, PhD; Stephane Champiat; Elena Garralda, MD; Alberto Hernando; Filip Janku, MD, PhD; Anjali Raina; Richard Sachse; David Bechard; Inna Krasnopolskaya; Stefano Ferrara; Patricia LoRusso, DO; | In-Progress Clinical Trials | Cytokine; NK/NK T cell; T cell lineages |
| 808 | Poster Presentation | Exploring resistance mechanism to pembrolizumab and ang-2 inhibitor trebananib (NCT03239145) using high-dimensional single-cell mass cytometry (CyTOF) | Osama E. Rahma, MD; Joanna Baginska, PhD; Martha Brainard; Anita Giobbie-Hurder, MS; Kevin Tyan, BA; James Cleary; Benjamin Schlechter; Anna K. Maloney; Michael P. Manos, BA; Rizwan Romee, MD; Mariano Severgnini, MSc; F. Stephen Hodi, Jr., MD; | In-Progress Clinical Trials | Angiogenesis; Antibody; Checkpoint blockade; Clinical trial; Monocyte/Macrophage; Myeloid cells; NK/NK T cell; T cell; T cell lineages; Targeted therapy |
| 809 | Poster Presentation | Phase 2 trial of neoadjuvant and adjuvant PD-1 checkpoint blockade in local-regionally advanced, resectable HNSCC indicates pathological response is associated with high disease-free survival | Trisha M. Wise-Draper, MD, PhD; Shuchi Gulati, MD, FACP; Vinita Takiar; Sarah Palackdharry; Francis P. Worden, MD; Matthew Old, MD; John M. Kaczmar, MD; Neal Dunlap, MD; Benjamin Hinrichs, MD; Diana Bell; Yash Patil; Muhammad Kashif Riaz, MD; Layne Weatherford, PhD; Aubrey Hamilton; Sheena Lanverman; Michelle Mierzwa; Keith Casper; Jonathan Mark; Alice Tang; Chad Zender; Ann Gillenwater; Mario Medvedovich; J. Jack Lee, PhD; Roman Jandarov; Maura L. Gillison, MD, PhD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; T cell |
| 810 | Poster Presentation | Preliminary Safety, Tolerability and Efficacy Results of KN026 in combination with KN046 in Patients with HER2 aberrated solid tumors | Jifang Gong, MD; Lin Shen, MD,PhD; Jifang Gong, MD; Zhi Dong; Dan Liu; June Xu; Jing Yang; Yue Yang; Yakun Qi; Jie Men; Paul Kong; Ting Xu; | In-Progress Clinical Trials | Bispecifics; Checkpoint blockade; Solid tumors |
| 812 | Oral Presentation | Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer | Lei Zheng, PhD MD; Carol Judkins; Jessica Hoare; Rachel Klein; Rose Parkinson; Hao Wang; Haihui Cao; Jennifer Durham; Katrina Purtell; Ana De Jesus-Acosta; Dung T. Le, MD; Amol Narang; Robert A. Anders, MD, PhD; Richard Burkhart; William Burns; Christopher Wolfgang; Elizabeth D. Thompson, MD PhD; Daniel A. Laheru; Jin He, MD, PhD; Elizabeth M. Jaffee, MD; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical study; Costimulation; Solid tumors; Surgery; T cell; Tumor microenvironment; Vaccine |
| 814 | Poster Presentation | MCLA-145 (CD137xPD-L1): a potent CD137 agonist and immune checkpoint inhibitor that that does not show signs of peripheral toxicity. | Kees Bol, PhD; Wilfred Marissen, PhD; Jeroen Elaissais-Schaap, PhD; Paul J. Tacken, PhD; Steef Engels; Liang-chuan Wang, PhD; Arpita Mondal; Mark Throsby, PhD; Alan Roberts, PhD; Patrick Mayes, PhD; Cecile Geuijen, PhD; | Combination Immunotherapies | Bispecifics; Antibody; Checkpoint blockade; Costimulation; Immune suppression; Immune toxicity; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 816 | Poster Presentation | Evaluating the potential of harnessing anti-leukemia T cells for the treatment of T cell Acute Lymphoblastic Leukemias (T-ALL) | Todd A. Triplett, PhD; Sarah E. Church, PhD; Tyler D. Hether; Joshua F. Rios; Srividya Kottapalli; Nisha Holay, B.S.; | Combination Immunotherapies | Checkpoint blockade; Coinhibition; Cytokine; Immune contexture; Leukemia/Lymphoma; Pediatric tumors; T cell; T cell lineages; Tumor microenvironment; Tumor stroma |
| 817 | Poster Presentation | DT095895, a selective EP4 receptor antagonist with monotherapy efficacy in syngeneic mouse model(s) and best-in-class properties | Anne-Laure Blayo; Laurène Deshons; Alexia Dumont; Christel Franchet; Célia Halter; Ludovic Herbin; Gaël Hommet; Stanislas Mayer; Alban Bessede; Imane Nafia; Marjorie Sidhoum; Xavier Leroy; Stéphan Schann; | Combination Immunotherapies | Biomarkers; Checkpoint blockade; Immune suppression; Solid tumors; Tumor microenvironment |
| 818 | Poster Presentation | Synergistic cancer immunotherapy using tumor tissue-derived exosomes and artificially produced bacterial outer membrane vesicles | Kyong-su Park, PhD; Jan Lötvall; Kristina Svennerholm; Rossella Crescitelli; Cecilia Lässer; Inta Gribonika; | Combination Immunotherapies | Extracellular vesicles/exosomes; Cytokine; Dendritic cell; Inflammation; Neoantigens; T cell; Tumor antigens; Vaccine |
| 819 | Poster Presentation | Targeting vasoactive intestinal peptide receptor signaling: A novel approach to enhance anti-tumor response in pancreatic ductal adenocarcinoma | Sruthi Ravindranathan, PhD, MS; Passang Tenzin; Sanjay Chandrasekaran, MD; Brandon Ware; Mohammad Y. Zaidi, MD, MS; Shuhua Wang, MD; Rohan K. Dhamsania, BS; Jingru Zhu; Susan N. Thomas, PhD, BS; Anish Majumdar,; Gregory B. Lesinski, PhD; Bassel El-rayes, MD; Edmund K. Waller, MD, PhD; | Combination Immunotherapies | Solid tumors |
| 820 | Poster Presentation | MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells | Paul J. Tacken, PhD; Liang-chuan Wang, PhD; Rinse Klooster; Pieter Fokko Van Loo, PhD; Jing Zhou, MD, PhD; Arpita Mondal; Yao-Bin Liu; Arjen Kramer; Thomas Condamine, PhD; Alla Volgina; Linda Hendriks; Hans van der Maaden; Eric Rovers; Steef Engels; Floris Fransen; Renate den Blanken-Smit; Vanessa Zondag-van der Zande; Abdul Basmeleh; Willem Bartelink; Ashwini Kulkarni; Wilfred Marissen, PhD; Cheng-Yen Huang; Leslie Hall; Shane Harvey; Chrysi Kanellopoulou, PhD; Shaun Stewart; Horacio Nastri; Lex Bakker, PhD; Ton Logtenberg; Simon Plyte; Patrick Mayes, PhD; Mark Throsby, PhD; Cecile Geuijen, PhD; | Combination Immunotherapies | Bispecifics; Antibody; Checkpoint blockade; Coinhibition; Costimulation; Immune adjuvant; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 821 | Poster Presentation | Class specific HDAC inhibition differentially affects the function of specific T cell subsets | Nisha Holay, B.S.; Uma Giri, Ph.D.; Carla Van Den Berg, Pharm.D.; Gail Eckhardt, MD; Todd A. Triplett, PhD; | Combination Immunotherapies | Post-translational modifications; Epigenetics; Cytokine; T cell; T cell lineages |
| 822 | Poster Presentation | Local radiotherapy synergizes with tumor-specific TCR redirected T cells in the rejection of prostate cancer | Marco Catucci; Veronica Basso; Chiara Lucrezia Deantoni; Simone Baroni; Antonello Spinelli; Massimo Freschi; Cesare Cozzarini; Claudio Fiorino; Nadia Di Muzio; Silvia C. Formenti, MD; Sandra Demaria, MD; Anna Mondino; | Combination Immunotherapies | Adoptive immunotherapy; Radiotherapy; Solid tumors |
| 823 | Poster Presentation | CD4 T cells are essential for an anti-tumor effect in a B78 murine melanoma tumor model | Arika S. Feils, BS; Mackenzie Heck; Anna Hoefges, MS; Peter M. Carlson, BS; Luke Zangl; Ravi Patel, MD, PhD; Dmitriy Kravtsov; Jacquelyn A. Hank, PhD; Zachary S. Morris, MD, PhD; Alexander L. Rakhmilevich, MD, PhD; Paul M. Sondel, MD, PhD; Amy K. Erbe, PhD; | Combination Immunotherapies | Radiotherapy; T cell; T cell lineages; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 824 | Poster Presentation | Modulation of TLR3 protein in response to radiation in squamous cell lung carcinoma | Jeru M. Manuel, PhD; Ebru Tas, B.Sc; Cleopatra Rutihinda, B.Sc; Ayman J. Oweida, PhD; | Combination Immunotherapies | Gene expression; Radiotherapy; TLR; Tumor microenvironment |
| 825 | Oral Presentation | Deep immune profiling of SARS-CoV-2 associated immune microenvironment in cancer tissues from recovered COVID-19 patients | Denise Goh, BBiomedSc (Hons); Chun Chau Lawrence Cheung, BA, MMedSc; Xinru Lim; Tracy Zhijun Tien; Jeffrey Chun Tatt Lim; Sanjna Nilesh Nerurkar; Loong Shihleone; Peng Chung Cheow; Chung Yip Chan; Ye Xin Koh; Thuan Tong Tan; Shirin Kalimuddin; Wai Meng David Tai; Jia Lin Ng; Jenny Guek-Hong Low; Joe Poh Sheng Yeong; Tony Kiat Hon Lim; | COVID and Immunotherapy | COVID and Immunotherapy; Biomarkers; Chemokine; Cytokine; Immune contexture; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 826 | Poster Presentation | Risk of COVID-19 infection among patients receiving immune checkpoint inhibitor therapy: A tertiary care hospital system collaboration with the Massachusetts Department of Health | William Murphy, AB; Vartan Pahalyants, BA; Nicholas Theodosakis, MD; Leyre Zubiri, MD, PhD; Monina Klevens, DDS; Evelyn Lilly, MD; Kerry L. Reynolds, MD; Yevgeniy R. Semenov, MD, MA; | COVID and Immunotherapy | COVID and Immunotherapy; Epidemiology |
| 827 | Poster Presentation | Elucidating the Roles of PIK3IP1/TrIP Immune Regulation on Distinct T Cell Subsets in the Context of Cancer | Benjamin M. Murter, BS; Lawrence P. Kane, PhD; | Immune Cell Biology | Solid tumors; T cell; T cell lineages; Tumor microenvironment |
| 828 | Poster Presentation | Improved growth properties and immune surveillance in K-RAS G12V-transformed cells through overexpression of biglycan | Karthikeyan Subbarayan, MSc; Sandra Leisz; Chiara Massa, PhD; Sravankumar Balina; Anja Müller; Claudia Wickenhauser, MD, PhD; Barbara Seliger, MD, PhD; | Immune Cell Biology | Antigen presenting cells; Bioinformatics; Biomarkers; Gene expression; Solid tumors; Tumor antigens; Tumor evasion; Tumor microenvironment |
| 829 | Poster Presentation | Tumor alpha-fetoprotein inhibits cholesterol and steroid metabolism in monocyte-derived dendritic cells | Paul Munson, PhD; Juraj Adamik, PhD; Lisa H. Butterfield, PhD; | Immune Cell Biology | Dendritic cell; Gene expression; Immune suppression; Monocyte/Macrophage; Myeloid cells; Metabolism |
| 830 | Poster Presentation | Targeting cellular senescence to increase CAR-T cell fitness | Rashmi Bankoti; Hazal Pektas Akbal; Maddalena Adorno; Benedetta N. Di Robilant; | Immune Cell Biology | Epigenetics; Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Immune adjuvant; Leukemia/Lymphoma; Stem cell/cancer-initiating cell; Solid tumors |
| 831 | Poster Presentation | E3 ubiquitin ligase Cbl-b deficient CD8+ T cells overcome Treg cell-mediated suppression through IFN-γ and induce robust anti-tumor immunity | SeongJun Han, MSc; Zhe Qi Liu; Douglas Chung; Michael St. Paul; Carlos Garcia-Batres; Azin Sayad; Alisha R. Elford; Matthew J. Gold; Natasha Grimshaw; Pamela S. Ohashi, PhD; | Immune Cell Biology | Adoptive immunotherapy; Cytokine; Immune suppression; Immune tolerance; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor microenvironment |
| 832 | Poster Presentation | Unravelling human melanoma heterogeneity by 6-color multiplex immunofluorescence to overcome recurrence and resistance to therapy | Marcella Willemsen, MSc; Jenny Bulgarelli; Sudhir C. Kumar; Massimo Guidoboni, MD; John A. Kyte; Irwin Davidson; Rosalie M. Luiten; | Immune Cell Biology | Checkpoint blockade; T cell; Tumor antigens; Tumor evasion; Tumor microenvironment |
| 833 | Poster Presentation | The epigenomic landscape of human glioma-associated myeloid cells | Pravesh Gupta, PhD; Dapeng Hao, Ph.D.; Krishna Bojja Bojja; Tuan M. Tran; Minghao Dang, PhD; Jianzhuo Li; Atul Maheshwari, MD; Nicholas Navin, PhD; Linghua Wang, PhD; Krishna P. Bhat, PhD; Pravesh Gupta, PhD; | Immune Cell Biology | Epigenetics; Immune contexture; Monocyte/Macrophage; Myeloid cells; Tumor microenvironment |
| 834 | Poster Presentation | CRISPR-mediated in situ editing of liver resident macrophages for treating liver cancers | Zhutian Zeng; Wei Liu; | Immune Cell Biology | Monocyte/Macrophage; Myeloid cells; Targeted therapy |
| 835 | Poster Presentation | Structural difference caused by mutated residues is correlated with immunogenicity of neoantigens and specificity of reactive T cells | Tomoyo Shinkawa; Serina Tokita; Takayuki Kanaseki, MD, PhD; Toshihiko Torigoe, MD, PhD; | Immune Cell Types | Biomarkers; Neoantigens; T cell; Tumor antigens |
| 836 | Poster Presentation | Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy | Laura A. Ridgley, PhD; Angus G. Dalgleish, MD, PhD; Mark Bodman-smith; | Immune Cell Types | Checkpoint blockade; T cell; Vaccine |
| 837 | Poster Presentation | Interleukin-10 drives the development of T regulatory type 1 (Tr1) cells and is a target for immunotherapy | Yanchun Ma, MD student; Vera Bauer, Doctoral candidate; Tanja Riedel; Thomas Hofer; Martin Roecken; Ralph Mocikat; | Immune Cell Types | Cytokine; Immune suppression; Leukemia/Lymphoma; T cell; T cell lineages; Tumor microenvironment |
| 838 | Poster Presentation | Phenotypic and functional signatures of peripheral and tumor-resident γδ T cells are informative for outcome of checkpoint blockade in melanoma | Graham P. Pawelec, PhD; Kilian Wistuba-Hamprecht, PhD; | Immune Cell Types | Biomarkers; T cell; T cell lineages |
| 839 | Poster Presentation | Transcriptomic profiling of T-cell populations in non-muscle invasive and muscle invasive bladder cancer | Viktor Sincic, MSc; Milad Abolhalaj, MSc; Henrik Lilljebjörn; Alar Aab; Karin Hagerbrand, PhD; Peter Ellmark, PhD; Thoas Fioretos; Carl Borrebaeck; Fredrik Liedberg; Kristina Lundberg, PhD; | Immune Cell Types | RNA; Biomarkers; Gene expression; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; T cell; T cell lineages; Tumor evasion; Tumor microenvironment |
| 840 | Poster Presentation | Presence and distribution of immunosuppressive peptide P3028 in relation to immune phenotype of tonsillar cancer | Sabine Swoboda, MD; Rebecca Rosberg, M.Sc; David Gomez Jimenez; David Askmyr; Malin Lindstedt, PhD; Lennart Greiff; Leif Håkansson; | Immune Cell Types | Dendritic cell; Immune suppression; Monocyte/Macrophage; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 841 | Poster Presentation | CRISPR Cas9 library screen in primary T cells and diffuse large B cell lymphoma cells to identify modulators in tumor-immune interaction | Qian Li; Zhengang Peng; | Immune-stimulants and immune modulators | Bispecifics; Immune toxicity; Leukemia/Lymphoma; Solid tumors; T cell lineages |
| 842 | Poster Presentation | A novel agonistic anti-CD40 targeting strategy with an affinity peptide binding feature for antigen cargo functionality: improving peptide stability and T cell proliferation | Ida R. Olsson; Mohamed Eltahir, MD; Sara M. Mangsbo, PhD MSc; | Immune-stimulants and immune modulators | Antibody; Antigen presenting cells; Checkpoint blockade |
| 843 | Poster Presentation | Reproducible, MoA-reflecting Reporter-based Bioassays to Enable Drug Development of Biosimilars and Biobetters | Jeffrey D. Nelson, PhD; Richard Moravec; Dun Li; Jennifer Wilkinson; Frank Fan, PhD; Mei Cong, PhD; | Immune-stimulants and immune modulators | Antibody; Autoimmunity; CAR T cells; Cytokine; Immune suppression; T cell; T cell lineages; Targeted therapy |
| 844 | Poster Presentation | Immunomodulatory Activity of Epigenetic Drugs Combinations in Mesothelioma: Laying the Ground for New Immunotherapeutic Strategies | Sara Cannito, Health biology; Ornella Cutaia; Carolina Fazio; Maria Fortunata Lofiego; Francesca Piazzini; Laura Solmonese; LUANA CALABRÒ; Michele Maio, MD; Alessia Covre, PhD; | Immune-stimulants and immune modulators | RNA; Post-translational modifications; Epigenetics; Biomarkers; Gene expression; Tumor antigens; Tumor microenvironment |
| 845 | Poster Presentation | Developing more potent inhibitors of vasoactive intestinal peptide signaling with enhanced efficacy in mouse models of leukemia | Sruthi Ravindranathan, PhD, MS; Jian-ming Li, PhD; Yiwen Li, MS; Passang Tenzin; Anish Majumdar; Edmund K. Waller, MD, PhD; | Immune-stimulants and immune modulators | T cell |
| 846 | Poster Presentation | Neospora caninum - an Immunotherapeutic Protozoan Against Solid Cancers | Louis Lantier, PhD; Agathe Poupee-Beauge, PhD; Céline DUCOURNAU; Anne Di Tommaso, PhD; Stéphanie Germon, PhD; Nathalie Moiré, PhD; Gordon Lee, MBChB; Antoine Touze, PhD; Isabelle Dimier-Poisson, PhD; | Immune-stimulants and immune modulators | Antibody; Cytokine; Immune adjuvant; Immune suppression; Neoantigens; Solid tumors; Tumor antigens; Tumor microenvironment; Tumor stroma; Vaccine |
| 847 | Poster Presentation | Inflammasome Activation in M2 Macrophage Restrain the Immune Suppressive Function | Ronghua Zhang, Ph.D; Tienan Wang, PhD; Qing Lin; | Immune-stimulants and immune modulators | Cytokine; Immune monitoring; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; T cell; TLR |
| 848 | Poster Presentation | Prime-boost vaccination for the treatment of triple negative breast cancer | Seyedeh-Raheleh Niavarani; Christine Lawson, PhD; Lee-Hwa Tai, PhD; | Immune-stimulants and immune modulators | Biomarkers; Checkpoint blockade; Chemotherapy; Immune adjuvant; Surgery; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); TLR; Vaccine |
| 849 | Poster Presentation | Optimization of a GM3-containing liposomal vaccine that delivers antigen to CD169+ splenic macrophages | Maarten Nijen Twilhaar, Msc; Lucas Czentner Colomo; Joanna Grabowska; Alsya J. Affandi; Katarina Olesek; Hakan Kalay; Rene van Nostrum; Paul R. Crocker; Yvette van Kooyk; Gert Storm; Joke MM. den Haan; | Immune-stimulants and immune modulators | Antigen presenting cells; Monocyte/Macrophage; T cell; Targeted therapy; Vaccine |
| 850 | Poster Presentation | Immunological considerations for developing optimal whole tumor cell-derived cancer vaccines | Flavio Salazar Onfray, PhD; | Immune-stimulants and immune modulators | Clinical study; Dendritic cell; Immune adjuvant; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| 851 | Poster Presentation | Potent tumor-directed T cell activation and in vivo tumor inhibition induced by a 4-1BB x 5T4 ADAPTIR™ bispecific antibody | Michelle H. Nelson, PhD; Robert Miller; Anneli Nilsson; Lill Ljung; Allison Chunyk; Catherine McMahan; David Bienvenue; Maria Askmyr; Gabriela Hernandez-Hoyos; Sara Fritzell, PhD; | Immuno-conjugates and chimeric molecules | Bispecifics; Antibody; Costimulation; NK/NK T cell; Solid tumors; T cell |
| 852 | Poster Presentation | Differential expression of surface protein-encoding genes highlights therapeutic vulnerabilities of four SCLC subtypes | Elizabeth Park, PhD; Carl M. Gay, MD, PhD; C Allison Stewart, PhD; Kasey Cargill, PhD; Lixia Diao, PhD; Qi Wang, PhD; Robert J. Cardnell, PhD; Jing Wang, PhD; John V. Heymach, MD, PhD; Lauren A. Byers, MD; | Immuno-conjugates and chimeric molecules | Surfaceome; Antibody; Targeted therapy |
| 853 | Poster Presentation | Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients. | Mohamed Eltahir, MD; Erika A. Fletcher, MSc; Linn Dynesius; Justina Jarblad; Martin Lord; Ida R. Olsson; Mikaela Zekarias; Xiaojie Yu; Mark Cragg; Caroline Hammarstom; Kerstin Hamberg Levedahl; Martin Höglund; Gustav J. Ullenhag, PhD, MD; Mattias Mattsson; Sara M. Mangsbo, PhD MSc; | Immunotherapy Toxicities | Antibody; Cytokine; NK/NK T cell |
| 854 | Poster Presentation | Prediction of severe immune-related adverse events in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the United States | Mark Kalinich, PhD; William Murphy, AB; Shannon Wongvibulsin, PhD; Vartan Pahalyants, BA; Kun-Hsing Yu, MD, PhD; Feicheng Wang, PhD; Leyre Zubiri, MD, PhD; Vivek Naranbhai, MBChB, PhD, DPhil; Alexander Gusev; Shawn G. Kwatra, MD; Kerry L. Reynolds, MD; Yevgeniy R. Semenov, MD, MA; | Immunotherapy Toxicities | Immune toxicity |
| 855 | Poster Presentation | Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses | Thomas K. Le; Subuhi Kaul, MD; Shannon Wongvibulsin, PhD; Laura Cappelli, MD; Jarushka Naidoo, MB BCH MHS; Yevgeniy R. Semenov, MD, MA; Shawn G. Kwatra, MD; | Immunotherapy Toxicities | Checkpoint blockade; Clinical study; Epidemiology; Immune toxicity |
| 856 | Poster Presentation | Preliminary review of Diabetes Mellitus incidence in patients treated with immune checkpoint inhibitors (ICI) therapy – Roswell Park Comprehensive Cancer Center (RPCCC) experience | Zhen Zhang, PharmD, BCPS; Grazyna Riebandt, PharmD, BCOP; Rajeev Sharma, MD, FACE; Jordan Scott, BS; Lamya Hamad, RPh, MPH; Laurie Plewinski, BS; | Immunotherapy Toxicities | Antibody; Autoimmunity; Checkpoint blockade; Immune toxicity; Solid tumors |
| 857 | Poster Presentation | LAMP1 targeting of the large T antigen of Merkel cell polyomavirus elicits potent CD4+ T cell responses and prevents tumor growth | Claire Buchta Rosean, PhD; Pratima Sinha, PhD; David M. Koelle, MD; Paul Nghiem, MD, PhD; Teri Heiland, PhD; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| 858 | Poster Presentation | A bispecific antibody targeting CD40 and EpCAM induces superior anti-tumor effects compared to the combination of the monospecific antibodies | Peter Ellmark, PhD; Karin Hägerbrand; Mattias levin; Laura Von Schantz, -; Adnan Deronic, PhD; Laura Varas; Anna Säll; Karin Barchan; Doreen Werchau, BS; Lill Ljug; Mia Thageson; Anna Rosen, MSc; Christina Sakellariou; Malin Lindstedt, PhD; | Novel Single-Agent Immunotherapies | Extracellular vesicles/exosomes; Antibody; Dendritic cell; Neoantigens; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| 859 | Poster Presentation | Inhibition of the kinase activity of Hematopoietic Progenitor Kinase 1 enhances anti-PD-1-induced reinvigoration of human tumor-infiltrating CD8+ T cells | Yongjoon Lee; Seung Hyuck Jeon; A Yeong Park; Suyeon Jo; Jinhwa Lee; Su-Hyung Park; Jamie Jae Eun Kim, PhD; Eui-Cheol Shin; | Novel Single-Agent Immunotherapies | Checkpoint blockade; T cell; Tumor infiltrating lymphocytes (TILs) |
| 860 | Poster Presentation | Targeting immunosuppressive macrophages overcomes PARP-inhibitor resistance in BRCA1-associated triple-negative breast cancer | Anita K. Mehta, PhD; Emily Cheney; Christina Hartl; Constantia Pantelidou; Madison Oliwa; Jessica Castrillon; Jia-Ren Lin; Katie E. Hurst; Mateus de Oliveira Taveira; Nathan Johnson; William Oldham; Marian Kalocsay; Matthew Berberich; Sarah Boswell; Aditi Kothari; Shawn Johnson, BS; Deborah Dillon; Mikel Lipschitz; Scott J. Rodig, MD, PhD; Sandro Santagata; Judy Garber; Nadine M. Tung, MD; José Yélamos; Jessica E. Thaxton, PhD, MS; Elizabeth A. Mittendorf, MD, PhD; Peter K. Sorger; Geoffrey I. Shapiro, MD, PhD; Jennifer L. Guerriero, PhD; | Novel Single-Agent Immunotherapies | Antibody; Immune suppression; Monocyte/Macrophage; Myeloid cells; Metabolism; Tumor microenvironment |
| 861 | Poster Presentation | Development of FPA157, an anti-CCR8 depleting antibody engineered to preferentially eliminate tumor-infiltrating T regulatory cells | Andrew Rankin, PhD; Edwina Naik, PhD; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| 862 | Poster Presentation | Targeting PSGL-1, a novel macrophage checkpoint, repolarizes suppressive macrophages, induces an inflammatory tumor microenvironment, and suppresses tumor growth | Phuong A. Nguyen, PhD; Ryan Phennicie; Kevin Kauffman, PhD; Dominika Nowakowska, PhD; Mohammad Zafari; Veronica Komoroski; Steve Sazinsky, PhD; Joe Wahle, PhD; Denise Manfra, PhD; Shantashri Vaidya, PhD; Michael A. Brehm, PhD; Igor Feldman, PhD; Tatiana Novobrantseva, PhD; | Novel Single-Agent Immunotherapies | Antigen presenting cells; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Tumor stroma |
| 863 | Poster Presentation | Identification and characterization of an immunodominant SARS-CoV-2-specific CD8 T cell response | Anastasia Gangaev; Pia Kvistborg, PhD; | Other | T cell; Vaccine |
| 864 | Poster Presentation | The mesenchymal stromal compartment in colorectal cancer greatly alters the innate tumour immune microenvironment both in 2D and 3D culture systems | Niamh A. Leonard, MSc; Oliver Treacy, PhD; Hannah Egan, BSC; Grace O'Malley; Elena Tomas Bort; Eleonora Peerani; Thomas Ritter, Prof.; Daniela Loessner; Laurence J. Egan, MD; Aideen E. Ryan, PhD; | Tumor and Stromal Cell Biology | Antigen presenting cells; Cytokine; Immune suppression; Inflammation; Monocyte/Macrophage; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor stroma |
| 865 | Poster Presentation | Sugar high: Does the sialic acid profile of cancer-associated fibroblasts induce a more tumour-permissive microenvironment? | Hannah Egan, BSC; Niamh A. Leonard, MSc; Kevin Lynch, PhD; Oliver Treacy, PhD; Amir Nader; Margaret Sheehan, Dr; Sean Hynes, Dr; Laurence J. Egan, MD; Thomas Ritter, Prof.; John Daly; Aisling Hogan, Dr.; Michael O; Aideen E. Ryan, PhD; | Tumor and Stromal Cell Biology | Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 867 | Poster Presentation | Distinct genomic features across cytolytic subgroups in skin melanoma | Apostolos Zaravinos; Constantinos Roufas; Ilias Georgakopoulos-Soares; | Tumor and Stromal Cell Biology | Bioinformatics; Checkpoint blockade; Gene expression; Immune contexture; Immune suppression; Immune toxicity; Tumor antigens; Tumor evasion |
| 868 | Poster Presentation | PRELP-facilitated enhancement of MHC class I surface expression in B16F10 melanoma cells | Helene Schäfer, none; Karthikeyan Subbarayan, MSc; Barbara Seliger, MD, PhD; | Tumor and Stromal Cell Biology | Antigen presenting cells; Bioinformatics; Biomarkers; Gene expression; Solid tumors; Tumor antigens; Tumor evasion; Tumor microenvironment; Tumor stroma |
| 869 | Oral Presentation | Anti-LunX targeting therapy for lung cancer | Xiaohu Zheng; Weihua Xiao, MD, MS; Zhigang Tian, MD, PhD; | Tumor and Stromal Cell Biology | Antibody; Targeted therapy; Tumor antigens |
| 870 | Poster Presentation | Investigating sexual dimorphism in the tumor immune microenvironment of non-muscle invasive bladder cancer | Stephen Chenard, BScH; Stephen Chenard, BScH; Chelsea Jackson, PhD; Thiago Vidotto, MSc, PhD; Celine Hardy, BScH; Tamara Jamaspishvilli, MD, PhD; David Berman, MD, PhD; David Robert Siemens, MD; Madhuri Koti, DVM, MVSc, PhD; | Tumor and Stromal Cell Biology | B cell; Biomarkers; Gene expression; Immune contexture; Immune suppression; Monocyte/Macrophage; Tumor microenvironment; Tumor stroma |
| 871 | Poster Presentation | In Vitro immunoregulatory effect from Cervical Cancer derived Mesenchymal Stromal Cells over molecules expression in Monocyte derived Macrophage polarization. | Víctor A. Cortrés-Morales; Juan J. Montesinos; Luis Chávez-Sánchez; Sandra Espíndola-Garibay; Alberto Monroy-García; Teresa Apresa-García; Héctor Mayani; | Tumor and Stromal Cell Biology | Monocyte/Macrophage; Solid tumors; Tumor microenvironment |
| 872 | Poster Presentation | Neoadjuvant chemoradiotherapy enhances T cell infiltration in pancreatic ductal adenocarcinoma but high percentage of regulatory T cells associates with poor survival | Benjamin T. Fullerton, BA; Robyn D. Gartrell, MD; Thomas Enzler, MD PhD; Pan S. Kim, MD; Ladan Fazlollahi, MD, MPH; Andrew X. Chen, BS; Subha Perni, MD; Stuart P. Weisberg, MD, PhD; Emanuelle M. Rizk; Eun Jeong Oh; Xinzheng Guo; Codruta Chiuzan, PhD; Raul Rabadán, PhD; Donna Farber, PhD; Helen E. Remotti, MD; David P. Horowitz, MD; Yvonne M. Saenger, MD; | Tumor and Stromal Cell Biology | Chemotherapy; Radiotherapy; Regulatory T cell (Treg cell); T cell; Tumor microenvironment |
| 873 | Poster Presentation | Pharmacologic macrophage depletion affects metastasis formation by modulating systemic immune responses in a genetic pancreatic cancer model | Heidi Griesmann, PhD; Christof Drexel; Nada Milosevic; Bence Sipos; Thomas Gress; Patrick Michl; | Tumor and Stromal Cell Biology | Angiogenesis; Carcinogenesis; Monocyte/Macrophage; Regulatory T cell (Treg cell); Solid tumors; Tumor microenvironment |
